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Background: There is uncertainty about the most appropriate ways to manage non-respiratory sleep
disturbances in children with neurodisabilities (NDs).
Objective: To assess the clinical effectiveness and safety of NHS-relevant pharmacological and
non-pharmacological interventions to manage sleep disturbance in children and young people with
NDs, who have non-respiratory sleep disturbance.
Data sources: Sixteen databases, including The Cochrane Central Register of Controlled Trials, EMBASE
and MEDLINE, were searched up to February 2017, and grey literature searches and hand-searches
were conducted.
Review methods: For pharmacological interventions, only randomised controlled trials (RCTs) were
included. For non-pharmacological interventions, RCTs, non-randomised controlled studies and before-and-
after studies were included. Data were extracted and quality assessed by two researchers. Meta-analysis and
narrative synthesis were undertaken. Data on parents’ and children’s experiences of receiving a sleep
disturbance intervention were collated into themes and reported narratively.
Results: Thirty-nine studies were included. Sample sizes ranged from 5 to 244 participants. Thirteen
RCTs evaluated oral melatonin. Twenty-six studies (12 RCTs and 14 before-and-after studies) evaluated
non-pharmacological interventions, including comprehensive parent-directed tailored (n = 9) and
non-tailored (n = 8) interventions, non-comprehensive parent-directed interventions (n = 2) and other
non-pharmacological interventions (n = 7). All but one study were reported as having a high or unclear
risk of bias, and studies were generally poorly reported. There was a statistically significant increase in
diary-reported total sleep time (TST), which was the most commonly reported outcome for melatonin
compared with placebo [pooled mean difference 29.6 minutes, 95% confidence interval (CI) 6.9 to
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52.4 minutes; p = 0.01]; however, statistical heterogeneity was extremely high (97%). For the single melatonin
study that was rated as having a low risk of bias, the mean increase in TST was 13.2 minutes and the lower CI
included the possibility of reduced sleep time (95% CI –13.3 to 39.7 minutes). There was mixed evidence
about the clinical effectiveness of the non-pharmacological interventions. Sixteen studies included interventions
that investigated the feasibility, acceptability and/or parent or clinician views of sleep disturbance interventions.
The majority of these studies reported the ‘family experience’ of non-pharmacological interventions.
Limitations: Planned subgroup analysis was possible in only a small number of melatonin trials.
Conclusions: There is some evidence of benefit for melatonin compared with placebo, but the degree of
benefit is uncertain. There are various types of non-pharmacological interventions for managing sleep
disturbance; however, clinical and methodological heterogeneity, few RCTs, a lack of standardised outcome
measures and risk of bias means that it is not possible to draw conclusions with regard to their effectiveness.
Future work should include the development of a core outcome, further evaluation of the clinical effectiveness
and cost-effectiveness of pharmacological and non-pharmacological interventions and research exploring the
prevention of, and methods for identifying, sleep disturbance. Research mapping current practices and
exploring families’ understanding of sleep disturbance and their experiences of obtaining help may facilitate
service provision development.
Study registration: This study is registered as PROSPERO CRD42016034067.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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xix
Plain English summary
S leep problems such as difficulty settling at bedtime or night waking are more common and serious inchildren with disorders of development of the brain, for example autism, attention deficit hyperactivity
disorder and learning difficulties. Sleep problems can affect children’s and parents’ mental, physical and
emotional well-being, and, so, help with children’s sleep is a main concern for parents. There is a wide
range of drug and non-drug treatments available to manage sleep disturbance. However, very little is
known about whether or not these treatments make a difference; in other words, are these treatments
effective?
This study aimed to investigate this gap in knowledge. We reviewed previous research to find out what is
already known about the effectiveness of drug and non-drug treatments. Study results suggest that one
drug (melatonin) may be helpful for managing children’s sleep. However, we cannot tell how beneficial it
is. There are also many non-drug treatments (e.g. information leaflets, parent training groups, one-to-one
work between a parent and a professional). However, the studies evaluating these sorts of help tested
different treatments in different ways. This means that we cannot tell how beneficial each treatment
is. A limited number of studies also looked at families’ or professionals’ views and experiences of
these treatments.
Overall, research on treatments of sleep disturbance in children is limited, with only one drug (melatonin)
showing signs of benefit. Owing to the limited number of studies available and the largely poor quality of
this research, it is not possible to make any suggestions for clinical practice. More research is needed to
identify the best treatments for sleep problems among children with neurodisabilities.
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Scientific summary
Background
Sleep is essential for physical and mental functioning and well-being. Difficulties with sleep initiation, sleep
maintenance and sleep scheduling result in disturbed sleep not only for the individual, but often for other
family members as well. Non-respiratory sleep disturbances in children with neurodisabilities (NDs) are
more common and more severe than in children with typical development. However, sleep disturbance is
rarely a diagnostic criterion; rather, it co-occurs with a diagnosis of a ND. Non-respiratory causes of sleep
disturbance among children with NDs include behavioural factors (e.g. parenting), damage or disorders
affecting circadian rhythms, hyperarousal, pain, seizures, anxiety and the presence of medical technologies.
Many children have more than one sleep difficulty and the aetiology of sleep disturbance is often multifactorial.
Sleep disturbances are associated with poor cognitive, physical and/or emotional outcomes for children
and parents and result in increased demands on services. Help with sleep is a high priority for parents,
practitioners and other stakeholders. However, support is patchy and approaches to managing sleep
disturbance are variable and inconsistent. Interventions include pharmacological and non-pharmacological
approaches. Pharmacological interventions act on the physiological processes of sleep and/or the timing
of the sleep–wake cycle. All are prescribed ‘off-label’. Non-pharmacological interventions include
parent-directed psychoeducational interventions, chronotherapy, phototherapy, dietary changes and sensory
interventions. Evidence on intervention effectiveness is particularly limited for some of these approaches.
Importantly, the evidence on pharmacological and non-pharmacological interventions, and across all types
of NDs, has never been subject to a single review.
Objectives
l Assess the clinical effectiveness and safety of different intervention approaches to sleep disturbances
for children with NDs and, when possible, to:
¢ Examine whether or not the clinical effectiveness of an intervention differs for different types of
ND, different causes of sleep disturbance and different types of sleep disturbance.
¢ Review and evaluate evidence regarding the use of more than one intervention approach,
sequentially or in combination, to manage a specific cause of sleep disturbance.
¢ Review and evaluate evidence regarding the impact of the setting and/or skills/qualifications of
practitioners on intervention effectiveness.
l Assess evidence regarding the acceptability and feasibility of sleep disturbance interventions.
l Describe the settings in which sleep disturbance interventions are being delivered, and by whom.
l Make recommendations, when appropriate, with respect to the management of sleep disturbance
among children with NDs generally and/or with respect to particular NDs.
l Identify and describe interventions that look promising and are of relevance and/or feasible to the NHS
but that have not been robustly evaluated.
l Make recommendations regarding priorities for future primary research on this topic.
Methods
We undertook a systematic review of pharmacological and non-pharmacological interventions for
non-respiratory sleep disturbance among children aged 0–18 years with NDs.
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In February and March 2016 (updated in February 2017) we searched Applied Social Sciences Index and
Abstracts, The Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews,
Conference Proceedings Citation Index, Cumulative Index to Nursing & Allied Health, Database of Abstracts of
Reviews of Effects, EMBASE, Health Management Information Consortium, MEDLINE, MEDLINE In-Process &
Other Non-Indexed Citations, PsycINFO, Science Citation Index, Social Care Online, Social Policy & Practice,
ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform and UK Clinical Trials
Gateway. The Social Care Online, Social Policy & Practice, Health Management Information Consortium,
Conference Proceedings Citation Index and PsycINFO all provide some coverage of reports and other
unpublished documents, so the available grey literature are represented in the search results. The reference
lists of relevant systematic reviews and included studies were also scanned. There were no limits on date,
language or study designs. Studies of children and young people with NDs experiencing non-respiratory sleep
disturbances were included. Studies of NHS-relevant pharmacological and non-pharmacological interventions
targeted at improving sleep in any setting with and without a comparator were eligible. For pharmacological
interventions, only randomised controlled trials (RCTs) were included. For non-pharmacological interventions,
RCTs and other study designs, with and without a comparator, were eligible. Qualitative and quantitative
studies of parents’ or children’s experiences of receiving a sleep disturbance intervention were included.
Key study characteristics and results were extracted and quality assessed independently by two researchers.
When possible, a meta-analysis was undertaken and, when feasible, subgroup analyses considering previous
interventions and NDs were undertaken. When meta-analysis was not possible, a narrative synthesis approach
was adopted. Qualitative and quantitative data on parents’ or children’s experiences of receiving a sleep
disturbance intervention were collated into themes or topic areas. A descriptive narrative of these findings
was produced.
Results
A total of 39 studies were identified: 25 RCTs and 14 before-and-after studies (one with a control group).
Sample sizes varied (range 5–244 participants). Thirteen RCTs investigated a pharmacological intervention,
namely the use of oral melatonin. Twenty-six studies investigated non-pharmacological interventions. Nine
of these evaluated parent-directed tailored interventions, eight evaluated parent-directed non-tailored
interventions and two evaluated non-comprehensive parent-directed interventions. A further seven studies
evaluated other non-pharmacological interventions: dietary interventions, n = 2; alternative medicine,
n = 1; exercise-based interventions; n = 1; weighted blankets, n = 1; faded bedtime with response costs,
n = 1; and light therapy with a daytime activities programme, n = 1.
With the exception of one study, all studies were rated as having a risk of bias. Findings from the
pharmacological interventions suggest that there was evidence of benefit with melatonin compared with
placebo. There was a statistically significant increase in diary-reported total sleep time (TST), which was the
most commonly reported outcome, with melatonin compared with placebo [pooled mean difference 29.6
minutes, 95% confidence interval (CI) 6.9 to 52.4 minutes; p = 0.01]; however, the statistical heterogeneity
was extremely high (97%). For the single melatonin study that was rated as having a low risk of bias,
the mean increase in TST was 13.2 minutes and the lower CI included the possibility of reduced sleep time
(95% CI –13.3 to 39.7 minutes). It is difficult to draw conclusions as regards the clinical effectiveness of
the non-pharmacological interventions, owing to the limited number of RCTs, the variation and range of
outcome measures and the risk of studies being underpowered to detect an effect.
Sixteen of the interventions included in the clinical effectiveness review were also investigated in terms of
their feasibility and/or acceptability and/or the parent/clinician views of the intervention. These outcomes
are referred to as ‘family experience’ data; however, such data were limited. The majority of studies used
quantitative methods to investigate family experiences of non-pharmacological interventions with the
exception of one study, which reported on difficulties with administering medication.
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Conclusions
The evidence on the management of sleep disturbances in children with NDs is limited and largely of
poor quality. There is some evidence of benefit for melatonin compared with placebo. The extent of this
benefit is uncertain and so it is not possible to make recommendations for practice. There is a range of
non-pharmacological interventions for sleep disturbance. The clinical effectiveness of these interventions
is unclear, owing to the limited number of RCTs, the heterogeneous nature of the interventions and
outcomes used and the insufficient power in studies to detect any effect.
Implications for health care
It has not been possible to draw conclusions about the clinical effectiveness of pharmacological or
non-pharmacological interventions owing to the quality of research and the lack of available evidence.
Recommendations for research
l The development of a core set of outcome measures would facilitate the evaluation of future assessments
of the impact of pharmacological and non-pharmacological interventions for sleep disturbance.
l Further exploration of existing tools, practices and strategies to identify sleep problems in children with
ND disorders in routine practice would be beneficial.
l Trials comparing slow-release and fast-release melatonin may be useful.
l Further investigation of combined or sequential use of melatonin (or other pharmacological
interventions) and parent-directed interventions is suggested.
l Trials evaluating parent-directed interventions are needed. They should include an exploration of
intervention feasibility and acceptability. Interventions addressing sleep initiation should be prioritised.
l Evaluations of low-intensity parent-directed interventions – evaluated to date in children with
recognised sleep disturbance – as preventative interventions are recommended.
l Research that maps current practices and explores families’ understanding of sleep disturbance, and
their experiences of obtaining help, is suggested in order to inform developments in service provision.
l All studies should seek to include a health economics evaluation.
Study registration
This study is registered as PROSPERO CRD42016034067.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Introduction
This project was undertaken in response to a commissioning brief from the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme. The call was for a systematic review to
address the question of which interventions – pharmacological and non-pharmacological – are clinically
effective for non-respiratory sleep disturbances in children with neurodisabilities (NDs) and which have
generalisable, as opposed to disorder-specific, effects. The brief requested a broad systematic review
to ‘take stock’ of the current evidence that is available on what works and for whom and to identify
promising interventions for future primary research. The following two sections describe the definitions
used to identify the scope of the review; we then move on to discuss, specifically, the issue of sleep
disturbance in children with NDs.
Sleep disturbance
Sleep has been described as an active ‘restorative process’1 and is essential for optimal physical and
mental functioning and well-being. It is a complex process: the timing, duration and quality of sleep is
the outcome of the interplay of biological processes, socioenvironmental influences and behaviours.
As a result, there is a wide range of reasons why an individual’s sleep may be affected in some way and,
for children with NDs, the cause may be multifactorial.2–9
The International Classification of Sleep Disorders – Third Edition (ICSD-3)10 lists the current diagnostic
categorisation of sleep disorders as follows: insomnia, sleep-related breathing disorders, central disorders
of hypersomnolence (e.g. narcolepsy), circadian rhythm sleep–wake disorders, parasomnias, sleep-related
movement disorders and ‘other sleep disorders’.
The extent to which sleep is disturbed, or interrupted, is a diagnostic criterion for insomnias and circadian
rhythm sleep–wake disorders. That said, it is accepted that there needs to be room for clinical judgement
regarding the clinical significance of the extent of sleep disturbance.11
However, although the ICSD-3 provides a classification and diagnostic framework, it is important to note
that, in paediatric research at least, very few studies actually use the ICSD-3 criteria to define or screen
research participants.12,13 Instead, in both the clinical and research literature, a number of different phrases
are used to describe the manifestations of a sleep disorder in terms of the impact that it has on an
individual’s sleep: sleep disturbance, sleep problems and sleep difficulties.2 Such terms have all been used
for issues related to falling asleep (i.e. sleep initiation) and staying asleep, as opposed to night wakings or
very early waking (i.e. sleep maintenance). The scope of this review was guided by the commissioning
brief, which made two clear specifications: it should be concerned with ‘non-respiratory sleep disturbance’
and sleep disturbance (experienced by the child and/or parent) should be a feature of the presenting
problem. The ICSD-3 classification was use to specify sleep disorders that were relevant, or not, to the
review. Three types of sleep disorder were not relevant because disturbed sleep is not a diagnostic feature,
namely sleep-related breathing disorders, central disorders of hypersomnolence (e.g. narcolepsy) and
sleep-related movement disorders. Interventions that addressed sleep disturbances that aligned with the
diagnostic features of insomnias or circadian sleep–wake cycle disorders were included. In addition,
we included parasomnias because of the potential impact that they could have on parental sleep.
However, for reasons noted above, we did not require studies to use the ICSD-3 to define or screen
participants. We briefly set out the ICSD-3 definitions of these disorders in the following sections.
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Insomnia disorders
The ICSD-3 definition of insomnia is as follows: a persistent difficulty with sleep initiation, duration,
consolidation or quality, which occurs despite adequate opportunity and circumstances for sleep and
results in some form of daytime impairment. It comprises three subcategories: (1) chronic insomnia
disorder, (2) short-term insomnia disorder and (3) other insomnia disorders. In children, chronic insomnia
also includes behavioural insomnia disorders, the aetiology of which is located in the practices of parents
around bedtime/settling and responding to night/early-morning wakings.12 Behavioural insomnias are
common in childhood, with an even higher prevalence among children with NDs.14
Circadian rhythm sleep–wake disorders
Circadian rhythm sleep–wake disorders are characterised by abnormalities in the length, timing and/or
regularity of the sleep–wake cycle relative to the day–night cycle. It is caused by genetic, neurological or
visual pathway damage/disorders affecting circadian rhythms, including melatonin release.14,15
Parasomnias
Parasomnias were included in the review because of the impact that they have on parents’ sleep. The
ICSD-3 defines parasomnias as sleep-related occurrences that represent undesirable physical or cognitive
experiences (e.g. sleep terrors, sleep walking) occurring out of sleep, during the transition from sleep to
the awake state or from the awake state to sleep. They are more common in children than in adults.16
Childhood neurodisability
A consensus definition offered by Morris et al.17 defines NDs as:
. . . congenital or acquired long-term conditions that are attributed to impairment of the brain and/or
neuromuscular system and create functional limitations.
A wide range of conditions fall under this definition, including cerebral palsy, autism spectrum disorder
(ASD), Down syndrome and other chromosome disorders, epilepsy, attention deficit hyperactivity disorder
(ADHD), neurometabolic degenerative conditions (e.g. Batten disease), genetic disorders (e.g. Rett
syndrome), as well as non-specific diagnoses such as ‘learning/intellectual disability’ and ‘developmental
delay’. The involvement of the brain and/or neuromuscular system means that children can experience a
range of impairments (e.g. sensory, learning, physical/motor function and speech and language) and
health complications or clinical needs (e.g. respiratory, orthopaedic, gastroenterological and pain
management). The severity of impairment can range from mild to profound. The fact that it is not
uncommon for some conditions to co-occur adds to the complexity and severity of impairment. It is not
surprising, therefore, that many children with NDs are frequent users of the health service at all levels:
community, primary care inpatient and outpatient settings.18
In terms of epidemiology, some NDs are quite common (e.g. autism affects ≈1 in 100 children, cerebral
palsies affect ≈1 in 400 children and severe intellectual disabilities affect ≈3 in 1000 children). However,
also within this ‘cluster’ of conditions are very rare syndromes [e.g. tuberous sclerosis (incidence of < 1 in
100,000) and ataxia telangiectasia (incidence of < 1 in 40,000)].19 Estimates of the overall prevalence of
ND among the child population in England vary depending on the measure/indicator used and all are
flawed in some way. However, it is generally accepted that ≈4 in 100 children have a ND and that children
with NDs constitute the largest group of disabled children.19
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Sleep disturbances in children with neurodisabilities
Sleep disturbances in children with NDs are more common and more severe than in children with typical
development.14,15 However, non-respiratory sleep disturbance is very rarely a diagnostic criterion. Indeed,
this is the case only with respect to four conditions: Rett syndrome, Angelman syndrome, Smith–Magenis
syndrome and Williams syndrome.20
The impacts of sleep disturbance
Sleep disturbance can have an impact on all members of the family: the child and their parents and
siblings. Indeed, often it is the parents’ own sleep deprivation or poor sleep quality that precipitates them
to seek help with their child’s sleep.9,21 Child sleep problems are associated with poor outcomes for
parents, such as heightened levels of parental stress and irritability,22,23 and for children, including poorer
educational progress and daytime behaviour problems.24 These outcomes in themselves increase demands
on statutory services, as well as creating further additional support needs, such as respite care.25,26 The
wider association between sleep quality and economic consequences has also been described.27,28 Parents
consistently highlight the need for support with their child’s sleep problems,29,30 although, historically, little
time has been allocated to training the relevant professionals to provide this kind of support.31 Parents,
practitioners and other stakeholders agree that research on sleep management interventions is a priority
with respect to children with NDs.32
Interventions for non-respiratory sleep disturbance
Interventions to address sleep disturbance among children with NDs examine both pharmacological and
non-pharmacological approaches.
Pharmacological interventions act on an aspect of the physiological processes of sleep and/or the timing of
the sleep–wake cycle; the most frequently used interventions are melatonin (a hormone playing a key role
in the timing of the sleep–wake cycle), clonidine (which inhibits noradrenaline activity and hence has a
soporific effect) and antihistamines [which inhibit neurotransmitters (histamines) that are involved in
wakefulness/alertness].33–35 All are prescribed ‘off-label’. Other pharmacological interventions are used in
relation to children’s sleep, such as medications to manage seizures and pain; however, these are outside
the scope of this review because the primary purpose of the intervention is not sleep disturbance.
Non-pharmacological interventions address other causes of disturbances in sleep initiation, maintenance
and/or scheduling and are wide-ranging in approach. Interventions that are available within and/or outside
the NHS include:
l behavioural and cognitive behavioural interventions – addressing behavioural aspects of sleep including
parents’ management of sleep behaviours and routines
l chronotherapy – intervening in the timing of sleep within the 24-hour cycle
l phototherapy (or ‘bright light therapy’) – using light exposure to effect changes in the circadian rhythm
l dietary interventions – removing stimulants and restricting to hypoallergenic food
l sensory interventions, including weighted blankets36 and ‘safe space’ bed tents37
l cranial osteopathy38
l changing the bedroom environment, for example by removing any televisions or other stimulatory
materials and adjusting heating and/or lighting.
Current guidance on the management of sleep disturbance in children advocates that once clinical (e.g.
pain or seizures) or respiratory reasons for sleep disturbance are excluded, behavioural approaches that seek
to change parents’ responses to sleep-related problems should be the ‘first port of call’ for any child,33,39–41
with pharmacological intervention (and to date, this is typically melatonin) suggested in cases in which such
approaches prove ineffective, which should be used alongside behavioural parent-directed approaches.2,42
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The justification for this is that, in common with children with typical development, the origins of sleep
difficulties for many disabled children are behavioural, located in the way in which parents address and
manage their child’s sleep.4,43,44 The intensity of behavioural intervention depends on the complexity
of the sleep problem and/or child/family-centred factors. Sleep problems that cannot be resolved through
low-intensity approaches (e.g. simple information leaflets, verbal information/guidance during a routine
appointment, one-off ‘sleep management workshops’) may require a more tailored and sustained approach
involving a detailed assessment of the sleep problem, the creation of a bespoke sleep management strategy
(based on behaviour modification principles) and time-limited (typically face-to-face) support as parents
implement the strategy. In recent years, there has also been an increasing interest in using groups, as
opposed to a series of one-to-one sessions, to deliver behavioural sleep support to parents.45 Furthermore,
online ‘self-directed’ sleep management interventions for adults are now available (e.g. Sleepio.com), and
the management of sleep disturbance also appears within the curricula of newly available online parenting
interventions for parents of children with typical development and disabilities (e.g. Stepping Stones Triple P).
Constrained resources and wider changes in the way in which health care is delivered mean that it is likely
that these newer modes of delivering behavioural sleep management intervention, such as groups and
self-management, will increasingly be considered and used by clinicians and parents.46 It was important,
therefore, that this review examined evidence of the impact that the mode of delivery has on outcomes.
The availability of sleep interventions and the organisation of sleep
disturbance services
A number of different services deliver a sleep management intervention to children with NDs. They include
community paediatric teams, general practitioners, health visitors, specialist paediatric neurology/autism/
ADHD services, child and adolescent mental health services and tertiary sleep services. Within the UK,
third-sector organisations (e.g. Sleep Scotland, Scope, the Children’s Sleep Charity) are also highly active in
this area. Such organisations offer education/training to parents and professionals on sleep and behavioural
approaches to managing sleep difficulties, as well as sleep intervention services. Some NHS trusts are
commissioning services of this kind from third-sector organisations such as these.
Although there has been no systematic analysis of the way that sleep disturbance in children with NDs is
managed by the NHS, a recent survey of paediatricians by the British Paediatric Respiratory Society led to the
conclusion that services for sleep disorders in children were ‘chaotic and unplanned . . . often unfunded and
frequently perceived as inadequate for local needs’.47 Current practice in prescribing medicines such as
melatonin has been described as haphazard48 and access to behavioural interventions as patchy.49
There are a number of reasons for this current state of affairs, including the apparent absence of education on
sleep disorders and sleep management in medical school education,50 a lack of recognition of the importance of
assessing/checking for sleep disturbance, lack of knowledge/skills or resources to deliver non-pharmacological
interventions, parental expectations regarding their child’s sleep, the complexity and range of conditions falling
under the umbrella of NDs and the complexity of sleep disturbance and its potential causes. In addition,
although there have been some attempts to develop sleep management pathways within paediatrics, these
have been restricted to particular types of sleep disturbance and/or sleep intervention and/or diagnostic groups,
for which the evidence is more plentiful and/or of higher quality.47,51,52
Informing the development of a robust evidence base
A robust evidence base is clearly required to inform the development of a paediatric ND sleep management
pathway for non-respiratory disturbance that integrates pharmacological and non-pharmacological
interventions. A first step towards this, as noted in the commissioning brief, is to ‘take stock’ of the existing
evidence base. Our preliminary scoping found that previous systematic reviews have mainly focused on
either individual NDs51,53–57 and/or single interventions or pharmacological interventions only.7,53,56,57
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
Three reviews that included pharmacological and non-pharmacological interventions were restricted by type
of population: children with ASDs,51 children aged 0–12 years with cerebral palsy or traumatic brain injury58
and children with ADHD.54 One review with a wide population of chronic health conditions in patients
aged up to 19 years (including NDs) investigated non-pharmacological interventions (behavioural and non-
behavioural);1 another review of behavioural interventions focused on disabled children aged up to 8 years.59
The search end dates for the previous reviews we identified ranged from 2004 to 2013. None of the previous
reviews addressed the research question in the commissioning brief and a new review was considered
appropriate.
Given the complexity of sleep disturbance in children with ND, and in contrast to previous reviews, it was
essential that our review evaluated pharmacological and non-pharmacological interventions, as much as
existing evidence allows, across the range of NDs and age groups. This allows identification of evidence
gaps, as well as the accumulation of knowledge on which sleep disturbance interventions work (solely or
in combination with other interventions) and for whom they work within the diverse population of children
with NDs.
Aims and objectives
There were two overarching aims of this review: (1) to identify the implications for practice for non-respiratory
sleep disturbance in children with NDs, evidence permitting, and (2) to inform the focus and priorities of
a future call by NIHR for primary research in this area. Unlike previous systematic reviews, we have sought
to be holistic in terms of both the population (all children with a ND) and the types of intervention
(i.e. pharmacological and non-pharmacological). The objectives were to:
l evaluate and compare the clinical effectiveness of different intervention approaches to sleep
disturbances for children with NDs and, when possible, to:
¢ examine whether or not intervention clinical effectiveness differs for different types of ND, different
causes of sleep disturbance and different types of sleep disturbance (i.e. sleep initiation, sleep
maintenance and sleep scheduling)
¢ review and evaluate evidence regarding the use of more than one intervention approach,
sequentially or in combination, to manage a specific cause of sleep disturbance
¢ review and evaluate evidence regarding the impact that the setting and/or skills/qualifications of
practitioners have on intervention clinical effectiveness
l describe and compare evidence regarding the acceptability and feasibility of sleep disturbance
interventions
l describe the settings in which sleep disturbance interventions are being delivered, and by whom
l make recommendations, when appropriate, with respect to the management of sleep disturbance
among children with ND generally and/or with respect to particular NDs
l identify and describe interventions that look promising and are of relevance to and/or feasible for the
NHS but that have not been robustly evaluated
l make recommendations regarding priorities for future primary research on this topic
l disseminate the findings in a timely and effective way.
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Chapter 2 Methods
This systematic review was undertaken in accordance with Systematic Reviews: CRD’s Guidance forUndertaking Reviews in Health Care60 and reported in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses.61
The review protocol was published prospectively and was registered with PROSPERO as CRD42016034067
(see www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=34067??).
Inclusion and exclusion criteria
Studies were assessed for eligibility based on the criteria detailed in the following sections.
Population
Studies of children and young people with NDs who were experiencing non-respiratory sleep disturbances
were eligible for inclusion in the review.
l Children and young people aged from 0 to 18 years were eligible. We did not expect to find many
studies targeted at very young infants. Some previous reviews have used a lower age cut-off point
of 3 months and others have not. Given the comprehensive nature of the review, we did not use a
lower age cut-off point. ND was defined in accordance with the consensus definition developed by
Morris et al.:17
. . . congenital or acquired long-term conditions that are attributed to impairment of the brain
and/or neuromuscular system and create functional limitations.
l Non-respiratory sleep disturbances, of any duration, related to the initiation, maintenance or scheduling
of sleep, diagnosed by a health-care professional based on parental/carer or child report or sleep
observation were eligible.
l Excluded non-respiratory sleep disorders were central disorders of hypersomnolence (in which daytime
sleepiness is not caused by nocturnal sleep disturbance or misaligned circadian rhythms) and
sleep-related movement disorders.
We excluded studies of respiratory-related sleep disturbances. However, NDs are complex conditions
and sleep disturbances may have multifactorial causes. Therefore, we included studies in which the
respiratory-related component was being controlled and the focus of the intervention was another cause
of sleep disturbance. We also excluded studies in which the main focus of the intervention was not
treatment of the sleep disturbance (e.g. interventions to control seizures when sleep outcomes were also
reported) and studies of mixed populations of children with and without a ND, unless the results were
reported separately for the two groups or the sample was predominantly (> 90%) children with a ND.
Intervention
NHS-relevant pharmacological and non-pharmacological interventions targeted at improving sleep initiation,
maintenance, scheduling or sleep quality in any setting were eligible for inclusion. For pharmacological
studies, ‘NHS relevant’ was defined as relating to drugs that are licensed for use for this indication in
children or that are currently used for this purpose in the NHS. For non-pharmacological studies, ‘NHS
relevant’ was defined as those interventions meeting current practice standards; for example, behavioural
interventions that used punishment were excluded. Multicomponent interventions were eligible.
The NHS-relevant pharmacological interventions were melatonin, clonidine and antihistamines.
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The NHS-relevant non-pharmacological interventions included (but were not restricted to):
l behavioural interventions delivered in a range of settings such as primary, secondary and tertiary or
community, outpatient or inpatient that were delivered in groups or to individual children/families by
health-care professionals
l self-help booklets, web-based packages and other online support
l behavioural/cognitive–behavioural interventions addressing behavioural aspects of sleep, including
parents’ management of sleep behaviours and routines
l chronotherapy – intervening in the timing of sleep within the 24-hour cycle
l phototherapy (or ‘bright light therapy’) – using light exposure to effect changes in the circadian rhythm
l dietary interventions – removing stimulants, restricting to hypoallergenic food
l sensory interventions, including weighted blankets and ‘safe space’ bed tents
l cranial osteopathy
l changing the bedroom environment, for example by removing any televisions or other stimulatory
materials and adjusting heating and/or lighting.
Comparator
Studies using no intervention, waiting list control, placebo or another NHS-relevant intervention were
eligible for inclusion.
Outcomes
The following outcomes were assessed.
Primary outcomes:
l child’s sleep-related outcomes – parent-/carer- and child-reported outcomes relating to the initiation,
maintenance, scheduling or quality of sleep (using measures such as sleep diaries, standardised scales,
e.g. the Composite Sleep Disturbance Index or Epworth Sleepiness Scale) and objective measures such
as actigraphy (used to calculate outcomes such as total sleep duration, time taken to fall asleep or
sleep efficiency)
l parent sleep-related outcomes – quality of sleep
l measures of perceived parenting confidence and/or efficacy and/or understanding of sleep/sleep
management (which are particularly relevant for parent training/behavioural interventions that seek to
change the way that parents manage sleep disturbance).
Secondary outcomes:
l child-related quality of life, daytime behaviour and cognition
l parent/carer quality of life and well-being, including global quality of life (e.g. Short Form questionnaire –
36 items) and more specific outcomes such as physical well-being, mental well-being, and mental health
(e.g. stress, depression)
l family functioning
l adverse events, including side effects from medication.
Data on uptake of the intervention, retention and intervention adherence were used as indicators of the
acceptability and feasibility of the intervention. Quantitative or qualitative data on parents’/children’s
experiences of receiving a sleep disturbance intervention included:
l the acceptability and feasibility of the intervention
l other experiences of receiving the intervention
l satisfaction with intervention outcomes and ‘fit’ with their priorities with regard to their child’s sleep
disturbances; views/perspectives on the mechanisms by which outcomes were achieved.
METHODS
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Study design
Randomised controlled trials (RCTs) and non-randomised controlled studies, such as controlled before-and-
after studies and cohort studies with a control group, were included. Both parallel and crossover RCTs
were eligible for inclusion. Concerns have been expressed by others that a crossover design may be
inappropriate owing to uncertainty about the duration of the effect of interventions on sleep patterns and
circadian rhythm and, therefore, on the most appropriate duration for the washout period.48 We agree
with these concerns. However, given that the aim was to undertake a broad review and, as there were
few RCTs likely to be available, we included crossover studies.
In order to achieve the second objective of the review, studies without a control group were included in
the absence of controlled studies, that is, cohort studies and before-and-after studies. This was because
they could include potentially promising interventions that were at an early stage of evaluation. Case
studies were not eligible for inclusion.
Qualitative and quantitative studies were included if they reported data on parents’ or children’s
experiences of receiving a sleep disturbance intervention (including intervention acceptability), such as the
process of receiving the sleep intervention, satisfaction with intervention outcomes and ‘fit’ with their
priorities with regard to their child’s sleep disturbances, and views/perspectives on the mechanisms by
which outcomes were achieved. Data could be collected as part of studies of clinical effectiveness or
studies that only sought to examine research questions on experiences and satisfaction.
Literature searches
The available evidence was identified by carrying out systematic searches of electronic databases, and
reference checking of relevant reviews and included studies. The list of included studies identified from the
electronic searches was shared with clinicians in the team to establish if there were any relevant studies
that were missing. The searches were undertaken by an experienced information specialist and the search
strategy was peer reviewed by a second information specialist.
Information sources
A range of databases were searched in February and March 2016 and updated in February 2017 to
ensure coverage from the fields of health, nursing and allied health, and social care. We searched Applied
Social Sciences Index and Abstracts (ASSIA), The Cochrane Central Register of Controlled Trials (CENTRAL),
Cochrane Database of Systematic Reviews, Conference Proceedings Citation Index, Cumulative Index to
Nursing & Allied Health, Database of Abstracts of Reviews of Effects, EMBASE, Health Management
Information Consortium, MEDLINE, MEDLINE In-Process & Other Non-indexed Citations, PsycINFO,
Science Citation Index, Social Care Online and Social Policy & Practice.
The Social Care Online, Social Policy & Practice, Health Management Information Consortium, Conference
Proceedings Citation Index and PsycINFO all provide some coverage of reports and other unpublished
documents; therefore, the available grey literature are represented in the search results.
In addition, ClinicalTrials.gov, the World Health Organization (WHO) International Clinical Trials Registry
Platform and the UK Clinical Trials Gateway were searched for trials, both ongoing and completed. No limits
on date, language or study design were applied in the searches. Full details of search strategies used and
numbers of records retrieved are given for each database in Appendix 1.
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While the search results were being scanned, some additional search terms that had not been included in
the original search strategies were identified. Consequently, we carried out some further searches of each
of the databases that incorporated these new terms alongside the original search strategy. Details of these
additional search strategies can be found in Appendix 2.
The reference lists of relevant systematic reviews and included studies were also scanned.
Screening and study selection
The database search results were all loaded into EndNote bibliographic software [version 17.0.2.7390,
Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA] and deduplicated.
There was a three-stage screening process to manage the large number of records. First, the titles of
the records were screened for relevance. Two researchers did this jointly for 10% of the titles, and the
remainder were screened independently by a single researcher. Records that were identified as potentially
relevant based on their title were screened independently by two researchers. When there was no
consensus, a third member of the team was consulted. The full texts of potentially relevant papers were
ordered. Finally, full papers were independently screened against the eligibility criteria by two researchers.
Disagreements were resolved by consensus or by consultation with a third team member if necessary.
Data extraction
A data extraction form for study details was developed and piloted. A Microsoft Excel 2010® spreadsheet
(Microsoft Corporation, Redmond, WA, USA) was used to extract the outcome data. Owing to the various
ways in which adverse events were described in papers, data for this outcome were extracted separately
into a table using Microsoft Word 2010® (Microsoft Corporation, Redmond, WA, USA). All data were
extracted by one researcher and checked by a second. Details of the data items extracted are available in
Appendix 3. For the purposes of this review, we extracted follow-up data relating to the assessment time
point closest to the end of the intervention.
Assessment of risk of bias
The Cochrane risk of bias tool62 was used to assess the quality of RCTs and the newly developed tool,
A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI),
was used to assess the non-randomised controlled before-and-after studies.63 Uncontrolled before-and-
after studies were assessed using questions adapted from ACROBAT-NRSI, as used in another HTA
review.64 Risk of bias was independently assessed by two researchers. Disagreements were resolved
through consensus and through discussion with a third researcher if necessary. In addition, for crossover
trials, we assessed whether or not an appropriate analysis using paired data was conducted and whether
or not there was a treatment by period interaction, as undertaken in a previous systematic review including
crossover studies.65
A summary risk-of-bias score was calculated following guidance.62 This score was calculated as follows: any
study that had one or more of the domains on the risk-of-bias tool classified as ‘no’ was considered to be
rated as having a high risk of bias. Any study that had one or more domains classified as ‘unclear’ on the
risk-of-bias tool was considered to be rated as having an unclear risk of bias. To be considered to have a
rating of a low risk of bias, a study needed to meet the criteria on all domains on the risk-of-bias tool and
classify them as ‘yes’.
METHODS
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For studies containing qualitative and quantitative data on parents’ and/or children’s satisfaction with the
intervention, take-up, retention and adherence to the intervention and experiences of the intervention,
the quality of the study was assessed and reported using the quality appraisal checklist of Hawker et al.66
It was not possible to blind the types of non-pharmacological interventions and comparators used in the
studies under consideration. In addition, owing to the nature of the outcomes measured, robust, blinded
outcome assessment was difficult. Although actigraphy-based child sleep outcomes are more objective
than parent-reported measures, we did not consider these to be true objective outcomes, with
non-blinding unlikely to introduce bias. Therefore, all of the measures were regarded as having the
capacity to be influenced by lack of blinding.
Analysis
The synthesis aimed to:
1. Assess the clinical effectiveness of the interventions for sleep disturbance, in particular interventions that
may work across conditions.
2. Inform future research by identifying gaps in the evidence and identifying interventions that are the
most promising front runners to be considered for future primary research.
First, narrative and tabular summaries of key study characteristics were undertaken. This allowed a
mapping of which interventions have been investigated for which ND and for which type of sleep
disturbance (e.g. sleep initiation) in order to identify interventions that have been investigated across
conditions. We also mapped information on the feasibility and acceptability of each of the interventions.
Synthesis involved paired meta-analyses and narrative synthesis.
Meta-analyses
Pharmacological intervention studies
When sufficient data for our primary and secondary outcomes were available, they were pooled in
quantitative synthesis using a random-effects model (for continuous outcomes). As data sets often
included both parallel and crossover trials, or just crossover trials, data were pooled using the generic
inverse variance method in RevMan version 5 (The Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark).67 Only crossover trials with a washout period were included in meta-analyses, for
which data from both treatment periods were used. For trials without a washout period, we considered
using data from the first period only; however, in the event, this was not possible, as data summaries were
not provided by treatment period for these trials.
The recommendations provided in the Cochrane handbook were followed as closely as possible.68
The mean difference (MD) between melatonin (M) and placebo (P) at the end point was either taken
as reported in the article or calculated as the difference in means for each group/period:
MD =meanM − meanP. (1)
When a 95% confidence interval (CI) for the group means was presented instead of a standard deviation
(SD) (e.g. Garstang and Wallis69), the SD was calculated using the formula:
SD =
ffiffiffiffi
N
p
× (upper confidence limit− lower confidence limit)/(2 × t − value), (2)
where the t-value was obtained by entering = tinv(1–0.95, N-1) in a cell in a Microsoft Excel spreadsheet.
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For the crossover trials, when only means and SDs for the measurements of the intervention (melatonin)
and the control (placebo) were available, the SD of within-participant differences between M and P
measurements was estimated using the formula:
SDdiff =
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2M + SD
2
P − (2ρSDMSDP).
q
(3)
The correlation coefficient ρ was estimated from other studies reporting all three SDs for the same
outcome or by using 0.5 when no other studies were available to use.
The standard error (SE) of the MD was calculated using:
SE (MD) = SDdiff/
ffiffiffiffi
N
p
, (4)
where N is the sample size, or by dividing the MD by the t-statistic when this was presented for a
two-sample t-test of the period differences (e.g. Weiss et al.70).
To transform the parallel-group trial data for entry into the generic inverse variance facility, a two-sample
t-test was conducted to calculate the unadjusted difference (and SE of the MD) between the groups at
follow-up (post intervention) using raw group summary data (N, mean and SD).
Statistical heterogeneity between trials was assessed using the I2 statistic.71 Two sources of potential
clinical and methodological heterogeneity were identified for the pharmacological intervention trials,
and subgroup analyses were conducted based on these, when appropriate:
1. type of neurological disorder – population primarily with ASD
2. receipt of prior intervention – whether or not participants were offered an additional intervention prior
to the start of the study.
The risk of publication bias was not formally assessed.
When data could not be pooled, summaries of the findings for each trial and outcome are presented with
a (estimated unadjusted) MD and 95% CI between melatonin and control at follow-up.
Adverse event data are summarised narratively.
Non-pharmacological intervention studies
Non-pharmacological intervention studies included parallel-group RCTs and before-and-after studies.
Owing to insufficient data for each outcome and/or significant heterogeneity in study design and
intervention, data were not pooled in meta-analyses. Narrative and quantitative summaries of the findings
for each trial and outcome are presented. For continuous data in the RCTs, the preferred choice was
difference in end-point data; however, when a (estimated unadjusted) MD between intervention and
control at follow-up could not be calculated, the difference in change scores from baseline to follow-up
was presented instead.
We had planned to undertake a mixed-treatment comparison of the multiple treatment options;72
however, this was not possible owing to the paucity of RCTs for interventions other than melatonin.
Adverse event data are summarised narratively.
Narrative synthesis
Although we planned to undertake separate quantitative and qualitative syntheses, this was to a large
extent not possible, as few studies could be pooled. With the exception of the melatonin trials, there was a
large degree of variability between studies evaluating different classes of interventions. For example, for
METHODS
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behavioural interventions, there was wide variability in aspects of the interventions such as mode of delivery,
duration and intensity of interventions, as well as in the comparators used. There was also variability in
the conditions being studied, outcomes reported and the measures used to assess individual outcomes,
follow-up times and types of data reported. Consequently, there were few instances in which it became
appropriate to pool the data. Thus, it became necessary to adopt a principally narrative synthesis to report
the findings. We present a narrative synthesis as our main analysis, with comparisons made for melatonin
versus placebo, which were the only interventions that we judged could be appropriately compared.
Narrative synthesis was undertaken when quantitative synthesis was not appropriate or there were
insufficient data, and applied mainly to the non-pharmacological interventions. When possible, we display
outcomes in a forest plot, even when studies are not statistically pooled, to aid exploration of study results.
When feasible, we investigated the subgroup characteristics outlined previously. Non-pharmacological
studies were grouped by type of intervention (i.e. comprehensive parent-directed tailored, comprehensive
parent-directed non-tailored or non-comprehensive) and comparator if heterogeneous. We explored
outcomes by type of sleep disturbance with the aim of identifying effects that may be transferable to other
NDs. Results are discussed in the context of ratings of risk of bias in the individual studies.
In terms of the qualitative data analysis, the topic areas that were subject to review were well defined;
we therefore adopted a thematic approach to data extraction, analysis and synthesis.60,73 To start, studies
were grouped into pharmacological, behavioural and other non-pharmacological studies. For each,
a descriptive report of relevant studies, and topic areas covered, was produced. The tabulated data were
then scrutinised and analytical notes were made that summarised findings across studies with respect to
the topic areas. Part of this process involved testing for contradictions in the evidence.74
The synthesis interrogated such data, when available, to assist in identifying interventions that could be
generalisable across conditions and those that are condition specific.75,76 Factors taken into consideration
in identifying promising interventions included feasibility of delivery of the intervention in a NHS setting,
acceptability to children and families, evidence of clinical effectiveness or in the direction of clinical
effectiveness based on CIs (taking into consideration the clinical significance of the estimates).
Protocol changes
During the course of the review, we identified numerous RCTs for the melatonin studies. We therefore
decided to include only RCTs for this intervention. For all other interventions, we have included any design
except case studies, as per the original protocol. Some studies reported multiple case studies that were not
eligible for inclusion in the review. We made the decision to exclude uncontrolled studies with fewer than
10 participants.
Patient and public involvement
Three parents of children with NDs (two mothers, one father) acted as project advisors. They were
recruited from a permanent parent consultation group of the chief investigator’s research unit. These
parents were invited to the project team meetings, which were held three times over the course of
study and were attended by the research team and all co-applicants. Each parent attended at least one
meeting. They were also consulted, via e-mail, regarding the implications of the findings of the review.
The children’s diagnoses included autism and rare, genetic conditions. At the first meeting, an early item on
the agenda was a presentation of an overview of systematic reviews as a research method. Throughout the
meetings, the parents were encouraged to share their experiences and opinions, and their contributions
provided useful contextual information.
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Chapter 3 Results
Study selection
The searches identified 23,292 records: 21,529 records were identified from the original searches
undertaken in February and March 2016, 1563 were identified from the updated searches undertaken in
February 2017, 194 were identified from trial registries and 6 were identified from subsequent reference
checking (Figure 1). After removing duplicate references, 15,745 titles were screened. On the basis of
titles, 14,420 titles were excluded; a further 937 were excluded on reading the abstract.
Full-text articles were sought for the remaining 388 records. We could not obtain full-text articles for 30 of
the records. Of these, 11 were conference abstracts that were not available in full text22,77–86 and five were
trial registry entries that were recorded as ‘complete’ but had no study results available.87–91 We contacted
the authors to check whether or not there were any publications from the trials and received one response
that the authors did not intend to publish the results as fewer than 10 participants had been recruited
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FIGURE 1 Flow chart of the study selection process.
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into the study.91 Two trials were registered as ‘terminated’ with no published results (one owing to poor
recruitment,92 and the other for unknown reasons 93 and our attempt to contact authors did not elicit a
response). One trial was registered as ‘study status unknown’94 with no published results; we contacted
the authors but received no response. Five trials were eligible but ongoing so were excluded from the
review as results were not yet available.95–99 A further six articles could not be obtained from the
British Library.100–105
A total of 358 full-text articles were, therefore, assessed, including two non-English language papers
that required translation. Of these, 117 articles (33%) were excluded because the intervention was out
of scope or sleep disturbance was not the target of the intervention, 110 (31%) were excluded based on
study design, 55 (15%) were excluded owing to the population, 6 (2%) were excluded based on the
outcomes evaluated and 5 trials (1%) identified from trial registries were related to studies that had been
completed and had already been identified through the searches and included in the review.36,48,49,106,107
Appendix 4 lists all studies excluded at full-text screening and reasons for exclusions.
Overview of included studies
There were 39 included studies reported in 64 articles. Although we sought to include studies published in
any language, all the studies meeting the eligibility criteria were published in English. The included studies
were from the UK (n = 13, 33%), the USA (n = 10, 26%), Australia (n = 6, 15%), Canada (n = 5, 13%),
the People’s Republic of China (n = 1, 2.6%), the Netherlands (n = 1, 2.6%), Hong Kong (n = 1, 2.6%),
Italy (n = 1, 2.6%) and Israel (n = 1, 2.6%).
Thirteen RCTs investigated a pharmacological intervention, which in all cases was oral melatonin
(Table 1). We did not identify any eligible pharmacological studies investigating clonidine or antihistamines.
Twenty-six studies investigated non-pharmacological interventions, of which 12 were RCTs. Of these, nine
(35%) evaluated parent-directed tailored interventions; eight (31%) evaluated parent-directed non-tailored
interventions; two (8%) evaluated non-comprehensive parent-directed interventions; and seven (27%)
evaluated other non-pharmacological interventions – dietary interventions (n = 2, 5%), alternative medicine
(n = 1, 3%), exercise-based intervention (n = 1, 3%), faded bedtime with response costs (n = 1, 3%),
weighted blankets (n = 1, 3%) and a light therapy plus a behavioural programme (n = 1, 3%). Thirteen
studies explored feasibility and/or acceptability and/or parent/clinician views of sleep disturbance
interventions.36,49,106,107,122–130
The mean age of the children included in the studies ranged from 2 to 12 years. In 16 studies (41%),
participants were described in terms of a single ND diagnosis as follows: ADHD (n = 5), autism spectrum
condition (ASC) (n = 3), ASD (n= 3), epilepsy (n = 1), tuberous sclerosis (n = 1), ‘mental retardations’ (we have
replaced this term with ‘learning disability’; this is interchangeable with the term ‘intellectual disability’) (n = 2)
and severe ND (n = 1). In 22 studies (56%), participants were reported to have two or more NDs. One study
did not report participants’ NDs. There was also a range of sleep disturbance represented in the eligible
studies. Owing to the different terminology used to describe sleep disturbances in the eligible studies, we have
classified sleep disturbance under the following headings: sleep initiation (n= 30, 77%) (e.g. sleep latency,
sleep association, settling, bedtime resistance and insomnia); sleep maintenance (n = 26, 67%) (e.g. night
waking, waking time, parasomnia, co-sleeping and sleep fragmentations) and sleep scheduling (n = 1, 2.5%)
(e.g. daytime sleepiness). Three studies (7%) reported that parents completed sleep questionnaires or
assessment tools to determine their child’s eligibility, including the Sleep Behaviour Questionnaire,131 Quine
sleep index132 and the Children’s Sleep Habits Questionnaire (CSHQ).133 Five studies (13%) did not specify the
types of sleep disturbance eligible for inclusion. Children often had multiple sleep disturbances.
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TABLE 1 Characteristics of studies of melatonin interventions
Study details and
design
Participants
randomised (total N
and by group) Trial treatments Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of
bias (low,
unclear,
high)
Melatonin vs. placebo: parallel-group RCTs
Appleton et al. (2012)48
Associated
publications:
Gringras et al.
(2012),108
Appleton et al.
(2011),109
Appleton et al.
(2012)48
UK
N = 146 (melatonin,
n = 70; placebo,
n = 76)
Melatonin: 0.5 mg, 45 minutes
before bedtime for 12 weeks
Placebo: matching capsule,
0.5 mg for 12 weeks
Melatonin and placebo dose
could be raised to 2 mg, 6 mg to
12mg in first 4 weeks then
maintained
Problems with sleep
initiation and sleep
maintenance
Melatonin:
106.0 months
(34.8 months)
Placebo:
100.7 months
(37.4 months)
DD alone, and
DD + other
Yes Low
Cortesi et al. (2012)110
Italy N = 160 (melatonin,
n = 40; melatonin
and CBT, n= 40;
CBT, n= 40; placebo,
n = 40)
Melatonin: controlled release,
3 mg at 21.00 hours for
12 weeks
CBT: four, weekly individual
sessions
Melatonin and CBT: as above
Placebo: identical tablet, 3 mg at
21.00 hours for 12 weeks
Problems with sleep
initiation and sleep
maintenance
Melatonin: 6.8 years
(0.9 years)
Melatonin and CBT:
6.4 years (1.1 years)
CBT: 7.1 years
(0.7 years)
Placebo: 6.3 years
(1.2 years)
ASD None stated High
Van der Heijden et al. (2007)111
Associated
publications:
Hoebert et al.
(2009)112
The Netherlands
N = 107 (melatonin,
n = 54; placebo,
n = 53)
Melatonin: fast release, 3 mg
(if < 40 kg), 6 mg (if > 40 kg) at
19.00 hours for 4 weeks
Placebo: identical appearing
placebo at 19.00 hours for
4 weeks
Problems with sleep
initiation
Melatonin: 9.1 years
(2.3 years)
Placebo: 9.3 years
(1.8 years)
ADHD None stated Unclear
continued
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TABLE 1 Characteristics of studies of melatonin interventions (continued )
Study details and
design
Participants
randomised (total N
and by group) Trial treatments Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of
bias (low,
unclear,
high)
Crossover trials
Camfield et al. (1996)113
Individualised ‘N of
1 crossover trials’
Canada
N = 6 Melatonin: 0.5 mg for three
cases, 1.0 mg for three cases,
taken at 18.00 hours
Placebo: identical capsule
Ten-week trial. For each of
the five 2-week intervals,
participants were randomised to
receive placebo or melatonin for
1 week with the alternate agent
given in the second week
Problems with sleep
initiation and sleep
maintenance
7.3 years (4.6 years) Mixed Yes High
Dodge and Wilson (2001)114
Associated
publications:
Hoebert et al.
(2009)112
USA
N = 36 Melatonin: 5 mg at 20.00 hours
for 2 weeks
Placebo: capsule and filler packaged
to be identical to the melatonin,
5mg at 20.00 hours for 2 weeks
Washout period: 1 week
‘Chronic sleep
problems’
89 months (NR) Mixed (mainly
cerebral palsy)
Yes Unclear
Garstang and Wallis (2006)69
UK N = 11 Melatonin: 5 mg for 4 weeks
Placebo: dose NR, for 4 weeks
Washout period: 1 week
Problems with sleep
initiation and sleep
maintenance
8.6 years (3.1 years) ASD only, and
ASD + learning
disability
Yes High
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Study details and
design
Participants
randomised (total N
and by group) Trial treatments Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of
bias (low,
unclear,
high)
Jain et al.115 (2015)
Associated
Publications: Jain
et al. (2014)116
USA
N = 11 Melatonin: sustained release,
9 mg 30 minutes before bedtime
for 4 weeks
Placebo: identical appearance to
melatonin tablets, dose NR
Washout period: 1 week
A score of > 30 on the
Sleep Behaviour
Questionnaire
8.4 years (1.3 years) Epilepsy None stated High
Wasdell et al. (2008)117
Associated
publications: Carr
et al. (2007)118
Canada
N = 51 Melatonin: controlled release,
5 mg, 20–30 minutes before
bedtime for 10 days
Placebo: identical to melatonin,
5 mg, 20–30 minutes before
bedtime for 10 days
‘Placebo washout’: 3–5 days
Problems with sleep
initiation and sleep
maintenance
7.4 years (NR) Mixed Yes Unclear
Weiss et al. (2006)70
Canada N = 23 Melatonin: short-acting, 5 mg,
20 minutes before bedtime for
10 days
Placebo: for 10 days
‘Placebo washout’: 5 days
Problems with sleep
initiation
10.3 years (NR) ADHD Yes Unclear
continued
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TABLE 1 Characteristics of studies of melatonin interventions (continued )
Study details and
design
Participants
randomised (total N
and by group) Trial treatments Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of
bias (low,
unclear,
high)
Wirojanan et al. (2009)119
USA N = 18 Melatonin: 3 mg, 30 minutes
before bedtime for 2 weeks
Placebo: 3 mg, 30 minutes
before bedtime for 2 weeks
No washout period
‘Sleep problem’ 5.5 years (3.6 years) Mixed (fragile X
Syndrome/ASD)
None stated Unclear
Wright et al. (2011)106
UK N = 20 Melatonin: standard release,
2 mg, 30–40 minutes before
bedtime for 3 months
Placebo: identical to melatonin,
2 mg, 30–40 minutes before
bedtime for 3 months
Melatonin and placebo dose
increased by 2 mg every 3 nights
to a maximum of 10mg. Taken
for 3 months
Washout period: 1 month
Problems with sleep
initiation and sleep
maintenance
9.0 years (2.9 years) Mixed (autism
and Asperger
syndrome)
Yes Unclear
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Study details and
design
Participants
randomised (total N
and by group) Trial treatments Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of
bias (low,
unclear,
high)
Melatonin vs. melatonin-crossover trials
Hancock et al. (2005)120
UK N = 8 (≤ 18 years,
n = 5)
Melatonin: 1 × 5mg plus
1 × 5-mg placebo, 30 minutes
before bedtime for 2 weeks
Melatonin: 2 × 5mg of melatonin
(10mg in total), 30 minutes
before bedtime for 2 weeks
Washout period: 2 weeks
Quine sleep index
score of at least 6
All: 12.1 years
(10.0 years)
≤ 18 years: 6.9 years
(4.0 years)
Tuberous
sclerosis
None stated High
Jan et al. (2000)121
Canada N = 16 (≤ 18 years,
n = 15)
Melatonin: sustained release,
variable doses from 2mg to
10mg, 30 minutes before
bedtime for 11 days
Control: fast-release melatonin,
variable doses from 2mg to
10mg for 11 days
No washout period
‘Chronic sleep wake
disorders’
All: 10.1 years
(4.9 years)
≤ 18 years: 9.3 years
(4.1 years)
Mixed None stated High
CBT, cognitive–behavioural therapy; DD, developmental delay; NR, not reported.
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Melatonin
Study characteristics
Table 1 is a summary of the characteristics of the melatonin studies, and Appendix 5 provides further details.
Of the 13 RCTs evaluating oral melatonin, which were undertaken in Canada, Italy, the Netherlands, the UK
and the USA, 10 compared melatonin with placebo only; one compared melatonin, cognitive–behavioural
therapy and a combination of the two with placebo; and two compared two regimens of melatonin (5 mg
vs. 10 mg, and fast release vs. sustained release). Ten were crossover trials and three were parallel-group
RCTs. Observed sample sizes ranged from 6 to 160 participants.
Assessment of risk of bias
A summary assessment of risk of bias for each RCT is provided in Table 1 and the full risk-of-bias
assessment involving each bias domain is provided in Appendix 6 and Report Supplementary Material 1.
One trial was rated as having a low risk of bias.48 The ratings of risk of bias in the remaining RCTs were
high or unclear; therefore, the findings from these studies may not be robust.
We could not locate a registered protocol for nine trials69,70,106,110,113–115,117,119 and one trial protocol was
registered retrospectively,111 making it unclear whether or not the studies were free of selective reporting.
Seven studies provided no, or little, detail regarding sequence generation;70,106,111,113,114,117,119 and four
studies provided little or no detail regarding allocation concealment.110,113,114,119 For three studies, how
blinding was undertaken was unclear.69,70,113 In three studies, the analysis of incomplete outcome data was
not considered69,110 or was unclear.114
Melatonin versus placebo
Eleven trials (n = 589 randomised participants) compared melatonin with placebo: eight crossover
trials,69,70,106,113–115,117,119 two two-armed parallel-group trials,48,111 and one four-armed trial of oral melatonin,
cognitive–behavioural therapy, oral melatonin plus cognitive–behavioural therapy and placebo.110
The washout period used by the crossover trials varied. One had no washout period,119 one had a 1-month
washout period106 and the remaining five trials had a washout period of between 3 and 7 days.69,70,114,115,117
Camfield et al.113 reported six ‘N of 1’ crossover trials with no washout period.
Six of the trials varied drug dosages depending on the child’s age and/or weight and tolerance of dosage
(see Table 1). The dose ranges were 0.5–1 mg,113 0.5–12 mg,48 3–6 mg111 and 2–10 mg.106 Fixed dosages
were 3 mg (n = 2),110,119 5 mg (n = 4)69,70,114,117 and 9 mg.115 Matched placebos were used except for in one
trial,70 in which the placebo was not explicitly described, although in this trial the authors reported that
each patient received a blister card of 30 days’ supply of medication.
The length of time that melatonin was prescribed for varied between studies: 10 days,70,117 2 weeks,114,119
4 weeks,69,111,115 5 weeks113 and 12 weeks.48,106,110
The age of participants included in these trials ranged from 1 to 18 years, although the mean age across
studies was broadly similar, ranging from 5.5 to 10.3 years (see Table 1). The ND that was represented
varied. Four trials included children with a mixed range of neurodevelopmental disabilities,48,113,114,117
three trials included only children with ASC,69,106,110 two trials included children with ADHD,70,111 one trial
included children with ASD and/or fragile X syndrome119 and one trial included children with epilepsy.115
The type of sleep disturbances reported in the participants also varied. Most trials had more than one
criterion for inclusion in the trial and included children with a mix of sleep disturbances (see Table 1)
relating to sleep initiation48,69,70,106,110,111,113,117 and sleep maintenance.48,69,106,110,113,117 However, two trials
focused on a single sleep problem (‘sleep onset insomnia’111 and ‘initial insomnia’70) and one trial required
a score of > 30 in the Sleep Behaviour Questionnaire.115 Two studies did not specify the type of sleep
problems eligible for inclusion.114,119
RESULTS
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Seven trials specified in their inclusion criteria that a preceding psychoeducational or behavioural sleep
management intervention had to have been ineffective.48,69,70,106,113,114,117 In five of these trials, guidance
on sleep was provided as part of the trial in the form of a behaviour therapy advice booklet,48 tailored
sleep hygiene advice,117 a sleep hygiene intervention,70 a sleep hygiene advice leaflet69 and behaviour
management and parenting support.106 In four of these trials, only children who continued to experience
sleep problems were randomised.48,70,106,117
Across these 11 trials, 19 sleep-related outcomes were measured (see Appendix 7). The most commonly
measured outcomes were total sleep time (TST) (n = 11), sleep onset latency (SOL) (n = 10), number of
night wakings (n = 6) and sleep efficiency (n = 5). Additional outcomes included arousals, bedtime, CSHQ,
difficulty falling asleep, sleep onset, time from drug to sleep, longest sleep episode, the Sleep Behaviour
Questionnaire, percentage of sleep stages, wake after sleep onset (WASO), nights without awakening,
wake-up time, naptime, moving time, ‘interdaily stability’, ‘interdaily variability’ and ‘L5’ (average activity
during the least active 5 hours). Definitions of outcome measures can be found in Appendix 7.
All trials had follow-up periods that commenced immediately following the completion of the intervention:
10 days,70,117 2 weeks,114,119 4 weeks,69,111,115 10 weeks113 or 12 weeks.48,106,110
Global measures and composite scores
Total sleep time
All 11 trials48,69,70,106,110,111,113–115,117,119 (n = 589 randomised participants) assessed TST (see Appendix 7); four
measured this using parent-reported sleep diaries only,69,106,113,114 whereas the remaining seven48,70,110,111,115,117,119
used both actigraphy and sleep diaries. However, of these, three report only actigraphy-measured TST
data,110,111,119 as the sleep diaries were used purely to inform, or verify, actigraphy data. This follows existing
guidance on the interpretation of actigraphy data.134 The remaining four trials48,70,115,117 reported TST derived
from both parent-completed sleep diaries and actigraphy data.
Data from seven trials using sleep diary-reported TST were pooled: six crossover trials with a washout
period (n = 122 analysed participants),69,70,106,114,115,117 and one parallel-group trial (n = 110).48 Note that in
the forest plot (Figure 2), the sample sizes presented count participants in crossover trials twice (as being in
the melatonin and placebo groups), so the figures reported in the text and shown in the figures may not
match for this reason. There was a statistically significant increase in sleep diary-reported TST with melatonin
compared with placebo (pooled MD 29.6 minutes, 95% CI 6.9 to 52.4 minutes; p = 0.01; see Figures 2
and 3). Statistical heterogeneity was high (I2 = 97%) and this treatment effect is unlikely to be generalisable,
although the effect estimates were all in the direction of benefit with melatonin. Heterogeneity was reduced
when studies were stratified based on whether or not the study population was exclusively ASD or not (test
for subgroup differences: p < 0.001; I2 = 99%); there was a pooled MD of 64.7 minutes (95% CI 58.8 to
70.7 minutes, I2 = 0%) for the studies of ASD (n = 24), and a smaller pooled MD of 15.9 minutes (95% CI
9.2 to 22.6 minutes, I2 = 31%) for the studies of mixed or other populations (n = 208). There was only a
single study (n = 9) in which participants had no prior sleep hygiene or behavioural intervention limiting the
usefulness of this subgroup analysis; the overall results did not substantially change with removal of this
study (pooled MD 33.0 minutes, 95% CI 8.6 to 57.4 minutes, n = 223; Figure 3). When the single trial rated
as having a low risk of bias is considered alone, the increase in sleep time with melatonin was 13.2 minutes
(95% CI –13.3 to 39.7 minutes).48
The study of six ‘N of 1’ trials in six participants also reported sleep diary TST but, owing to the unusual
trial design, could not be included in the meta-analysis.113 The authors reported no ‘notable difference in
sleep pattern or daytime behaviour between melatonin and placebo weeks’113 and provided raw data for
each participant. From this, we calculated the MD between melatonin and placebo for parent-reported TST
to be 13.9 minutes in favour of the melatonin group (95% CI –6.8 to 34.6 minutes; p = 0.14).
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– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CI
Melatonin Placebo
Study first author MD SE Weight
65.40 (59.32 to 71.48)
52.30 (26.04 to 78.56)
64.73 (58.81 to 70.65)
ASD
Garstang (2006)69
Wright (2011)106
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.91, df = 1 (p = 0.34); I2 = 0%
Test for overall effect: z = 21.43 (p < 0.00001)
65.4
52.3
3.1
13.4
7
17
24
7
17
24
15.5%
13.0%
28.5%
13.20 (– 13.26 to 39.66)
18.00 (– 7.87 to 43.87)
11.30 (5.43 to 17.18)
31.20 (15.91 to 46.49)
15.00 (5.59 to 24.41)
15.87 (9.15 to 22.59)
Not ASD
Appleton (2012)48
Dodge (2001)114
Jain (2015)115
Wasdell (2008)117
Weiss (2006)70
Subtotal (95% CI)
Heterogeneity: τ2 = 17.61; χ2 = 5.80, df = 4 (p = 0.21); I2 = 31%
Test for overall effect: z = 4.63 (p < 0.00001)
13.2
18
11.3
31.2
15
13.5
13.2
3
7.8
4.8
51
20
9
50
19
149
59
20
9
50
19
157
12.7%
13.0%
15.5%
14.7%
15.3%
71.5%
29.63 (6.91 to 52.35)Total (95% CI)
Heterogeneity: τ2 = 855.84; χ2 = 181.18, df = 6 (p < 0.00001); I2 = 97%
Test for overall effect: z = 2.56 (p = 0.01)
Test for subgroup differences: χ2 = 114.43, df = 1 (p < 0.00001); I2 = 99.1%
173 181 100.0%
100
Favours placebo Favours melatonin
total total
FIGURE 2 Sleep diary-reported TST: melatonin vs. placebo and ASD subgroup analysis. df, degrees of freedom; IV, instrumental variable.
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– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CI
Melatonin Placebo
Study first author MD SE Weight
13.20 (– 13.26 to 39.66)
18.00 (– 7.87 to 43.87)
65.40 (59.32 to 71.48)
31.20 (15.91 to 46.59)
15.00 (5.59 to 24.41)
52.30 (26.04 to 78.56)
33.01 (8.62 to 57.41)
Prior intervention
Appleton (2012)48
Dodge (2001)114
Garstang (2006)69
Wasdell (2008)117
Weiss (2006)70
Wright (2011)106
Subtotal (95% CI)
Heterogeneity: τ2 = 830.93; χ2 = 95.01, df = 5 (p < 0.00001); I2 = 95%
Test for overall effect: z = 2.65 (p = 0.008)
13.2
18
65.4
31.2
15
52.3
13.5
13.2
3.1
7.8
4.8
13.4
51
20
7
50
19
17
164
59
20
7
50
19
17
172
12.9%
13.0%
15.5%
14.7%
15.3%
13.0%
84.5%
11.30 (5.42 to 17.18)
11.30 (5.42 to 17.18)
No prior intervention
Jain (2015)115
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 3.77 (p = 0.0002)
11.3 3 9
9
9
9
15.5%
15.5%
29.63 (6.91 to 52.35)Total (95% CI)
Heterogeneity: τ2 = 855.84; χ2 = 181.18, df = 6 (p < 0.00001); I2 = 97%
Test for overall effect: z = 2.56 (p = 0.01)
Test for subgroup differences: χ2 = 2.88, df = 1 (p = 0.09); I2 = 65.2%
173 181 100.0%
100
Favours placebo Favours melatonin
total total
FIGURE 3 Sleep diary-reported TST: melatonin vs. placebo and prior intervention subgroup analysis. df, degrees of freedom; IV, instrumental variable.
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2
5
Five trials48,110,111,115,117 (n = 266 analysed participants) were pooled for actigraphy-measured TST, comprising
two crossover trials with a washout period (n = 60)115,117 and three parallel-group trials (n = 206).48,110,111
Weiss et al.70 used actigraphy to measure TST post intervention and reported that there was no significant
difference between melatonin and placebo, but the study did not provide data on this outcome to allow it
to be included in the meta-analysis.
There was a statistically significant increase in actigraphy-measured TST with melatonin compared with
placebo (pooled MD 31.9 minutes, 95% CI 14.8 to 49.1 minutes; p < 0.001) (Figure 4). Heterogeneity
was high (I2 = 76%) and this treatment effect is unlikely to be generalisable, although the effect estimates
were all in the direction of benefit with melatonin. There was no statistically significant difference in effect
between the studies in which participants received or did not receive a prior intervention (test for subgroup
differences, p = 0.48; I2 = 0%). Subgroup analysis by type of ND was not possible.
One study without a washout period119 (n= 12 analysed participants) reported a MD in actigraphy-measured TST
post intervention of 21 minutes between melatonin and placebo, favouring melatonin. Using non-parametric
analysis methods, the authors report p-values of 0.0019 and 0.02 for this outcome, based on data sets produced
using two different approaches for dealing with missing data (complete case and last observation carried
forward). This outcome was also analysed using a paired t-test, giving a p-value of 0.057. We have estimated the
95% CI for the MD of 21 minutes as –0.7 to 42.7 minutes.
For TST based on polysomnography at 4 weeks immediately post intervention,115 there was no significant
difference between melatonin and placebo, with a reported MD of 39.3 minutes (favouring placebo,
95% CI –34.7 to 113.3 minutes, n = 10).
Sleep efficiency
Five trials48,110,111,115,117 (n = 475 randomised participants) reported sleep efficiency (i.e. the ratio of TST to total
time in bed): one trial used both actigraphy and parent report,117 three used actigraphy data only48,110,111
and one trial used polysomnography.115
Cortesi et al.110 also measured the percentage of children who achieved a sleep efficiency in the normative
level of > 85% at the 12-week assessment.
Four trials48,110,117,135 (n = 255 analysed participants) for actigraphy-measured sleep efficiency were pooled,
comprising three parallel trials (n = 205) and one crossover trial with a washout period (n = 50). There was
no statistically significant difference in sleep efficiency with melatonin compared with placebo (pooled MD
4.76% favouring melatonin, 95% CI –0.95% to 10.47%; p = 0.10; Figure 5). Heterogeneity was high
(I2 = 94%) and this treatment effect is unlikely to be generalisable; although the trials did consistently
report very small differences between groups in the proportion of time spent in bed asleep, these are
unlikely to be clinically meaningful.
For the single trial117 reporting parent-reported sleep efficiency (n = 50 analysed participants), there was no
statistically significant difference between groups (MD 0.30% favouring melatonin, 95% CI –0.90% to
1.49%; p = 0.62).
Cortesi et al.110 reported the percentage of children who achieved a sleep efficiency in the normative range
(> 85%) as 46.43% of the melatonin group compared with none of the placebo group.
Jain et al.115 reported no difference in polysomnography-measured sleep efficiency (MD 3.8% favouring
melatonin, 95% CI –2.5% to 10.1%, n = 10).
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– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CIStudy first author MD SE
Melatonin Placebo
Weight
29.30 (– 10.68 to 69.28)
23.40 (7.92 to 38.88)
24.17 (9.73 to 38.61)
Prior intervention
Appleton (2012)48
Wasdell (2008)117
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.07, df = 1 (p = 0.79); I2 = 0%
Test for overall effect: z = 3.28 (p = 0.001)
29.3
23.4
20.4
7.9
30
50
80
29
50
79
11.2%
23.1%
34.3%
64.90 (46.28 to 83.52)
18.50 (– 4.04 to 41.04)
23.20 (11.64 to 34.76)
35.49 (7.70 to 63.28)
No prior intervention
Cortesi (2012)110
Van der Heijden (2007)111
Jain (2015)115
Subtotal (95% CI)
Heterogeneity: τ2 = 519.89; χ2 = 15.59, df = 2 (p = 0.0004); I2 = 87%
Test for overall effect: z = 2.50 (p = 0.01)
64.9
18.5
23.2
9.5
11.5
5.9
35
41
10
86
32
39
10
81
21.3%
19.1%
25.2%
65.7%
31.93 (14.76 to 49.09)Total (95% CI)
Heterogeneity: τ2 = 269.16; χ2 = 16.52, df = 4 (p = 0.002); I2 = 76%
Test for overall effect: z = 3.65 (p = 0.0003)
Test for subgroup differences: χ2 = 0.50, df = 1 (p = 0.48); I2 = 0%
166 160 100.0%
100
Favours placebo Favours melatonin
total total
FIGURE 4 Actigraphy-measured TST: melatonin vs. placebo. df, degrees of freedom; IV, instrumental variable.
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– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CI
Melatonin Placebo
Study first author MD SE total Weight
5.40 (– 0.52 to 11.32)
0.50 (– 1.52 to 2.52)
2.13 (– 2.40 to 6.65)
Prior intervention
Appleton (2012)48
Wasdell (2008)117
Subtotal (95% CI)
Heterogeneity: τ2 = 6.91; χ2 = 2.36, df = 1 (p = 0.12); I2 = 58%
Test for overall effect: z = 0.92 (p = 0.36)
5.4
0.5
3.02
1.03
30
50
80
28
50
78
21.2%
26.6%
47.8%
10.80 (8.72 to 12.88)
2.40 (– 0.56 to 5.36)
6.67 (– 1.56 to 14.90)
No prior intervention
Cortesi (2012)110
Van der Heijden (2007)111
Subtotal (95% CI)
Heterogeneity: τ2 = 33.58; χ2 = 20.73, df = 1 (p < 0.00001); I2 = 95%
Test for overall effect: z = 1.59 (p = 0.11)
10.8
2.4
1.06
1.51
35
41
76
32
39
71
26.5%
25.6%
52.2%
4.76 (– 0.95 to 10.47)Total (95% CI)
Heterogeneity: τ2 = 30.83; χ2 = 52.00, df = 3 (p < 0.00001); I2 = 94%
Test for overall effect: z = 1.63 (p = 0.10)
Test for subgroup differences: χ2 = 0.90, df = 1 (p = 0.34); I2 = 0%
156 149 100.0%
100
Favours placebo Favours melatonin
total
FIGURE 5 Actigraphy-measured sleep efficiency: melatonin vs. placebo. df, degrees of freedom; IV, instrumental variable.
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Sleep initiation
Sleep onset latency
Ten trials48,69,70,106,110,111,114,117,119 (n = 583 randomised participants) measured SOL, the time from bedtime to
sleep onset time (see Appendix 7): three trials reported parent-reported SOL data only;69,106,114 two reported
actigraphy-measured SOL data only;110,119 four reported both actigraphy-measured and parent-reported
SOL data;48,70,111,117 and one used polysomnography- and actigraphy-measured data, but reported only the
results of the polysomnography.115 As with TST, trials reporting actigraphy data stated that it was informed,
or verified, by parent-reported sleep diaries.
Cortesi et al.110 also calculated the percentage of children who met either a standard sleep criterion for
SOL of ≤ 30 minutes or a reduction of SOL by 50%. Wright et al.106 used an additional measure of SOL
defined as the duration of time between taking the medication and falling asleep.
For parent-reported/sleep diary SOL, six trials48,69,70,106,114,117 (n= 223 analysed participants) were pooled,
comprising five crossover trials with a washout period (n = 110)69,70,106,114,117 and one parallel-group trial
(n = 113).48 There was a statistically significant decrease (favouring melatonin) in SOL for melatonin compared
with placebo (pooled MD –35.6 minutes, 95% CI –50.9 to –20.3 minutes; p < 0.001; Figure 6). Heterogeneity
was high (I2 = 89%) and the treatment effect is unlikely to be generalisable, although the effect estimates
were all in the direction of benefit with melatonin. There was a statistically significant difference in effect
between the studies of children with ASD and those with mixed and other populations (test for subgroup
differences, p < 0.001; I2 = 93%). There was a larger difference in the ASD group between melatonin and
placebo, with a mean reduction in favour of melatonin of 50.9 minutes (95% CI –55.5 to –46.2 minutes)
compared with 27.41 minutes (95% CI –39.1 to –15.7 minutes) in the other group. Subgroup analysis by
whether or not participants had received a prior intervention was not possible.
For actigraphy-measured SOL, five trials48,70,110,111,117 (n = 265 analysed participants) were pooled, comprising
three parallel trials (n = 196)48,110,111 and two crossover trials with a washout period (n = 69).70,117 There was a
statistically significant decrease (favouring melatonin) in actigraphy-reported SOL (pooled MD –23.4 points,
95% CI –30.9 to –15.8 points; p < 0.001; Figure 7). There was moderate heterogeneity (I2 = 48%). Based on
the subgroup analysis, there was no statistically significant difference in effect between studies in which
participants had or did not have a prior intervention (test for subgroup differences, p = 0.55; I2 = 0%).
A subgroup analysis based on neurodevelopmental condition was not possible.
For both sleep diary-measured and actigraphy-measured SOL, the single study rated as having a low risk of
bias48 reported a statistically significant improvement with melatonin compared with placebo (see Figures 6
and 7).
The crossover study without a washout period119 (n = 12 analysed participants) reported a statistically
significant decrease in mean SOL for the melatonin period, compared with the placebo period, using a
non-parametric analysis (complete-case analysis, p = 0.02; last observation carried forward, p = 0.0001),
but this difference is not significant when tested using a paired t-test (MD –28.08 minutes; p = 0.10;
estimated 95% CI –2.5 to 58.7 minutes).
Cortesi et al.110 used an additional indicator of SOL (the percentage of children who met a criterion of SOL
of ≤ 30 minutes or a reduction of SOL by 50% post intervention) and reported that 39% of the melatonin
group versus 0% of the placebo group achieved these changes (n = 66 analysed participants). Jain et al.115
(n = 10), using polysomnography, reported that melatonin significantly reduced the mean SOL compared
with placebo, with a reported MD of –11.4 minutes (95% CI –17.2 to –5.6 minutes).
Wright et al.106 (n = 17) reported a significant decrease in SOL with melatonin compared with placebo
[MD 51.7 minutes (SD 71.9 minutes; p = 0.012; estimated 95% CI 16.5 to 86.9 minutes)].
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– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CI
Melatonin Placebo
Study first author MD SE total total Weight
– 51.00 (– 55.70 to – 46.30)
– 46.70 (– 72.77 to – 20.63)
– 50.86 (– 55.49 to – 46.24)
ASD
Garstang (2006)69
Wright (2011)106
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.10, df = 1 (p = 0.75); I2 = 0%
Test for overall effect: z = 21.54 (p < 0.00001)
– 51
– 46.7
2.4
13.3
7
17
24
7
16
23
20.8%
13.1%
34.0%
– 37.50 (– 58.86 to – 16.14)
– 30.00 (– 57.44 to – 2.56)
– 33.40 (– 44.96 to – 21.84)
– 15.70 (– 25.70 to – 5.70)
– 27.41 (– 39.13 to – 15.69)
Not ASD
Appleton (2012)48
Dodge (2001)114
Wasdell (2008)117
Weiss (2006)70
Subtotal (95% CI)
Heterogeneity: τ2 = 74.44; χ2 = 6.79, df = 3 (p = 0.08); I2 = 56%
Test for overall effect: z = 4.59 (p < 0.00001)
– 37.5
– 30
– 33.4
– 15.7
10.9
14
5.9
5.1
54
17
50
19
140
59
17
50
19
145
15.0%
12.6%
18.9%
19.5%
66.0%
– 35.55 (– 50.85 to – 20.26)Total (95% CI)
Heterogeneity: τ2 = 286.69; χ2 = 43.60, df = 5 (p < 0.00001); I2 = 89%
Test for overall effect: z = 4.56 (p < 0.00001)
Test for subgroup differences: χ2 = 13.31, df = 1 (p = 0.0003); I2 = 92.5%
164 168 100.0%
100
Favours melatonin Favours placebo
FIGURE 6 Sleep diary-measured SOL: melatonin vs. placebo. df, degrees of freedom; IV, instrumental variable.
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0
– 100 – 50 0 50
MD
IV, random, 95% CI
MD
IV, random, 95% CI
Melatonin Placebo
Study first author MD SE total total Weight
– 35.70 (– 64.51 to – 6.89)
– 25.30 (– 35.88 to – 14.72)
– 26.54 (– 36.47 to – 16.60)
Prior intervention
Appleton (2012)48
Wasdell (2008)115
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.44, df = 1 (p = 0.51); I2 = 0%
Test for overall effect: z = 5.24 (p < 0.00001)
– 35.7
– 25.3
14.7
5.4
24
50
74
25
50
75
6.0%
23.9%
29.8%
– 34.40 (– 47.73 to – 21.07)
– 18.70 (– 32.03 to – 5.37)
– 16.00 (– 22.86 to – 9.14)
– 22.07 (– 32.89 to – 11.26)
No prior intervention
Cortesi (2012)110
Van der Heijden (2007)111
Weiss (2006)70
Subtotal (95% CI)
Heterogeneity: τ2 = 59.53; χ2 = 5.81, df = 2 (p = 0.05); I2 = 66%
Test for overall effect: z = 4.00 (p < 0.0001)
– 34.4
– 18.7
– 16
6.8
6.8
3.5
35
41
19
95
32
39
19
90
18.7%
18.7%
32.7%
70.2%
– 23.35 (– 30.91 to – 15.78)Total (95% CI)
Heterogeneity: τ2 = 33.23; χ2 = 7.66, df = 4 (p = 0.10); I2 = 48%
Test for overall effect: z = 6.05 (p < 0.00001)
Test for subgroup differences: χ2 = 0.35, df = 1 (p = 0.55); I2 = 0%
169 165 100.0%
100
Favours melatonin Favours placebo
FIGURE 7 Actigraphy-measured SOL: melatonin vs. placebo. df, degrees of freedom; IV, instrumental variable.
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1
Sleep maintenance
Number of night wakings
Six trials69,106,113,114,117,119 (n = 142 randomised participants) reported the number of night wakings.
Four crossover trials with a washout period were pooled (n = 94 analysed participants).69,106,114,117 There
was no difference in the mean number of night wakings with melatonin compared with placebo (pooled
MD –0.04 points, 95% CI –0.22 to 0.13 points; p = 0.61; Figure 8). Heterogeneity was high (I2 = 84%),
although the results were fairly consistent, with the exception of those of Dodge and Wilson.114 Based on
the subgroup analysis, there was no statistically significant difference in effect between studies based on
ND (test for subgroup differences, p = 0.06; I2 = 71%).
The crossover study without a washout period119 reported no significant difference for the melatonin
period compared with the placebo period by either the non-parametric analyses or the paired t-test
[MD by paired t-test –0.07 points (favours melatonin, p = 0.73; estimated 95% CI –0.44 to 0.30 points)].
Wasdell et al.117 reported no statistically significant treatment difference (p = 0.48) for melatonin compared
with placebo (estimated MD –0.41 points favouring melatonin, 95% CI –1.47 to 0.66 points).
Other outcomes
Six out of the 11 trials reported other outcomes of interest,110,111,113,115,117,119 although, with the exception of
WASO (night waking duration and/or frequency after the child falls asleep), which was reported by two
studies,110,115 each outcome measure was reported by only a single study. These data are summarised in
Table 2.
Melatonin versus melatonin
Two crossover trials120,121 (n = 24 randomised participants) compared melatonin with melatonin. Jan et al.121
compared controlled-release with fast-release melatonin, and Hancock et al.120 compared a dose regimen
of 5 mg with a dose regimen 10 mg of melatonin.
Jan et al.121 did not have a washout period between the two intervention phases, whereas Hancock et al.120
had a 2-week washout period. Hancock et al.120 compared a fixed-dose regimen of 5 mg with 10 mg of
melatonin regardless of the child’s age. The authors did not report whether or not the melatonin was
controlled or fast release. The final average dose for controlled-release melatonin for Jan et al.121 was
5.7 mg (range 2–12 mg), and the final average dose for fast-release melatonin was 7 mg (range 2–15 mg).
Jan et al.121 reported that the dosage for fast-release melatonin varied for each child depending on the
dosage deemed by the trial team to be most effective for that child. However, the controlled-release
melatonin was approximately 50% of the fast-release dose, which the authors stated was to avoid possible
adverse side effects, as they had no previous information on the use of controlled-release melatonin in
children. The duration of the intervention was 11 days for Jan et al.121 and 2 weeks for Hancock et al.120
The age of participants included in the trials ranged from 18 months to 31 years for Hancock et al.120 (eligible
participants < 18 years, n = 5, mean age 6.9 years); and from 4 to 21 years for Jan et al.121 (eligible participants
< 18 years, n = 15, mean age 9.3 years). Children in Hancock et al.120 had severe neurodevelopmental
difficulties, whereas the ND in the Jan et al.121 study was tuberous sclerosis. The sleep disturbance in both
studies focused on both sleep initiation and maintenance: in Hancock et al.120 ‘severe sleep problems’,
confirmed by a Quine sleep index score of at least 6 out of a possible 8, and for Jan et al.121 ‘chronic
wake–sleep disorders’.
In Jan et al.,121 the inclusion criterion was that children had already been treated with fast-release
melatonin for > 3 months but slept for < 5–6 hours. No additional guidance or leaflets on sleep
management were provided to parents in either of the trials.
RESULTS
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– 100 – 50 0 50
MD
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Melatonin Placebo
Study or subgroup MD SE total total Weight
– 0.18 (– 0.22 to – 0.14)
– 0.10 (– 0.30 to 0.10)
– 0.18 (– 0.22 to – 0.14)
ASD
Garstang (2006)69
Wright (2011)106
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.62, df = 1 (p = 0.43); I2 = 0%
Test for overall effect: z = 9.02 (p < 0.00001)
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7
17
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7
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24
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22.2%
53.0%
0.20 (0.02 to 0.38)
– 0.06 (– 0.24 to 0.12)
0.07 (– 0.18 to 0.32)
Not ASD
Dodge (2001)114
Wasdell (2008)115
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 4.17, df = 1 (p = 0.04); I2 = 76%
Test for overall effect: z = 0.54 (p = 0.59)
0.2
– 0.06
0.09
0.09
20
50
70
20
50
70
23.5%
23.5%
47.0%
– 0.04 (– 0.22 to 0.13)Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 18.54, df = 3 (p = 0.0003); I2 = 84%
Test for overall effect: z = 0.51 (p = 0.61)
Test for subgroup differences: χ2 = 3.53, df = 1 (p = 0.06); I2 = 84%
94 94 100.0%
100
Favours melatonin Favours placebo
FIGURE 8 Parent-reported number of night wakings: melatonin vs. placebo. df, degrees of freedom; IV, instrumental variable.
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TABLE 2 Other outcome results from studies of pharmacological interventions
Study Outcome
Time point, mean (SD) MD between
melatonin and
placebo (95% CI)Baseline Follow-up
Global measures and composite scores
Cortesi et al.
(2012)110
CSHQ
(total points)
Melatonin: 66.67 (8.55)
Placebo: 64.20 (4.85)
Melatonin only: 54.78 (6.22)
Placebo: 64.80 (4.52)
–10.02 (–12.71 to –7.33)
WASO (minutes) Melatonin: 73.71 (45.00)
Placebo: 69.75 (45.21)
Melatonin: 42.21 (22.35)
Placebo: 70.15 (42.76)
–27.94 (–44.58 to –11.30)
Jain et al. (2015)115 Sleep Behaviour
Questionnaire
(total points)
Overall: 59.2 (10.5 ) Melatonin: 52.4 (5.4)
Placebo: 48.3 (7.4)
3.4 (–2.2 to 9.0)
WASO (minutes) Overall: 60.6 (24.0) Melatonin: 42.3 (30.3)
Placebo: 57.3 (31.6)
–22.2 (–34.1 to –10.3)
Wasdell et al.
(2008)117
Somnolog longest
sleep episode
(minutes)
Overall: 415.41 (106.23) Melatonin: 453.30 (118.41)
Placebo: 434.26 (109.09)
18.3 (–5.0 to 41.6)
Actigraph longest
sleep episode
(minutes)
Overall: 185.17 (102.63) Melatonin: 199.37 (100.46)
Placebo: 189.25 (99.98)
7.9 (–16.6 to 32.4)
Sleep initiation
Cortesi et al.
(2011)7
Bedtime
(units unclear)
Melatonin: 23.45 (1.15)
Placebo: 23.41 (1.19)
Melatonin: 22.30 (1.10)
Placebo: 23.51 (1.12)
–1.21 (–1.76 to –0.66)
Van der Heijden
et al. (2007)111
Sleep onset
(hour : minutes)
Melatonin: 21:40
(0.59 minutes)
Placebo: 21:38
(0.47 minutes)
Melatonin: 21:13 (0:58)
Placebo: 21:48 (0:48)
–35 minutes
(–59 to –11 minutes)
Difficulty falling
asleepa (points)
Melatonin: 3.4 (0.9)
Placebo: 3.2 points
(0.7 points)
Melatonin: 2.2 (0.9)
Placebo: 3.1 points
(1.0 points)
–0.9 (–1.3 to –0.5)
Jain et al. (2015)115 Bedtime
(hour : minutes)
Overall: 21:44
(0.75 minutes)
Melatonin: 21:57
(0.91 minutes)
Placebo: 21:49
(0.72 minutes)
6.8 minutes
(–23.3 to 9.7 minutes)
Wirojanan et al.
(2009)119
Sleep onset time
(hour : minutes)
NR Melatonin: 20:43
(1.39 minutes)
Placebo: 21:25
(2.00 minutes)
–42 minutes
(–74.8 to –9.2 minutes)
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TABLE 2 Other outcome results from studies of pharmacological interventions (continued )
Study Outcome
Time point, mean (SD) MD between
melatonin and
placebo (95% CI)Baseline Follow-up
Sleep maintenance
Camfield et al.
(1996)113
Nights without
awakening
NR Raw data for nights without
awakening between 22:00
and 07:00 hours per day/the
number of days of complete
data:
Melatonin: 2/25 (8%); 0/21
(0%); 7/35 (20%); 10/29
(34%); 4/33 (12%); 26/35
(74%)
Placebo: 2/28 (7%); 0/25
(0%); 1/31 (3%); 4/30
(13%); 1/31 (3%); 24/35
(69%)
8.9 (–0.1 to 17.9)
Van der Heijden
et al. (2007)111
Wake up timeb
(hour : minutes)
Melatonin: 07:25 (0.39)
Placebo: 07:25 (0.34)
Melatonin: 07:21
(0.40 minutes)
Placebo: 07:33
(0.26 minutes)
–12.0 minutes
(–27.1 to 3.1 minutes)
Moving timeb (%) Melatonin: 11.95 (4.38)
Placebo: 10.43 (3.69)
Melatonin: 12.79 (8.20)
Placebo: 12.30 (3.88)
0.5 (2.4 to 3.4)
Jain et al. (2015)115 Wake time
(hour:minutes)
Overall: 7:09 (1:04) Melatonin: 7:31
(1.09 minutes)
Placebo: 7:11 (1.09 minutes)
–18.1 minutes
(–0.2 to –36.0 minutes)
Sleep scheduling
Cortesi et al.
(2012)110
Naptime
(units unclear)
Melatonin: 33.57 (56.63)
Placebo: 37.33 (56.19)
Melatonin: 17.00 (33.11)
Placebo: 36.10 (33.28)
–19.10 (–35.43 to –2.77)
Other outcomes
Van der Heijden
et al. (2007)111
Interdaily stabilityb,c
(points)
Melatonin: 0.65 (0.13)
Placebo: 0.64 (0.15)
Melatonin: 0.66 (0.16)
Placebo: 0.68 (0.11)
–0.02 (–0.08 to 0.04)
Intradaily
variabilityb,d
(points)
Melatonin: 0.65 (0.18)
Placebo: 0.67 (0.15)
Melatonin: 0.69 (0.23)
Placebo: 0.63 (0.14)
0.06 (–0.03 to 0.15)
L5 (average
activity during
the least active
5 hours) (points)
Melatonin: 44.89
(26.72)
Placebo: 36.01 (27.09)
Melatonin: 39.57 (28.86)
Placebo: 50.56 (28.67)
–11.0 (–24.0 to 2.0)
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Across both trials, four sleep-related outcomes were measured (see Appendix 8). Hancock et al.120 measured
TST, SOL and number of night wakings, whereas Jan et al.121 measured ‘changes in sleep pattern’ as their
only outcome. The results of these outcomes are summarised in Table 3 for participants aged < 18 years.
Each outcome measure was reported by a single study. There was no evidence of benefit on any of the
sleep-related outcomes for the RCT that compared controlled-release melatonin with fast-release
melatonin121 or the RCT that compared a dose of 5 mg of melatonin with 10 mg of melatonin.120
Adverse events
Eleven out of the 13 trials measured adverse events,48,70,106,110,111,114,115,117,119–121 which were collected and
reported in different ways across the studies (Table 4).
One study reported adverse event data using the standardised assessment tool ‘treatment-emergent signs
and symptoms’, which classified events into seven domains: somnolence, increased excitability, mood
swings, seizures, rash, hypothermia and cough.48 Signs and symptoms were graded as ‘no symptoms’, ‘mild
symptoms’, ‘moderate symptoms’ and ‘severe symptoms’. Seriousness and causality were also assessed. In
two studies,110,115 adverse events were determined at each in-person/telephone call visit by the study team and
recorded in the participant’s chart; one study measured adverse events using study-specific questionnaires
completed by parents;106 one reported using a standardised form;70 one reported using parent-completed
questionnaires, in which the origin of the questionnaire was not reported;114 two reported measuring adverse
events using open-ended interviews;111,117 one study reported only that adverse effects were reported by
parents;120 and in one study it was unclear how the data were collected.119
TABLE 2 Other outcome results from studies of pharmacological interventions (continued )
Study Outcome
Time point, mean (SD) MD between
melatonin and
placebo (95% CI)Baseline Follow-up
Jain et al. (2015)115 Arousal index per
hour of sleep
Overall: 12.9 (7.4) Melatonin: 10.3 (4.1)
Placebo: 12.3 (6.8)
2.5 (–2.5 to 7.5)
Percentage of sleep stages (%)
N1 Overall: 6.3 (2.9) Melatonin: 4.0 (2.0)
Placebo: 4.8 (2.8)
–0.1 (–0.5 to 0.3)
N2 Overall: 42.6 (5.2) Melatonin: 44.0 (9.2)
Placebo: 42.6 (8.1)
–2.9 (–10.5 to 4.7)
N3 Overall: 28.9 (3.4) Melatonin: 32.6 (8.3)
Placebo: 27.4 (4.8)
–5.5 (–7.6 to –3.4)
REM stage (%) Overall: 22.2 (3.7) Melatonin: 19.4 (4.2)
Placebo: 25.2 (5.1)
5.8 (4.2 to 7.4)
REM latency
(minutes)
Overall: 136.2 (43.6) Melatonin: 135.2 (53.1)
Placebo: 98.1 (52.8)
–58.3 (–36.2 to –80.4)
NR, not reported; REM, rapid eye movement.
a Mean difficulty falling asleep as reported by parents, averaged over 7 days on a scale of 1 (not difficult) to 5
(very difficult).
b Data available from online supplementary material, not reported in paper.
c Range from 0 to 1, with higher values indicating more stable rhythms.
d Range from 0 to 2, with higher values indicating more fragmented rhythms.
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TABLE 3 Outcome results from trials comparing melatonin with melatonin
Study Outcome
Time point, mean (SD) MD between
interventions
(95% CI)Baseline Follow-up
Global measures and composite scores
Hancock et al. (2005)120 TST (minutes) NR Melatonin, 5 mg: 548.6 (18.9)
Melatonin, 10 mg: 548.0 (34.6)
–0.6 (–35.8 to 34.6)
Jan et al. (2000)121 Changes in
sleep pattern
N/A Improvements in the sleep patterns, to the
satisfaction of the caregivers, were observed in
10 participants during the controlled-release
period relative to the fast-release period
N/A
Sleep initiation
Hancock et al. (2005)120 SOL (minutes) NR Melatonin, 5 mg: 70.0 (58.0)
Melatonin, 10 mg: 68.4 (46.9)
–1.6 (–37.4 to 34.2)
Sleep maintenance
Hancock et al. (2005)120 Number of
night wakings
NR Melatonin, 5 mg: 0.8 (0.4)
Melatonin, 10 mg: 1.0 (0.9)
0.3 (–0.7 to 1.2)
N/A, not applicable; NR, not reported.
TABLE 4 Adverse events in studies evaluating melatonin
Study AEs Method of collection
Appleton et al.
(2012)48
Melatonin: mild AEs, n= 151; moderate AEs, n= 35; severe AEs,
n = 3 (waking up in the night because of nightmares, severe
irritation to skin, seizure)
Other non-treatment-emergent signs and symptoms: fatigue, n= 8;
headache, n= 10; other, n= 31. Seizures: pre randomisation, n = 49;
post randomisation, n= 211
Placebo: mild AEs, n= 195; moderate AEs, n= 28; severe AEs, n = 4
(dislocated elbow in accident at school, petechiae covering the
dorsum of the right hand, choking on dinner, vomiting caused by
viral illness, which caused dehydration)
Other non-treatment-emergent signs and symptoms: fatigue, n= 8;
headache, n= 7; other, n = 40. Seizures: pre randomisation, n= 61;
post randomisation, n= 192
Treatment-emergent signs
and symptoms tool
Camfield et al.
(1996)113
Not reported Not reported
Cortesi et al.
(2012)110
No AEs were reported or observed Recorded during face-to-face
visits/telephone calls by study
team
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TABLE 4 Adverse events in studies evaluating melatonin (continued )
Study AEs Method of collection
Van der Heijden
et al. (2007)111
Associated paper:
Hoebert et al.
(2009)112
Melatonin: one AE, n= 5, two AEs, n= 4, three AEs, n= 1. There
were no discontinuations or withdrawals as a result of AEs. None of
the AEs required treatment. At 3 weeks post intervention: headache,
n= 3; hyperactivity, n = 3; dizziness, n= 2; abdominal pain, n= 2;
nose bleeding, n= 1; itching lumps on the skin, n= 1; painful lumps
on the skin, n= 1; diarrhoea, n= 1; decrease of mood, n= 1;
maintenance of insomnia, n= 1. At 2 years after participation: 7 out
of 24 parents reported one or more AE: bedwetting, n= 2,
abnormal faeces, n= 2; drowsiness, n = 2; dizziness, n = 1; sleep
maintenance problems, n= 1; skin pigment changes, n= 1;
decreased mood, n= 1
Placebo: no AEs reported
Long-term follow-up (mean follow-up time 3.66 years) with
94 parents of children who participated in the Van der Heijen et al.111
trial: 19 children experienced AEs that they or their parents attributed
to melatonin treatment. The majority of parents (63.2%) reported
multiple AEs; seven reported one AE; four reported two AEs; four
reported three AEs and four parents reported four AEs. Ten children
had AEs that were self-limiting. In six children the AEs persisted and
were a reason to discontinue treatment in three out of six children. In
three children it was not mentioned in the questionnaire if the AEs
were self-limiting or not. Dizziness, n= 4; visual disturbances, n = 2;
melatonin treatment bedwetting, n= 3; excessive morning sedation,
n= 2; sleep maintenance insomnia, n = 3; constipation, n = 1;
headache, n = 2; profuse perspiration, n= 1; nausea, n= 2;
decreased mood, n= 1; skin pigment changes, n= 2; daytime
laziness, n= 1; nightmares, n = 2; and change in behaviour, n= 1
Open-ended interviews
Parent-completed
questionnaire
Dodge and
Wilson (2001)114
Melatonin: more moody, n = 1; more ‘hyper’, n= 1. No reported
changes in seizure frequency
Placebo: more moody, n = 1; more ‘hyper’, n= 1 (different child).
No reported changes in seizure frequency
Parent-completed
questionnaire
Garstang and
Wallis (2006)69
Not reported Not reported
Hancock et al.
(2005)120
No adverse effects were reported during the trial
Seizures (n = 5). There was no change in the frequency (or type) of
seizures seen compared with the baseline period before melatonin
treatment at either dose
‘Reported by parents’
Jain et al.
(2015)115
Melatonin: AEs (n = 4); increased severity of headache (n= 1).
‘Unrelated adverse events’: bronchitis and ear infection (n= 1),
agitation (n= 1) and increased urinary frequency (n = 1 continued
from placebo phase)
Placebo: AEs n= 2. ‘Unrelated adverse events’: agitation
(n= 1 continued from melatonin phase) and increased urinary
frequency (n = 1)
Recorded during face-to-face
visits/telephone calls by study
team
Jan et al.
(2000)121
No adverse effects were experienced during the trial Not explicitly stated –
response to melatonin was
measured through sleep
charts and parental history
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TABLE 4 Adverse events in studies evaluating melatonin (continued )
Study AEs Method of collection
Wasdell et al.
(2008)117
Associated paper:
Carr et al.
(2007)118
98 AEs reported across arms
Melatonin: 36%. Most common AEs: seizures, n = 11; cold/flu/
infection, n = 8; gastrointestinal illness, n= 5; agitation, n= 4;
anxiety, n= 2 – considered consistent with patient’s medical history
and not related to melatonin; headache, n= 2 – considered
consistent with patient’s medical history and not related to
melatonin. 40% of AEs in treatment group were from one patient:
seizures, agitation, gagging and headaches, which were considered
consistent with patient’s medical history
‘Treatment with controlled release melatonin was well tolerated and
no treatment differences were evident on vital signs or physical
examinations’117
Placebo: 40% (and 24% in placebo washout phases)
Most common AEs: cold/flu/infection, n= 10; seizures, n= 8;
gastrointestinal illness, n = 5; and behavioural problems (agitation,
anxiety, irritability, emotional lability), n = 7. One serious AE
consistent with participant’s medical history (aspiration pneumonia
requiring hospitalisation) occurred during placebo treatment in the
first period of the crossover trial
After 3-month open-label phase: 16 AEs reported, consistent with
pre-existing medical conditions. One serious AE: patient admitted to
hospital for 3 days owing to an upper respiratory infection
Prospective long-term, open-label follow-up of melatonin: mean
(SD), frequency of AEs: nausea, 0.15 (0.65), 0–4; vomiting, 0.05
(0.22), 0–1; diarrhoea, 0.10 (0.37), 0–1; impaired appetite, 0.05
(0.31), 0; weight loss, 0.05 (0.31), 0–2; confusion, 0 (0), 0; excessive
morning sedation, 0.12 (0.51), 0–3; depression, 0.10 (0.63), 0–4;
irritability, 0.27 (0.71), 0–3; hyperactive behaviour, 0.10 (0.37),
0–2; deterioration of behaviour, 0.10 (0.49), 0–3; regression of
development, 0 (0), 0; precocious puberty, 0 (0), 0; increase in
seizures, 0.07 (0.26), 0–1; nasal allergy, 0.12 (0.40), 0–2; rash, 0.12
(0.46), 0–2; deterioration in asthma, 0.07 (0.35), 0–2; worsening of
balance, 0.02 (0.16), 0–1; new tremor, 0.05 (0.22), 0–1; headache,
0.07 (0.35), 0–2; visual disturbance, 0.02 (0.16), 0–1; interference
with other medications, 0 (0), 0; interference with other therapies,
0 (0), 0
Open-ended interviews
Telephone call with
caregivers
Weiss et al.
(2006)70
Melatonin: 20% of all AEs reported during the melatonin phase
Placebo: 23% of all AEs reported during the placebo phase
All mild/moderate adverse effects with exception of one severe AE
(migraine). Rash from actigraph (n = 2)
No serious AEs and no clinically significant changes in vital signs or
abnormalities on physical examination
Recorded on a standardised
form that included severity,
timing and relationship to the
study drug
Wirojanan et al.
(2009)119
No side effects were reported by parents Unclear
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Three trials reported that no adverse events were observed or reported during the trial.110,119,121 Further
details of the adverse events reported can be found in Table 4. Overall, melatonin was tolerated and the
adverse event profile appeared to be similar between the melatonin and placebo groups.
Summary
Eleven RCTs (eight crossover and three parallel trials) compared melatonin, of varying doses and duration,
with placebo. The mean age of participants ranged from 5.5 to 10.3 years and some studies included
children with a single ND, whereas others included mixed populations. Children had mostly sleep initiation
and/or sleep maintenance problems and in the majority of studies had been offered a prior intervention,
ranging from a sleep hygiene advice leaflet to behaviour management and parenting support. Only three
child-related sleep outcomes were reported by more than half of the studies, with many of the additional
outcomes assessed by a single study. None of the studies assessed parent-related outcomes.
One study was assessed as having a low risk of bias, with the remaining studies having an unclear or high
risk of bias. When possible, studies were grouped in the synthesis by ND (ASD vs. mixed or other groups)
and by whether or not they had received a prior intervention. However, the results of the subgroup
analyses should be interpreted with caution, rather than be considered definitive, as they are based on
summary data and are, therefore, observational rather than randomised comparisons as in a trial. In
addition, some of the subgroups contained a particularly small number of studies.
There was evidence of benefit with melatonin compared with placebo, although the precise extent of the
benefit, which children might benefit the most and the clinical importance of the benefit remain uncertain.
The overall benefit was similar for diary-reported and actigraphy-recorded TST. Based on two small studies
of children with ASD, there was a mean increase in diary-recorded TST of 64.78 minutes with melatonin
compared with placebo (95% CI 58.8 to 70.7 minutes); for the five mixed or other ND studies, the mean
increase was 15.9 minutes (95% CI 9.2 to 22.6 minutes). For the single study that was rated as having a
low risk of bias (mixed population), the mean increase in TST was 13.2 minutes and the lower CI included
the possibility of reduced sleep time (95% CI –13.3 to 39.7 minutes). The findings were similar for SOL.
The benefit was greatest for the ASD studies in which there was a mean reduction of 50.9 minutes
(95% CI –55.5 to –46.2 minutes) in diary-measured SOL, based on two small studies, whereas there
was a smaller mean reduction of 27.4 minutes (95% CI –39.1 to –15.7 minutes) for the mixed and other
population subgroup. For the single study with a low risk of bias (mixed population), the mean reduction
in SOL was 37.5 minutes (95% CI –58.9 to –16.1 minutes). For other outcomes, there was some evidence
TABLE 4 Adverse events in studies evaluating melatonin (continued )
Study AEs Method of collection
Wright et al.
(2011)106
Authors report that there were no statistically significant differences
between treatment and placebo in the frequencies of reported side
effects (but do not give actual numbers), including the following:
daytime drowsiness, dizziness, headaches, vomiting, tummy aches,
reduced appetite, low mood, anxiety, irritability, reduced alertness,
confusion, tearfulness, diarrhoea, constipation, rashes, sort throat,
ear aches, asthma, fit/seizure, mild tremor and ‘other’. Daytime
drowsiness, reduced appetite, reduced alertness and diarrhoea
were reported as ‘never present’ more often in the placebo than
treatment group, but the difference was not statistically significant.
There were no serious AEs
One child stopped medication during an influenza episode and did
not continue as sleep ‘continued to be good’. There were no known
reports of seizures or asthma during the trial. One child displayed
increased moodiness and self-injurious behaviour but clinicians
reported that these were long-standing problems for the child
Study-specific questionnaire
AE, adverse event.
RESULTS
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of statistically significant benefit with melatonin for sleep initiation outcomes but not sleep maintenance
outcomes, such as number of night wakings, although some of the single studies may not have been
sufficiently powered to detect an effect.
A single RCT121 compared controlled-release and fast-release melatonin and one RCT120 compared a 5 mg
and a 10 mg dose of melatonin, both with a high risk of bias. There was no evidence of benefit with
either strategy.
Non-pharmacological studies
Study characteristics
Twenty-six studies evaluated non-pharmacological interventions: 12 RCTs, one controlled before-and-after
study and 13 uncontrolled before-and-after studies. Sample sizes ranged from 5 to 244 participants.
Studies were conducted in Australia, Canada, China, Hong Kong, Israel, the UK and the USA. A summary
of key characteristics is provided in Table 5 and further details are provided in Appendix 9.
We grouped studies, based on the intervention, into the following: parent-directed tailored interventions
(n = 9), parent-directed non-tailored interventions (n = 8), non-comprehensive parent-directed interventions
(n = 2) and ‘other’ non-pharmacological interventions (n = 7). Intervention and control details for
non-pharmacological studies are outlined in Appendix 10.
Parent-directed interventions can be conceived as psychoeducational interventions that have the objective of
‘training’ parents to manage their child’s sleep disturbance by equipping them with the relevant knowledge and
skills. These interventions vary in their intensity and different modes are used to deliver the training, including
individual work, group work, teaching workshops and written material. Nineteen studies21,49,107,123–129,138,146,149,151,152,
155,162,163 of parent-directed interventions were included in the review. The interventions varied considerably in
terms of a number of characteristics. There was no consistency in the terminology used by study authors to
describe the interventions, and the terms that were used to describe an intervention were not routinely defined.
This was not unexpected. Generally, reporting of non-pharmacological interventions is acknowledged to be
much poorer than for pharmacological studies.164 However, it carries the risk of erroneous comparison of
interventions or pooling of studies.
Therefore, a framework to describe the parent-directed interventions represented in this study was developed by
the research team. It included intervention characteristics posited as being an ‘active ingredient’ of an intervention
and/or having an impact on intervention effectiveness, for example, intensity, duration, mode of delivery and
whether the intervention was condition specific or ND generic. There was incomplete reporting on these
intervention characteristics across the studies. We defined tailored and non-tailored interventions as follows:
l Tailored – a face-to-face clinical assessment by a trained practitioner guides clinical decision-making
regarding the management of a specific child’s sleep disturbance. A sleep management plan specific to
the child/family is developed, and training in implementing that plan is delivered. There is extended
‘implementation support’, that is, ongoing support and advice as the parents implement changes to
sleep management strategies and practices. The intervention is typically delivered on a one-to-one
basis. However, an intervention that used teaching workshops and one-to-one work was also
categorised as tailored123,124 because it fulfilled the criteria defined above.
l Non-tailored – the delivery of a standard ‘training curriculum’. The curriculum may include
opportunities for a parent to be supported to operationalise the material learnt for their child’s sleep
disturbance. Some implementation support may also be included. Among the studies included in this
review, such interventions were delivered in a number of ways: written material, single-session
workshops, group delivery and one-to-one work.
DOI: 10.3310/hta22600 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 60
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TABLE 5 Study details for studies evaluating non-pharmacological interventions
Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Parent-directed tailored interventions: RCTs
Beresford et al. (2012)21
UK
Associated
publications:
Beresford et al.,
(2013)136 Stuttard
et al. (2015)45,137
Parallel RCT
N= 13
Intervention
group: n= 7
Comparison
group: n= 6
Intervention group: two face-to-face
sessions for assessment, development of
sleep management strategy and training
parent in strategy. Implementation
support delivered via telephone calls
Comparison group: usual approach to
providing sleep management intervention
– as above but implementation support
delivered via home visits
Problems with sleep
initiation and
maintenance
Intervention group:
2.86 years (0.82 years)
Comparison group:
2.67 years (1.07 years)
Mixed None stated High
Hiscock et al. (2015)138
Australia
Associated
publications:
Papadopoulos
et al. (2015)139
Parallel RCT
N= 244
Intervention
group: n= 122
Comparison
group: n= 122
Intervention group: one session for
assessment, development of sleep
management strategy and training
parent in strategy. Implementation
support delivered via one face-to-face
session and one telephone call
Comparison group: usual care
Problems with sleep
initiation
Intervention group:
10.3 years (1.8 years)
Comparison group:
9.9 years (2.1 years)
ADHD + LD or
ASD/Asperger
syndrome
None stated Higha
Johnson et al. (2013)107
USA
Associated
publications:
Turner (2013)140
Parallel RCT
N= 40
Intervention
group: n= 20
Comparison
group: n= 20
Intervention group: one session
for assessment, development of
sleep management strategy; five
sessions training parent in strategy.
Implementation support delivered
via one face-to-face session
Comparison group: non-sleep-related
parent education delivered in identical
manner to intervention group
Problems with sleep
initiation and
maintenance
Intervention group:
3.5 years (0.98 years)
Comparison group:
3.6 years (1.12 years)
Autism and ASD None stated High
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Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Moss et al. (2014)124
Australia
Associated
publications:
O’Connell et al.
(2012 and
2010)141,142
Parallel RCT
N= 26
Intervention
group: n= 13
Comparison
group: n= 13
Intervention group: two training
workshops followed by a home visit
for assessment and development of
sleep-managed strategy. Implementation
support delivered via one home visit
followed by telephone calls as needed
Comparison group: waiting list control
Problems with sleep
initiation, maintenance
and scheduling and
snoring
11.74 years (2.53 years)
(NR separately)
Mixed One child taking
melatonin
High
Sciberras et al. (2011)125
Australia
Associated
publications:
Sciberras et al.,
(2010)143 Sciberras
and Rinehart,
(2015)144 Fulton
et al. (2010)145
Parallel RCT
N= 27
Intervention
group: n= 14
Comparison
group: n= 13
Intervention group: two sessions for
assessment, development of sleep
management strategy and training
parent in the strategy. Implementation
support delivered via a single telephone
call followed by a further face-to-face
session if needed
Comparison group: single session for
assessment, development of sleep
management strategy and training
parent in the strategy. No
implementation support
Problems with sleep
initiation
Intervention group:
12.1 years (2.2 years)
Comparison group:
10.9 years (2.5 years)
ADHD None stated High
Parent-directed tailored interventions: before-and-after studies
Austin et al. (2013)123
Australia N= 8 Two training workshops followed
by a home visit for assessment and
development of sleep management
strategy, followed by a third workshop.
Implementation support delivered via
weekly telephone calls
Problems with sleep
initiation and
maintenance
4.0 years (1.9 years) Mixed None stated High
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TABLE 5 Study details for studies evaluating non-pharmacological interventions (continued )
Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Beresford et al. (2013)21
UK
Associated
publications:
Beresford et al.,
(2013)136 Stuttard
et al. (2015)45,137
Intervention 2
N= 12 Two sessions for assessment,
development of sleep management
strategy and training parent in strategy.
Implementation support delivered via
fortnightly face-to-face sessions
Problems with sleep
initiation and
maintenance
2.88 years (1.25 years) Mixed None stated High
Quine and Wade (1991)146
UK
Associated
publications:
Wade and
Wade (1991)147
N= 25 Two sessions for assessment,
development of sleep management
strategy and training parent in strategy.
Implementation support delivered via
face-to-face sessions
Problems with sleep
initiation and
maintenance
Mean (SD) NR
(range 3–21 years)
LD None stated High
Weiskop et al. (2005)126
Australia
Before and after
with multiple
baseline
N= 13 Four sessions for assessment,
development of sleep management
strategy and training parent in strategy.
Implementation support (via telephone
calls) delivered from outset of
intervention, continuing after training
sessions completed with a face-to-face
session and further telephone calls
Problems with sleep
initiation and
maintenance
5.1 years (2.0 years) Mixed One child
was taking
medication for
behaviour and
sleep problems
High
Parent-directed non-tailored interventions: RCTs
Adkins et al. (2012)127
USA N= 36 Intervention group: training curriculum
contained in a booklet provided to parent
Problems with sleep
initiation
6.4 years (2.6 years)
(NR separately)
Mixed None stated High
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Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Associated
publications:
Malow et al.
(2011)148
Parallel-group RCT
Intervention
group: n= 18
Comparison
group: n= 18
Comparison group:
no booklet provided
Montgomery et al. (2004)49
UK
Associated
publications:
Montgomery
et al. (2004)49
Parallel-group RCT
N= 66
Intervention
group a: n= 22
Intervention
group b: n= 34
Comparison
group: n= 26
Intervention group a: training curriculum
contained in a booklet provided to
parent
Intervention group b: training curriculum
(identical to that contained in booklet)
delivered via face-to-face session
Comparison group: no intervention
(waiting list)
Problems with sleep
initiation and
maintenance
Mean (SD) NR (range
27–101 months, NR
separately)
Mixed None stated High
Malow et al. (2014)128
USA
Parallel-group RCT
N= 80
Intervention
group: n= 39
Comparison
group: n= 41
Intervention group: training curriculum
delivered via two group-delivered
sessions. Implementation support
delivered via telephone calls
Comparison group: training curriculum
delivered via single face-to-face session.
Implementation support delivered via
telephone calls
Problems with sleep
initiation
Intervention group:
5.9 years (2.8 years)
Comparison group:
5.6 years (2.6 years)
Mixed None stated High
Parent-directed non-tailored interventions: before-and-after studies
Beresford et al. (2012)21
UK N= 22 Group delivery of training curriculum
over four sessions
Problems with sleep
initiation
8.91 years (3.25 years) Mixed None stated High
continued
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TABLE 5 Study details for studies evaluating non-pharmacological interventions (continued )
Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Associated
publications:
Beresford et al.
(2013)136 Stuttard
et al. (2015)45,137
Intervention 3
Beresford et al. (2012)21
UK
Associated
publications:
Beresford et al.
(2013)136 Stuttard
et al. (2015)45,137
Intervention 4
N= 25 Training curriculum delivered via a single
half-day workshop
Problems with sleep
initiation and
maintenance
7.0 years (3.3 years) Mixed None stated High
Bramble (1997)149
UK
Associated
publications:
Bramble (1996)122
N= 15 Training curriculum delivered via single
session. Implementation support
delivered via telephone calls
Problems with sleep
initiation and
maintenance
7.2 years (2.6 years) Mixed Previous
interventions
indicated but
not described,
other than as
sedatives
High
Reed et al. (2009)129
Canada
Associated
publications: Reed
et al. (2008)150
N= 22 Group delivery of training curriculum
over three sessions
Problems with sleep
initiation and
maintenance
5.8 years (2.7 years) ASD None stated Unclear
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Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Yu et al. (2015)151
Hong Kong N= 54 Group delivery of training curriculum
over three sessions, supported by weekly
telephone calls. Implementation support
delivered via telephone calls
Problems with sleep
initiation and
maintenance
4.78 years (0.85 years) ASD and
Asperger
syndrome
None stated High
Non-comprehensive parent-directed interventions: RCTs
Wiggs and Stores (1998)152
UK
Associated
publications: Wiggs
and Stores (1999
and 2001)153,154
Cluster RCT
N= 30
Intervention
group: n= 15
Comparison
group: n= 15
Intervention group: tailored intervention.
Single session for assessment,
development of sleep management
strategy and training parent in strategy.
Implementation support delivered via
telephone calls
Comparison group: no intervention
Problems with sleep
initiation and
maintenance
Intervention group:
8.21 years (2.7 years)
Comparison group:
10.77 years (3.8 years)
Mixed None stated High
Non-comprehensive parent-directed interventions: before-and-after study
Peppers et al. (2016)155
USA N= 23 Intervention group: prescriptive sleep
hygiene intervention. One session
delivered by a practitioner
Global measure of
sleep disturbance
(CSHQ) used to define
eligibility to receive
intervention
Mean (SD) NR
(range 5–11 years)
NR None stated High
Other interventions – RCTs
Francis and Dempster (2002)156
Australia
Crossover RCT
N= 5 Intervention group: the intervention
contained valerian of 500mg per tablet,
30mg per kg of body weight, single nightly
dose ≥ 1 hour before bedtime, 2 weeks
Comparison group: to give the same
appearance and odour, placebo contained
25mg of whole-root Valeriana edulis
extract, 2 weeks
Problems with sleep
initiation and
maintenance
6.6 years (3.4 years) Mixed None stated High
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
0
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
8
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
B
e
re
sfo
rd
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
4
7
TABLE 5 Study details for studies evaluating non-pharmacological interventions (continued )
Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Gringras et al. (2014)36
UK
Crossover RCT
N= 73 Intervention group: weighted blanket
2.25 kg (small) or 4.5 kg (large). 12–16
days and were given by researchers at
home/clinic visits
Comparison group: placebo blanket
Problems with sleep
initiation and
maintenance
Weighted blanket first:
8.7 years (3.3 years)
Control blanket first:
9.9 years (2.8 years)
Mixed None stated High
Piazza et al. (1997)157
USA
Parallel-group RCT
N= 14
Intervention
group: n= 7
Comparison
group: n= 7
Intervention group: faded bedtime with
response cost, 10 days. The study author
delivered the face-to-face (home) visits
and booklet intervention
Comparison group: bedtime scheduling
Problems with sleep
maintenance and
initiation
Intervention group:
6.7 years (2.6 years)
Comparison group:
8.3 years (3.0 years)
Mixed Children were
excluded if
receiving
pharmacological
interventions for
sleep. No other
previous
interventions
reported
High
Other non-pharmacological interventions: non-randomised study designs
Guilleminault et al. (1993)158
USA N= 14 Light therapy and behavioural
programme. Daily light exposure at
07.00 and 12.00 hours
Problems with sleep
maintenance and ‘lack
of sleep consolidation’
2.9 years (range
9 months to 4 years)
Moderate to
severe learning
disability
Eight children
had attended
sleep clinics and
centres for
treatment. Some
children had had
behavioural
treatments
High
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Study details and
design
Participants
randomised
(total N and by
group) Intervention details Sleep disturbance Mean age (SD) ND disorder
Previous sleep
hygiene/
behavioural
interventions
Risk of bias
(low, unclear,
high)
Oriel et al. (2016)159
USA
A–B–A withdrawal
design
N= 8 Aquatic exercise programme.
60 minutes of aquatic exercise
two times per week
Parent/guardian report
of sleep dysfunction
8.9 years (SD NR, range
6–11 years)
ASD None stated High
Yehuda et al. (2011)160
Israel
Controlled before
and after
N= 78
Intervention
group: n= 40
Comparison
group: n= 38
(Healthy control
n= 22 not
included)
Intervention group: essential fatty acids
supplement, 90 g of α-linolenic and
360 g of linoleic acid in mineral oil.
Two capsules per day for 10 weeks
Comparison group: placebo
Sleep deprived (All) mean (SD) NR
(range 9–12 years)
ADHD None stated Unclear
Yu and Hong (2012)161
China
Before and after
N= 30 Acupuncture and ear-point taping.
Two courses of acupuncture treatment,
once every other day, three times a
week, with 36 sessions constituting
one course. Ear-point taping was given
three times a week, with 36 sessions
constituting one course. Two courses
were required
Problems with sleep
initiation, maintenance
and abnormal sleep
state (including
apnoea)
6.9 years (3.1 years) Learning
disability
None stated High
LD, learning disability; NR, not reported.
a This study was rated as having a low risk of bias for all domains except blinding, which was not possible owing to the nature of the intervention. However, in keeping with the guidance
outlined in Chapter 2, Assessment of risk of bias, it has been rated as having a high risk of bias, as the subjective outcomes may have been influenced by the lack of blinding.
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All but two of the parent-directed interventions were comprehensive in their content, that is, they included
training across three topic areas: sleep and sleep processes, sleep hygiene and the management of
specific problem behaviours (e.g. night wakings). The remaining two interventions, which were classified
as non-comprehensive parent-directed interventions, focused on a single topic area related to managing
sleep disturbance. One was concerned only with sleep hygiene training155 and the other focused on
particular behavioural strategies to manage specific problem behaviours.152
Assessment of risk of bias
A summary assessment of risk of bias for each RCT is provided in Table 5 and the full risk-of-bias assessment
involving each bias domain is provided in Appendix 21. Overall, the studies were rated as having a risk of
bias that was high (n = 24) or unclear (n = 2); therefore, the findings from these studies may not be robust.
Following the guidance outlined in Chapter 2, Assessment of risk bias, one study was rated as having a high
risk of bias, as blinded outcome assessment was not possible.138 However, this study had no other important
limitations and all other domains were rated as having a low risk of bias.
We were unable to find a registered protocol for 10 RCTs,21,36,49,107,124,125,127,128,152,156 making it unclear
whether or not the studies were free of selective reporting. Eight trials provided little or no detail regarding
sequence generation.21,36,49,107,124,127,152,157 Ten RCTs provided little or no detail regarding allocation
concealment.21,36,49,107,124,125,127,128,152,156 In all RCTs, blinded outcome assessment was not undertaken21,36,49,107,
125,127,128,138,152 or it was unclear whether or not blinding occurred.124,156 In eight RCTs, the analysis of
incomplete outcome data was not considered21,36,125,128,152 or it was unclear whether or not the authors had
considered this.107,124,127
Eleven non-randomised designs21,123,126,146,149,155,159–163 were reported as having a risk of bias owing to a
probable or unclear risk of confounding of the effect of the intervention. Fourteen studies were reported as
having a risk of bias because of how they selected participants, for example by not reporting inclusion and/or
exclusion criteria, selecting participants from one setting only or including more males than females.21,123,126,
129,146,149,151,155,158–163 There was likely or unclear bias reported in the measurement of intervention outcomes
in seven studies, for example few or no details provided about how outcomes were measured.21,126,146,159–161
One further study160 was reported as having unclear bias because of departures from intended interventions,
owing to missing data and to the selection of the reported results.
Parent-directed tailored interventions
Nine studies evaluated parent-directed, comprehensive tailored interventions (Table 6). Seven studies
evaluated the clinical effectiveness of these interventions: three two-armed parallel-group RCTs107,124,138
with a range of no intervention comparators (i.e. usual care, waiting list control or non-sleep related parent
education); and four before-and-after studies.21,123,126,146 Two further RCTs21,125 evaluated alternative ways
of delivering an intervention. One compared the mode by which implementation support was provided:
home visit versus telephone call.21 The other compared the intensity of practitioner involvement when
delivering the intervention: brief versus extended.125
Six studies included children with a range of neurodevelopmental conditions,21,123,124,126,146 two included
children with a diagnosis of ADHD125,138 and one included children with a diagnosis of ASD.107
Interventions varied in terms of the total number of sessions delivered; the number of sessions spent in
assessment; the development of, and training in, a sleep management plan; the duration of the intervention;
and the mode of delivery (see Table 6). The number of assessment/training sessions ranged from one21,138 to
five107 sessions in the RCTs; and from two21,146 to four sessions123,126 in the other study designs. In the RCTs,
the intervention duration was one session,125 4 weeks138 and 10 weeks,21 and was not reported in two
studies.107,124 In the other studies,21,123,126,146 the duration of the intervention ranged from 6 to 28 weeks.
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TABLE 6 Details of parent-directed tailored interventions
Study
Total duration of
intervention
(including period
of implementation
support) Mode of delivery
Number of
sessions and
location
Mode of delivering implementation
support, and intensity, once regular
sessions with practitioner were
completed
Intervention
described as
developed for
specific ND? Manual?
Follow-up, from
baseline
RCTs
Hiscock et al.
(2015)138
4 weeks Face to face One (home or clinic) Face to face (n= 1), later followed by a
telephone call (n= 1)
Yes, ADHD No 3 and 6 months
Johnson et al.
(2013)107
NR Face to face Five (home and clinic) Face to face (n= 1) Yes, ASD Yes 1 and 2 months
Moss et al. (2014)124 15 weeks Teaching workshops
and face to face
Two workshops and
one face-to-face
session (home)
Home visit (n= 1), followed by telephone
calls, ‘on a needs basis for approximately
2 months’
No Yes 15 and 23 weeks
Before-and-after studies
Austin et al. (2013)123 15 weeks Teaching workshops
and face to face
Two workshops,
one home visit and
one workshop
Approximately weekly telephone call for
6-week period
No Yes 19 weeks
Beresford et al.
(2012)21
12–16 weeks Face to face Two (clinic, home) Fortnightly sessions at clinic No No 12 and 24 weeks
Quine and Wade
(1991)146
6–28 weeks Face to face Two (home) Described as ‘weekly’ home visits,
although study authors also report
frequency decided between practitioner
and parent and diminishing in intensity
No Yes 3 months
Weiskop et al.
(2005)126
Minimum 7 weeks Face to face Four (a mixture of
home and clinic),
plus at least weekly
telephone contact
between sessions
‘Review session’ 5 weeks after session 4;
telephone calls ‘gradually reduced’ after
session 5
No Yes 3 and 12 months
RCT comparisons of intervention delivery
Beresford et al.
(2012)21
10 weeks Face to face One (home) Home visit approximately weekly
for 6–8 weeks vs. telephone call
approximately weekly for 6–8 weeks
No 10 and 22 weeks
Sciberras et al.
(2011)125
1 session vs. 4 weeks Face to face One (clinic) vs. two
(clinic)
None vs. telephone call (n = 1) followed
by a face-to-face session (clinic) if needed
Yes, ADHD No 2 months
NR, not reported.
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1
The intervention was delivered in the home and/or clinic for four RCTs107,124,125,138 and solely in the home
for one.21 All before-and-after study interventions were delivered in both homes and in clinics, apart from
one study, in which the intervention was delivered solely in the home.146 Implementation support in the
RCTs, once regular sessions were completed, ranged from none,125 to one or two further contacts107,138 and
to regular contacts over a period of several weeks.21,124 All before-and-after studies had implementation
support involving regular contact of between 6 and 28 weeks.21,123,126,146
The age of participants varied, with a mean age ranging from 2.67 to 12.1 years for the RCTs21,107,124,125,138
and from 2.88 to 5.1 years for the before-and-after studies.21,123,126,146 Most RCTs had more than one criterion
for inclusion in the trial and included children with a mix of sleep disturbances (see Table 6) relating to sleep
initiation only,125,138 sleep initiation and maintenance21,107 or sleep initiation, maintenance and scheduling.124
All before-and-after studies included children with sleep initiation and maintenance disturbances.21,123,126,146
There was limited reporting of prior interventions. Two RCTs excluded children who were already receiving
specialist sleep input138 or who were using sleep supplements.107 One RCT124 reported that children were
taking medication prescribed for behaviour and sleep problems; however, it was not clear if melatonin was
being taken to aid sleep. One before-and-after study126 reported that one child was taking medication for
behaviour and sleep problems.
Twenty-seven different sleep-related outcomes were measured (see Appendices 11–13). First outcome
measurement time points ranged from immediately post intervention to 2 months post intervention
(see Table 6). Five trials measured additional follow-up time points; however, in this review we focus
only on the outcomes closest to the end of the intervention.
Given the variation in interventions in terms of, for example, number of sessions, implementation support
and mode of delivery, as well as differences in comparator and length of follow-up, a narrative synthesis
was undertaken of the parent-directed tailored interventions.
Disorder global measures and composite scores
Total sleep time
Two RCTs (n= 284)107,138 reported actigraphy-measured TST and a before-and-after study126 presented parent-
reported TST. However, because of the way in which data were reported, we are unable to calculate the MD
from pre to post intervention or a CI.126 Sleep management interventions seek to increase duration of TST.
There was no evidence of a statistically significant difference in change in actigraphy-measured TST
from baseline to post intervention for a tailored parent-directed intervention compared with usual care
(MD 10.9 minutes, 95% CI –19.0 to 40.8 minutes).138 There was also no difference between the comparator
and intervention groups post intervention for a group receiving a tailored parent-directed intervention
compared with non-sleep-related parent education (MD 26.0 minutes, 95% CI –35.1 to 87.1 minutes).107
Sleep efficiency
Two RCTs (n = 284)107,138 reported actigraphy-measured sleep efficiency, that is, the ratio of TST to total
time in bed, informed by or verified using sleep diaries. Greater sleep efficiency is preferable. There was
no evidence of a statistically significant difference in change in actigraphy-measured sleep efficiency
from baseline to post intervention for a tailored parent-directed intervention compared with usual care
(MD –1.6%, 95% CI –5.2% to 1.9%),138 or in the difference between groups post intervention for a
tailored parent-directed intervention compared with non-sleep-related parent education (MD –1.0%,
95% CI –7.6% to 5.6%).107
The Children’s Sleep Habits Questionnaire
Four RCTs (n = 310)21,124,125,138 and two before-and-after studies21,123 reported the CSHQ total score. The
CSHQ is a validated parent-reported assessment of child sleep.133 Higher scores on the CSHQ indicate a
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greater severity of the sleeping disturbance, either because of the frequency or number of different
behaviours presenting.
There was a statistically significant reduction (i.e. improvement) in total CSHQ score in one RCT of a
parent-directed tailored intervention compared with a usual care control. However, Hiscock et al.,138 in
another RCT, found no statistically significant improvement using a parent-directed tailored intervention
compared with waiting list control,124 although the direction of effect was in a positive direction. No
evidence of a difference was observed in the RCTs of extended versus brief intervention125 and face-to-face
implementation support compared with telephone-delivered implementation support,21 although the
direction of effect was the same (Table 7).
There was a decrease (i.e. an improvement) in total CSHQ score post intervention compared with pre
intervention in one before-and-after study;123 however, it was not possible to estimate the MD between
pre and post intervention in a second study as it was not a matched sample.21
TABLE 7 Outcome results for CSHQ score in parent-directed tailored interventions
Study
Time point, mean CSHQ score (SD)
MD (95% CI)Baseline Follow-up
RCTs
Beresford et al. (2012)21 Intervention group: 59.50
points (11.82 points)
Control group: 53.33 points
(4.27 points)
Intervention group: 52.17
points (11.44 points)
Control group: 53.33 points
(8.76 points)
–1.16 points
(–14.27 to 1.95 points)a
Hiscock et al. (2015)138 Intervention group: 57.8 points
(8.8 points)
Control group: 59.0 points
(7.8 points)
Intervention group: 50.1 points
(8.3 points)
Control group: 55.1 points
(8.6 points)
Adjusted: –6.6 points
(–8.5 to –4.6 points)b
–5.0 points
(–7.6 to –2.4 points)a
Moss et al. (2014)124 Intervention group:
56.20 points (9.38 points)
Control group: 51.38 points
(7.54 points)
Intervention group: 46.50
points (7.29 points)
Control group: 51.12 (6.51)
–4.62 points
(–10.83 to 1.59 points)a
Sciberras et al. (2011)125 NR Intervention group: (change
score) 5.09 points (5.12 points)
Control group: (change score)
6.82 points (8.02 points)
–1.73 points
(–7.11 to 3.65 points)c
Before-and-after studies
Austin et al. (2013)123 55.43 points (7.68 points) 47.57 points (9.14 points) –7.86 points
(–14.39 to –1.33 points)a
Beresford et al.
(2012)21
59.55 points (7.59 points) 56.57 points (10.77 points) Cannot be estimated.d
Effect size given as 0.42
NR, not reported.
a Estimated unadjusted difference at follow-up (post intervention) between intervention and control group for RCTs and
change from pre to post intervention for before-and-after studies.
b Reported in paper.
c Difference in change scores from baseline to 2 months between intervention and control groups.
d As not a matched sample (n= 11 pre intervention and n= 7 post intervention).
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Other global measures and composite scores
Several further composite scores and global outcome measures were reported by single studies. One RCT138
(n= 244) of a tailored parent-directed intervention compared with usual care reported a statistically significant
reduction in parent-reported moderate or severe sleep problems (Table 8). There appeared to be improvement
at follow-up in three further outcomes measured in two before-and-after studies (see Table 8).21,123
Sleep initiation
Sleep onset latency
One RCT (n = 40)107 reported actigraphy-measured SOL, the time from bedtime to sleep onset time, which
was verified using sleep diaries. One before-and-after study reported on SOL using sleep diaries123 and
another reported SOL using parent-completed visual graphs.126
There was no evidence of a statistically significant difference in SOL in the RCT107 of a tailored parent-directed
intervention compared with non-sleep-related parent education (MD 4 minutes, 95% CI –15.0 to 23.0
minutes). One before-and-after study showed no statistically significant difference pre and post intervention
(MD 43 minutes, 95% CI –30 to 116 minutes).123 The results reported in the other study126 are based on
visual graphs without any associated numerical data; therefore, we are unable to present a MD and CI.
Other sleep initiation outcomes
Two further before-and-after studies measured time to settle at night. One reported a statistically
significant improvement in time to settle at night (MD –91.3 minutes, 95% CI –112.6 to –69.9 minutes)146
and the other did not report data for any sleep initiation outcomes.126
TABLE 8 Other global and composite outcomes of parent-directed tailored interventions
Study Outcome
Time period, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Hiscock et al.
(2015)138
Moderate or severe sleep
problems – parent/caregiver
reported (none/mild and
moderate/severe)
NR but eligibility
criteria of ‘parent
reported moderate
to severe sleep
problems’
Intervention group:
30%
Comparison group:
56%
Adjusted odds ratio 0.30
(0.16 to 0.59)a
Difference in absolute risk
25.7% (14.1% to 37.3%)a
Before-and-after studies
Austin et al.
(2013)123
Sleep Disturbance Index NR NR No data reported other
than that pre- and post-
treatment scores differed
significantly (z=−2.37;
p< 0.05)
Beresford
et al. (2012)21
Parent-set child sleep goal(s) 2.64 (2.11) 6.50 (2.14) Cannot be estimatedb
Beresford
et al. (2012)21
Change in goal attainment
rating
N/A Improved: 75.0%
No change: 12.5%
Deteriorated:
12.5%
N/A
NR, not reported; N/A, not applicable.
a Reported in paper.
b As not a matched sample (n = 11 pre intervention and n= 8 post intervention).
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Sleep maintenance
Night wakings
Three before-and-after studies123,126,146 reported night wakings using parent-reported diaries (n = 46),
although each study defined the outcome differently.
One study reported a statistically significant reduction in the number of night wakings post intervention
(MD –2.7, 95% CI –3.0 to –2.4).146 Another showed a statistically significant reduction in the time in minutes
it took to settle the child after night wakings (MD –24.0 minutes, 95% CI –44.7 to –3.3 minutes).123 For the
third study,126 which measured number of night wakings per week, the results reported by the authors are
based on visual graphs without associated numerical data; therefore, we are unable to present the MD
and CI.
Other sleep maintenance outcomes
A variety of other outcomes related to sleep maintenance were reported by single studies. One RCT138
(n = 244) reported WASO (night waking duration and/or frequency after the child falls asleep) and found
no evidence of a statistically significant difference between a tailored parent-directed intervention and
usual care (Table 9). Another RCT125 (n = 27) comparing an extended versus brief intervention found that
there was a greater reduction (i.e. now ‘no’ or only a ‘mild’ sleep problem) in sleep problems at 2 months
for the extended intervention group compared with the brief intervention group. One before-and-after
study146 reported statistically significant improvements in mean minutes per night the child was awake, and
number of nights the child does not sleep in their own bed. Another before-and-after study126 reported
measuring the number of nights per week that the child fell asleep in their own bed and the number of
nights per week that the child co-slept; however, the authors reported insufficient data to determine the
effects of the intervention on these outcomes (see Table 9).
TABLE 9 Other sleep maintenance outcomes of parent-directed tailored interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs: sleep maintenance
Hiscock et al. (2015)138 WASO (minutes) NR NR 1.5 (–16.9 to 19.9)a
Sciberras et al. (2011)125 Parent/caregiver reported
‘no’ or ‘mild’ sleep problems
NR Intervention group:
25%
Control group: 64%
–39% (–74% to –4%)b
Before-and-after studies: sleep maintenance
Quine and Wade (1991)146 Mean minutes per night the
child was awake
70.2 (32.1) 3.2 (4.7) –67.0 (–90.4 to –43.6)c
Quine and Wade (1991)146 Number of nights child does
not sleep in own bed per week
5.6 (0.9) 0.1 (0.4) –5.5 (–6.3 to –4.7)c
Weiskop et al. (2005)126 Number of nights per week
that child fell asleep in own bed
NR NR NR
Weiskop et al. (2005)126 Number of nights per week
that child co-slept
NR NR NR
NR, not reported.
a Reported in paper, difference in change from baseline to 3 months.
b Estimated unadjusted difference in percentage at 2 months.
c Estimated change from pre to post intervention for sample of 15 children with waking problems.
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Child-related quality of life, daytime behaviour and cognition
Cognition outcomes
No studies reported child cognition outcomes.
Attention deficit hyperactivity disorder symptoms
Two RCTs (n = 271)125,138 reported on the severity of ADHD symptoms using the total score of the ADHD
Rating Scale IV,165 which is a validated parent- or teacher-completed questionnaire that has been used to
assess the presence and severity of symptoms by parents/carers of children with ADHD. A higher score
indicates more severe problems.
The authors of a RCT125 comparing an extended versus brief parent-directed tailored intervention reported
only that there was ‘minimal change in ADHD symptoms . . . across both groups at 2 and 5 months’.125
There was a statistically significant reduction in symptom severity as measured by the parent-reported
ADHD Rating Scale IV in another RCT138 comparing a tailored parent-directed intervention with usual care
(adjusted MD –3.7 points, 95% CI –6.1 to –1.2 points; unadjusted MD –3.5 points, 95% CI –6.5 to –0.5
points). However, the difference in the teacher-reported ADHD Rating Scale IV score was not statistically
significant at 3 months’ follow-up (adjusted MD –2.4 points, 95% CI –5.3 to 0.4 points; unadjusted MD
–5.3 points, 95% CI –9.2 to –1.4 points).
Pediatric Quality of Life Inventory
Two RCTs125,138 (n = 271) reported on the child’s quality of life using the Pediatric Quality of Life Inventory
(PedsQL) version 4.0. The PedsQL is a validated parent-completed questionnaire that assesses parents’
perception of quality of life in paediatric patients with chronic health conditions. Higher scores indicate
better health-related quality of life.
There was a statistically significant improvement in the PedsQL in one RCT138 comparing a tailored parent-
directed intervention with usual care (adjusted MD 9.4 points, 95% CI 5.6 to 13.2 points; unadjusted MD
10.6 points, 95% CI 6.0 to 15.2 points). In the other RCT, there was no statistically significant difference in
change scores from baseline to 2 months between groups receiving the extended versus brief formats of a
parent-directed tailored intervention on the PedsQL (MD 4.27 points, 95% CI –2.48 to 11.02 points).125
Daytime behaviour
Three RCTs (n = 297) of parent-directed tailored interventions reported other child-related quality of life,
daytime behaviour and cognition outcomes.124,125,138 These data are summarised in Table 10. Hiscock
et al.138 reported statistically significant improvements in the Daily Parent Rating on the Evening and Morning
Behaviour Scale score, in parent- and teacher-reported Strengths and Difficulties Questionnaire scores and
in backwards digit recall, a parent-directed tailored intervention, compared with the usual care control
group.138 Another RCT124 reported that there was no statistically significant difference in the Developmental
Behaviour Checklist when comparing a parent-directed tailored intervention with waiting list control.
A third RCT125 found that there was no statistically significant difference between extended and brief format
sessions in the Daily Parent Rating on the Evening and Morning Behaviour Scale score.
For the before-and-after studies, one123 reported a statistically significant improvement in the Developmental
Behaviour Checklist166 post intervention. A second before-and-after study146 evaluated child daytime
behaviour and cognition using the Behavior Problem Index (BPI)167 and reported a statistically significant
reduction in total BPI score. A third before-and-after study126 evaluated children’s sleep behaviour goals and
reported improvements post intervention, although we were unable to report the MD and CI, as the authors
provided insufficient data to enable this.
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TABLE 10 Other outcomes of parent-directed tailored interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
Child-related quality of life, daytime behaviour and cognition
RCTs
Hiscock et al.
(2015)138
Daily parent rating of
evening and morning
behaviour (total)
Intervention group:
22.6 points
(5.0 points)
Control group:
22.7 points
(5.8 points)
Intervention group:
16.6 (5.8 points)
Control group:
21.0 (5.8 points)
Adjusted: –4.7 points
(–6.5 to –2.8 points)a
–4.4 points
(–6.2 to –2.6 points)b
Hiscock et al.
(2015)138
SDQ – parent report
(total)
Intervention group:
22.6 points
(5.7 points)
Control group:
21.9 points
(5.4 points)
Intervention group:
18.6 points (5.0 points)
Control group:
21.4 points (5.4 points)
Adjusted: –3.0 points
(–4.3 to –1.7 points)a
–2.8 points
(–4.4 to –1.2 points)b
Hiscock et al.
(2015)138
SDQ – teacher report
(total)
Intervention group:
15.0 points
(7.3 points)
Control group:
17.2 points
(6.8 points)
Intervention group:
13.5 points (6.6 points)
Control group:
17.2 points (6.8 points)
Adjusted: –1.7 points
(–3.4 to –0.1 points)a
–3.7 points
(–5.7 to –1.7 points)b
Hiscock et al.
(2015)138
Backwards digit
recall
NR NR Adjusted: 5.2 points
(0.03 to 10.4 points)a
Moss et al. (2014)124 Developmental
Behaviour Checklist
(Parent Version)
Intervention group:
66.20 points
(25.66 points)
Control group:
72.29 points
(16.50 points)
Intervention group:
57.70 points
(27.10 points)
Control group:
69.25 points
(14.95 points)
11.55 points
(–31.61 to 8.51 points)b
Sciberras et al.
(2011)125
Daily Parent Rating
on the Evening and
Morning Behaviour
scale
NR Intervention group:
(change score) 4.13 points
(9.63 points)
Control group: (change
score) 0.67 points
(3.77 points)
3.46 points
(–2.43 to 9.35 points)c
Before-and-after studies
Austin et al.
(2013)123
Developmental
Behaviour Checklist
(Parent Version)
87.00 points
(25.81 points)
74.57 points
(27.96 points)
12.43 points
(2.25 to 22.61 points)d
Quine and Wade
(1991)146
BPI 13.0 points
(4.6 points)
9.7 points (4.3 points) –3.3 points
(–5.1 to –1.5 points)d
Weiskop et al.
(2005)126
Child’s sleep
behaviour goals
NR 12/25 goals (48%) were
achieved with 100%
success, and the mean
achievement scale was
76.3%
N/A
BPI, Behavior Problem Index; N/A, not applicable; NR, not reported; SDQ, Strengths and Difficulties Questionnaire.
a Reported in paper.
b Estimated unadjusted difference at follow-up between intervention and control group.
c Estimated difference in change scores.
d Estimated change from pre to post intervention.
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Other child-related sleep outcomes
Parent help-seeking for sleep problem
One RCT138 (n = 244) collected parent reports of other professional help sought for their child’s sleep.
Parents of children in the intervention group were less likely than parents of children in the control group
to seek help for their child’s sleep from a health professional (e.g. general practitioner, paediatrician
or psychologist) (14% vs. 20% at 3 months), but this difference was not statistically significant.
School attendance
Two RCTs (n = 271) reported on school attendance, defined as the number of days missed from school.125,138
Both reported only that there was no difference in this outcome between the intervention groups.125,138
Parent-related outcomes
Three RCTs124,125,138 and one before-and-after study146 reported parent-carer-related outcomes. The outcomes
measured and methods of assessment are summarised in Appendix 12.
Depression Anxiety Stress Scales
Two RCTs (n = 271) reported on parental stress using the Depression Anxiety Stress Scales (DASS).125,138 The
DASS are a validated self-report instrument designed to measure the three related negative emotional states
of depression, anxiety and tension/stress. Higher scores indicate worse depression, anxiety and stress.
There was no evidence of a statistically significant difference in the DASS for a parent-directed tailored
intervention compared with usual care (adjusted MD –5.3 points, 95% CI –13.0 to 2.4 points; unadjusted
MD –5.3 points, 95% CI –13.1 to 2.5 points).138 Sciberras et al.125 found no evidence of a statistically
significant difference in change scores from baseline to month 5 (data not available for 2-month follow-up)
between the extended and brief intervention groups (MD 1.82 points, 95% CI –1.03 to 4.67 points).
Other parent-/carer-related outcomes of parent-directed tailored interventions
Two RCTs (n = 53)124,125 and one before-and-after study146 reported other parent-/carer-related outcomes of
parent-directed tailored interventions. These data are summarised in Table 11. These outcomes focused on
parental stress and morale124,146 and parent work attendance.125
There was a statistically significant reduction (i.e. improvement) in the Parenting Stress Index – Short
Form when comparing a parent-directed tailored intervention with a waiting list control.124 Another RCT125
found a statistically significant difference in parent work attendance for an extended versus a brief version
of a parent-directed tailored intervention.
The before-and-after study found both a statistically significant reduction in maternal stress, as measured
by the Malaise Inventory, and an improvement in maternal morale, as measured by the Cantrill ladder,
from pre to post intervention.146
Measures of perceived parenting confidence and/or efficacy and/or understanding of
sleep/sleep management
One RCT21 and two before-and-after studies21,146 reported on measures of perceived parenting confidence
and/or efficacy and/or understanding of sleep/sleep management. Details of how these were measured are
summarised in Appendix 13.
Parenting Sense of Competence scale and satisfaction and efficacy subscales
One RCT (n = 13)21 and one before-and-after study (n = 12)21 used the Parenting Sense of Competence
(PSOC) scale.168 The PSOC scale is a validated self-completed questionnaire. A higher score indicates a
higher sense of parenting competence.
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No evidence of a statistically significant difference was found in the RCT comparing modes of delivering
implementation support (face to face vs. telephone) for either the satisfaction (MD 6.17 points, 95% CI
–5.75 to 18.09 points) or the efficacy (MD –0.50 points, 95% CI –9.66 to 8.66 points) subscales of the
PSOC scale.21 Both satisfaction and efficacy subscale scores increased post intervention in the before-and-
after study; however, a MD and CI was not calculated, as the summary data presented were not reported
for a matched sample pre and post intervention.21
Other measures of perceived confidence and/or efficacy and/or understanding of
sleep/sleep management
One before-and-after study146 measured improvement in parental knowledge of behavioural principles using the
Knowledge of Behavioural Principles as Applied to Children test.169 The Knowledge of Behavioural Principles as
Applied to Children test is a validated multiple choice instrument that assesses verbal understanding of basic
behavioural principles. Higher scores indicate better knowledge scores. There was a significant improvement
between pre and post intervention in the parents’ knowledge scores (MD 2.2 points, 95% CI 1.7 to 2.7 points).
Summary
Nine studies evaluated parent-directed, comprehensive tailored interventions.21,107,123–126,138,146 There were
five RCTs,21,107,124,125,138 three of which107,124,138 were rated as having a high risk of bias and compared the
intervention with usual care or other control, one125 of which was rated as having a high risk of bias and
compared brief with extended versions of an intervention and another of which21 was rated as having a
high risk of bias and compared different modes of delivering implementation support. There were also four
before-and-after studies21,123,126,146 that were rated as having a high or an unclear risk of bias. The mean
age of participants ranged from 2.7 to 12.1 years. The majority of studies21,123–126,138,146 included children
with a mixed range of NDs, with three studies107,125,146 including children with a single condition. The
majority of studies21,107,123,126,146 also included children with a mix of sleep disturbances, mainly sleep
initiation and/or sleep maintenance problems.
TABLE 11 Other parent-/carer-related outcomes of parent-directed tailored interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Moss et al.
(2014)124
Parenting Stress
Index – Short Form
Intervention group:
89.30 points
(18.70 points)
Control group: 103.63
points (20.04 points)
Intervention
group: 80.50 points
(15.23 points)
Control group:
103.00 points
(21.84 points)
–22.50 points (–39.02 to
–5.98 points)a
Sciberras et al.
(2011)125
Parental work
attendance
NR NR ‘At three months, intervention
parents reported fewer days late
for work as a result of their child’s
behaviour than control parents
(p = 0.02, non-parametric test for
trend) and fewer missed days at
work (p= 0.03)’
Before-and-after studies
Quine and
Wade (1991)146
Maternal stress
(Malaise Inventory)
6.4 points
(4.1 points)
3.8 points
(2.8 points)
–2.6 points (–1.5 to –3.7 points)a
Quine and
Wade (1991)146
Maternal morale
(Cantrill ladder)
6.7 points
(2.2 points)
7.6 points
(1.3 points)
0.9 points (0.2 to 1.6 points)a
NR, not reported.
a Estimated unadjusted difference at follow-up between intervention and control group for RCTs and change from pre to
post intervention for before-and-after studies.
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Although all of the studies used face-to-face sessions with parents (at home or in a clinic) as the primary mode
of delivery and were similar insofar as the content was classified as comprehensive, there was considerable
variation in the duration of the intervention, the number of sessions delivered and the extent of implementation
support when the sessions had finished, for example through follow-up telephone contact.
Overall, there was mixed evidence about the effects of parent-directed tailored interventions compared with
usual care or other control, with limited evidence of benefit on more objective actigraphy child-related sleep
outcomes and more evidence of benefit on parent-reported child outcomes and a few parent outcomes.
Conclusions are hampered by the limited number of RCTs, the multitude of outcome measures and the
risk of studies being underpowered to detect an effect. A single study138 was rated as having a low risk
of bias for all domains except for blinding, as the outcomes may have been influenced by the lack of
blinded outcome assessment. This RCT138 of a parent-directed comprehensive tailored intervention (with
implementation support) compared with usual care, which provided the best available evidence identified,
reported a small increase in TST in favour of the intervention, but the lower CI covered the possibility of
worsening of TST (MD 10.9 minutes, 95% CI –19.0 to 40.8 minutes). A second RCT of a parent-directed
comprehensive tailored intervention (with implementation support) compared with usual care had a similar
finding (MD 26.0 minutes, 95% CI –35.1 to 87.1 minutes).107 There was also no statistically significant
improvement in other actigraphy-measured sleep outcomes with the intervention compared with control
(sleep efficiency, WASO, SOL), measured by either or both studies. There was a statistically significant
improvement in child sleep habits (CSHQ) and in parent-reported child sleep problems in one of these
studies,138 as well as child behaviour and quality of life (parent-reported ADHD Rating Scale IV, PedsQL,
Parent Daily Reporting of Morning and Evening Behaviour). The third RCT124 reported no statistically
significant difference in child behaviour (Developmental Behaviour checklist). One RCT138 reported no
statistically significant improvement in parental stress (DASS) with the intervention compared with control,
whereas another RCT124 reported a statistically significant improvement (Parenting Stress Index – Short
Form). The four before-and-after studies21,123,126,146 showed improvement across several child-related and
parent-related outcomes.
Based on a single RCT,21 there was no statistically significant difference in the clinical effectiveness of
home-delivered compared with telephone-based implementation support on child sleep outcomes
(CSHQ) or parental outcomes (PSOC scale). Based on a single RCT,125 there was a statistically significant
improvement in parental work attendance and parent-reported child sleep problems with an extended
versus brief intervention but no difference for multiple other child-related and parent-related outcomes.
Parent-directed non-tailored interventions
Eight studies evaluated parent-directed non-tailored interventions (Table 12): two two-armed parallel-group
RCTs,49,127 one three-armed parallel-group RCT49 and five before-and-after studies.129,149,151,162,163 Non-tailored
parent-directed intervention involves the delivery of a standard ‘training curriculum’. The curriculum may
include opportunities for a parent to be supported to operationalise the material learnt for their child’s sleep
disturbance. Some implementation support may also be included.
The interventions varied in terms of the number of training sessions, the mode of delivery and the provision
of implementation support. The number of sessions ranged from zero (leaflet provision only)127 to two for the
RCTs49 and from one149,163 to three and four sessions for the before-and-after studies.129,151,162 The duration
of the intervention was relatively short for RCTs, up to 2 weeks,128 but was longer for the before-and-after
studies, ranging from a single session149,163 to 7 weeks.151 Interventions also varied in terms of whether or not
‘implementation support’ was provided to parents. Some did not offer any implementation support (n = 3),
some offered it during training sessions only (n = 2) and others also offered it for a time-limited period
after all the sessions had been completed (n = 3). The curricula of four of the interventions included the
opportunity within sessions for parents to operationalise learning for their child’s specific sleep problem.
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TABLE 12 Overview of non-tailored interventions and study design
Study
Total duration
of intervention
Intervention details (active arms only)
Was the
intervention
described as
having been
developed for
a specific ND? Manual?
Length of follow-up,
from baselineMode of delivery
Number of
sessions over
which the
curriculum
was delivered
Was there an
opportunity to
operationalise
curriculum content
for the child’s sleep
problem?
Mode of delivering
implementation support, and
intensity, once curriculum
was delivered: mode and
intensity
RCTs
Adkins et al.
(2012)127
N/A Booklet N/A No None Yes, ASD N/A 2 weeks
Before-and-after studies
Beresford et al.
(2012)162
5 weeks Group 4 Yes None (but included within
curriculum for group session)
No Yes 5, 17 and 29 weeks
Beresford et al.
(2012)163
1 session Teaching workshop 1 No None No Yes 12 and 24 weeks
Bramble (1997)149 1 session Face to face (clinic) 1 Minimal (‘only minor
individual tailoring’)
Telephone calls on 3 consecutive
days after session. Additional
calls arranged if necessary
No Yes 2 weeks, 4 months
and 18 months
Reed et al. (2009)129 3 weeks Group 3 Yes None (but included within
curriculum for group sessions)
Yes, ASD Yes 7 weeks
Yu et al. (2015)151 7 weeks Group, plus weekly
telephone calls
3 Yes Weekly for 4 weeks Yes, ASD Yes 3, 7 and 11 weeks
RCT comparisons of intervention delivery
Montgomery et al.
(2004)49
N/A vs. 1 session Booklet vs. face to face N/A vs. 1 No vs. no None vs. none No Yes 6 weeks
Malow et al. (2014)128 2 weeks Face to face vs. group 1 vs. 2 Yes Weekly telephone call (n= 2)
after sessions completed
Yes, ASD Yes 1 month
N/A, not applicable.
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1
The RCTs investigated interventions delivered both via written materials and through individual work
(face to face and telephone calls). The mode of delivery was in booklet format for two RCTs49,127 and was
face to face for the third RCT, which was supplemented with two weekly telephone calls.128 The mode of
intervention delivery for the before-and-after studies was predominantly in group format, apart from in
one study.149 Implementation support was included in two before-and-after studies, which took the form
of telephone calls for 3 days following the initial session for one study149 and weekly for 4 weeks for
the other.151
The comparators in the three trials were no intervention,127 individual versus group delivery of an intervention128
and, in a three-arm trial, written material versus face-to-face delivery of material versus no intervention control.49
For four interventions, study authors reported that the content of the intervention was informed by the
nature of the target population, namely children with ASDs.
One RCT and three before-and-after studies included children with a range of NDs.49,149,162,163 Two RCTs
and two before-and-after studies included children with ASD only.127–129,151
The age of participants ranged from 2 to 5.9 years in the RCTs,49,127,128 and from 4.8 to 8.9 years for the
before-and-after studies.129,149,151,162,163 Children in the RCTs had problems with sleep initiation127,128 and
problems with both sleep initiation and maintenance.49 Children in the before-and-after studies had
problems with both sleep initiation and maintenance, with the exception of one study.162 Only one study149
reported on whether or not the child had received any prior interventions.
Table 12 provides an overview of the studies evaluating the non-tailored parent training interventions.
The RCTs49,127,128 reported on five outcomes and the before-and-after studies129,149,151,162,163 reported on 10
outcomes. The most commonly reported outcome measures used were the CSHQ,127–129,151,162,163 TST,127,128,151
SOL,127,128,149,151 WASO127,128,151 and child daytime behaviour.128,129,149,151 No studies measured child cognition
outcomes.
Sixteen different sleep-related outcomes were measured (see Appendices 14–16). The first outcome
measurement time points ranged from 2 weeks to 7 weeks from baseline (see Table 12). Four trials149,151,162,163
measured additional follow-up time points; however, in this review, we focus only on the outcomes closest
to the end of the intervention.
Given the variations in intervention characteristics (e.g. mode of delivery, number of sessions, availability of
implementation support), study design and study objectives, it was not considered appropriate to pool the
RCT data. Therefore, the studies are described in a narrative synthesis.
Child-related outcomes
The outcomes measured and methods of assessment are summarised in Appendix 14.
Global measures and composite scores
Total sleep time
Two RCTs (n = 116)127,128 and one before-and-after study (n = 25)129 evaluated actigraphy-measured TST
informed by the use of sleep diaries following existing guidance on the interpretation of actigraphy data.134
In one of the RCTs,127 no evidence of a statistically significant difference in actigraphy-measured TST was
found for an intervention comprising the provision of written information compared with no intervention
(MD 12.2 minutes, 95% CI –25.1 to 49.5 minutes). A similar finding was reported by the RCT that
compared the modes of delivering a sleep management training curriculum to parents (i.e. face to face vs.
group) [MD –7.2 minutes (favours group intervention), 95% CI –29.7 to 15.3 minutes].128 The authors also
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report the findings of a post hoc analysis, pre and post intervention, for the two groups combined, which
are not described in this report.
The before-and-after study129 narratively reports that there were no ‘significant changes’ in TST following a
group intervention.
Sleep efficiency
Two RCTs (n = 116)127,128 reported actigraphy-measured sleep efficiency (the percentage of time spent in
bed asleep) informed or verified by sleep diaries. The authors of the RCT127 that evaluated the provision
of sleep management training via written material, compared with no intervention, report a statistically
significant difference in the mean change (baseline to treatment) for the two groups (p = 0.04); however,
we were able to calculate the unadjusted difference between the two groups only post intervention and
this difference was not statistically significant (MD 2.7%, 95% CI 2.0% to 7.4%). Similarly, no significant
difference in this outcome was reported by the RCT128 that compared face-to-face delivery with group
delivery of an intervention (MD –1.1%, 95% CI –3.6% to 1.4%). The authors also report the findings of a
post hoc analysis for sleep efficiency, pre and post intervention, for the two groups combined, which are
not described in this report.
The Children’s Sleep Habits Questionnaire
One RCT (n = 80)128 and four before-and-after studies (n = 126)129,151,162,163 reported the CSHQ total score.
The CSHQ is a validated parent-reported assessment of child sleep.133 Higher scores on the CSHQ indicate
a greater severity of the sleeping disturbance resulting from either the frequency or number of different
behaviours presenting. The RCT reported the CSHQ results only for all participants in the two treatment
groups (combining participants receiving group and individual education) and not for each group separately.
For the RCT,128 there was no statistically significant difference in total CSHQ score post intervention between
the group receiving face-to-face delivery and the group delivery arm (Table 13). In a post hoc analysis, the
authors report merging the two arms and report combined before-and-after outcomes, which are not
described here. Two before-and-after studies, one evaluating a three-session group-delivered intervention129
TABLE 13 Outcome results for CSHQ of parent-directed non-tailored interventions
Study
Time point, mean CSHQ score (SD)
MD (95% CI)Baseline Follow-up
RCTs
Malow et al. (2014)128 NR NR NR
Before-and-after studies
Beresford et al. (2012)162 57.86 (9.76) 51.79 (8.91) Cannot be estimated.a
Effect size given as 0.20
Beresford et al. (2012)163 56.58 (9.50) 55.56 (10.76) Cannot be estimated.b
Effect size given as 0.02
Reed et al. (2009)129 56.63 (9.21) 49.74 (9.24) –6.89 points
(–2.58 to –11.2 points)c
Yu and Hong (2015)151 55.11 (8.38) 51.76 (7.53) –3.34 points
(–1.4 to –5.3 points)d
NR, not reported.
a MD could not be calculated as it is not a matched sample (pre intervention, n= 21; post intervention, n= 14).
b MD could not be calculated as it is not a matched sample (pre intervention, n= 24; post intervention, n= 18).
c The change from pre to post intervention.
d The change from pre to post intervention, which was calculated using the SD of MD reported in the paper, from which
the 95% CI was estimated.
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and the other evaluating a four-session group-delivered intervention with implementation support,151 report
a statistically significant improvement (i.e. a decrease) in CSHQ total score post intervention compared with
pre intervention. For two additional before-and-after studies,162,163 it was not possible to estimate the MD in
total CSHQ score between pre and post intervention, as they were not matched samples; however, the
studies report small or very small effect sizes.
Parent-set child sleep goals
Two before-and-after studies (n = 47) – one evaluating a single-session group-delivered intervention163 and
the other evaluating a group-delivered intervention over four sessions162 – reported parent-set child sleep
goals using a goal attainment rating scale. This was a 10-point rating scale used to indicate the extent to
which a goal has been achieved, from 1 = very far from this goal to 10 = I have achieved my goal.
Both studies reported that, post intervention, the mean goal attainment rating had ‘significantly improved’
compared with the pre-intervention rating. It was not possible to estimate the MD between the scores at
pre and post intervention, as neither study reported data for a matched sample.
These same before-and-after studies162,163 also reported the proportion of children that had improved,
deteriorated or not changed in the goal attainment rating (improvement/deterioration based on whether
or not the goal scores have moved 1 point in a positive or negative direction). Both studies reported that,
post intervention, the majority of parents reported an improvement in goal attainment rating compared
with pre intervention. In one study,162 93% of participants had improved and there was no change in the
other 7% and, in the other study,163 65% improved, 19% had no change and 16% had deteriorated.163
Family Inventory of Sleep Habits
One RCT (n = 80)128 and two before-and-after studies (n = 79)129,151 evaluated child sleep outcomes using
the Family Inventory of Sleep Habits (FISH). FISH is a validated parent-completed scale to assess sleep
hygiene in children with ASD170 and a higher score indicates better sleep hygiene.
The RCT128 reported the results of a post hoc analysis for all participants in the two treatment groups
(group and individual education) combined and not for each group separately; therefore, these data are
not reported here. One of the before-and-after studies129 also did not report data for the total score (only
for each item separately) and, therefore, they are not reported here. The other before-and-after study151
of a group-delivered sleep management intervention reported statistically significant improvements (data
reported only at week 11) in total FISH score post intervention compared with pre intervention (MD 1.38,
95% CI 0.05 to 2.71).
Composite sleep disturbance score
One RCT (n = 66)49 reported a composite sleep disturbance score. The composite sleep disturbance score
was calculated from parent-completed diaries to identify sleep problems, covering settling frequency,
settling duration, night waking frequency and night waking duration. A higher score on the composite
sleep disturbance score indicates more severe sleep problems.
This study compared no intervention with either the intervention delivered in written format or via a
face-to-face session and it reported that there was no statistically significant difference between these
delivery methods post intervention (MD 0.15, 95% CI –1.38 to 1.68). The trial also included a third,
‘control’, arm that received no treatment for the first 6 weeks after randomisation, following which
participants were re-randomised to receive either the conventional treatment or the booklet treatment.
The authors compared the two active arms (written format and face to face) with the control and found
statistically significant differences between the written format group and the control group (MD 3.20,
95% CI 1.89 to 4.51), and between the face-to-face format and the control group (MD 3.35, 95% CI
2.32 to 4.38).49
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Severity of sleep problems
One before-and-after study, evaluating an individually delivered parent-directed tailored intervention, used
a visual analogue scale to capture parent-reported ‘severity of sleep problems’, ranging in score from
0 = no problem to 10 = very severe problem.149 The author reported a statistically significant improvement
for the group post intervention compared with pre intervention but does not present sufficient data to
allow for a MD and 95% CI to be calculated.
Sleep initiation
Sleep onset latency
Two RCTs (n = 116)127,128 and two before-and-after studies (n = 40)129,149 listed SOL (the time from bedtime
to sleep onset time) as an outcome. Bramble149 described SOL as ‘mean time to settle’, whereas the other
studies described SOL as the time from bedtime to sleep onset time.
In the RCT evaluating the provision of written information, no evidence of a statistically significant
difference in SOL was found between this intervention and no intervention (Table 14).127 Similarly, the
authors of the second RCT128 comparing modes of delivery (individual vs. group) reported that they found
no evidence of a statistically significant difference between the two groups in terms of this outcome.
The authors also report the findings of a post hoc analysis for SOL, pre and post intervention, for the
two groups combined, which are not described in this report.
One before-and-after study129 only narratively reports that there were no ‘significant changes’ in SOL
following a group intervention. The other before-and-after study149 that evaluated ‘mean time to settle’
reported a statistically significant reduction in mean time to settle following a face-to-face session.
Sleep maintenance
Wake after sleep onset
The outcome measure was WASO (night waking duration and/or frequency after the child falls asleep)
in two RCTs (n = 116)127,128 and one before-and-after study.129
TABLE 14 Outcome results for SOL of parent-directed non-tailored interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Adkins et al. (2012)127 SOL (minutes) Intervention group:
56.7 (27.1)
Control group:
52.1 (25.1)
Intervention group:
49.5 (26.7)
Control group:
61.3 (47.0)
–11.8 (–37.3 to 13.7)
Malow et al. (2014)128 SOL (minutes) Individual: 59.8 (31.6)
Group: 56.0 (25.2)
Individual: 39.5 (21.6)
Group: 39.7 (21.5)
–0.2 (–9.9 to 9.5)
Before-and-after studies
Reed et al. (2009)129 SOL (minutes) NR NR NR
Bramble (1997)149 Mean time to settle
(minutes)
58.6 (24.6) 15.8 (7.8) –42.8 (–61.0 to –24.6)
NR, not reported.
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The RCT127 comparing an intervention (provision of written material) with no intervention found that there
was no evidence of a statistically significant difference at follow-up between the two groups (MD 0.5,
95% CI –18.9 to 19.9). The RCT128 comparing individual and group delivery of an intervention also
reported that there was no statistically significant difference between the groups on this outcome measure
(MD –0.2, 95% CI –9.9 to 9.5). When the two treatment groups were combined, the mean change from
pre to post intervention was –3.5 minutes (95% CI –7.3 to 0.3 minutes). The before-and-after study only
narratively reports that there were no ‘significant changes’ in WASO following a group intervention.129
Child behaviour
Child behaviour was evaluated using four different outcome measures: (1) the Child Behavior Checklist
(CBCL), (2) the Repetitive Behaviour Scale – Revised (RBS-R), (3) the Parental Concerns Questionnaire (PCQ)
and (4) the BPI.
The Child Behavior Checklist
One RCT (n = 80)128 and one before-and-after study (n = 54)151 used the CBCL to investigate changes in
daytime behaviour problems.171 The CBCL is a validated parent-completed outcome measure for identifying
problem behaviour in children, which is comprised of eight subscales. A higher score indicates more severe
problems. Although the before-and-after study reported a total CBCL score, the RCT reported the following
subscales of the CBCL only: anxious/depressed, attention, ADHD and withdrawn.
The RCT comparing individual with group delivery of an intervention reported that there was no difference
between the two arms at follow-up, although data were not presented separately for the two groups.128
With the two groups combined, the mean change from baseline to post intervention was as follows:
anxious/depressed –2.2 (95% CI –3.7 to –0.7), attention –3.3 (95% CI –5.4 to –1.2), ADHD 0.54 (95% CI
–1.3 to 2.4) and withdrawn –2.8 (95% CI –4.8 to –0.8).
The before-and-after study evaluated a group-delivered intervention (with implementation support offered
via telephone) and did not find evidence of a statistically significant improvement in total CBCL scores post
intervention (week 7) (MD –0.91, 95% CI –2.48 to 0.66).151
The Repetitive Behaviour Scale – Revised
One RCT (n = 80)128 and one before-and-after study (n = 25)129 evaluated child daytime behaviour using
the RBS-R (total).172 A lower RBS-R score indicates fewer problems.
The authors of the RCT, comparing group and individual delivery, reported that they found no evidence
of a statistically significant difference in the change from baseline in daytime behaviours between the two
groups post intervention (data not provided). The authors also report the findings of a post hoc analysis for
RBS-R, pre and post intervention, for the two groups combined, which are not described in this report.128
In the before-and-after study129 that evaluated a group-delivered intervention, a statistically significant
improvement (i.e. decrease) was observed post intervention compared with pre intervention (MD –1.22,
95% CI –2.06 to –0.38).
The Parental Concerns Questionnaire
Two before-and-after studies (n = 79)129,151 evaluated child daytime behaviour using the PCQ.173 The PCQ is
designed as a parent interview screening instrument assessing the severity of developmental and associated
psychiatric symptomatology using a four-point scale. A higher PCQ score indicates more severe problems.
Both of the before-and-after studies129,151 evaluated group-delivered interventions, one of which included
implementation support.151 A total score could not be derived for one study,129 as the authors did not
report this (data reported for each subscale of the PCQ separately). The other study151 found no evidence
of a statistically significant change in the PCQ scores post intervention (data reported for week 11 only)
compared with pre intervention (MD –1.38, 95% CI –2.82 to 0.06).
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The Behavior Problem Index
One before-and-after study (n = 15)149 evaluated child daytime behaviour using the BPI.167 The BPI is a
validated parent-reported outcome measure of child behaviour. Higher scores indicate a greater level of
behaviour problems.
The authors reported the BPI at 4 months’ follow-up only and reported a statistically significant improvement
for the group post intervention, with a score of 22.1 (SD 12.4), compared with a pre-intervention score of
32.6 (SD 13.6) (MD –10.5, 95% CI 3.3 to 17.7).149
Child’s health-related quality of life
One RCT (n = 80)128 measured health-related quality of life using the PedsQL.174 The PedsQL is a validated
parent-completed questionnaire that assesses parents’ perception of quality of life in paediatric patients
with chronic health conditions. Higher scores indicate better health-related quality of life.
The authors of the RCT,128 comparing group delivery with individual delivery of a sleep management
intervention, reported that they found no evidence of a statistically significant difference in the change
from baseline in PedsQL score between the two groups post intervention (data not provided). The authors
also report the findings of a post hoc analysis for PedsQL, both pre and post intervention, for the two
groups combined, which are not described in this report.
Parent outcomes
Several studies assessed parent outcomes. The outcome domains assessed were mental well-being,129,149,151
quality of sleep149,151 and parents’ sense of competence.128,162,163
Quality of sleep
A before-and-after study (n = 15)149 of an individually delivered intervention with implementation support
measured self-reported quality of sleep using the Maternal Sleep Scale.175 The Maternal Sleep Scale is a
validated self-completed questionnaire that measures mothers’ sleep quality, with higher scores indicating
better sleep quality.
The authors reported the Maternal Sleep Scale scores at the end of the treatment phase and reported a
statistically significant improvement for the group post intervention, with a mean score of 7.1 (SD 2.3),
compared with a pre-intervention mean score of 4.1 (SD 2.3) (MD 3, 95% CI 1.7 to 4.3).149
A second before-and-after study (n = 54)151 of a group-delivered intervention with implementation support
used the Pittsburgh Sleep Quality Index to measure parents’ self-reported quality of sleep. The Pittsburgh
Sleep Quality Index is a validated self-report questionnaire that assesses sleep quality.176 Lower scores
denote a healthier sleep quality. No statistically significant change on this measure was reported following
the intervention (week 7) (MD –0.51, 95% CI –1.37 to 0.35).151
Parent/carer mental well-being
Two before-and-after studies (n = 79)129,151 assessed parental stress using the Parenting Stress Index – Short
Form.177 The Parenting Stress Index – Short Form is a validated self-completed outcome measure used for
measuring parenting stress. A higher score indicates higher levels of parental stress.
Both studies evaluated group-delivered interventions, one with implementation support151 and one
without.129 Neither reported a statistically significant change on the Parenting Stress Index – Short Form in
post-intervention compared with pre-intervention scores (Table 15).
A further before-and-after study149 assessed psychological distress using the Malaise Inventory. The Malaise
Inventory is a validated self-completed questionnaire that measures psychological distress.178 A higher score
on the Malaise Inventory indicates higher psychological distress. This study evaluating an individually
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delivered sleep intervention with implementation support reported a statistically significant improvement in
scores on the Malaise Inventory post intervention compared with pre intervention (see Table 15).149
Parenting sense of competence
One RCT (n = 80)128 and two before-and-after studies (n = 47)162,163 assessed parents’ sense of competence
using the PSOC scale.168 The PSOC scale is a validated self-completed questionnaire. A higher score
indicates a higher parenting sense of competence. This scale comprises two subscales: sense of efficacy
and parenting satisfaction.
The authors of the RCT,128 comparing group and individual delivery, reported that they found no evidence
of a statistically significant difference in the change from baseline in PSOC between the two groups
post intervention (data not presented). The authors also reported the findings of a post hoc analysis for
parenting sense of competence, both pre and post intervention, for the two groups combined, which are
not described in this report.
One before-and-after study162 reported a statistically significant improvement in the PSOC-efficacy (effect size
0.82), but not PSOC-satisfaction (effect size 0.38), from pre to post intervention, following a four-session
group intervention; however, a MD and 95% CI could not be calculated, as data were not reported for a
matched sample. The second before-and-after study163 reported very little change in scores on PSOC-efficacy
and PSOC-satisfaction 12 weeks after attending a single-session workshop (effect sizes –0.15 and 0.11,
respectively); however, a MD and 95% CI could not be calculated as data were not reported for a
matched sample.
Summary
Eight studies49,127–129,149,151,162,163 evaluated parent-directed non-tailored interventions to manage sleep
disturbance in children with NDs. We defined non-tailored interventions as those comprising the delivery
of a standard ‘training curriculum’. All the non-tailored interventions were comprehensive in their content,
covering material on sleep and sleep processes, sleep hygiene and the management of specific problem
behaviours (e.g. night wakings). Within this set of interventions, the design of the curriculum may include
opportunities for parents to be supported to operationalise the material learnt for their child’s sleep
disturbance. Some implementation support (i.e. support to parents as they implement new ways of
managing their child’s sleep disturbance) may also be included.
Compared with the tailored interventions reported in the previous section, the non-tailored interventions
evaluated by studies included in this review were much more diverse in terms of mode of delivery [i.e. written
material, group delivery (single vs. multiple sessions) and one-to-one work]. In addition, they differed in terms
of the extent to which they could accommodate the specific information and training needs parents may have
in terms of their own child’s condition and/or sleep problem. Furthermore, some included implementation
support, but others did not. When implementation support was provided, it was always via telephone calls.
The eight studies included one RCT127 that compared intervention (written material) and no intervention
and five before-and-after studies.129,149,151,162,163 Three129,151,162 evaluated a group-delivered intervention
comprising three or four sessions, one163 evaluated a single-session workshop and one evaluated an
TABLE 15 Outcome results for parent/carer mental well-being of parent-directed non-tailored interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
Reed et al. (2009)129 Parental Stress Index – Short Form 96.10 (23.40) 94.00 (23.00) –2.1 (–12.9 to 8.7)
Yu and Hong (2012)161 Parental Stress Index – Short Form 82.55 (8.15) 81.73 (8.32) 0.82 (–1.63 to 3.27)
Bramble (1997)149 Malaise Inventory 8.7 (4.3) 4.7 (3.9) –4.0 (–1.7 to –6.3)
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individually delivered intervention.149 One RCT49 compared two modes of delivering the same training
curriculum (written material vs. face-to-face session) with no intervention. The final RCT128 compared
delivery of the same training curriculum via group and individual delivery. All the studies were rated as
having a high risk of bias.
Four interventions127–129,151 were developed specifically for children with ASDs, and only children with these
conditions were recruited to the studies. In the remaining four studies,49,149,162,163 the interventions were
evaluated using samples of children with a range of NDs. The mean age of children recruited to the studies
ranged from 2.0 to 8.9 years. The majority of studies reported that the children had problems with both
sleep initiation and sleep maintenance.
The conclusions that can be drawn are limited, owing to the rating of the high risk of bias, the use of
post-intervention follow-up time points and the risk of studies being underpowered to detect an effect.
In addition, a large number of different outcome measures were used and these evaluated a range of
outcome domains. We organise the findings in terms of mode of delivery and, when relevant, availability
of implementation support.
A single trial evaluated the impact of an intervention comprising the provision of written information
(and no implementation support) with no intervention.127 There was no evidence of benefit at 2 weeks
post intervention, as measured using actigraphy-collected sleep outcomes data (TST, Sleep Efficiency, SOL
and WASO). Another three-armed trial49 compared the provision of written information or the delivery of
the same material via a single face-to-face session with a waiting list control group. Neither active arm
included the provision of implementation support. Evidence of benefit at 6 weeks post intervention,
based on a parent-report measure (composite sleep disturbance score), was reported for both modes of
intervention delivery compared with the control group (written information vs. control, MD 3.20, 95% CI
1.89 to 4.51; face-to-face delivery vs. control, MD 3.35, 95% CI 2.32 to 4.38). The study was not powered
to detect a difference between the two active arms. No other child outcomes, or parent outcomes, were
assessed by these studies. There is, therefore, mixed and very limited evidence regarding the impact that
the provision of written information with no implementation support has on child sleep outcomes only.
Given the differences in outcome measures, differences in post-intervention follow-up time points and
the high risk of bias for both studies, it is not possible to draw further conclusions regarding this sort of
intervention. Furthermore, no conclusions can be drawn regarding the relative benefits of written versus
face-to-face delivery of training on sleep management.
One before-and-after study149 evaluated an intervention comprising a single face-to-face training session
and implementation support available for up to 2 weeks after the session. The authors report significant
improvements post intervention on non-standardised sleep outcome measures and a standardised measure
of child behaviour (BPI) but data were not fully presented. Given the study limitations, no conclusions can
be drawn from this evidence.
Two before-and-after studies evaluated multisession (n = 3 or 4) group-delivered interventions for which
no implementation support was available after the group sessions were completed.129,162 In one study,
outcomes were reassessed immediately post intervention;129 in the other study, this took place 1 month
post intervention.162 Both studies report improvements in child sleep outcomes measured using the same
standardised parent-report measure (CSHQ) (for Beresford et al.,162 the pre- and post-intervention samples
were not matched and the reported effect size was 0.2; for Reed et al.,129 the MD was –6.89, with a
95% CI of –2.58 to –11.2) and, for one study (Beresford et al.162), using achievement of parent-set sleep
goals (progress towards goals, 93% of participants; no progress, 7% of participants). However, one of
the studies129 also used actigraphy to collect sleep outcomes data (TST, SOL, WASO). No benefits were
reported on these outcomes. Reed et al.129 also reported evidence of benefit in terms of parent-reported
child behaviour (RBS-R). A further before-and-after study151 also evaluated a multisession (n = 3) group-
delivered intervention but also offered implementation support after the group sessions had finished via
weekly telephone calls (duration unclear). This study also used the CSHQ to measure child sleep outcomes
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and reported significant improvements immediately post intervention (MD –3.34, 95% CI –1.4 to –5.3).
Child behaviour outcomes were also assessed (CBCL and PCQ) and no benefits were reported. Beresford
et al.162 also report significant improvements in self-reported parental efficacy but not parenting satisfaction
(PSOC scale); however, pre- and post-intervention samples were not matched so a MD and CI could not be
calculated. Reed et al.129 and Yu and Hong161 investigated parenting stress using the Parenting Stressing
Index; neither study reported a change in this outcome between pre- and post-intervention time points.
Yu and Hong161 also report no effect on parent-reported sleep quality (Pittsburgh Sleep Quality Index).
Taken together, there is some limited evidence of benefit for group-delivered interventions in terms of
parent-reported child sleep outcomes. We would again, however, note that these studies were rated as
having a high risk of bias. It is not possible to draw further conclusions with respect to other child, or
parent, outcomes.
A RCT128 compared delivery of the same training curriculum via a multisession (n = 2) group-delivered
intervention and a single intervention; both arms included the same level of implementation support. No
differences in outcomes (1 month post intervention) between the two modes of delivery were reported on
actigraphy-derived sleep outcomes (TST, Sleep Efficiency, SOL and WASO) or parent-reported measures of
child sleep (CSHQ and FISH), behaviour (CBCL and RBS-R) or quality of life (PedsQL). As this is a single
study that was rated as having a high risk of bias, and it is not clear if it was adequately powered, no
conclusions can be drawn.
The final mode of intervention delivery evaluated was a single workshop (5 hours) delivered to groups of up
to 20 parents.163 No implementation support was available. Parent-reported sleep outcome measures (CSHQ
and attainment of parent-identified sleep goals) were readministered 3 months after the workshop. Benefits
on these indicators were reported by the authors (PSOC-efficacy, effect size 0.82; PSOC-satisfaction, effect
size 0.38). However, MD and CIs could not be calculated, as the data were not reported for a matched
sample. Given that this mode of intervention delivery was evaluated by only a single study that was rated as
having a high risk of bias, no further conclusions can be drawn.
Non-comprehensive parent-directed interventions
Two studies evaluated parent-directed sleep management interventions, which we classified as being
non-comprehensive in their content, that is, the content of the training was focused on just one topic
area related to sleep disturbance (whereas interventions that were classified as comprehensive addressed
sleep and sleep processes, sleep hygiene and the management of specific problem behaviours, such as
night waking).
One intervention, evaluated using a cluster RCT152 with an attention control arm, comprised a tailored
intervention that was restricted to training parents on behavioural principles of managing problem sleep
behaviours, including functional analysis and behaviour management strategies. A single session with a
practitioner, delivered in families’ homes, was followed by telephone calls on at least a weekly basis to
support the implementation of sleep management strategies. The total duration of implementation
support was variable, continuing up to 3 months after the session with the practitioner. A description
of the ‘attention control’ intervention was not provided. Although this appears to be a cluster trial, the
description of the recruitment and randomisation processes is unclear and, so, for the purposes of this
analysis, we have treated it as if it were an individually randomised trial. There were insufficient data to
allow for any potential clustering and, in any case, the nature of the clustering was unclear.
A before-and-after study155 evaluated the second non-comprehensive intervention. This intervention was
restricted to training parents on principles of sleep hygiene only and was a single session delivered in a
clinic. No implementation support was provided.
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The mean age of participants in the RCT152 was 9.49 years and the children had a mixed range of NDs.
Neither the children’s ages nor their NDs were reported by the before-and-after study.155 Neither study
reported whether or not the child/parent had received any prior interventions.
A total of 37 sleep-related outcomes were measured in the RCT152 (see Appendices 15–17). Follow-ups
were conducted post intervention at ‘visit 4’ (approximately 1 month post randomisation) and ‘visit 6’
(approximately 3 months post randomisation). Here, when data are available for both time points, we
report data from visit 4 as, for the majority of the sample, contact with a sleep practitioner had ceased
by this point.152 A total of four sleep-related outcomes were measured in the before-and-after study155
(see Appendices 15 and 17). Follow-ups were conducted after 6 weeks, at the end of the intervention.
Table 16 provides an overview of the studies evaluating the non-comprehensive parent-directed
interventions.
Child sleep-related outcomes
Global measures and composite scores
Both the RCT153 (n = 30) and the before-and-after study155 (n = 23) reported global sleep outcomes and
composite scores, although they used different measures (Table 17).
The RCT152 of the intervention restricted to training on behaviour modification principles found a
statistically significant difference in Composite Sleep Index-measured child sleep compared with no
intervention at ‘visit 4’. There was no statistically significant difference in actigraphy-measured TST for
children in the intervention and control groups at visit 4. The before-and-after study,155 evaluating the
intervention providing training in sleep hygiene, reported a statistically significant improvement in CSHQ
total score at 6 weeks post intervention.
Sleep maintenance
The RCT152 (n = 30) of the intervention restricted to training on principles of behaviour modification
reported a variety of actigraphy-measured sleep maintenance outcomes.
TABLE 16 Details of ‘non-comprehensive’ parent-directed interventions
Study
Total
duration of
intervention
Mode of
delivery
Number of
sessions and
location
Opportunity to
operationalise
curriculum
content for
child’s sleep
problem?
Mode of
delivering
implementation
support, and
intensity, once
regular sessions
with practitioner
were completed
Intervention
described as
developed
for specific
ND? Manual?
RCTs
Wiggs
and Stores
(1998)152
Unclear Face to face
(home)
1 (home) Yes Weekly telephone
calls. Continued
for at least 1
month, total
duration unclear
No Yes
Before-and-after studies
Peppers,
et al.
(2016)155
1 session Face to face
(clinic)
1 (clinic) Yes None Yes, ADHD Unclear
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There were statistically significant reductions in fragmentation index (percentage of immobile phases
during sleep period that were ≤ 30 seconds of duration), movement during sleep and movement index
(percentage of sleep period spent moving) for both groups from pre intervention to visit 4; however,
the differences between the groups at follow-up were not statistically significant (Table 18).152
Other child outcomes
The RCT152 (n = 30) comparing the intervention restricted to training on behaviour modification principles
with an attentional-control-measured child daytime behaviour using the parent-completed, and teacher-
completed, Aberrant Behavior Checklist (ABC) (Table 19).179 No statistically significant differences on ABC
subscales (parent, or teacher, report) between the intervention and control arms were found post
intervention, except for the parent-reported stereotypies subscale.
TABLE 17 Outcome results for global measures and composite scores for other parent-directed interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Wiggs and Stores
(1998)152
Composite Sleep Index Intervention group:
6.73 (2.31)
Control group:
7.23 (2.26)
Intervention group:
3.79 (1.89)
Control group:
6.62 (1.89)
–2.83 (–4.24 to –1.42)a
TST (hours) Intervention group:
9.2 (0.3)
Control group:
9.1 (0.9)
Intervention group:
9.6 (0.6)
Control group:
9.4 (0.9)
0.2 (–0.4 to 0.8)a
Before-and-after studies
Peppers et al. (2016)155 CSHQ 50.13 (7.16) 43.74 (6.49) 6.4 (4.3 to 8.5)b
a The estimated unadjusted difference at follow-up between the intervention and control groups.
b As reported in the paper: the change from pre to post intervention.
TABLE 18 Outcome results for sleep maintenance of other parent-directed interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
Wiggs and Stores
(1998)152
Fragmentation index (%) Intervention group:
16.5 (3.7)
Control group:
17.8 (5)
Intervention group:
11.9 (4.1)
Control group:
11.9 (5.7)
0.0 (–3.7 to 3.7)a
Movement during sleep Intervention group:
1.9 (1.6)
Control group:
2.7 (2.9)
Intervention group:
1.4 (0.5)
Control group:
1.3 (0.8)
0.1 (–0.4 to 0.6)a
Movement index (%) Intervention group:
11.3 (5.1)
Control group:
13.1 (6.4)
Intervention group:
9.0 (2.7)
Control group:
8.8 (3.0)
0.2 (–1.9 to 2.3)a
a The estimated unadjusted difference at follow-up between the intervention and control groups.
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TABLE 19 Other child outcomes for non-comprehensive parent-directed interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Wiggs and Stores
(1998)152
ABC (parent report)a
Inappropriate speech Intervention group:
2.47 (2.88)
Control group: 4.53
(5.13)
Intervention group:
2.36 (1.95)
Control group: 4.38
(3.64)
–2.02
(–4.20 to 0.16)c
Hyperactivity Intervention group:
21.13 (9.69)
Control group: 24.20
(14.18)
Intervention group:
18.07 (11.12)
Control group: 22.31
(13.16)
–4.24
(–13.35 to 4.87)c
Stereotypies Intervention group:
3.93 (2.74)
Control group: 6.07
(4.59)
Intervention group:
2.86 (2.44)
Control group: 6.46
(3.71)
–3.60
(–5.95 to –1.25)c
Lethargy Intervention group:
7.20 (6.03)
Control group: 8.13
(6.63)
Intervention group:
5.14 (7.10)
Control group: 7.69
(8.78)
–2.55
(–8.52 to 3.42)c
Irritability Intervention group:
15.07 (7.40)
Control group: 15.07
(7.79)
Intervention group:
12.07 (8.46)
Control group: 14.54
(8.35)
–2.47
(–8.76 to 3.82)c
ABC (teacher report)b
Inappropriate speech Intervention group:
2.14 (3.51)
Control group: 1.50
(1.95)
Intervention group:
1.08 (1.93)
Control group: 1.42
(2.02)
–0.34
(–1.82 to 1.14)c
Hyperactivity Intervention group:
13.36 (8.53)
Control group: 14.43
(11.76)
Intervention group:
10.75 (8.00)
Control group: 8.33
(10.43)
2.42
(–4.53 to 9.37)c
Stereotypies Intervention group:
2.00 (2.39)
Control group: 3.93
(5.88)
Intervention group:
1.50 (2.35)
Control group: 3.00
(4.57)
–1.50
(–4.22 to 1.22)c
Lethargy Intervention group:
5.29 (4.12)
Control group: 10.36
(10.34)
Intervention group:
4.00 (4.71)
Control group: 4.42
(4.01)
–0.42
(–3.69 to 2.85)c
Irritability Intervention group:
7.93 (5.57)
Control group: 11.29
(11.19)
Intervention group:
6.83 (6.83)
Control group: 5.42
(7.05)
1.41
(–3.78 to 6.60)c
continued
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The before-and-after study155 (n = 23) of an intervention training in sleep hygiene principles reported a
statistically significant improvement in scores on an assessment tool capturing severity of ADHD symptoms.
Parent outcomes
The RCT152 (n = 30) comparing the intervention restricted to training on behaviour modification principles
with an attentional control reported on a range of parent outcomes, including:
l maternal TST (actigraphy)
l maternal fragmentation index (actigraphy)
l maternal movement during sleep (actigraphy)
l maternal movement index (actigraphy)
l maternal daytime sleepiness (Epworth Sleepiness Scale)
l paternal daytime sleepiness (Epworth Sleepiness Scale)
l maternal satisfaction with their own sleep (six-point Likert scale)
l paternal satisfaction with their own sleep (six-point Likert scale)
l maternal stress (Malaise Inventory)
l paternal stress (Malaise Inventory)
l maternal perceived ability to control difficult sleep-related behaviour of their child (visual analogue scale)
l paternal perceived ability to control difficult sleep-related behaviour of their child (visual analogue scale)
l maternal perceptions of their partner’s ability to control difficult sleep-related behaviour of their child
(visual analogue scale)
l paternal perceptions of their partner’s ability to control difficulty sleep-related behaviour of their child
(visual analogue scale).
Further details of how these outcomes were measured are provided in Appendix 22. The data are
summarised in Table 20.
We found no statistically significant differences between the groups at follow-up for any of these
outcomes except father’s satisfaction with child’s sleep.
TABLE 19 Other child outcomes for non-comprehensive parent-directed interventions (continued )
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
Before-and-after studies
Peppers et al. (2016)155 Vanderbilt Assessment
Scale – Parent Form
(questions 1–9)
11.39 (7.75) 7.52 (8.41) –3.87
(–7.37 to –0.37)c
Vanderbilt Assessment
Scale – Parent Form
(questions 10–18)
9.30 (9.08) 6.39 (8.51) –2.91
(–4.81 to –1.01)c
a Visit 4.
b Visit 6.
c The estimated unadjusted difference at follow-up between the intervention and control groups for RCTs and change
from pre to post intervention for before-and-after studies.
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TABLE 20 Other parent outcomes for other parent-directed non-pharmacological interventions (Wiggs and Stores152)
Outcome
Time period, mean (SD)
MD (95% CI)Baseline Follow-up
Global measures
TST (maternal) Intervention group: 6.9 (0.9)
Control group: 7.5 (0.8)
Intervention group: 7.6 (0.7)
Control group: 7.2 (1.4)
0.4 (–0.4 to 1.2)a
Sleep maintenance
Fragmentation index (%) Intervention group: 10.3 (4.5)
Control group: 10.4 (3.9)
Intervention group: 9.7 (3.9)
Control group: 9.8 (3.2)
–0.1 (–2.8 to 2.6)a
Movement during sleep Intervention group: 1.6 (1.2)
Control group: 1.5 (0.5)
Intervention group: 1.2 (0.5)
Control group: 1.6 (1.7)
–0.4 (–1.3 to 1.9)a
Movement index (%) Intervention group: 9.6 (3.7)
Control group: 10.6 (6.0)
Intervention group: 7.6 (4.2)
Control group: 7.2 (2.4)
0.4 (–2.2 to 3.0)a
Sleep scheduling (Epworth Sleepiness Scale)
Mothers Intervention group: 5.67 (4.32)
Control group: 7.47 (4.94)
Intervention group: 4.07 (2.67)
Control group: 6.31 (4.01)
–2.24 (–4.79 to 0.31)a
Fathers Intervention group: 10.38 (5.03)
Control group: 8.00 (4.71)
Intervention group: 9.83 (5.06)
Control group: 9.75 (3.77)
0.08 (–3.26 to 3.42)a
Quality of sleep (satisfaction with own sleep)
Mothers Intervention group: 4.27 (1.16)
Control group: 4.07 (1.44)
Intervention group: 2.93 (1.27)
Control group: 3.85 (1.57)
–0.92 (–1.99 to 0.15)a
Fathers Intervention group: 3.08 (1.26)
Control group: 2.67 (1.30)
Intervention group: 2.17 (1.03)
Control group: 2.50 (1.31)
–0.33 (–1.21 to 0.55)a
Other outcomes
Maternal stress Intervention group: 8.36 (4.27)
Control group: 8.73 (3.51)
Intervention group: 6.14 (4.96)
Control group: 8.69 (4.66)
–2.55 (–6.15 to 1.05)a
Paternal stress Intervention group: 5.27 (2.61)
Control group: 5.92 (3.85)
Intervention group: 4.25 (2.38)
Control group: 5.13 (4.16)
–0.88 (–3.41 to 1.65)a
Satisfaction with child’s
sleep (mother)
Intervention group: 3.67 (1.53)
Control group: 3.53 (1.36)
Intervention group: 3.29 (1.44)
Control group: 3.27 (1.27)
0.02 (–1.00 to 1.04)a
Satisfaction with child’s
sleep (father)
Intervention group: 4.62 (1.19)
Control group: 3.92 (0.90)
Intervention group: 2.50 (1.31)
Control group: 3.87 (1.36)
–1.37 (–2.37 to -0.37)a
Satisfaction with ability to
cope with child’s sleep
(mother)
Intervention group: 3.79 (1.53)
Control group: 3.27 (1.10)
Intervention group: 2.43 (0.94)
Control group: 2.77 (1.30)
–0.34 (–1.19 to 0.51)a
Satisfaction with ability to
cope with child’s sleep
(father)
Intervention group: 3.83 (2.67)
Control group: 2.67 (1.44)
Intervention group: 3.58 (1.19)
Control group: 3.38 (1.19)
0.20 (–0.69 to 1.09)a
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Measures of perceived confidence and/or efficacy and/or understanding of sleep/
sleep management
Both the RCT152 and the before-and-after study155 reported on measures of perceived confidence and/or
efficacy and/or understanding of sleep/sleep management.
The RCT152 reported on parents’ orientation to internal or external control beliefs as measured using the
internality/externality control scale. These data are summarised in Table 21 and details of how these outcomes
were measured are provided in Appendix 23. There were significant between-group differences for the father
measures. The before-and-after study155 measured perceived confidence and efficacy using a parent satisfaction
Likert-type scale. The authors narratively report that 87% of the responses were positive; however, it is unclear
whether or not these positive responses related to child’s sleep and/or the intervention.
Summary
Two studies evaluated tailored interventions that were non-comprehensive in terms of their content.
Thus, although comprehensive parent-directed interventions (tailored and non-tailored) covered material on
sleep and sleep processes, sleep hygiene and the management of specific problem behaviours (e.g. night
wakings), non-comprehensive interventions focused on just one of these aspects. Both non-comprehensive
interventions were, however, tailored interventions, that is, the intervention was personalised to the specific
child and family context.
A RCT152 evaluated a parent-directed intervention in which the content was restricted to behavioural
principles of managing problem sleep behaviour. This intervention was delivered via a single face-to-face
session followed by implementation support at least weekly for up to 3 months (duration as required).
The comparator group was an attention control in which parents attended a single session with a practitioner
(same duration as active arm, session content not described). We treated follow-up data collected 1 month
after the face-to-face session as post-intervention outcomes. The sample included a range of NDs and the
mean age of the children was 8.21 years. The rating of risk of bias was high.
Post intervention, an actigraphy-derived measure of sleep outcome (TST) was no different between the
intervention and control arms, with similar findings for other actigraphy-derived measures (fragmentation
index, movement during sleep and movement index). However, significant differences in scores post
TABLE 20 Other parent outcomes for other parent-directed non-pharmacological interventions (Wiggs and Stores152)
(continued )
Outcome
Time period, mean (SD)
MD (95% CI)Baseline Follow-up
Perceived ability to control
difficult sleep-related
behaviour of own child
(mother)
Intervention group: 5.51 (2.52)
Control group: 4.87 (2.96)
Intervention group: 7.21 (2.15)
Control group: 6.52 (2.00)
0.69 (–0.86 to 2.24)a
Perception of partner’s
ability to control difficult
sleep-related behaviour of
their child (mother)
Intervention group: 5.61 (3.00)
Control group: 4.38 (2.42)
Intervention group: 5.05 (2.26)
Control group: 6.19 (1.83)
–1.14 (–2.68 to 0.40)a
Perceived ability to control
difficult sleep-related
behaviour of own child
(father)
Intervention group: 5.42 (3.26)
Control group: 4.93 (2.96)
Intervention group: 5.35 (2.65)
Control group: 5.34 (2.50)
0.01 (–1.92 to 1.94)a
Perception of partner’s
ability to control difficult
sleep-related behaviour of
their child (father)
Intervention group: 6.46 (2.53)
Control group: 7.36 (2.26)
Intervention group: 5.60 (2.98)
Control group: 6.35 (2.51)
–0.75 (–2.81 to 1.31)a
a The estimated unadjusted difference at follow-up between the intervention and control groups.
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intervention on a parent-reported child sleep measure (Composite Sleep Index), favouring the intervention
group, were found (MD –2.83, 95% CI –4.24 to –1.42). In addition, post intervention, fathers’ (but not
mothers’) ratings of satisfaction with the child’s sleep (non-standardised measure) were higher for the
intervention group than for the control group (MD –1.37, 95% CI –2.37 to 0.37).
The study also assessed child behaviour (parent and teacher report) using five subscales (inappropriate
speech, hyperactivity, stereotypies, lethargy and irritability) of the ABC. Post intervention, no significant
differences between the intervention and control arms were found on any subscale scores except
parent-reported stereotypies. Here, a benefit to the intervention group was reported (MD –3.6, 95% CI
–5.95 to 1.25).
In terms of mothers’ and fathers’ outcomes, sleep outcomes [actigraphy-derived (mothers only): TST,
fragmentation index, movement during sleep; self-report: Epworth Sleepiness Scale, non-standardised
measure of satisfaction with sleep] and other outcomes (psychological distress (Malaise Inventory),
non-standardised measures of perceptions of own and partner’s ability to control child’s difficult
sleep-related behaviour) were monitored. No differences between intervention and control arms were
found post intervention for any of these outcomes.
Overall, given that there is just one trial – and it has a high risk of bias – no conclusions can be drawn
regarding the effectiveness of parent-directed sleep management interventions in which the content was
restricted to behavioural principles of managing problem sleep behaviour.
TABLE 21 Measures of perceived confidence and/or efficacy and/or understanding of sleep/sleep management:
non-comprehensive parent-directed interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Wiggs and Stores (1998)152 Internality (mother) Intervention group:
10.71 (3.29)
Control group:
9.60 (4.85)
Intervention group:
11.71 (4.12)
Control group:
9.85 (3.63)
1.86 (–1.04 to 4.76)a
Externality (mother) Intervention group:
12.29 (3.29)
Control group:
12.93 (4.71)
Intervention group:
11.50 (4.05)
Control group:
13.08 (3.64)
–1.58 (–4.46 to 1.30)a
Internality (father) Intervention group:
12.73 (5.14)
Control group:
12.00 (4.77)
Intervention group:
13.64 (4.59)
Control group:
10.38 (2.97)
3.26 (0.37 to 6.15)a
Externality (father) Intervention group:
10.27 (5.14)
Control group:
11.00 (4.77)
Intervention group:
9.36 (4.59)
Control group:
12.63 (2.97)
–3.27 (–6.16 to –0.38)a
Before-and-after studies
Peppers et al. (2016)155 Parent satisfaction NR NR 87% of the responses
were positive
NR, not reported.
a The estimated unadjusted difference at follow-up between the intervention and control groups.
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In the second non-comprehensive parent-directed intervention, the content was restricted to sleep
hygiene.155 This was evaluated using a before-and-after study design. The intervention, specific to children
with ADHD, was delivered via a single session between parent and practitioner. No implementation
support was offered. The ages of children recruited to the study were not reported. Risk of bias was high.
Follow-up was 6 weeks post intervention.
Post intervention, scores on the parent-reported CSHQ had improved (MD 6.4, 95% CI 4.3 to 8.5). A
measure of ADHD symptom severity was also used (Vanderbilt Assessment Scale), and improvements were
also reported on this measure post intervention (Vanderbilt Assessment Scale questions 1–9, MD –3.87,
95% CI –7.37 to 0.37; Vanderbilt Assessment Scale questions 10–18, MD –2.91, 95% CI –4.81 to 1.01).
(Changes in scores on a non-standardised measure of parent satisfaction were also reported, although it is
unclear if this is capturing satisfaction with the child’s sleep and/or the intervention per se).
In terms of this intervention, given that the evidence is limited to a before-and-after study with a high risk
of bias, no conclusions regarding its impact on children’s sleep or ADHD symptoms can be drawn.
Other non-pharmacological interventions
Seven studies36,156–161 evaluated other types of non-pharmacological interventions (see Table 9 and
Appendix 18).
One crossover RCT compared valerian (dried and crushed whole root from the Valeriana edulis plant)
with placebo;156 one crossover RCT compared weighted blankets with placebo blankets;36 one parallel RCT
compared faded bedtime with response costs and bedtime scheduling;157 three uncontrolled before-and-
after studies evaluated light therapy and a behavioural programme,158 an aquatic exercise programme159
and acupuncture and ear-point taping;161 and one controlled before-and-after study compared essential
fatty acid supplements with placebo.160
The total intervention duration ranged from 12 days to 36 weeks36,156,160,161 and was not specified in
two studies.158,159
Three studies included children with a mixed range of NDs.36,156,157 Two included children with learning
disabilities,158,161 one included children with a diagnosis of ASD159 and one included children with a
diagnosis of ADHD.160
The age of participants varied, with a mean age range of 6.7–10.8 years for the RCTs36,156,157 and a mean
age range of 2.9–8.8 years for the uncontrolled before-and-after studies.158,159,161 The controlled before-
and-after study reported the participants’ ages as between 9 and 12 years.160 All RCTs included children
with sleep initiation and sleep maintenance disturbances.36,156,157 The before-and-after studies included
children with a mix of sleep disturbances (see Table 9) relating to sleep maintenance and ‘lack of sleep
consolidation’,158 sleep dysfunction,159 ‘sleep deprived’160 and sleep initiation, maintenance and abnormal
sleep state.161
There was limited reporting of prior interventions. One parallel RCT reported that children were excluded if
they were receiving pharmacological interventions for sleep.157 One before-and-after study reported that
over half of the study sample had attended sleep clinics and centres for treatment, with some children
receiving behavioural treatments.158
A total of 17 child sleep-related outcomes were measured by the RCTs (see Appendix 18). Commonly
measured child sleep-related outcomes included SOL,36,156,157 night waking,36,156,157 TST,36,156 sleep
quality36,156 and child daytime behaviour and cognition.36,156 A total of 10 child sleep-related outcomes
were measured by the before-and-after studies (see Appendix 18) and these were mainly measured by
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single studies. The majority of outcomes reported by before-and-after studies were measured by single
studies. However, TST was measured by two studies.158,159
In all studies, follow-up was conducted immediately following the completion of the intervention, and this
varied between studies. For the RCTs, the follow-up times were at 2 weeks,156 at 4 weeks36 and after the
last 10 days of an ‘on average 8-week’ treatment.157 For the before-and-after studies, the follow-up times
were at 10 weeks160 and at 6 months.158 For one before-and-after study, the length of the follow-up was
unclear and it was reported as ‘after treatment’.161 The final study, Oriel et al.,159 adopted an A–B–A
withdrawal design, in which A was a control phase and B was a treatment phase. Outcomes were
reported at 4 (A1), 8 (B) and 12 (A2) weeks from the start of the intervention.159 We report all outcomes
for Oriel et al.159 at 8 weeks, which was when the intervention ceased.
Global measures and composite scores
Total sleep time
Two RCTs (n = 78)36,156 and two before-and-after studies158,159 (n = 22) reported TST (Table 22).
TABLE 22 Outcome results for TST of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Francis and Dempster
(2002)156
TST (hours) Combined: 9.93 (0.56) Intervention group:
10.28 (0.43)
Control group:
9.94 (0.7)
0.34 (–0.42 to 1.10)a
Gringras et al. (2014)36 TST (minutes)
(actigraphy)
Combined: 452.8 (59.7) Intervention group:
452.8 (65.0)
Control group:
455.4 (65.8)
–4.2 (–13.6 to 5.2)a
TST (minutes)
(sleep diary)
Combined: 531.8 (109.6) Intervention group:
528.9 (127.1)
Control group:
513.0 (154.1)
15.9 (–6.8 to 38.6)a
Before-and-after studies
Guilleminault et al. (1993)158 TST (minutes) Responders: 204 (24)
Non-responders: 192 (51)
Overall: 196 (40)
Responders:
425 (55)
Non-responders:
202 (40)
Overall: 281 (48)
Responders: 221
(162 to 280)b
Non-responders:
10 (–26 to 46)b
Overall:
85 (59 to 111)b
Oriel et al. (2016)159 TST (minutes) 493.59 (60.51) 576.91 (37.48) 83.32
(17.55 to 149.09)c
a Estimated unadjusted difference between intervention and control groups at follow-up.
b Estimated change from pre to post intervention.
c Estimated change from A1 to B.
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One study reported TST using actigraphy-verified sleep diary data,156 one study measured TST using sleep
diary and actigraph data;36 and one measured TST via ‘semiweekly’ telephone calls from researchers to
parents/guardians. Results show that there was no statistically significant difference in TST between
valerian and placebo groups.156 There was no statistically significant difference in actigraphy- or sleep
diary-reported TST for weighted blankets compared with control blankets.36 There was a statistically
significant increase in TST between periods A1 and B following an aquatic exercise intervention159 and
from pre to post intervention following light therapy and a behavioural programme.158
Other global measures and composite scores
One RCT36 (n = 73) and two before-and-after studies161 (n = 38) reported further global measures and
composite scores (Table 23). There was a statistically significant difference in Composite Sleep Disturbance
Index score (but not sleep efficiency) with weighted blankets compared with placebo blanket.36
Two before-and-after studies159,161 measured CSHQ total score (validated parent-reported assessment of
child sleep, with higher scores indicating a greater severity of the sleeping disturbance),159,161 although one
reported this only for baseline.159 A statistically significant reduction in total CSHQ score was reported
following acupuncture and ear-point taping post intervention.161
Sleep initiation
Bedtime settling
Two RCTs36,156 (n = 78) and one before-and-after study159 (n = 8) reported SOL (Table 24). One RCT reported
SOL using a sleep diary only156 and one used a parental diary and actigraphy.36 The before-and-after study
measured SOL via telephone calls from parents to researchers.159
There was no statistically significant difference in SOL with valerian treatment compared with placebo156
or following an aquatic exercise intervention.159 There was no statistically significant difference in
actigraphy- or parent-reported SOL for the RCT of weighted blankets.36
One RCT narratively reported exactly what time the child fell asleep at night.157 Among the eight participants
who had issues with sleep initiation at baseline, trained observers reported that three out of the four
participants who received the faded bedtime and response costs intervention experienced improved sleep
initiation during the last 10 days of treatment, with one participant continuing to have issues falling asleep.
TABLE 23 Other global measure and composite score outcomes of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Gringras et al. (2014)36 Sleep efficiency
(%)
Combined: 72.7 (8.8) Intervention group: 73.6 (9.5)
Control group: 74.2 (8.0)
–0.3 (–1.7 to 1.1)a
CSDI Combined: 12.2 (2.1) Intervention group: 10.8 (2.3)
Control group: 11.4 (2.0)
–0.7 (–1.3 to –0.1)a
Before-and-after studies
Yu and Hong (2012)161 CSHQ (total) 57.97 (4.58) 46.47 (5.13) –11.50
(–13.33 to –9.67)a
CSDI, Composite Sleep Disturbance Index.
a Estimated unadjusted difference between intervention and control group at follow-up for RCTs and change from pre to
post intervention for before-and-after studies.
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Of the three participants who reported sleep initiation issues at baseline and received ‘bedtime scheduling’
(the control), two participants improved, one worsened and one saw little difference to their sleep initiation
after 10 days of treatment.157
Sleep maintenance
Night waking
Three RCTs36,156,157 (n = 92 participants randomised) and one before-and-after study159 (n = 8) reported
night waking using actigraphy,156 sleep diary,36 observations157 and telephone calls from parents
to researchers.159
Results are summarised in Table 25. These show that there was no statistically significant reduction in time
awake during the night (night waking) following valerian treatment.156 There was no statistically significant
difference in number of night wakings following an aquatic exercise programme,159 although the baseline
number of wakings was very low, or for weighted blankets compared with placebo blankets.36
Piazza et al.157 narratively reported that all five participants who received the faded bedtime and response
costs intervention saw improvements to night wakings. Following bedtime scheduling of the six control
participants who had issues with night wakings at baseline, two participants improved, two saw little
difference and one had worsened night wakings.157
Other sleep maintenance outcomes
Two RCTs36,157 (n = 87) and one before-and-after study158 (n = 14) reported other outcomes related to sleep
maintenance (Table 26). The before-and-after study evaluating light therapy and a behavioural programme
reported sleep diary-measured ‘longest wake and sleep periods during a 24-hour cycle’. Data for this
outcome were reported only graphically and it was not possible to estimate results from the graph.158
One RCT narratively reported that all six of the participants who received the faded bedtime and response
costs intervention and had problems with early waking at baseline had improved on this outcome during
TABLE 24 Outcome results for sleep initiation of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Francis and
Dempster
(2002)156
SOL (minutes) Combined: 41.14
(20.99)
Intervention group: 23.49
(13.42)
Control group: 39.14 (34.68)
–15.65
(–53.31 to 22.01)a
Gringras et al.
(2014)36
SOL (minutes)
(actigraphy)
Combined: 76.5 (46.1) Intervention group: 71.4 (48.2)
Control group: 70.6 (44.3)
2.1 (–5.5 to 9.7)a
SOL (minutes)
(sleep diary)
Combined: 69.9 (47.6) Intervention group: 55.6 (37.8)
Control group: 57.2 (42.8)
–1.6 (–6.7 to 3.5)a
Before-and-after studies
Oriel et al.
(2016)159
SOL (minutes) 38.95 (21.19) 21.76 (15.94) 19.11
(–40.95 to 6.57)a
a Estimated unadjusted difference between intervention and control group at follow-up for RCTs and change from pre to
post intervention for before-and-after studies.
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the last 10 days of treatment. In the control group, two out of the six participants reported improvements
in early wakings, one worsened and three saw little or no change following bedtime scheduling.157
There was no difference between the treatment groups at follow-up in Gringas et al.36 in terms of time
awake after sleep onset and the proportion of nights with one or more awakening.
Sleep quality
Two RCTs36,156 (n = 78) and one before-and-after study160 (n = 78) reported quality of sleep (Table 27).
There was a statistically significant improvement in sleep diary-measured sleep quality from baseline for
children who received both valerian treatment and placebo; however, the difference in this outcome at
follow-up between the groups was not statistically significant.156 There was also improvement in sleep
quality for children who received fatty acids and placebo, as measured on a ‘short questionnaire’.160
TABLE 26 Other sleep maintenance outcomes for other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Gringras et al.
(2014)36
Time awake
after sleep onset
(minutes)
Combined: 85.4 (45.1) Intervention group: 84.6 (42.6)
Control group: 84.5 (41.5)
–2.5 (–9.5 to 4.5)a
Proportion of
nights with
≥ 1 waking
Combined: 0.3 (0.3) Intervention group: 0.2 (0.3)
Control group: 0.2 (0.3)
–0.01 (–0.06 to 0.04)a
Piazza et al.
(1997)157
Hours of
disturbed sleep
Intervention group:
1.44 (SD NR)
Control group: 1.37 (SD NR)
Intervention group: 0.53 (SD NR)
Control group: 1.10 (SD NR)
0.57b
NR, not reported.
a Estimated unadjusted difference between intervention and control group at follow-up.
b Data too limited to calculate 95% CI.
TABLE 25 Outcome results for night waking of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Francis and
Dempster
(2002)156
Nocturnal
time awake
(minutes)
Combined: 17.92 (8.21) Intervention group: 6.85 (7.16)
Control group: 8.38 (9.07)
–1.53 (–11.83 to 8.77)a
Gringras et al.
(2014)36
Number of
night wakings
Combined: 20.9 (8.0) Intervention group: 19.5 (7.0)
Control group: 19.5 (6.8)
–0.2 (–1.1 to 0.7)a
Before-and-after studies
Oriel et al.
(2016)159
Number of
night wakings
0.99 (0.77) 0.37 (0.41) –0.62 (–1.45 to 0.21)a
a Estimated unadjusted difference between the intervention and control groups at follow-up for RCTs and change from
pre to post intervention for before-and-after studies.
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Gringras et al.36 measured children’s perceptions of sleep quality using a smiley face rating scale. Parents’
perceptions of their child’s sleep quality were also measured. Parents were asked ‘Compared with before
the trial, when my child was not using any special sensory blanket, if my child woke at night, he or she
seemed: more agitated; no different from usual; calmer; and not applicable as so few awakenings’.
Gringras et al.36 also reported parent’s perceptions of their child’s sleep improvement. These data are
summarised in Table 27.
TABLE 27 Sleep quality outcomes of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
RCTs
Francis and
Dempster
(2002)156
Sleep quality Combined:
5.34 (1.49)
Intervention group: 7.54 (1.47)
Control group: 6.71 (1.29)
0.83 (–0.90 to 2.56)a
Gringras
et al.
(2014)36
Children’s
perceptions of
sleep qualityb
NR Intervention group: smiley face 56%,
neutral face 30% and unhappy face
14%
Control group: smiley face 35%,
neutral face 47% and unhappy face
18%
–
Parent’s
perceptions of
child’s sleep
qualityc
– Intervention group: more agitated,
0%; no different from usual, 44%;
calmer, 35%; and N/A as few
awakenings, 21%
Control group: more agitated, 5%; no
different from usual, 62%; calmer,
14%; N/A as few awakenings, 20%
–
Sleep
improvement
(parent
perceptions)d
NR Intervention group: very much
improved, 15%; much improved,
36%; minimally improved, 31%;
no change, 13%; minimally worse,
3%; much worse, 1%; very much
worse, 0%
Control group: very much improved,
1%; much improved, 15%; minimally
improved, 24%; no change, 49%;
minimally worse, 6%; much worse,
4%; very much worse, 0%
–
Before-and-after studies
Yehuda
et al.
(2011)160
Quality of sleep ADHD-FA:
1.0 (0.8)
ADHD-vehicle:
1.2 (0.7)
ADHD-FA: 3.8 (0.7)
ADHD-vehicle: 1.4 (0.8)
ADHD FA: 2.8 (2.6 to 3.0)
ADHD vehicle:
0.2 (–0.05 to 0.4)e
ADHD-FA, attention deficit hyperactivity disorder – fatty acid; N/A, not applicable; NR, not reported.
a Estimated unadjusted difference between the intervention and control groups at follow-up.
b ‘Which best describes how you have felt about your sleep over the past 2 weeks?’.
c ‘Compared with before the trial when my child was not using any special sensory blanket, if my child woke at night,
he or she seemed . . .’.
d ‘Compared with before the trial when child was not using any special sensory blanket, my child’s sleep is . . .’.
e Change from pre to post intervention, reported separately for the two groups.
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One before-and-after study158 evaluating light therapy plus a behavioural programme reported sleep
diary-measured distribution of sleep bouts during a 24-hour cycle. Data for this outcome were reported
graphically, with no narrative discussion from the authors, and could not be extracted.
Child-related quality of life, daytime behaviour and cognition
Two RCTs36,156 (n = 78) reported on child daytime behaviour using a sleep diary156 and the ABC.36
There was no statistically significant difference in daytime behaviour and cognition for total ABC score or
subscale scores between the weighted blanket group and the control blanket group at 4 weeks from
baseline (MD –2.3, 95% CI –5.4 to 0.8).36 Francis and Dempster156 used the sleep diary data to narratively
describe anecdotal changes in child behaviour, but quantitative data were not reported.
Other outcomes
One RCT (n = 73) and one controlled before-and-after study (n = 78) reported other outcomes of
interest.36,160 The RCT reported that there were no significant differences for the total Sensory Behaviour
Questionnaire or its subscales between the weighted blanket group and the control blanket group.36 The
controlled before-and-after study that compared essential fatty acid supplements with placebo reported a
variety of other child-related outcomes at the end of the 10-week intervention period.160 These data are
summarised in Table 28.
Adverse events
Two out of the seven studies reported adverse events (Table 29).36,160 One study36 reported how adverse
events were measured, namely through parents reporting to a 24-hour telephone number and weekly
face-to-face or telephone-based reviews with parents. Five studies did not report adverse events.156–159,161
TABLE 28 Other outcomes of other non-pharmacological interventions
Study Outcome
Time point, mean (SD)
MD (95% CI)Baseline Follow-up
Child-related quality of life
Gringras
et al. (2014)36
Sensory Behaviour
Questionnaire
Combined: 148.8 (42.4) Intervention group:
138.6 (41.3)
Control group:
142.4 (46.2)
–4.9 (–10.2 to 0.4)a
Other outcomes
Yehuda et al.
(2011)160
Degree of fatigue
in general during
the day
ADHD-FA: 2.3 (1.0)
ADHD-vehicle 2.6 (0.8)
ADHD-FA: 4.0 (0.3)
ADHD-vehicle 3.0 (0.9)
ADHD-FA: 1.7 (1.4 to 2.0)b
ADHD-vehicle 0.4 (0.1 to 0.7)b
Level of good
mood in general
ADHD-FA: 2.2 (1.1)
ADHD-vehicle 2.0 (0.9)
ADHD-FA: 3.7 (0.9)
ADHD-vehicle 2.4 (1.0)
ADHD-FA: 1.5 (1.2 to 1.8)b
ADHD-vehicle 0.4 (0.1 to 0.7)b
Level of ability to
concentrate during
the day
ADHD-FA: 2.0 (1.3)
ADHD-vehicle 1.9 (1.1)
ADHD-FA: 3.8 (0.8)
ADHD-vehicle 2.4 (1.2)
ADHD-FA: 1.8 (1.4 to 2.2)b
ADHD-vehicle 0.5 (0.1 to 0.9)b
Percentage of
homework
completed in
general
ADHD-FA: 2.0 (1.3)
ADHD-vehicle 2.3 (1.5)
ADHD-FA: 3.3 (1.2)
ADHD-vehicle 2.9 (1)
ADHD-FA: 1.3 (0.9 to 1.7)b
ADHD-vehicle 0.6 (0.2 to 1.0)b
ADHD-FA, attention deficit hyperactivity disorder – fatty acid; ADHD-vehicle, placebo comparator group of ADHD children.
a Estimated unadjusted difference between the intervention and control groups at follow-up.
b Change from pre to post intervention reported separately for the two groups.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
Summary
Seven studies evaluated seven types of non-pharmacological interventions. These interventions were all
different from each other. Therefore, we summarise the findings from each study in turn.
Weighted blankets were evaluated using a crossover RCT, with a non-weighted blanket as the control
intervention.36 The intervention was developed for children with ASD, and all children recruited to the
study had this diagnosis. They were aged between 5 and 16 years. The trial was rated as having a high risk
of bias. Outcomes were measured over each 2-week treatment period. Data on 27 children in each arm
were analysed.
No benefits in terms of TST and SOL (derived from actigraphy) or a number of other sleep outcomes
derived from parent-completed sleep diaries (number of wakings/night, proportion of nights with more
than one waking and total time awake after sleep onset) were reported for children in the weighted
blanket group compared with the non-weighted blanket group. Similarly, no benefits from a weighted
blanket were reported in terms of child behaviour (ABC) or increased sensitivities to sensory stimulation
(Sensory Behaviour Questionnaire). There were no serious adverse events.
Valerian, a herb prepared in tablet form, was evaluated with a placebo using a RCT156 in a sample of five
children with a range of NDs aged 7–14 years who had difficulties with sleep initiation and/or sleep
maintenance. The rating of risk of bias was high.
At 2 weeks post intervention, there was no difference between arms in terms of TST, SOL and duration of
time awake during the night. Parents’ perceptions of sleep quality (measured using a non-standardised
visual analogue scale) did not differ significantly between trial arms post intervention. No other quantitative
data on child outcomes were reported. Adverse events were not reported.
Essential fatty acid supplement preparation in tablet form was evaluated using a controlled before-and-after
study.160 All children (active arm, n = 40; placebo, n = 38), aged 9–12 years, recruited to the study were
diagnosed with ADHD and were described as ‘sleep deprived’. The study was rated as having a high risk
of bias.
TABLE 29 Adverse events in studies evaluating other non-pharmacological interventions
Study Adverse events reported Measures used
Francis and Demspter
(2002)156
NR
Gringras et al. (2014)36 No serious adverse events were reported
Two-day skin rash, n = 1 (may have been related to the
weighted blanket). The authors report that all other adverse
events were unrelated illnesses such as colds, fever,
chickenpox, broken bone in hand (number of children with
other unrelated adverse events was not reported)
A 24-hour telephone number
was available to parents for
reporting adverse events
Weekly parent reviews
(face to face or telephone)
Guilleminault et al.
(1993)158
NR. Heat caused by the artificial light was reported as the
only complication to light therapy treatment
NR
Oriel et al. (2016)159 NR
Piazza et al. (1997)157 NR NR
Yehuda et al. (2011)160 Fatty acid supplement: transient stomach upset and
diarrhoea, n= 3; dizziness, n= 2
NR
Yu and Hong (2012)161 NR
NR, not reported.
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At 10 weeks post intervention, scores on a non-standardised measure of sleep quality did not differ
between active and placebo groups. A number of other parent-reported child outcomes were evaluated
using non-standardised, parent-reported indicators (degree of fatigue in general during the day, level of
good mood in general, level of ability to concentrate during the day and percentage of homework
completed in general). No significant difference between active and placebo arms was found for these
outcomes. Transient gastric problems were reported for some children in the active group.
An aquatic exercise programme for children with ASD (mean age 8.8 years) and ‘sleep dysfunction’ was
evaluated using a before-and-after study design.159 Eight children were recruited to the study. The study
was rated as having a high risk of bias. The outcomes at 8 weeks post intervention were reviewed.
Biweekly telephone interviews with parents were used to collect data, from which TST and SOL were
calculated. Increased TST post intervention was reported (MD 83.3 minutes, 95% CI 17.55 to 149.09
minutes). No other changes to child sleep outcomes were reported. Adverse events were not reported.
Acupuncture and ear-point taping were also evaluated using a controlled before-and-after study design.161
Thirty children (mean age 6.9 years) with sleep initiation or maintenance difficulties and/or an ‘abnormal
sleep state’ were recruited to the study. All were described as having learning disabilities. It was not clear
when post-intervention outcomes data were collected. The study was rated as having a high risk of bias.
At post intervention, a significant improvement in scores on a parent-reported sleep outcome measure
(CSHQ) was reported (MD –11.50, 95% CI –13.33 to –9.67).
A light therapy intervention combined with a programme of daytime schedules and activities was evaluated
using a before-and-after study.158 Fourteen children, aged 9 months to 4 years, were recruited to the study.
They were described as having learning disabilities. The study was rated as having a high risk of bias.
Outcomes were measured at 6 months post intervention. Five out of 14 children were reported to have
‘responded to treatment’ as measured by increases in TST (calculated from information collected by the
study team during regular interviews with parents), which were reported to have improved post intervention.
There were no serious adverse events.
Finally, the relative effectiveness of faded bedtime and response costs with bedtime scheduling was
investigated using a parallel RCT.157 The trial took place in an inpatient unit for children with very severe
behaviour problems. The children (n = 14, 7 per arm) recruited to the trial had a range of NDs and sleep
disturbances relating to sleep maintenance and ‘sleep consolidation’. They were aged 4–14 years. The
trial was rated as having a high risk of bias. Outcomes were measured pre intervention and 10 days post
intervention. Only narrative reports of sleep outcomes (based on observational data) are provided.
Overall, there is no evidence of benefit for weighted blankets, although we note that this was a single
study that was rated as having a high risk of bias. Issues regarding study design and study bias mean that
no conclusions can be drawn regarding the impact of the following interventions: valerian, fatty acid
supplements, light therapy with daytime activities programme, acupuncture and ear-point taping, and an
aquatic exercise programme. Finally, we note that the last two studies described157,158 were both reported
almost 25 years ago, and no further studies replicating these interventions are reported. It is questionable
whether or not they remain relevant or accepted approaches to managing sleep disturbance in children
with NDs.
Issues of feasibility, acceptability and experiences of receiving and
implementing a sleep management intervention
Sixteen of the interventions included in the clinical effectiveness review also investigated the feasibility,
acceptability and/or parent/clinician views of sleep disturbance interventions.36,49,106,107,122–130 Going forward,
we use the term ‘family experience’ to refer to this topic area.
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Fourteen of these interventions were parent-directed interventions,21,49,107,123–129,149 the remaining two were
evaluations of melatonin106 and weighed blankets,36 respectively. For 11 out of the 16 interventions, data
on family experience are reported in papers alongside the presentation of data on outcomes. For one
intervention,149 these data are reported in a separate paper.122 A further four interventions were collectively
investigated with respect to the above issues and findings were reported separately to papers reporting
intervention outcomes.130
No additional studies relevant to this topic were identified through searches. We would note that separate
but relevant literature on parents’ views and attitudes towards pharmacological and non-pharmacological
interventions for sleep disturbance in children with NDs was identified (e.g. Goodday et al.,180 Keenan
et al.181). However, this body of work did not fall within the scope of this review, as these studies explored
parental views of multiple sleep interventions.
A number of data collection methods were used, including questionnaires, structured interview and
semistructured interviews (individual and group).
Ten studies36,49,107,122–125,127–129 devised an intervention evaluation questionnaire to explore family experience.
One of these studies also included semistructured interviews with a subsample.124 A further study used
a modified version of a previously published intervention evaluation questionnaire.126 All collected data
from parents, apart from one study that sought children’s views about the weighted blanket they had
been using.36
A further study used semistructured interviews to collect data from parents via individual interviews or
groups.130 Finally, one study reported data on reasons for study dropout. Appendix 19 reports the
methods used.106
Quality appraisal
The quality appraisal of ‘family experience’ studies used the tool created by Hawker et al.,66 chosen
because it was developed for use in reviews in which both qualitative and quantitative data are included
and data in this review have been generated by studies using different paradigms. The tool was used in
two ways. First, for studies (n = 2) in which a primary objective was to investigate family experience, and
this is reported in a separate paper, a full quality appraisal was conducted (see Appendix 20). Second, for
studies (n = 10) in which ‘family experience’ was a secondary study objective and was a minor element
of evidence presented in any papers, the tool was used by the team to appraise, but not individually rate,
the quality of the studies and evidence presented. One study106 reported data that were a part of routine
data collection within a trial (i.e. the reason for study dropout). We did not subject this specific element of
the study to a separate quality appraisal.
For the 10 studies36,49,107,123–129 for which ‘family experience’ was a secondary objective, the quality of studies
and study reporting was very mixed. A number of issues were frequently noted that affected the quality
of the ‘family experience’ objectives of these studies. First, family experience was sometimes not explicitly
identified as a research objective. In addition, parent characteristics (e.g. gender, educational achievement,
ethnicity and first language) were rarely reported. This is a significant omission, given that the majority
of interventions represented in the ‘family experience’ data set were parent-directed interventions. Data
collection tools were inadequately reported and/or study-specific tools were developed that, it would appear,
had not undergone any piloting or been developed in consultation with parents. Descriptions of the analysis
of family experience data were typically missing or very limited. Analyses were descriptive and opportunities
to explore factors affecting experiences were not exploited. Based on the description of the data collection
instruments, it appeared that, in some studies, not all findings were reported.
Findings
Findings on family experience can be found in Appendix 19.
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Melatonin
One of the evaluations of melatonin reported that a child was withdrawn from the study owing to
difficulties administering the medication to the child. No further data on family experience were identified
with respect to the pharmacological interventions.106
Weighted blanket
Children taking part in the RCT evaluating weighted blankets were asked to describe their feelings about
using the study blanket using a three-point scale (‘really liked’, ‘just OK’ or ‘really disliked’).36 A greater
proportion of children in the intervention group reported liking their blanket, but the differences in
responses between the intervention and control groups were not significant.36
Parent-directed interventions
A number of themes, or topic areas, can be identified in the data reported:
l parents’ experiences of accessing the intervention (e.g. time of day or competing demands on time)
l parents’ experiences of implementing a sleep management strategy
l parents’ views about the elements of the intervention that had an impact on the outcomes experienced
l parents’ experiences as service users or of the process of receiving the intervention
l recommending the intervention to other parents.
It should be noted that some data that were identified as potentially relevant to these topic areas were
ambiguous and open to different interpretations; for example, ‘satisfaction’ may refer to satisfaction with
outcomes achieved or satisfaction with the way that an intervention is delivered. Data of this nature,
although extracted and presented in Appendix 19, are not reported in the following narrative.
Parents’ experiences of accessing the intervention
This topic was not widely or consistently explored. One study124 reported that the majority of participants
(five out of six) in their interview subsample believed that time pressures on parents and the time needed
to make the initial commitment to embark on the intervention were barriers to parents accessing and
completing such an intervention. In addition, one interviewee spontaneously mentioned that the time of
day of the intervention was a ‘least-liked’ element of the intervention. A further study126 reported that the
time-consuming nature of the intervention was identified as something that was ‘least liked’ about the
intervention they received. However, the authors do not clarify whether this refers to time attending
sessions or the time required to implement a sleep management strategy. Johnson et al.107 report data on
very high levels of attendance at intervention sessions, which could be regarded as proxy evidence regarding
the accessibility of the intervention.
Parents’ experiences of implementing the sleep management strategy
Five studies report parents’ views on the acceptability of the intervention, specifically the acceptability
of the sleep management strategy that they were instructed to implement. Implementing new ways of
managing sleep disturbance (e.g. not settling to sleep, night-time wakings) are likely to generate resistance
and negative responses (e.g. crying) on the part of the child.
Bramble122 reported that a minority (3/15) of their sample found this process ‘rather tough’ but were
willing to continue. Two out of the twelve participants in Weiskop et al.126 identified ‘sticking to bedtime
routine’ as the least-liked element of the intervention. Austin et al.123 reports that three out of five parents
in their study found that implementing sleep management strategies was stressful. However, Moss et al.124
reported that 21 out of 26 study participants described the implementation of the treatment plans as
acceptable or very acceptable, and no improvements to the intervention were suggested. Both Austin
et al.123 and Weiskop et al.126 also asked study participants if they would recommend the intervention to
other parents and all said that they would.
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Beresford et al.130 describes parents’ accounts of the demands that implementing, and sustaining, a sleep
management strategy can place on them. A number of barriers to implementation were also identified.
These included lack of consistency across caregivers, changes and disruptions in usual routines (e.g. owing
to illness or holidays) and difficulties with the home environment, particularly if the child had to share
with siblings.130
Adherence to implementing a sleep management strategy is an additional facet to this topic. Two studies
provided relevant data.107,125 First, Scibberas et al.125 reported that ‘Most caregivers reported that they could
implement sleep management strategies “at least half of the time” ’. No further details are provided.
Second, Johnson et al.107 collected clinicians’ ratings of study participants’ adherence to the intervention
(including evidence of implementation of sleep management strategies) based on their observations during
intervention sessions. In this study, an attention control arm was used; the intervention delivered to this
arm was purely educational and did not require parents to implement behaviour management strategies.
Over 90% adherence was reported for both study arms (active arm, 93%, 75–100%; control arm,
98%, 75–100%).
Parents’ views about the elements of the intervention that had an impact on the
outcomes experienced
Two approaches to exploring this topic were used. Some studies asked participants to rate the helpfulness,
utility or relevance of a pre-set list of the different elements of the intervention they had received,107,122,123,125,128
although this varied in terms of how fine-grained the elements were. Overall, there is consistent evidence that
parents report the training delivered via the interventions as relevant and useful. It is not clear from the way
that the data are reported whether or not parents vary in which elements they find particularly helpful.
Differences in data collection instruments and ambiguities of language make further synthesis of the
data impossible.
Other studies elicited parents’ (spontaneous) views via interviews124,127,130 or free-text responses in
questionnaires.126 Across these studies, the following were identified by parents as being important to
supporting the achievement of positive sleep outcomes: receiving education on various aspects of sleep
and sleep management,124,130 training in specific strategies to manage problem behaviours (communication,
behavioural or sensory),124,127,130 that the intervention is tailored to the child,124,130 provision of one-to-one
instruction,126 peer support via group delivery,130 that attention is paid to developing parents’ confidence
regarding their parenting,130 use of mechanisms for keeping track of progress (e.g. sleep diary)130 and giving
implementation support.124,126,130
Parents’ experiences as service users or of the process of receiving the intervention
The mode of delivery is a core element of the service user experience. This was evaluated in one of the
trials included in the review.128 This study also captured data on family experience, including preference
regarding mode of delivery. A smaller proportion of study participants in the individual delivery arm
reported that they would have preferred the alternative mode of delivery than those in the group delivery
arm (3/41 vs. 8/39).128
There were limited data on this topic area. A single participant (1/12) in the study by Weiskop et al.126
found that the training sessions were too long. Reed et al.129 reports that 10 out of 18 study participants
believed that the duration of the intervention was sufficient.
Recommending the intervention to other parents
Five studies123,126,128,129,144 specifically collected data on whether or not study participants would recommend
the intervention to other parents. Three studies123,126,129 reported that all parents receiving the intervention
would recommend it to other parents. The other studies128,144 reported that the great majority of study
participants said that they would recommend the intervention. Malow et al.128 compared the responses of
parents receiving the intervention via individual face-to-face sessions with those receiving it via group
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delivery. A greater proportion of study participants receiving the intervention face to face reported that
they would recommend the intervention than those in the group delivery arm (38/41 vs. 32/39).128
Summary
Thirteen studies concerning family experience of sleep management interventions were identified, reporting
16 sleep management interventions in total.36,49,106,107,122–130 All but one106 of the studies concerned
non-pharmacological interventions: 14 were parent-directed interventions49,107,122–130 and one was a study
of weighted blankets.36 For these studies, data were predominantly quantitative (total n = 225) and typically
collected using a questionnaire specifically designed for the study. One study124 supplemented questionnaire
data through semistructured interviews with a subsample (n = 6) of study participants. A further study130
(n = 35), which investigated the family experience of four parent-directed sleep management interventions,
used entirely qualitative methods. Study quality varied.
The pharmacological study106 reported data relevant to family experience106 concerning difficulties
administering the medication. This was reported within the context of reporting on reasons for study
withdrawal, rather than the study explicitly seeking to include an exploration of the family experience
along with the evaluation of the medicine.106
Therefore, the most extensive data set concerns parents’ experiences of receiving and implementing
a sleep management intervention (11 studies21,49,107,123–129,149). The data were organised around five
themes: parents’ experiences of accessing the intervention, parents’ experiences of implementing a sleep
management strategy, parents’ views about the elements of the intervention that had an impact on the
outcomes experienced, parents’ experiences as service users and recommending the intervention to others.
Across all these themes, the data are very limited. There are a number of reasons for this. First, the pool of
studies is very small. Second, many studies collected very few data. Third, studies typically used their own
data collection instrument, thus hindering the pooling of data.
With these caveats, the following comments are made. There is very little evidence on parents’ experiences
of accessing sleep management interventions. One study reported that parents believed that the time
requirements associated with receiving a sleep management intervention could be a barrier to parents
accessing an intervention.124 Another found that the time-consuming nature of the intervention was a
feature of the intervention that was ‘least liked’ by some study participants.126 However, across all studies,
only one participant is reported as finding the duration of the intervention too long.126
Parents’ experiences of implementing a sleep management strategy were explored by five studies.107,122,123,126,130
A consistent theme across all – although it was not universally reported by study participants – is the
challenges and demands placed on parents as they implement the strategy. Despite this, all of the studies that
asked parents if they would recommend the intervention to others reported unanimous or high levels of
recommendation. On a related point, a further study144 reported exploring parents’ judgements as to their
adherence to a sleep management strategy and it suggests that consistent adherence to sleep management
interventions should not be assumed. Another study identified a range of factors that may further interfere
with implementing a sleep management strategy.130
Support with implementing a sleep management intervention was consistently identified by studies that
offer data on elements of interventions that parents believe support positive outcomes. In terms of mode
of delivery, both individual work and group delivery are identified as supporting positive outcomes: one
offering the opportunity for a highly tailored intervention and the other offering peer support.
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Chapter 4 Discussion
Introduction
Overall, the evidence on the management of sleep disturbance in children with NDs is very thin – in
volume, scope and quality – particularly given that this group of conditions or diagnoses represents the
majority of disabled children, and when the incidence and severity of sleep disturbance is greater than
that for children with typical development. The conclusions that we have been able to draw regarding
intervention effectiveness are limited to melatonin. Here, the conclusion is drawn that there is evidence of
benefit; however, the clinical importance of the benefit is not certain. Therefore, there are no implications
for health-care practice.
This lack of evidence is more compelling – as is the argument for strategic investment in this topic – given our
understanding of the health, social and economic impacts of sleep deprivation. It is not surprising that in a
national research prioritisation exercise for children with NDs, the management of sleep disturbance was ranked
in the top 10 research priorities,32 with both pharmacological and parent-directed interventions specified.
In this chapter, first, we present the strengths and limitations of the study and then public and patient
involvement. Second, we discuss pharmacological interventions and principal findings with respect to this
intervention approach. Third, we consider parent-directed interventions, providing an overview of these
interventions before reporting principal findings and discussing the implications of these findings. Fourth, we
move on to discuss other non-pharmacological interventions, presenting the principal findings with respect to
this range of interventions. A final section discusses the issues and challenges for future research in this area.
Strengths and limitations of the study
We undertook thorough searches for eligible studies that included systematic searches of 16 databases,
without language restrictions, and included sources for unpublished studies. We used standard methods,
for example having two researchers undertake key study processes such as study selection, to reduce error
and bias. The risk of bias in the included studies was assessed, although this assessment was often limited
by poor reporting. We included small before-and-after studies that cannot provide a reliable estimate of
the clinical effectiveness of an intervention because of the lack of a control group. These were included in
order to help identify interventions that may be worth considering for evaluation in future RCTs. To
militate against the limitations of some of the study designs included, we have clearly distinguished
between randomised and non-randomised designs in the synthesis. We have also taken account of their
limitations when drawing conclusions.
Given the number of interventions that were under consideration, a mixed-treatment comparison would
have been the ideal statistical approach, permitting ranking of the benefits and harms of the different
treatment options.72 However, owing to the heterogeneity of the non-pharmacological studies, statistical
pooling was not considered appropriate. As a result of the sparsity of combined and sequential interventions
and poor reporting of any prior interventions received by participants in studies, a robust analysis of the
impact that single, combined and sequential interventions had on clinical effectiveness was not possible.
Similarly, any other planned subgroup analysis was possible only for the melatonin trials and this was limited
by the small number of studies and the potential for confounding with other study characteristics.
It is not possible to blind the types of interventions and comparators used in the studies under consideration.
In addition, owing to the nature of the outcomes measured, robust blinded outcome assessment is likely to
be difficult. Although actigraphy-based child sleep outcomes are more objective than parent-reported
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measures, we did not consider these to be true objective outcomes, with non-blinding being unlikely to have
introduced bias. Therefore, all of the included non-pharmacological RCTs were rated as having a high risk
of bias, even though blinding of treatment and comparator is not possible. For one study that compared a
parent-directed tailored intervention with control,138 this led to an overall rating of high risk of bias, despite
all the other bias domains for that study being rating as having a low risk of bias. We acknowledge that
applying the Cochrane criteria ‘less strictly’ would have led to this study having an overall rating of low risk
of bias. This is an issue for all non-pharmacological studies in this area and we believe that it is unhelpful to
have these studies rated as having a high risk of bias, as evidence from non-pharmacological interventions
will always look weaker than that from pharmacological studies. Equally, we acknowledge that there is a risk
of overestimating the clinical effectiveness of an intervention in which allocation is unblinded and outcomes
have an element of subjectivity and may be influenced by lack of blinding. There is currently no established
method of blinded outcome assessment in this field that we are aware of and further work in this area may
be beneficial. There may also be value in further consideration by methodologists about how lack of blinding
is graded in studies when blinding is not possible and the outcomes are subjective. Adoption of statistical
approaches used in surgical studies, such as secondary statistical analyses taking into account participants’
treatment allocation, may also have some value.182
Patient and public involvement
Three parents of children with ND (two mothers and one father) acted as project advisors. They were
recruited from a permanent parent consultation group of the chief investigator’s research unit. The children’s
diagnoses were autism and a rare, genetic condition.
The parents were invited to the project team meetings, which were held three times over the course of
study and attended by the research team and all co-applicants. They were also occasionally consulted
between meetings via e-mail.
Each parent attended at least one meeting. At the first meeting, an early item on the agenda was a
presentation of an overview of systematic reviews as a research method. At the meetings, parents actively
engaged in discussions. Their experiences also provided useful contextual information for the research team,
some of whom had no prior experience of working in this topic area or with this particular group of children.
Pharmacological interventions
Research on the management of sleep disturbance affecting children with NDs is dominated by two
intervention approaches: melatonin and parent-directed interventions. In terms of other pharmacological
interventions, a small number of trials of other medicines were identified [acebutolol (Sectral®, Promius Pharma
LLC, Princeton, NJ, USA ), eszopiclone (Lunesta®, Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA),
gabapentin (Neurontin®, Pfizer Inc., New York City, NY, USA), ramelteon (Rozerem®, Takeda Pharmaceutical
Company Ltd, Osaka, Japan) and zolpidem (Ambien®, Sanofi S.A., Paris, France)] but fell outside the eligibility
criteria set for this review (these criteria were decided in consultation with clinicians). The review was,
therefore, restricted to melatonin, clonidine and antihistamines. No studies of clonidine or antihistamines that
fulfilled our study inclusion criteria were identified.
Principal findings: pharmacological interventions
There was evidence of benefit of melatonin compared with placebo, although the precise extent of the
benefit, which children may benefit the most and the clinical importance of the benefit remain uncertain.
Discussion of principal findings: pharmacological interventions
This conclusion concurs with the issues raised by the team that conducted the only trial of (fast-release)
melatonin rated as having a low risk of bias included in the review.48 In it, the study sample comprised
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children with developmental delay and some with additional diagnoses, including epilepsy, autism or a
specific genetic or chromosomal disorder. The authors note that ‘the sheer heterogeneity of the population
studied has inevitably limited our ability to accurately estimate the impact of melatonin treatment for
individual groups of patients with specific clinical (genetic), behavioural or developmental presentations’.48
A core inclusion criterion for the Appleton et al.48 trial was that a parent-directed intervention – in the form
of an advice booklet – had not successfully addressed the presenting sleep disturbance. For over half of
the children recruited to the trial (56%), this intervention did not sufficiently address the sleep disturbance
and they were randomised to the melatonin or placebo arms. This finding does lend support to the
argument, and based on understandings of types and aetiologies of sleep disturbance in children with
NDs, that pharmacological and non-pharmacological approaches may both be required. It can also be
taken to suggest that for some types of sleep disturbance, recourse to melatonin should occur only once
attempts to change the way that a family may be managing the sleep disturbance have been tried.
Parent-directed interventions
Behavioural insomnias (difficulties with bedtime settling and self-settling after night wakings) are defined
as sleep patterns and behaviours developed through unhelpful sleep behaviours and sleep management
practices.183 Parent-directed interventions seek to provide parents with the knowledge and skills to change
these patterns and behaviours.
This review adopted the term ‘parent-directed interventions’ to refer to sleep management interventions
that involve training parents to respond to their child’s sleep problems in different ways. The use of the
term ‘parent-directed’ was deliberate. It emphasises that the direct recipient of the intervention is the
parent, not the child. The child is merely the recipient of the outcomes the intervention achieves with
respect to the parent. This has implications for the way in which such interventions should be understood
and evaluated.
We categorised parent-directed interventions as comprehensive and non-comprehensive. Comprehensive
interventions included training parents in evaluating the bedroom environment, paying attention to
daytime and bedtime activities and routines (or sleep hygiene practices) and providing training in the use
of particular behavioural strategies to manage specific problems related to settling and night waking.
The majority of interventions were comprehensive, with two ‘non-comprehensive’ interventions also being
included: one evaluating training on particular behaviour management strategies only152 and the other
providing sleep hygiene training for parents of children with ADHD.155
We made a further distinction with respect to these interventions: tailored versus non-tailored. Tailored
interventions consisted of an assessment of the child’s sleep and wider family context, which was then
used to developed a personalised sleep management strategy. This approach necessarily meant that these
interventions were delivered individually. They also all included implementation support, that is, contact
between the practitioner and parent as the sleep management strategy in order to provide support or
advice and/or suggest and supervise changes to the strategy.
Non-tailored interventions, in contrast, comprised the delivery of a standard ‘training curriculum’ in
managing sleep disturbance in children with NDs. These were delivered via written material, in groups
and/or individually. Some of these interventions had opportunities for parents to apply learning to their
own child and/or implementation support.
This review identified some core intervention characteristics by which these interventions could be
classified: comprehensive versus non-comprehensive; tailored versus non-tailored; mode(s) of delivery;
number of practitioner–parent contacts; availability of implementation support; and condition-specific or
generic ND.
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Principal findings: parent-directed interventions
Studies of parent-directed interventions took two broad forms: (1) they were concerned with the clinical
effectiveness of the intervention compared with no intervention or (2) they were testing different approaches to
delivering the same intervention (e.g. varying mode of delivery or intensity of contact between the practitioner
and the parent). There was variability between interventions in terms of intervention characteristics, such as
mode of delivery, intensity, duration and availability of implementation support. Overall, the quality of the
evidence was rated as having a high or unclear risk of bias in reporting and, therefore, the findings of these
studies cannot be considered robust.
In terms of the tailored interventions, there was mixed evidence about the effects of these interventions on
child (and parent) outcomes. There was limited evidence of benefit on more objective measures of sleep
outcomes (actigraphy, verified or not with parent-completed sleep diaries). More evidence of benefit was
found on parent-reported outcomes and a few parent outcomes. Conclusions are hampered by the limited
number of RCTs, the multitude of outcome measures and the risk of studies being underpowered to
detect an effect. Two small RCTs investigated specific intervention characteristics: mode of delivering
implementation support21 and a brief versus extended (with implementation support) version of an
intervention.125 The rating of a high risk of study bias and the trials being underpowered mean that no
conclusions can be drawn.
Compared with the tailored interventions, the non-tailored interventions evaluated were even more diverse
in terms of a number of intervention characteristics, including mode of delivery [i.e. written material, group
delivery (single vs. multiple sessions) and one-to-one work], the extent to which they accommodated
parents’ individual learning and training needs and whether or not implementation support was available.
Overall, the conclusions that can be drawn from this evidence are limited owing to the high risk of bias,
the wide range in post-intervention follow-up time points and the risk of studies being underpowered to
detect an effect. In addition, a large number of outcome measures were used, capturing a wide range of
outcome domains.
There was mixed and very limited evidence regarding the impact that the provision of written information
to parents had on managing their child’s sleep disturbance. No conclusions can be drawn regarding the
relative benefits of written versus face-to-face delivery of sleep management training to parents. There is
some limited evidence of benefit for group-delivered interventions in terms of parent-reported sleep
outcomes (but not reported for more objective measures of sleep). A single RCT128 compared the individual
delivery of an intervention via a single session with delivery of the same training via two group-delivered
sessions. The rating of having a high risk of study bias and the trial being underpowered means that no
conclusions can be drawn from the study findings. No RCTs were identified that evaluated a single-session
workshop approach to delivering sleep management training to parents. It is useful to note that this mode
of delivery is widely accessible to parents in the UK via statutory and non-statutory providers.
Two non-comprehensive parent-directed interventions are also reported by this study. The first is a trial
(rated as having a high risk of bias) that evaluated an intervention in which the content was restricted to
training on behavioural principles of managing problem behaviour compared with an attention control
intervention.152 The content of the second intervention was restricted to sleep hygiene principles and
practices,155 which was evaluated using a before-and-after study design.
Discussion of principal findings: parent-directed interventions
It is relevant to briefly contextualise these findings on parent-directed interventions within the wider
evidence base on the clinical effectiveness of parent-directed interventions for managing sleep in children
with typical development. Here, a recent review, which identified 15 trials110,127,184–197 and 11 before-and-
after studies,149,198–208 concluded that there was ‘moderate support’ for such interventions for young
children (≤ 5 years). A paucity of trials that included older children and adolescents limited any conclusions
being drawn with respect to these older age groups.184 The authors recommend that, for young children
who have typical development and are healthy, parent-directed interventions should be implemented with
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‘no hesitation’. Furthermore, although noting the lack of evidence, the authors also recommend that they
are used for older children and adolescents.
For children with NDs, however, additional factors may be at play in the development of behavioural
insomnias, which may have implications for the content and scope of the training and advice given to
parents, the duration of support parents may require to implement new sleep management approaches and
strategies and the clinical effectiveness of a parent-directed intervention.209 These include communication
difficulties (both parental communication about bedtime and sleep and the child’s ability to understand sleep
cues or communicate their needs),210,211 sensory sensitivities,209 cognitive delay and arousal associated with
daytime behaviour problems.212 This has implications for the design of future evaluations.
Parent-directed interventions as complex interventions: implications
Parent-directed interventions to manage sleep disturbance in children with NDs can be regarded as ‘complex
intervention’, that is, they comprise a number of different interconnected elements. Early guidance, issued by
the Medical Research Council on developing and evaluating complex interventions,213,214 has subsequently
been developed and refined, including the need for intervention development and evaluation to be theory
driven.215 The theory underlying or informing an intervention will identify its ‘active ingredients’ and the factors
that may moderate or mediate their therapeutic action. Although accepted as a fundamental feature of
pharmacological studies, the notion of ‘active ingredients’ is as relevant and important to our understanding
and evaluation of non-pharmacological interventions.216,217 However, adoption of robust approaches to the
evaluation of complex interventions, in which a theory of change has informed the study design and outcomes
measured and the active ingredients are clearly defined and specified, remains patchy.218
Specifying a theory of change, and the active ingredients, to complex interventions such as parent-delivered
sleep management interventions requires looking not only at content of the ‘training’ delivered to parents,
per se, but also at the features of the individuals involved in delivery, at the context, or mode, in which the
training is delivered and in the implementation.216,219 It would be fair to say that the influence of this thinking
and methodological debate has, to date, had relatively little impact on evaluations of parent-directed, sleep
management interventions for children with NDs. Behavioural theories (e.g. extinction, positive reinforcement)
are explicitly identified as underpinning all the sleep management strategies on which parents were trained in
the comprehensive parent-directed interventions and one of the non-comprehensive interventions.152 In
addition, the influence of social learning theory220 on choices about the techniques used to teach and train
parents is apparent (e.g. the use of role-play, modelling, observation, group problem-solving). However, a
theory of the process by which upskilling a parent in sleep management results in changes in a child’s sleep,
and the factors that have an impact on that process, is left (relatively) undiscussed and unexplored. This is
evidenced by the fact that only a small minority of the studies measured changes in parents’ knowledge of
sleep management, perceived parenting confidence, collected data on parents’ characteristics and/or sought
to assess the extent to which parents accurately or consistently applied their training.
The evidence reviewed regarding the ‘family experience’ of parent-directed sleep management interventions
offers some, limited, insights into the process by which parent-directed interventions affect changes in the
duration or quality of a child’s sleep and the factors that parents believe facilitate or hinder this process.
However, the story appears complex. Thus, for example, although support with implementing new approaches
to managing their child’s sleep disturbance was consistently identified as a valued or helpful aspect of the
intervention received by parents, views on mode of delivery revealed that there were different benefits in
group versus individual delivery. Exposure to other parents’ experiences and access to peer support were
identified as supporting positive outcomes. In terms of individually delivered interventions, a key benefit
reported by parents was the scope to personalise an intervention to the child and the family’s specific needs
and context. It is also important to note that parents are likely to vary in their abilities, capacities and/or
willingness to access the different modes of delivery.221
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Other non-pharmacological interventions
Seven other types of non-pharmacological intervention were included: valerian,156 weighted blankets,36
a sleep management intervention delivered in a specialist inpatient setting,157 light therapy alongside a
daytime activities programme,158 an aquatic exercise programme,159 acupuncture and ear-point taping 161
and fatty acid supplements.160 The evaluations of two of these interventions – the sleep management
intervention delivered in a specialist inpatient setting157 and light therapy alongside a daytime activities
programme158 – were both carried out ≥ 20 years ago. We have included them in this review but their
current relevance may be open to question.
Principal findings
There was no evidence that weighted blankets – an intervention that parents can purchase and use
without professional supervision or receive via a prescription from statutory health services – were clinically
effective. Issues of study design and ratings of high risk of study bias mean that no conclusions can be
drawn regarding the impact of the following interventions: valerian, fatty acid supplements, light therapy
with daytime activities programme, acupuncture and ear-point taping and the aquatic exercise programme.
Future research: overarching issues and challenges
A key aim of this review was to make recommendations regarding priorities for future research on this
topic. In this section, we consider some overarching issues and challenges.
Outcomes and outcome measurement
A number of issues need to be addressed in future research to generate robust and meaningful evidence
that, in future reviews, can be subject to meta-analysis.
First, a large number of different child sleep outcomes and measurement tools were used by the studies
included in this review. Our synthesis of the studies was partly hampered by this diversity of outcome
measures in relation to both child sleep outcomes and other outcomes for children and their parents.
Only TST was measured in the majority of studies and assessed in a similar way across studies. We would
note that when evidence of benefit of a sleep management intervention was reported – and actigraphy and
parent-report measures were used – benefit was more frequently observed with respect to parent-reported
measures. It is not clear whether this is because of issues of objectivity versus subjectivity in outcome
measurement or that these different measurement approaches are capturing qualitatively different outcomes.
Adverse events were reported in the majority of melatonin trials. However, the type of adverse event
reported, data collection methods used and reporting of adverse events varied. Standardisation of the
reporting and data collection methods for adverse events in future trials is important to understand the
safety of pharmacological interventions. This also has relevance for non-pharmacological studies, in which
interventions may have unintended consequences.
There were two additional issues: (1) variability in the outcome domains of interest, for example carer
outcomes were assessed in some studies and not others and (2) variability in the measure used to assess
specific outcome domains. Previous research has identified sleep as a key health outcome for children and
young people with ND, their parents30 and health-care professionals.222 However, based on searches of the
Core Outcome Measures In Effectiveness database (www.comet-initiative.org; accessed 21 June 2017), no
work has been undertaken to prioritise outcomes for children with NDs who experience sleep disturbances
and their parents. A core outcome set would greatly assist the usefulness of research in this field, in
which there are so many management options, allowing comparison between studies and also ensuring
that the outcomes that are assessed are of relevance to children, their parents and also the health-care
professionals involved in their care.
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Second, further work with families to establish what constitutes a meaningful and worthwhile change in
these outcome measures is important. Just one study49 adopted this approach, with a 50% reduction in
the composite sleep disturbance score identified by parents participating in the study as the minimum
change for the intervention to be considered worthwhile.
Meaningful and sufficient change may also have guided the duration of implementation support in
interventions in which the duration of this was reported as variable, or needs-led,21,124,146 but the heuristic for
ceasing implementation support was not explicitly reported. Furthermore, other studies reported an extended
period of implementation support but it was not clear whether this duration was predetermined or simply
what actually occurred when the intervention was delivered. An alternative, or additional, approach used by
a small number of studies was the setting of parent-identified goals for their child’s sleep, with progress
towards these goals tracked over follow-up time points. However, none of these studies used Goal
Attainment Scaling methodology,223,224 which allows identification of, and tracking of progress towards,
personalised intervention goals, with the creation of an aggregated score for each study participant, and
allows robust comparisons between participants. This would appear to be a measurement approach worth
considering in future research, alongside objective and other parent-reported outcome measures, as is the
case in evaluations of complex interventions in other fields.225
Third, consistency in follow-up time points based on an evidence-informed theory of change is required. This
is particularly an issue for non-pharmacological interventions in which the implementation of newly acquired
knowledge and skills in managing a child’s sleep may take time to have an effect. Thus, within the different
types of parent-directed interventions, consensus is required as to the most clinically meaningful follow-up
time points and whether or not evaluations should seek to also investigate maintenance of outcomes. This
would also assist in comparisons between studies in future systematic reviews and meta-analyses.
Fourth, further work is required to identify other relevant child outcome measures and the time points
at which such outcomes should be measured. Cognitive ability is an important example here. Little is
understood about the benefits of (even small) cumulative gains in sleep in terms of arresting neuronal and
cognitive loss.226 Thus, the identification of appropriate follow-up time points and meaningful measures of
cognition, an outcome that is challenging to accurately capture in children with severe learning disabilities,
are essential. The selection of other child outcome measures also needs to be evidence based and
informed by the intervention’s theory of change for that outcome.
Fifth, for parent-directed interventions, the development and application of a theory of change is required
in the selection of appropriate outcomes. This is because children’s sleep outcomes will be mediated by
the outcomes for parents achieved by the intervention, that is, the acquisition of new knowledge and
understanding of sleep, and training in managing sleep disturbance. Furthermore, evidence from the wider
literature on parenting interventions indicates that the extent to which these parent-centred outcomes are
achieved are mediated/moderated by a number of factors, located in parent, practitioner and intervention
characteristics. Only a minority of parent-directed interventions captured outcomes in this domain.
Similarly, few studies report parent characteristics.
The design of evaluations
As we have noted earlier, evaluations need to be designed in such a way that the evidence generated
addresses the key questions of what works, for whom and in what circumstances? Interestingly, a similar
call for evidence has been made with respect to evaluation of similar interventions for children with typical
development.184 It would be informative to explore subgroup analyses within any future trials. In order to
make any analyses more credible, it will be important to define these subgroups in advance, and the
direction of effect, based on existing evidence.227,228 Depending on the evaluation, subgroups may be in
terms of sleep problem, child, parent or intervention characteristics.
In addition, for parent-directed interventions, RCTs need to incorporate measures of adherence and/or
fidelity. These are loosely defined concepts. An evaluation of parent-directed interventions to manage autism
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symptoms usefully defined it as both the accuracy and comprehensiveness of the intervention delivered to
the parents by the practitioner and the consistency and competency of the parent as they implement new
approaches to managing their child’s sleep disturbance.229 Our review of ‘family experience’ data identified
that parents can find implementing a new sleep management strategy stressful and demanding. Only one
study125 attempted to assess this in any way, relying on parents’ reports of the proportion of times that they
implemented the new sleep management strategy. There are clearly significant challenges related to the
feasibility and costs associated with measuring parent’s adherence and fidelity to a sleep management
strategy given the time of day when parents will be implementing a sleep management strategy and the
home setting. Methodological research will be required to inform incorporating this into study designs.
Finally, the final follow-up time point for most studies allowed consideration of short-term outcomes only.
Future studies need to consider what longer-term follow-ups should be incorporated into study designs.
Evidence on longer-term outcomes is particularly pertinent for parent-directed interventions that require
significant investment in parents’, as well as practitioners’, time, physical and emotional resources (and
potentially entail significant, if short-term, disruption to the family). If available, such evidence would
support shared decision-making regarding the management of a child’s sleep disturbance.
Moving towards replication
At the moment, the evidence base predominantly comprises single evaluations of interventions. These are
principally either investigations into the management of sleep disturbance by a particular clinic or are
(typically) early evaluations of a newly developed intervention, prior to its implementation into routine
practice. There are just two instances of some sort of replication study; however, in both,123,124,128,129 there
are differences between the studies in the way the intervention was delivered. A taxonomy by which
interventions should be defined and adherence to Template for Intervention Description and Replication
(TIDieR) guidance164 in study reporting would support both replication and future evidence syntheses.
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Chapter 5 Conclusions
Implications for health care
The poor quality of evidence and/or uncertainty regarding the clinical significance of findings mean that
there are no implications for health-care practice.
Recommendations for research
Randomised controlled trials are required to assess a range of possible treatment options for sleep
disturbance in children with ND. Future trials need to be informed by a greater understanding of the
mechanisms by which non-pharmacological interventions may have an impact on a child’s sleep and on
outcomes and outcome measurement. Developing an understanding of these mechanisms will require
mixed-methods research.
Future research needs to take account of the range of types, or aetiologies, of sleep disturbance, including
behavioural, physiological (e.g. heightened arousal, anxiety or atypical melatonin profiles) and disorders of
the circadian rhythm,230 which will vary between NDs.
We would also highlight that reporting was poor across RCTs, before-and-after studies and in studies
reporting parents’ views and experiences of sleep management interventions. This was particularly the
case for the non-pharmacological interventions. Future research should follow the appropriate reporting
standards for the specific study design (www.equator-network.org; accessed 21 June 2017), including
giving detailed description of the interventions using the TIDieR checklist.164 Within the TIDieR checklist,
it is important that sufficient detail is given on the specific curricula/training content of each intervention
and the techniques used to teach and train parents.
Bearing all of these issues in mind, we recommend that the topic areas listed below are priorities for future
research. Generating robust evidence in these topic areas will support clinicians (and families) to make
evidence-informed decisions about the identification, prevention and management of sleep disturbance in
children with NDs. It will also support evidence-informed decision-making with respect to commissioning
of services. The suggested areas for future research are quite diverse. Although necessarily presented in an
order, it would seem important that all key stakeholders contribute to any prioritisation processes.
l The development of a core outcome set would be beneficial. This should be developed in consultation
with parents and carers, the children themselves, when possible, and health-care professionals and
others involved in supporting parents and children, using a structured process such as that developed
by the Core Outcome Measures In Effectiveness group.231 Similarly, standardising the adverse events
recorded, data collection methods used and level of detail reported is important for future evaluations
of pharmacological and non-pharmacological interventions.
l If not already recently conducted, a review of existing tools, practices and strategies to identify sleep
disturbance in children with NDs that are appropriate and feasible for use in routine practice is
recommended.
l If available in a suitable preparation for the population under consideration, a trial comparing a
slow-release formulation of melatonin with a fast-release formulation of melatonin is suggested.
l There are a range of possible other pharmacological interventions for this population, such as
clonidine, but eligible studies were not identified. Prioritisation of evaluations of alternative
pharmacological options to melatonin (e.g. clonidine) is recommended.
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l No studies were identified that evaluated a combined or sequential use of melatonin (or other medicines)
and parent-directed interventions. Studies of this nature are required because children may present with
different types of sleep disturbance and/or sleep problems. Specifically, an apparent subclinical benefit
of melatonin in managing sleep initiation difficulties may be beneficial in supporting the impact that a
parent-directed intervention has. We recommend trials to investigate this.
l Parent-directed interventions range considerably in the intensity of practitioner input, from the simple
provision of written material through to extended one-to-one contact and incorporation of implementation
support. Studies are required that will support clinician and parent decision-making regarding the
appropriate intervention. Evaluations of parent-directed interventions that allow for comparison of the
relative impacts/clinical effectiveness of different features of the interventions (e.g. mode of delivery, group
vs. individual and the nature of implementation support) are recommended, which should incorporate an
investigation into issues of feasibility and acceptability. Prioritisation of interventions to address sleep
initiation is suggested.
l None of the studies included in this review was presented as a preventative intervention. Rather,
clinical cut-off points of sleep disturbance severity and/or parent reports of a sleep disturbance that
had extended over some period of time were among study eligibility criteria. However, some types
of sleep disturbance are preventable and/or amenable to early intervention. The brief, less-intense,
parent-directed interventions included in this review (e.g. provision of information, single-session group
intervention or face-to-face intervention) would, however, appear to align with a preventative or early
intervention approach. Evaluating these types of intervention approaches in terms of the impact that
they have on preventing the development of sleep disturbance, per se, or in preventing a newly
emerging sleep disturbance increasing in severity is recommended.
l Studies that map current practices and provision and research into families’ understanding of sleep
disturbance and their experiences of seeking help are recommended. These would provide useful
evidence to support the development of provision.
Finally, and across all topic areas, we would recommend that evaluations include a comprehensive and
holistic economic evaluation, including costs to families.
CONCLUSIONS
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Appendix 1 Search strategies
Interface: Applied Social Sciences Index and Abstracts via ProQuest
Date range searched: no restriction.
Search date: 7 February 2016.
Records identified: 153.
Search strategy
((((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT(“Narcolepsy”)) OR
((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay*
OR problem*)) OR (bedtime* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (“bed time*” NEAR/3 (initial* OR pattern* OR routine* OR practice* OR
maintain* OR intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initial* OR pattern* OR routine* OR
practice* OR maintain* OR intervention* OR schedule*))) OR ((night* NEAR/3 (dysfunction* OR disorder*
OR difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (night* NEAR/3 (settle* OR settling OR
wake* OR awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (nocturnal
NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR
(nocturnal NEAR/3 (settle* OR settling OR wake* OR awake OR wakeful* OR waking* OR awaking* OR
awakening* OR wakening*))) OR ((sleep* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt*
OR disturb* OR delay* OR problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR awake OR
wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (sleep* NEAR/3 (initial* OR pattern*
OR routine* OR practice* OR maintain* OR intervention* OR schedule*)) OR (sleepless* OR insomnia* OR
parasomnia* OR “night terror*” OR nightterror* OR “night mare*” OR nightmare*) OR (“sleepwalk*” OR
“nighthawk*” .) OR (sleepwalk* OR sleepwalk* OR “sleep walk*” OR somnambulism) OR (narcolepsy
OR “nocturnal hyperkinesia”))) AND ((SU.EXACT(“Children”) OR SU.EXACT(“adolescentce”) OR SU.EXACT
(“Infants”)) OR (adolescent* OR baby OR babies OR child OR children OR boy OR boys OR girl OR girls OR
infant* OR infancy* OR juvenile* OR paediatric OR pediatric OR preschooler* OR schoolboy* OR schoolgirl*
OR schoolchild* OR teens OR teenager* OR toddler* OR youth OR youths OR “young people” OR “young
person*”))) AND (((SU.EXACT(“Developmentally disabled children”) OR SU.EXACT(“Developmentally delayed
children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT(“Developmental disorders”)) OR SU.EXACT
(“Angelman syndrome”) OR (SU.EXACT(“Attention deficit disorder”) OR SU.EXACT(“Attention deficit
hyperactivity disorder”)) OR SU.EXACT(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure
disorder” OR “Epilepsy” OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral palsy”) OR SU.EXACT
(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”) OR (SU.EXACT(“Prader - Willi syndrome”) OR
SU.EXACT(“Prader-Willi syndrome”))) OR (SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis
syndrome”) OR (SU.EXACT(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR (ADHD
or “attention deficit” OR “angelman syndrome”) OR (autism or autistic or asperges* OR “cerebral palsy”) OR
(“conduct disorder*” OR epilepsy or epileptic) OR (“Down* syndrome” OR “Fragile x syndrome”) OR (“Prader
Willi Syndrome” OR “Prader-Willi Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR
(developmental NEAR/2 (disability* OR delay*)) OR neurodisability* OR (neurodevelopment* NEAR/3 (delay*
OR disability* OR disease* OR disorder* OR dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disability* OR
disease* OR disorder* OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR disability* OR disease* OR
disorder* OR dysfunction)) OR (neuropsychol* NEAR/3 (delay* OR disability* OR disease* OR disorder*
OR dysfunction)))
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Interface: Cumulative Index to Nursing & Allied Health via EBSCOhost
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 1157.
Search strategy
Search terms Search options Results
S37 S20 AND S36 1157
S36 S34 OR S35 66,730
S35 ( developmental N2 (disabilit* or delay*) ) OR neurodisabilit* OR ( neurodevelopment*
N3 (delay* or disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuromotor* N3
(delay* or disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuropsychiatric* N3
(delay* or disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuropsychol* N3
(delay* or disabilit* or disease* or disorder* or dysfunction*) )
10,885
S34 ( ADHD or (attention deficit) ) OR (angelman syndrome) OR ( autism or autistic or
asperger* ) OR (cerebral palsy) OR (conduct disorder*) OR ( epilepsy or epileptic ) OR
(Down* syndrome) OR (Fragile x syndrome) OR (Prader Willi Syndrome) OR (Rett
syndrome) OR ( Smith-Magenis syndrome) OR (Williams syndrome)
58,518
S33 (MH “Williams Syndrome”) 374
S32 (MH “Smith-Magenis Syndrome”) 41
S31 (MH “Rett Syndrome”) 374
S30 (MH “Prader-Willi Syndrome”) 493
S29 (MH “Fragile X Syndrome”) 673
S28 (MH “Down Syndrome”) 5123
S27 (MH “Cerebral Palsy”) 8165
S26 (MH “Epilepsy+”) 11,511
S25 (MH “Child Behavior Disorders”) 6418
S24 (MH “Attention Deficit Hyperactivity Disorder”) 10,817
S23 (MH “Angelman Syndrome”) 136
S22 (MH “Developmental Disabilities”) 6552
S21 (MH “Child Development Disorders”) OR (MH “Child Development Disorders, Pervasive”) 3027
S20 S14 AND S19 9983
S19 S15 OR S16 OR S17 OR S18 793,040
S18 (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant*
or infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or
schoolgirl* or schoolchild* or teens or teenager* or toddler* or youth or youths or
young people or young person*)
793,040
S17 (MH “Adolescence”) 350,551
S16 (MH “Infant”) 118,046
S15 (MH “Child”) 313,998
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR
S13
41,776
S13 narcolepsy or nocturnal hyperkinesia 992
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Search terms Search options Results
S12 ( (sleepless* or insomnia* or parasomnia* or night terror* or nightterror* or night
mare* or nightmare*) ) OR ( sleep-wak* or night-wak* ) OR ( sleepwalk* or sleep-walk*
or sleep walk* or somnambulism )
9309
S11 ( (sleep* N3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking*
or awakening* or wakening*) ) OR ( (sleep* N3 (dysfunction* or disorder or disorder* or
difficult* or disrupt* or disturb* or delay* or problem*) ) OR ( sleep* N3 (initiat* or
pattern* or routine* or practice* or maintain* or intervention* or schedule*) )
17,544
S10 ( (nocturnal* N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay*
or problem*) ) OR ( (nocturnal* N3 (settle* or settling or wake* or awake or wakeful*
or waking* or awaking* or awakening* or wakening*) )
366
S9 ( (night* N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*) ) OR ( (night* N3 (settle* or settling or wake* or awake or wakeful* or
waking* or awaking* or awakening* or wakening*) )
996
S8 ( (bed time*) N3 (initiat* or pattern* or routine* or practice* or maintain* or
intervention* or schedule*) ) OR ( (bedtime*) N3 (initiat* or pattern* or routine* or
practice* or maintain* or intervention* or schedule*) )
94
S7 ( (bed time*) N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay*
or problem*) ) OR ( (bedtime*) N3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*) )
66
S6 (MH “Dreams”) 1111
S5 (MH “Parasomnias”) 662
S4 (MH “Narcolepsy”) 826
S3 (MH “Somnambulism”) 151
S2 (MH “Sleep+”) 16,169
S1 (MH “Sleep Disorders+”) 26,313
Interface: The Cochrane Central Register of Controlled Trials via
Wiley Online Library
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 458.
Search strategy
#1 MeSH descriptor: [Sleep Wake Disorders] explode all trees
#2 MeSH descriptor: [Sleep] explode all trees
#3 MeSH descriptor: [Somnambulism] explode all trees
#4 MeSH descriptor: [Narcolepsy] explode all trees
#5 sleep* near/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*):ti,ab,kw or sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or “night
mare*” or nightmare*:ti,ab,kw or “sleep-wak*” or “night-wak*”:ti,ab,kw or “sleep-wak*” or “night-
wak*” or sleepwalk* or “sleep-walk*” or “sleep walk*” or somnambulism:ti,ab,kw or narcolepsy or
“nocturnal hyperkinesia”:ti,ab,kw (Word variations have been searched)
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#6 nocturnal near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*):ti,ab,kw or nocturnal near/3 (settle* or settling or wake* or awake or wakeful* or waking* or
awaking* or awakening* or wakening*):ti,ab,kw or sleep* near/3 (dysfunction* or disorder* or difficult*
or disrupt* or disturb* or delay* or problem*):ti,ab,kw or sleep* near/3 (settle* or settling or wake* or
awake or wakeful* or waking* or awaking* or awakening* or wakening*):ti,ab,kw (Word variations have
been searched)
#7 night* near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or problem*):ti,
ab,kw or night* near/3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*):ti,ab,kw (Word variations have been searched)
#8 bed* near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or problem*):ti,
ab,kw and bed* near/3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*):ti,ab,kw (Word variations have been searched)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 MeSH descriptor: [Child] explode all trees
#11 MeSH descriptor: [Adolescent] explode all trees
#12 MeSH descriptor: [Infant] explode all trees
#13 adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc*
or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or teens
or teenager* or toddler* or youth or youths or “young people” or “young person*”:ti,ab,kw (Word
variations have been searched)
#14 #10 or #11 or #12 or #13
#15 #9 and #14
#16 MeSH descriptor: [Developmental Disabilities] explode all trees
#17 MeSH descriptor: [Child Development Disorders, Pervasive] explode all trees
#18 MeSH descriptor: [Angelman Syndrome] explode all trees
#19 MeSH descriptor: [Attention Deficit Disorder with Hyperactivity] explode all trees
#20 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees
#21 MeSH descriptor: [Conduct Disorder] explode all trees
#22 MeSH descriptor: [Epilepsy] explode all trees
#23 MeSH descriptor: [Cerebral Palsy] explode all trees
#24 MeSH descriptor: [Down Syndrome] explode all trees
#25 MeSH descriptor: [Fragile X Syndrome] explode all trees
#26 MeSH descriptor: [Prader-Willi Syndrome] explode all trees
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#27 MeSH descriptor: [Rett Syndrome] explode all trees
#28 MeSH descriptor: [Smith-Magenis Syndrome] explode all trees
#29 MeSH descriptor: [Williams Syndrome] explode all trees
#30 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31 ADHD or “attention deficit”:ti,ab,kw or “angelman syndrome”:ti,ab,kw or autism or autistic or
asperger*:ti,ab,kw or “cerebral palsy”:ti,ab,kw or “conduct disorder*”:ti,ab,kw (Word variations have
been searched)
#32 epilepsy or epileptic:ti,ab,kw or “Down* syndrome”:ti,ab,kw or “Fragile x syndrome”:ti,ab,kw or
“Prader Willi Syndrome”:ti,ab,kw or “Rett syndrome”:ti,ab,kw (Word variations have been searched)
#33 “Smith-Magenis syndrome”:ti,ab,kw or “Williams syndrome”:ti,ab,kw (Word variations have
been searched)
#34 developmental near/2 (disabilit* or delay*):ti,ab,kw or neurodisabilit*:ti,ab,kw or
neurodevelopment* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw or
neuromotor* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw (Word
variations have been searched)
#35 neuropsychiatric* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw or
neuropsychol* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw (Word
variations have been searched)
#36 #31 or #32 or #33 or #34 or #35
#37 #30 or #36
#38 #15 and #37
Interface: Cochrane Database of Systematic Reviews via Wiley Online Library
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 8.
Search strategy: the Cochrane Database of Systematic Reviews strategy was the same as the CENTRAL
strategy above.
Interface: Conference Proceedings Citation Index via Web of Science
Date range searched: no restriction.
Search date: 9 February 2016.
Records identified: 262.
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Search strategy
# Results Search options
#13 262 #12 AND #9
Indexes=CPCI-S Timespan=All years
#12 28,755 #11 OR #10
Indexes=CPCI-S Timespan=All years
#11 2014 TOPIC: (developmental NEAR/2 (disabilit* or delay*)) OR TOPIC: (neurodisabilit*) OR TOPIC:
(neurodevelopment* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuromotor* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR TOPIC:
(neuropsychiatric* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuropsychol* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*))
Indexes=CPCI-S Timespan=All years
#10 27,174 TOPIC: (ADHD or “attention deficit”) OR TOPIC: (“angelman syndrome”) OR TOPIC: (autism or autistic or
asperger*) OR TOPIC: (“cerebral palsy”) OR TOPIC: (“conduct disorder*”) OR TOPIC: (epilepsy or epilepti)
OR TOPIC: (“Down* syndrome”) OR TOPIC: (“Fragile x syndrome”) OR TOPIC: (“Prader Willi Syndrome”)
OR TOPIC: (“Rett syndrome”) OR TOPIC: (“Smith-Magenis syndrome”) OR TOPIC: (“Williams syndrome”)
Indexes=CPCI-S Timespan=All years
#9 1224 #8 AND #7
Indexes=CPCI-S Timespan=All years
#8 146,852 TOPIC: (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild*
or teens or teenager* or toddler* or youth or youths or “young people” or “young person*”)
Indexes=CPCI-S Timespan=All years
#7 10,583 #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes=CPCI-S Timespan=All years
#6 4957 TS=(sleep* NEAR/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*)) OR TS=(sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or “night
mare*” or nightmare*) OR TS=(sleep-wak* or night-wak*) OR TS=(sleepwalk* or sleep-walk* or “sleep
walk*” or somnambulism) OR TS=(narcolepsy or “nocturnal hyperkinesia”)
Indexes=CPCI-S Timespan=All years
#5 6374 TS=(nocturnal* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(nocturnal* NEAR/3 (settle* or settling or wake* or awake or wakeful* or waking*
or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3 (settle* or settling or wake* or
awake or wakeful* or waking* or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3
(dysfunction* or disorder or disorder* or difficult* or disrupt* or disturb* or delay* or problem*))
Indexes=CPCI-S Timespan=All years
#4 393 TS=(“bed time*” NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(bedtime* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb*
or delay* or problem*)) OR TS=(night* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*)) OR TS=(night* NEAR/3 (settle* or settling or wake* or awake
or wakeful* or waking* or awaking* or awakening* or wakening*))
Indexes=CPCI-S Timespan=All years
#3 641 TS=(narcolepsy)
Indexes=CPCI-S Timespan=All years
#2 20 TS=(somnambulism)
Indexes=CPCI-S Timespan=All years
#1 3818 TS=(sleep disorder*)
Indexes=CPCI-S Timespan=All years
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
Interface: Database of Abstracts of Reviews of Effects via Wiley Online Library
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 5.
Search strategy: the Database of Abstracts of Reviews of Effects strategy was the same as the CENTRAL
strategy above.
Interface: EMBASE via Ovid
Date range searched: 1974 to 3 February 2016.
Search date: 4 February 2016.
Records identified: 10,288.
Search strategy
1. exp Sleep Disorder/ (162,095)
2. Sleep/ (81,239)
3. Sleep Walking/ (1490)
4. Narcolepsy/ (6862)
5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (318)
6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (282)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (2451)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (3053)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem
$)).ti,ab. (1558)
10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1279)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (22,635)
12. (sleep$ adj3 (dysfunction$ or disorder or disorders or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (50,363)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule
$)).ti,ab. (13,975)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare
$).ti,ab. (29,033)
15. (sleep-wak$ or night-wak$).ti,ab. (11 to 232)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (981)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (5221)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (242,035)
19. exp Infant/ or exp Child/ or exp Adolescent/ (2,934,245)
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20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (2,021,633)
21. 19 or 20 (3,492,441)
22. Childhood Disintegrative Disorder/ (128)
23. Developmental Disorder/ (28,670)
24. Asperger Syndrome/ (3660)
25. Attention Deficit Disorder/ or Attention Deficit Disorder with Hyperactivity/ or Attention Deficit
Hyperactivity Disorder/ (43,642)
26. exp Autism/ (44,025)
27. Conduct Disorder/ (5234)
28. exp Epilepsy/ (194,464)
29. Cerebral Palsy/ (28,687)
30. Down Syndrome/ (29,198)
31. Fragile X Syndrome/ (6859)
32. Happy Puppet Syndrome/ (2139)
33. “Pervasive Developmental Disorder not otherwise specified”/ (790)
34. Prader-Willi Syndrome/ (4427)
35. Rett Syndrome/ (3903)
36. Smith Magenis Syndrome/ (480)
37. Williams Beuren Syndrome/ (2655)
38. (ADHD or attention deficit).ti,ab. (32,156)
39. angelman syndrome.ti,ab. (1370)
40. (autism or autistic or asperger$).ti,ab. (38,978)
41. cerebral palsy.ti,ab. (22,489)
42. conduct disorder$.ti,ab. (4762)
43. (epilepsy or epileptic).ti,ab. (137,265)
44. Down$ syndrome.ti,ab. (23,072)
45. Fragile x syndrome.ti,ab. (4278)
46. Prader Willi Syndrome.ti,ab. (3070)
47. Prader-Willi Syndrome.ti,ab. (3070)
48. Rett syndrome.ti,ab. (3072)
49. Smith-Magenis syndrome.ti,ab. (334)
50. Williams syndrome.ti,ab. (1688)
51. (developmental adj2 (disabilit$ or delay$)).ti,ab. (18,243)
52. neurodisabilit$.ti,ab. (271)
53. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (8726)
54. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (20)
55. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (428)
56. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (11,567)
57. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2857)
58. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or
40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or
57 (415,764)
59. 18 and 21 and 58 (10,326)
60. (animal/ or nonhuman/) not exp human/ (4,938,572)
61. 59 not 60 (10,288)
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Interface: Health Management Information Consortium via Ovid
Date range searched: 1979 to November 2015.
Search date: 8 February 2016.
Records identified: 10.
Search strategy
1. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (1)
2. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (4)
3. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (43)
4. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (29)
5. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem
$)).ti,ab. (2)
6. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1)
7. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (26)
8. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (262)
9. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule
$)).ti,ab. (77)
10. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare
$).ti,ab. (202)
11. (sleep-wak$ or night-wak$).ti,ab. (14)
12. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (1)
13. (narcolepsy or nocturnal hyperkinesia).ti,ab. (4)
14. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (36 to 213)
15. (ADHD or attention deficit).ti,ab. (200)
16. angelman syndrome.ti,ab. (0)
17. (autism or autistic or asperger$).ti,ab. (546)
18. cerebral palsy.ti,ab. (144)
19. conduct disorder$.ti,ab. (85)
20. (epilepsy or epileptic).ti,ab. (372)
21. Down$ syndrome.ti,ab. (255)
22. Fragile x syndrome.ti,ab. (12)
23. Prader Willi Syndrome.ti,ab. (3)
24. Prader-Willi Syndrome.ti,ab. (3)
25. Rett syndrome.ti,ab. (5)
26. Smith-Magenis syndrome.ti,ab. (0)
27. Williams syndrome.ti,ab. (0)
28. (developmental adj2 (disabilit$ or delay$)).ti,ab. (100)
29. neurodisabilit$.ti,ab. (13)
30. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (31)
31. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
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32. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
33. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (24)
34. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (7)
35. or/1-13 (559)
36. or/15-34 (1671)
37. 14 and 35 and 36 (10)
Interface: MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid
MEDLINE(R) via Ovid
Date range searched: 1946 to present.
Search date: 4 February 2016.
Records identified: 4314.
Search strategy
1. exp Sleep Wake Disorders/ (67,333)
2. Sleep/ (41,262)
3. Somnambulism/ (561)
4. Narcolepsy/ (3034)
5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (175)
6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (146)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (1573)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1850)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (1041)
10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (811)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (15,245)
12. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (34,423)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule$)).
ti,ab. (8810)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (17,408)
15. (sleep-wak$ or night-wak$).ti,ab. (7703)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (665)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (3478)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (125,134)
19. exp Infant/ or exp Child/ or Adolescent/ (3,027,976)
20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (1,603,721)
21. 19 or 20 (3,390,703)
22. exp Child Development Disorders, Pervasive/ (23,521)
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23. Developmental Disabilities/ (16,203)
24. Angelman Syndrome/ (996)
25. exp “attention deficit and disruptive behavior disorders”/ or attention deficit disorder with hyperactivity/
or asperger syndrome/ or autistic disorder/ (42,213)
26. Conduct Disorder/ (2623)
27. exp Epilepsy/ (138,055)
28. Cerebral Palsy/ (16,902)
29. Down Syndrome/ (21,645)
30. Fragile X Syndrome/ (4267)
31. Prader-Willi Syndrome/ (2411)
32. Rett Syndrome/ (1997)
33. Smith-Magenis Syndrome/ (107)
34. Williams Syndrome/ (1371)
35. (ADHD or attention deficit).ti,ab. (22,948)
36. angelman syndrome.ti,ab. (1106)
37. (autism or autistic or asperger$).ti,ab. (29,066)
38. cerebral palsy.ti,ab. (16,339)
39. conduct disorder$.ti,ab. (3664)
40. (epilepsy or epileptic).ti,ab. (92,832)
41. Down$ syndrome.ti,ab. (18,536)
42. Fragile x syndrome.ti,ab. (3622)
43. Prader Willi Syndrome.ti,ab. (2414)
44. Prader-Willi Syndrome.ti,ab. (2414)
45. Rett syndrome.ti,ab. (2494)
46. Smith-Magenis syndrome.ti,ab. (285)
47. Williams syndrome.ti,ab. (1375)
48. (developmental adj2 (disabilit$ or delay$)).ti,ab. (13,041)
49. neurodisabilit$.ti,ab. (135)
50. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (6427)
51. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (11)
52. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (304)
53. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (8341)
54. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2022)
55. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 (303,873)
56. 18 and 21 and 55 (4314)
Interface: PsycINFO via Ovid
Date range searched: 1806 to week 1 February 2016.
Search date: 4 February 2016.
Records identified: 1727.
Search strategy
1. exp Sleep Disorders/ (12,542)
2. Sleep/ (17,334)
3. Sleepwalking/ (384)
4. Narcolepsy/ (1251)
5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (184)
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6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (154)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (972)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1170)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (402)
10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (359)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (8609)
12. (sleep$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (17,897)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule$)).
ti,ab. (5748)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (12,114)
15. (sleep-wak$ or night-wak$).ti,ab. (4320)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (749)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (1836)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (44,643)
19. (childhood birth 12 yrs or adolescence 13 17 yrs).ag. (657,693)
20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (760,813)
21. 19 or 20 (950,005)
22. “3250”.cc. (35,406)
23. exp Pervasive Developmental Disorders/ (31,057)
24. exp Developmental Disabilities/ (12,448)
25. Neurodevelopmental Disorders/ (1374)
26. Attention Deficit Disorder/ (5012)
27. “Attention Deficit Disorder with Hyperactivity”/ (16,339)
28. exp Autism/ (23,157)
29. Aspergers Syndrome/ (2444)
30. Conduct Disorder/ (3750)
31. exp Epilepsy/ (22,293)
32. Cerebral Palsy/ (4098)
33. Down’s Syndrome/ (5404)
34. Fragile X Syndrome/ (1368)
35. Prader Willi Syndrome/ (454)
36. Rett Syndrome/ (694)
37. Williams Syndrome/ (848)
38. (ADHD or attention deficit).ti,ab. (26,445)
39. angelman syndrome.ti,ab. (269)
40. (autism or autistic or asperger$).ti,ab. (37,207)
41. cerebral palsy.ti,ab. (5354)
42. conduct disorder$.ti,ab. (6181)
43. (epilepsy or epileptic).ti,ab. (29,858)
44. Down$ syndrome.ti,ab. (6294)
45. Fragile x syndrome.ti,ab. (1495)
46. Prader Willi Syndrome.ti,ab. (568)
47. Prader-Willi Syndrome.ti,ab. (568)
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48. Rett syndrome.ti,ab. (887)
49. Smith-Magenis syndrome.ti,ab. (75)
50. Williams syndrome.ti,ab. (990)
51. (developmental adj2 (disabilit$ or delay$)).ti,ab. (10,810)
52. neurodisabilit$.ti,ab. (64)
53. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (3603)
54. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (5)
55. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (115)
56. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (5090)
57. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2035)
58. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or
56 or 57 (135,560)
59. 18 and 21 and 58 (1727)
Interface: Science Citation Index via Web of Science
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 2831.
Search strategy
# Results Search options
#13 2831 #12 AND #9
Indexes=SCI-EXPANDED Timespan=1900-2016
#12 225,596 #11 OR #10
Indexes=SCI-EXPANDED Timespan=1900-2016
#11 31,246 TOPIC: (developmental NEAR/2 (disabilit* or delay*)) OR TOPIC: (neurodisabilit*) OR TOPIC:
(neurodevelopment* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuromotor* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR TOPIC:
(neuropsychiatric* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuropsychol* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*))
Indexes=SCI-EXPANDED Timespan=1900-2016
#10 203,758 TOPIC: (ADHD or “attention deficit”) OR TOPIC: (“angelman syndrome”) OR TOPIC: (autism or autistic
or asperger*) OR TOPIC: (“cerebral palsy”)OR TOPIC: (“conduct disorder*”) OR TOPIC: (epilepsy or
epilepti) OR TOPIC: (“Down* syndrome”) OR TOPIC: (“Fragile x syndrome”) OR TOPIC:(“Prader Willi
Syndrome”) OR TOPIC: (“Rett syndrome”) OR TOPIC: (“Smith-Magenis syndrome”) OR TOPIC:
(“Williams syndrome”)
Indexes=SCI-EXPANDED Timespan=1900-2016
#9 12,415 #8 AND #7
Indexes=SCI-EXPANDED Timespan=1900-2016
#8 1,497,016 TOPIC: (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild*
or teens or teenager* or toddler* or youth or youths or “young people” or “young person*”)
Indexes=SCI-EXPANDED Timespan=1900-2016
#7 76,127 #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED Timespan=1900-2016
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# Results Search options
#6 36,633 TS=(sleep* NEAR/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*)) OR TS=(sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or
“night mare*” or nightmare*) OR TS=(sleep-wak* or night-wak*) OR TS=(sleepwalk* or sleep-walk*
or “sleep walk*” or somnambulism) OR TS=(narcolepsy or “nocturnal hyperkinesia”)
Indexes=SCI-EXPANDED Timespan=1900-2016
#5 47,890 TS=(nocturnal* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(nocturnal* NEAR/3 (settle* or settling or wake* or awake or wakeful* or waking*
or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3 (settle* or settling or wake* or
awake or wakeful* or waking* or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3
(dysfunction* or disorder or disorder* or difficult* or disrupt* or disturb* or delay* or problem*))
Indexes=SCI-EXPANDED Timespan=1900-2016
#4 3852 TS=(“bed time*” NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(bedtime* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb*
or delay* or problem*)) OR TS=(night* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*)) OR TS=(night* NEAR/3 (settle* or settling or wake* or awake
or wakeful* or waking* or awaking* or awakening* or wakening*))
Indexes=SCI-EXPANDED Timespan=1900-2016
#3 4917 TS=(narcolepsy)
Indexes=SCI-EXPANDED Timespan=1900-2016
#2 297 TS=(somnambulism)
Indexes=SCI-EXPANDED Timespan=1900-2016
#1 33,513 TS=(sleep disorder*)
Indexes=SCI-EXPANDED Timespan=All years
Interface: Social Care Online via www.scie-socialcareonline.org.uk
Date range searched: no restriction.
Search date: 4 February 2016.
Records identified: 35.
Search strategy
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Interface: Social Policy & Practice via Ovid
Date range searched: no restriction.
Search date: 8 February 2016.
Records identified: 48.
Search strategy
1. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (2)
2. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (12)
3. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (33)
4. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (44)
5. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem
$)).ti,ab. (4)
6. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (7)
7. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (67)
8. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (527)
9. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule$)).
ti,ab. (260)
10. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (258)
11. (sleep-wak$ or night-wak$).ti,ab. (41)
12. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (13)
13. (narcolepsy or nocturnal hyperkinesia).ti,ab. (5)
14. (ADHD or attention deficit).ti,ab. (941)
15. angelman syndrome.ti,ab. (8)
16. (autism or autistic or asperger$).ti,ab. (2638)
17. cerebral palsy.ti,ab. (344)
18. conduct disorder$.ti,ab. (431)
19. (epilepsy or epileptic).ti,ab. (292)
20. Down$ syndrome.ti,ab. (509)
21. Fragile x syndrome.ti,ab. (49)
22. Prader Willi Syndrome.ti,ab. (32)
23. Prader-Willi Syndrome.ti,ab. (32)
24. Rett syndrome.ti,ab. (20)
25. Smith-Magenis syndrome.ti,ab. (3)
26. Williams syndrome.ti,ab. (12)
27. (developmental adj2 (disabilit$ or delay$)).ti,ab. (590)
28. neurodisabilit$.ti,ab. (19)
29. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (64)
30. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
31. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
32. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (32)
33. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (12)
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34. or/1-13 (993)
35. or/14-33 (5507)
36. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (139,979)
37. 34 and 35 and 36 (48)
Trial registers
In addition to the searches of the bibliographic databases, searches of the following trials registers were
carried out: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform and the UK Clinical
Trials Gateway.
ClinicalTrials.gov via https://clinicaltrials.gov
This resource was searched on 9 February 2016 using a number of small focused search strategies. The
results (103 records) were loaded into bibliographic software and, after deduplication, there were a total
of 70 records. The strategies and numbers identified are given below:
l Sleep disorders & children & angelman (3)
l Sleep disorders & children & attention deficit/ADHD (13)
l Sleep disorders & children & autism (16)
l Sleep disorders & children & conduct disorder (46)
l Sleep disorders & children & epilepsy (10)
l Sleep disorders & children & down syndrome (5)
l Sleep disorders & children & cerebral palsy (1)
l Sleep disorders & children & fragile x syndrome (0)
l Sleep disorders & children & prader willi syndrome (2)
l Sleep disorders & children & Rett syndrome (1)
l Sleep disorders & children & Smith-Magenis syndrome (6)
l Sleep disorders & children & Williams syndrome (0)
The World Health Organization International Clinical Trials Registry Platform via
http://apps.who.int/trialsearch/
This resource was searched on 9 February 2016 using the search terms ‘sleep AND children’ and 114
records for 108 trials were identified.
UK Clinical Trials Gateway via www.ukctg.nihr.ac.uk
This resource was searched on 9 February 2016 using the search phrase ‘sleep disorders and children’ and
16 trials were identified.
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Appendix 2 Additional searches using terms not
included in original search strategies
Interface: Applied Social Sciences Index and Abstracts via Proquest
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 154.
Search strategy
Set
number Searched for Databases Results
S1 ((((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT
(“Narcolepsy”)) OR ((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult* OR
disrupt* OR disturb* OR delay* OR problem*)) OR (bedtime* NEAR/3 (dysfunction* OR
disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (“bed
time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initiat* OR pattern* OR routine*
OR practice* OR maintain* OR intervention* OR schedule*))) OR ((night* NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (night* NEAR/3 (settle* OR settling OR wake* OR awake OR wakeful* OR
waking* OR awaking* OR awakening* OR wakening*)) OR (nocturnal NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (nocturnal NEAR/3 (settle* OR settling OR wake* OR awake OR wakeful*
OR waking* OR awaking* OR awakening* OR wakening*))) OR ((sleep* NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR awake OR wakeful* OR
waking* OR awaking* OR awakening* OR wakening*)) OR (sleep* NEAR/3 (initiat*
OR pattern* OR routine* OR practice* OR maintain* OR intervention* OR schedule*)) OR
(sleepless* OR insomnia* OR parasomnia* OR “night terror*” OR nightterror* OR “night
mare*” OR nightmare*) OR (“sleep-wak*” OR “night-wak*” .) OR (sleepwalk* OR
sleep-walk* OR “sleep walk*” OR somnambulism) OR (narcolepsy OR “nocturnal
hyperkinesia”))) AND ((SU.EXACT(“Children”) OR SU.EXACT(“Adolescence”) OR
SU.EXACT(“Infants”)) OR (adolescen* OR baby OR babies OR child OR children OR boy
OR boys OR girl OR girls OR infant* OR infanc* OR juvenile* OR paediatric OR pediatric
OR preschooler* OR schoolboy* OR schoolgirl* OR schoolchild* OR teens OR teenager*
OR toddler* OR youth OR youths OR “young people” OR “young person*”))) AND
(((SU.EXACT(“Developmentally disabled children”) OR SU.EXACT(“Developmentally
delayed children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT
(“Developmental disorders”)) OR SU.EXACT(“Angelman syndrome”) OR (SU.EXACT
(“Attention deficit disorder”) OR SU.EXACT(“Attention deficit hyperactivity disorder”))
OR SU.EXACT(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure disorder” OR
“Epilepsy” OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral
palsy”) OR SU.EXACT(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”) OR
(SU.EXACT(“Prader - Willi syndrome”) OR SU.EXACT(“Prader-Willi syndrome”))) OR
(SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis syndrome”) OR (SU.EXACT
(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR (ADHD or
“attention deficit” OR “angelman syndrome”) OR (autism or autistic or asperger* OR
“cerebral palsy”) OR ( “conduct disorder*” OR epilepsy or epileptic) OR (“Down*
syndrome” OR “Fragile x syndrome”) OR (“Prader Willi Syndrome” OR “Prader-Willi
Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR (developmental NEAR/2
(disabilit* OR delay*)) OR neurodisabilit* OR (neurodevelopment* NEAR/3 (delay* OR
disabilit* OR disease* OR disorder* OR dysfunction)) OR (neuromotor* NEAR/3 (delay*
OR disabilit* OR disease* OR disorder* OR dysfunction)) OR (neuropsychiatr* NEAR/3
(delay* OR disabilit* OR disease* OR disorder* OR dysfunction)) OR (neuropsychol*
NEAR/3 (delay* OR disabilit* OR disease* OR disorder* OR dysfunction)))
ASSIA 154
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Set
number Searched for Databases Results
S2 (((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT
(“Narcolepsy”)) OR ((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult*
OR disrupt* OR disturb* OR delay* OR problem*)) OR (bedtime* NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (“bed time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice*
OR maintain* OR intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initiat* OR
pattern* OR routine* OR practice* OR maintain* OR intervention* OR schedule*)))
OR ((night* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (night* NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR
(nocturnal NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (nocturnal NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)))
OR ((sleep* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR
(sleep* NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*)) OR (sleepless* OR insomnia* OR parasomnia* OR “night
terror*” OR nightterror* OR “night mare*” OR nightmare*) OR (“sleep-wak*” OR
“night-wak*” .) OR (sleepwalk* OR sleep-walk* OR “sleep walk*” OR
somnambulism) OR (narcolepsy OR “nocturnal hyperkinesia”)))
ASSIA 2877
S3 ((SU.EXACT(“Children”) OR SU.EXACT(“Adolescence”) OR SU.EXACT(“Infants”))
OR (adolescen* OR baby OR babies OR child OR children OR boy OR boys OR girl
OR girls OR infant* OR infanc* OR juvenile* OR paediatric OR pediatric OR
preschooler* OR schoolboy* OR schoolgirl* OR schoolchild* OR teens OR teenager*
OR toddler* OR youth OR youths OR “young people” OR “young person*”))
ASSIA 151,572
S4 (((SU.EXACT(“Developmentally disabled children”) OR SU.EXACT(“Developmentally
delayed children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT
(“Developmental disorders”)) OR SU.EXACT(“Angelman syndrome”) OR (SU.EXACT
(“Attention deficit disorder”) OR SU.EXACT(“Attention deficit hyperactivity disorder”))
OR SU.EXACT(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure disorder”
OR “Epilepsy” OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral
palsy”) OR SU.EXACT(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”) OR
(SU.EXACT(“Prader - Willi syndrome”) OR SU.EXACT(“Prader-Willi syndrome”)))
OR (SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis syndrome”) OR
(SU.EXACT(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR
(ADHD or “attention deficit” OR “angelman syndrome”) OR (autism or autistic or
asperger* OR “cerebral palsy”) OR ( “conduct disorder*” OR epilepsy or epileptic)
OR (“Down* syndrome” OR “Fragile x syndrome”) OR (“Prader Willi Syndrome” OR
“Prader-Willi Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR
(developmental NEAR/2 (disabilit* OR delay*)) OR neurodisabilit* OR
(neurodevelopment* NEAR/3 (delay* OR disabilit* OR disease* OR disorder* OR
dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disabilit* OR disease* OR disorder*
OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR disabilit* OR disease* OR
disorder* OR dysfunction)) OR (neuropsychol* NEAR/3 (delay* OR disabilit* OR disease*
OR disorder* OR dysfunction)))
ASSIA 17,586
S6 (intellectual* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*) ) OR
(mental* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*) ) OR
(learning NEAR/2 (disability or disabled or difficult*))
ASSIA 11,198
S7 (((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT
(“Narcolepsy”)) OR ((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult*
OR disrupt* OR disturb* OR delay* OR problem*)) OR (bedtime* NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (“bed time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice*
OR maintain* OR intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initiat* OR
pattern* OR routine* OR practice* OR maintain* OR intervention* OR schedule*)))
OR ((night* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (night* NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR
(nocturnal NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (nocturnal NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*))) OR
ASSIA
These databases
are searched for
part of your
query
154
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Set
number Searched for Databases Results
((sleep* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR
delay* OR problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR awake
OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (sleep*
NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*)) OR (sleepless* OR insomnia* OR parasomnia* OR
“night terror*” OR nightterror* OR “night mare*” OR nightmare*) OR (“sleep-
wak*” OR “night-wak*” .) OR (sleepwalk* OR sleep-walk* OR “sleep walk*” OR
somnambulism) OR (narcolepsy OR “nocturnal hyperkinesia”))) AND ((SU.EXACT
(“Children”) OR SU.EXACT(“Adolescence”) OR SU.EXACT(“Infants”)) OR (adolescen*
OR baby OR babies OR child OR children OR boy OR boys OR girl OR girls OR infant*
OR infanc* OR juvenile* OR paediatric OR pediatric OR preschooler* OR schoolboy*
OR schoolgirl* OR schoolchild* OR teens OR teenager* OR toddler* OR youth OR
youths OR “young people” OR “young person*”)) AND (((SU.EXACT
(“Developmentally disabled children”) OR SU.EXACT(“Developmentally delayed
children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT(“Developmental
disorders”)) OR SU.EXACT(“Angelman syndrome”) OR (SU.EXACT(“Attention deficit
disorder”) OR SU.EXACT(“Attention deficit hyperactivity disorder”)) OR SU.EXACT
(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure disorder” OR
“Epilepsy” OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral
palsy”) OR SU.EXACT(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”) OR
(SU.EXACT(“Prader - Willi syndrome”) OR SU.EXACT(“Prader-Willi syndrome”))) OR
(SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis syndrome”) OR
(SU.EXACT(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR
(ADHD or “attention deficit” OR “angelman syndrome”) OR (autism or autistic or
asperger* OR “cerebral palsy”) OR ( “conduct disorder*” OR epilepsy or epileptic) OR
(“Down* syndrome” OR “Fragile x syndrome”) OR (“Prader Willi Syndrome” OR
“Prader-Willi Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR
(developmental NEAR/2 (disabilit* OR delay*)) OR neurodisabilit* OR
(neurodevelopment* NEAR/3 (delay* OR disabilit* OR disease* OR disorder* OR
dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disabilit* OR disease* OR
disorder* OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR disabilit* OR
disease* OR disorder* OR dysfunction)) OR (neuropsychol* NEAR/3 (delay* OR
disabilit* OR disease* OR disorder* OR dysfunction)))
S8 (((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT
(“Narcolepsy”)) OR ((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult*
OR disrupt* OR disturb* OR delay* OR problem*)) OR (bedtime* NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (“bed time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice*
OR maintain* OR intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initiat* OR
pattern* OR routine* OR practice* OR maintain* OR intervention* OR schedule*)))
OR ((night* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (night* NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR
(nocturnal NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb*
OR delay* OR problem*)) OR (nocturnal NEAR/3 (settle* OR settling OR wake* OR
awake OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*))) OR
((sleep* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR
delay* OR problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR awake
OR wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (sleep*
NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*)) OR (sleepless* OR insomnia* OR parasomnia* OR
“night terror*” OR nightterror* OR “night mare*” OR nightmare*) OR (“sleep-
wak*” OR “night-wak*” .) OR (sleepwalk* OR sleep-walk* OR “sleep walk*” OR
somnambulism) OR (narcolepsy OR “nocturnal hyperkinesia”))) AND ((SU.EXACT
(“Children”) OR SU.EXACT(“Adolescence”) OR SU.EXACT(“Infants”)) OR (adolescen*
OR baby OR babies OR child OR children OR boy OR boys OR girl OR girls OR infant*
OR infanc* OR juvenile* OR paediatric OR pediatric OR preschooler* OR schoolboy*
OR schoolgirl* OR schoolchild* OR teens OR teenager* OR toddler* OR youth OR
youths OR “young people” OR “young person*”)) AND ((((SU.EXACT
(“Developmentally disabled children”) OR SU.EXACT(“Developmentally delayed
children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT(“Developmental
disorders”)) OR SU.EXACT(“Angelman syndrome”) OR (SU.EXACT(“Attention deficit
disorder”) OR SU.EXACT(“Attention deficit hyperactivity disorder”)) OR SU.EXACT
(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure disorder” OR
ASSIA
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Set
number Searched for Databases Results
“Epilepsy” OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral
palsy”) OR SU.EXACT(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”)
OR (SU.EXACT(“Prader - Willi syndrome”) OR SU.EXACT(“Prader-Willi syndrome”)))
OR (SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis syndrome”) OR
(SU.EXACT(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR
(ADHD or “attention deficit” OR “angelman syndrome”) OR (autism or autistic or
asperger* OR “cerebral palsy”) OR ( “conduct disorder*” OR epilepsy or epileptic)
OR (“Down* syndrome” OR “Fragile x syndrome”) OR (“Prader Willi Syndrome” OR
“Prader-Willi Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR
(developmental NEAR/2 (disabilit* OR delay*)) OR neurodisabilit* OR
(neurodevelopment* NEAR/3 (delay* OR disabilit* OR disease* OR disorder* OR
dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disabilit* OR disease* OR
disorder* OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR disabilit* OR
disease* OR disorder* OR dysfunction)) OR (neuropsychol* NEAR/3 (delay* OR
disabilit* OR disease* OR disorder* OR dysfunction))) OR ((intellectual* NEAR/2
(disabilit* or disabled or deficit* or handicap* or retard*) ) OR (mental* NEAR/2
(disabilit* or disabled or deficit* or handicap* or retard*) ) OR (learning NEAR/2
(disability or disabled or difficult*))))
S9 ((((SU.EXACT(“Sleep disorders”) OR SU.EXACT(“Sleep problems”)) OR SU.EXACT
(“Narcolepsy”)) OR ((“bed time*” NEAR/3 (dysfunction* OR disorder* OR difficult* OR
disrupt* OR disturb* OR delay* OR problem*)) OR (bedtime* NEAR/3 (dysfunction*
OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (“bed
time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*)) OR (“bed time*” NEAR/3 (initiat* OR pattern* OR
routine* OR practice* OR maintain* OR intervention* OR schedule*))) OR ((night*
NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay*
OR problem*)) OR (night* NEAR/3 (settle* OR settling OR wake* OR awake OR
wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (nocturnal
NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay*
OR problem*)) OR (nocturnal NEAR/3 (settle* OR settling OR wake* OR awake OR
wakeful* OR waking* OR awaking* OR awakening* OR wakening*))) OR ((sleep*
NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay*
OR problem*)) OR (sleep* NEAR/3 (settle* OR settling OR wake* OR awake OR
wakeful* OR waking* OR awaking* OR awakening* OR wakening*)) OR (sleep*
NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR intervention*
OR schedule*)) OR (sleepless* OR insomnia* OR parasomnia* OR “night terror*” OR
nightterror* OR “night mare*” OR nightmare*) OR (“sleep-wak*” OR “night-wak*” .)
OR (sleepwalk* OR sleep-walk* OR “sleep walk*” OR somnambulism) OR (narcolepsy
OR “nocturnal hyperkinesia”))) AND ((SU.EXACT(“Children”) OR SU.EXACT
(“Adolescence”) OR SU.EXACT(“Infants”)) OR (adolescen* OR baby OR babies OR
child OR children OR boy OR boys OR girl OR girls OR infant* OR infanc* OR juvenile*
OR paediatric OR pediatric OR preschooler* OR schoolboy* OR schoolgirl* OR
schoolchild* OR teens OR teenager* OR toddler* OR youth OR youths OR “young
people” OR “young person*”)) AND ((((SU.EXACT(“Developmentally disabled
children”) OR SU.EXACT(“Developmentally delayed children”)) OR (SU.EXACT
(“Developmental delays”) OR SU.EXACT(“Developmental disorders”)) OR SU.EXACT
(“Angelman syndrome”) OR (SU.EXACT(“Attention deficit disorder”) OR SU.EXACT
(“Attention deficit hyperactivity disorder”)) OR SU.EXACT(“Conduct disorders”) OR
SU.EXACT(“Complex partial seizure disorder” OR “Epilepsy” OR “Idiopathic childhood
epilepsy” OR “Landau-Kleffner syndrome” OR “Panayiotopoulos syndrome” OR
“Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral palsy”) OR SU.EXACT(“Down’s
syndrome”) OR SU.EXACT(“Fragile X syndrome”) OR (SU.EXACT(“Prader - Willi
syndrome”) OR SU.EXACT(“Prader-Willi syndrome”))) OR (SU.EXACT(“Rett syndrome”)
OR SU.EXACT(“Smith-Magenis syndrome”) OR (SU.EXACT(“Williams-Beuren
syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR (ADHD or “attention deficit” OR
“angelman syndrome”) OR (autism or autistic or asperger* OR “cerebral palsy”) OR
(“conduct disorder*” OR epilepsy or epileptic) OR (“Down* syndrome” OR “Fragile x
syndrome”) OR (“Prader Willi Syndrome” OR “Prader-Willi Syndrome”) OR (“Rett
syndrome” OR “Williams syndrome”)) OR (developmental NEAR/2 (disabilit* OR
delay*)) OR neurodisabilit* OR (neurodevelopment* NEAR/3 (delay* OR disabilit* OR
disease* OR disorder* OR dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disabilit*
OR disease* OR disorder* OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR
disabilit* OR disease* OR disorder* OR dysfunction)) OR (neuropsychol* NEAR/3
(delay* OR disabilit* OR disease* OR disorder* OR dysfunction))) OR ((intellectual*
ASSIA 20
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Set
number Searched for Databases Results
NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*) ) OR (mental* NEAR/
2 (disabilit* or disabled or deficit* or handicap* or retard*) ) OR (learning NEAR/2
(disability or disabled or difficult*))))) NOT ((((SU.EXACT(“Sleep disorders”) OR
SU.EXACT(“Sleep problems”)) OR SU.EXACT(“Narcolepsy”)) OR ((“bed time*” NEAR/3
(dysfunction* OR disorder* OR difficult* OR disrupt* OR disturb* OR delay* OR
problem*)) OR (bedtime* NEAR/3 (dysfunction* OR disorder* OR difficult* OR disrupt*
OR disturb* OR delay* OR problem*)) OR (“bed time*” NEAR/3 (initiat* OR pattern*
OR routine* OR practice* OR maintain* OR intervention* OR schedule*)) OR (“bed
time*” NEAR/3 (initiat* OR pattern* OR routine* OR practice* OR maintain* OR
intervention* OR schedule*))) OR ((night* NEAR/3 (dysfunction* OR disorder* OR
difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (night* NEAR/3
(settle* OR settling OR wake* OR awake OR wakeful* OR waking* OR awaking* OR
awakening* OR wakening*)) OR (nocturnal NEAR/3 (dysfunction* OR disorder* OR
difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (nocturnal NEAR/3
(settle* OR settling OR wake* OR awake OR wakeful* OR waking* OR awaking* OR
awakening* OR wakening*))) OR ((sleep* NEAR/3 (dysfunction* OR disorder* OR
difficult* OR disrupt* OR disturb* OR delay* OR problem*)) OR (sleep* NEAR/3
(settle* OR settling OR wake* OR awake OR wakeful* OR waking* OR awaking* OR
awakening* OR wakening*)) OR (sleep* NEAR/3 (initiat* OR pattern* OR routine* OR
practice* OR maintain* OR intervention* OR schedule*)) OR (sleepless* OR insomnia*
OR parasomnia* OR “night terror*” OR nightterror* OR “night mare*” OR
nightmare*) OR (“sleep-wak*” OR “night-wak*” .) OR (sleepwalk* OR sleep-walk*
OR “sleep walk*” OR somnambulism) OR (narcolepsy OR “nocturnal hyperkinesia”)))
AND ((SU.EXACT(“Children”) OR SU.EXACT(“Adolescence”) OR SU.EXACT(“Infants”))
OR (adolescen* OR baby OR babies OR child OR children OR boy OR boys OR girl OR
girls OR infant* OR infanc* OR juvenile* OR paediatric OR pediatric OR preschooler*
OR schoolboy* OR schoolgirl* OR schoolchild* OR teens OR teenager* OR toddler*
OR youth OR youths OR “young people” OR “young person*”)) AND (((SU.EXACT
(“Developmentally disabled children”) OR SU.EXACT(“Developmentally delayed
children”)) OR (SU.EXACT(“Developmental delays”) OR SU.EXACT(“Developmental
disorders”)) OR SU.EXACT(“Angelman syndrome”) OR (SU.EXACT(“Attention deficit
disorder”) OR SU.EXACT(“Attention deficit hyperactivity disorder”)) OR SU.EXACT
(“Conduct disorders”) OR SU.EXACT(“Complex partial seizure disorder” OR “Epilepsy”
OR “Idiopathic childhood epilepsy” OR “Landau-Kleffner syndrome” OR
“Panayiotopoulos syndrome” OR “Temporal lobe epilepsy”) OR SU.EXACT(“Cerebral
palsy”) OR SU.EXACT(“Down’s syndrome”) OR SU.EXACT(“Fragile X syndrome”)
OR (SU.EXACT(“Prader - Willi syndrome”) OR SU.EXACT(“Prader-Willi syndrome”))) OR
(SU.EXACT(“Rett syndrome”) OR SU.EXACT(“Smith-Magenis syndrome”) OR
(SU.EXACT(“Williams-Beuren syndrome”) OR SU.EXACT(“Williams’ syndrome”)) OR
(ADHD or “attention deficit” OR “angelman syndrome”) OR (autism or autistic or
asperger* OR “cerebral palsy”) OR ( “conduct disorder*” OR epilepsy or epileptic) OR
(“Down* syndrome” OR “Fragile x syndrome”) OR (“Prader Willi Syndrome” OR
“Prader-Willi Syndrome”) OR (“Rett syndrome” OR “Williams syndrome”)) OR
(developmental NEAR/2 (disabilit* OR delay*)) OR neurodisabilit* OR
(neurodevelopment* NEAR/3 (delay* OR disabilit* OR disease* OR disorder* OR
dysfunction)) OR (neuromotor* NEAR/3 (delay* OR disabilit* OR disease* OR disorder*
OR dysfunction)) OR (neuropsychiatr* NEAR/3 (delay* OR disabilit* OR disease*
OR disorder* OR dysfunction)) OR (neuropsychol* NEAR/3 (delay* OR disabilit* OR
disease* OR disorder* OR dysfunction))))
Interface: The Cochrane Central Register of Controlled Trials via
The Cochrane Library
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 15.
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Search strategy
#1 MeSH descriptor: [Sleep Wake Disorders] explode all trees
#2 MeSH descriptor: [Sleep] explode all trees
#3 MeSH descriptor: [Somnambulism] explode all trees
#4 MeSH descriptor: [Narcolepsy] explode all trees
#5 sleep* near/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or schedule*):
ti,ab,kw or sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or “night mare*” or
nightmare*:ti,ab,kw or “sleep-wak*” or “night-wak*”:ti,ab,kw or “sleep-wak*” or “night-wak*” or
sleepwalk* or “sleep-walk*” or “sleep walk*” or somnambulism:ti,ab,kw or narcolepsy or “nocturnal
hyperkinesia”:ti,ab,kw (Word variations have been searched)
#6 nocturnal near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or problem*):
ti,ab,kw or nocturnal near/3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*):ti,ab,kw or sleep* near/3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*):ti,ab,kw or sleep* near/3 (settle* or settling or wake* or awake or wakeful*
or waking* or awaking* or awakening* or wakening*):ti,ab,kw (Word variations have been searched)
#7 night* near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or problem*):ti,
ab,kw or night* near/3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*):ti,ab,kw (Word variations have been searched)
#8 bed* near/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or problem*):ti,
ab,kw and bed* near/3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*):ti,ab,kw (Word variations have been searched)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 MeSH descriptor: [Child] explode all trees
#11 MeSH descriptor: [Adolescent] explode all trees
#12 MeSH descriptor: [Infant] explode all trees
#13 adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc*
or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or teens
or teenager* or toddler* or youth or youths or “young people” or “young person*”:ti,ab,kw (Word
variations have been searched)
#14 #10 or #11 or #12 or #13
#15 #9 and #14
#16 MeSH descriptor: [Developmental Disabilities] explode all trees
#17 MeSH descriptor: [Child Development Disorders, Pervasive] explode all trees
#18 MeSH descriptor: [Angelman Syndrome] explode all trees
#19 MeSH descriptor: [Attention Deficit Disorder with Hyperactivity] explode all trees
#20 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees
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#21 MeSH descriptor: [Conduct Disorder] explode all trees
#22 MeSH descriptor: [Epilepsy] explode all trees
#23 MeSH descriptor: [Cerebral Palsy] explode all trees
#24 MeSH descriptor: [Down Syndrome] explode all trees
#25 MeSH descriptor: [Fragile X Syndrome] explode all trees
#26 MeSH descriptor: [Prader-Willi Syndrome] explode all trees
#27 MeSH descriptor: [Rett Syndrome] explode all trees
#28 MeSH descriptor: [Smith-Magenis Syndrome] explode all trees
#29 MeSH descriptor: [Williams Syndrome] explode all trees
#30 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31 ADHD or “attention deficit”:ti,ab,kw or “angelman syndrome”:ti,ab,kw or autism or autistic or asperger*:
ti,ab,kw or “cerebral palsy”:ti,ab,kw or “conduct disorder*”:ti,ab,kw (Word variations have been searched)
#32 epilepsy or epileptic:ti,ab,kw or “Down* syndrome”:ti,ab,kw or “Fragile x syndrome”:ti,ab,kw or
“Prader Willi Syndrome”:ti,ab,kw or “Rett syndrome”:ti,ab,kw (Word variations have been searched)
#33 “Smith-Magenis syndrome”:ti,ab,kw or “Williams syndrome”:ti,ab,kw (Word variations have
been searched)
#34 developmental near/2 (disabilit* or delay*):ti,ab,kw or neurodisabilit*:ti,ab,kw or neurodevelopment*
near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw or neuromotor* near/3 (delay*
or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw (Word variations have been searched)
#35 neuropsychiatric* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw or
neuropsychol* near/3 (delay* or disabilit* or disease* or disorder* or dysfunction*):ti,ab,kw (Word
variations have been searched)
#36 #31 or #32 or #33 or #34 or #35
#37 #30 or #36
#38 #15 and #37
#39 MeSH descriptor: [Intellectual Disability] explode all trees
#40 intellectual* near/2 (disabilit* or disabled or deficit* or handicap* or retard*):ti,ab,kw (Word
variations have been searched)
#41 (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$))
#42 (learning adj (disability or disabled or difficult$))
#43 #39 or #40 or #41 or #42
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#44 #37 or #43
#45 #9 and #14 and #44
#46 #45 not #38
Interface: Cumulative Index to Nursing & Allied Health via EBSCOhost
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 53.
Search strategy
Search
identification
number Search terms Results
S45 s44 NOT s42 53
S44 S14 AND S19 AND S43 1375
S43 S38 OR S39 OR S41 96,086
S42 S14 AND S19 AND S41 1322
S41 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32
OR S33 OR S34 OR S35
74,324
S40 S38 OR S39 33,365
S39 (MH “Intellectual Disability+”) 22,711
S38 ( intellectual* N2 (disabilit* or disabled or deficit* or handicap* or retard*) ) OR ( mental* N2
(disabilit* or disabled or deficit* or handicap* or retard*) ) OR ( learning N2 (disabilit* or
disabled or difficult*) )
26,110
S37 S20 AND S36 Rerun
S36 S34 OR S35 Rerun
S35 ( developmental N2 (disabilit* or delay*) ) OR neurodisabilit* OR ( neurodevelopment* N3
(delay* or disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuromotor* N3 (delay*
or disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuropsychiatric* N3 (delay* or
disabilit* or disease* or disorder* or dysfunction*) ) OR ( neuropsychol* N3 (delay* or
disabilit* or disease* or disorder* or dysfunction*) )
Rerun
S34 ( ADHD or (attention deficit) ) OR (angelman syndrome) OR ( autism or autistic or asperger* )
OR (cerebral palsy) OR (conduct disorder*) OR ( epilepsy or epileptic ) OR (Down* syndrome)
OR (Fragile x syndrome) OR (Prader Willi Syndrome) OR (Rett syndrome) OR ( Smith-Magenis
syndrome) OR (Williams syndrome)
Rerun
S33 (MH “Williams Syndrome”) Rerun
S32 (MH “Smith-Magenis Syndrome”) Rerun
S31 (MH “Rett Syndrome”) Rerun
S30 (MH “Prader-Willi Syndrome”) Rerun
S29 (MH “Fragile X Syndrome”) Rerun
S28 (MH “Down Syndrome”) Rerun
S27 (MH “Cerebral Palsy”) Rerun
S26 (MH “Epilepsy+”) Rerun
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Search
identification
number Search terms Results
S25 (MH “Child Behavior Disorders”) Rerun
S24 (MH “Attention Deficit Hyperactivity Disorder”) Rerun
S23 (MH “Angelman Syndrome”) Rerun
S22 (MH “Developmental Disabilities”) Rerun
S21 (MH “Child Development Disorders”) OR (MH “Child Development Disorders, Pervasive”) Rerun
S20 S14 AND S19 Rerun
S19 S15 OR S16 OR S17 OR S18 Rerun
S18 (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or
schoolchild* or teens or teenager* or toddler* or youth or youths or young people or young
person*)
Rerun
S17 (MH “Adolescence”) Rerun
S16 (MH “Infant”) Rerun
S15 (MH “Child”) Rerun
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 Rerun
S13 narcolepsy or nocturnal hyperkinesia Rerun
S12 ( (sleepless* or insomnia* or parasomnia* or night terror* or nightterror* or night mare* or
nightmare*) ) OR ( sleep-wak* or night-wak* ) OR ( sleepwalk* or sleep-walk* or sleep walk*
or somnambulism )
Rerun
S11 ( (sleep* N3 (settle* or settling or wake* or awake or wakeful* or waking* or awaking* or
awakening* or wakening*) ) OR ( (sleep* N3 (dysfunction* or disorder or disorder* or
difficult* or disrupt* or disturb* or delay* or problem*) ) OR ( sleep* N3 (initiat* or pattern*
or routine* or practice* or maintain* or intervention* or schedule*) )
Rerun
S10 ( (nocturnal* N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*) ) OR ( (nocturnal* N3 (settle* or settling or wake* or awake or wakeful* or
waking* or awaking* or awakening* or wakening*) )
Rerun
S9 ( (night* N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*) ) OR ( (night* N3 (settle* or settling or wake* or awake or wakeful* or waking* or
awaking* or awakening* or wakening*) )
Rerun
S8 ( (bed time*) N3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*) ) OR ( (bedtime*) N3 (initiat* or pattern* or routine* or practice* or maintain* or
intervention* or schedule*) )
Rerun
S7 ( (bed time*) N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*) ) OR ( (bedtime*) N3 (dysfunction* or disorder* or difficult* or disrupt* or disturb*
or delay* or problem*) )
Rerun
S6 (MH “Dreams”) Rerun
S5 (MH “Parasomnias”) Rerun
S4 (MH “Narcolepsy”) Rerun
S3 (MH “Somnambulism”) Rerun
S2 (MH “Sleep+”) Rerun
S1 (MH “Sleep Disorders+”) Rerun
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Interface: Conference Proceedings Citation Index via Web of Science
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 12.
Search strategy
# Search options Results
#17 #16 not #13
Indexes=CPCI-S Timespan=All years
12
#16 #15 AND #9
Indexes=CPCI-S Timespan=All years
274
#15 #14 OR #11 OR #10
Indexes=CPCI-S Timespan=All years
31,261
#14 TOPIC: (intellectual* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*)) OR TOPIC:
(mental* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*)) OR TOPIC: (learning NEAR/2
(disability or disabled or difficult*))
Indexes=CPCI-S Timespan=All years
3386
#13 #12 AND #9
Indexes=CPCI-S Timespan=All years
262
#12 #11 OR #10
Indexes=CPCI-S Timespan=All years
28,814
#11 TOPIC: (developmental NEAR/2 (disabilit* or delay*)) OR TOPIC: (neurodisabilit*) OR TOPIC:
(neurodevelopment* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuromotor* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR TOPIC:
(neuropsychiatric* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuropsychol* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*))
Indexes=CPCI-S Timespan=All years
2019
#10 TOPIC: (ADHD or “attention deficit”) OR TOPIC: (“angelman syndrome”) OR TOPIC: (autism or autistic
or asperger*) OR TOPIC: (“cerebral palsy”) OR TOPIC: (“conduct disorder*”) OR TOPIC: (epilepsy or
epilepti) OR TOPIC: (“Down* syndrome”) OR TOPIC: (“Fragile x syndrome”) OR TOPIC: (“Prader Willi
Syndrome”) OR TOPIC: (“Rett syndrome”) OR TOPIC: (“Smith-Magenis syndrome”) OR TOPIC:
(“Williams syndrome”)
Indexes=CPCI-S Timespan=All years
27,231
#9 #8 AND #7
Indexes=CPCI-S Timespan=All years
1227
#8 TOPIC: (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or
schoolchild* or teens or teenager* or toddler* or youth or youths or “young people” or “young
person*”)
Indexes=CPCI-S Timespan=All years
148,172
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes=CPCI-S Timespan=All years
10,610
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# Search options Results
#6 TS=(sleep* NEAR/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*)) OR TS=(sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or “night
mare*” or nightmare*) OR TS=(sleep-wak* or night-wak*) OR TS=(sleepwalk* or sleep-walk* or “sleep
walk*” or somnambulism) OR TS=(narcolepsy or “nocturnal hyperkinesia”)
Indexes=CPCI-S Timespan=All years
4969
#5 TS=(nocturnal* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(nocturnal* NEAR/3 (settle* or settling or wake* or awake or wakeful* or waking*
or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3 (settle* or settling or wake* or
awake or wakeful* or waking* or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3
(dysfunction* or disorder or disorder* or difficult* or disrupt* or disturb* or delay* or problem*))
Indexes=CPCI-S Timespan=All years
6394
#4 TS=(“bed time*” NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(bedtime* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb*
or delay* or problem*)) OR TS=(night* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*)) OR TS=(night* NEAR/3 (settle* or settling or wake* or awake
or wakeful* or waking* or awaking* or awakening* or wakening*))
Indexes=CPCI-S Timespan=All years
395
#3 TS=(narcolepsy)
Indexes=CPCI-S Timespan=All years
641
#2 TS=(somnambulism)
Indexes=CPCI-S Timespan=All years
20
#1 TS=(sleep disorder*)
Indexes=CPCI-S Timespan=All years
3826
EMBASE via Ovid
Date range searched: 1974 to 16 March 2016.
Search date: 17 March 2016.
Records identified: 281.
Search strategy
1. exp Sleep Disorder/ (163,578)
2. Sleep/ (81,807)
3. Sleep Walking/ (1497)
4. Narcolepsy/ (6905)
5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (321)
6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (284)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (2464)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (3072)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem
$)).ti,ab. (1566)
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10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1285)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (22,772)
12. (sleep$ adj3 (dysfunction$ or disorder or disorders or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (50,790)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule
$)).ti,ab. (14,079)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare
$).ti,ab. (29,260)
15. (sleep-wak$ or night-wak$).ti,ab. (11,301)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (987)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (5254)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (244,169)
19. exp Infant/ or exp Child/ or exp Adolescent/ (2,954,891)
20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (2,038,598)
21. 19 or 20 (3,517,560)
22. Childhood Disintegrative Disorder/ (128)
23. Developmental Disorder/ (28,919)
24. Asperger Syndrome/ (3698)
25. Attention Deficit Disorder/ or Attention Deficit Disorder with Hyperactivity/ or Attention Deficit
Hyperactivity Disorder/ (44,022)
26. exp Autism/ (44,576)
27. Conduct Disorder/ (5292)
28. exp Epilepsy/ (196,376)
29. Cerebral Palsy/ (29,042)
30. Down Syndrome/ (29,384)
31. Fragile X Syndrome/ (6913)
32. Happy Puppet Syndrome/ (2147)
33. “Pervasive Developmental Disorder not otherwise specified”/ (796)
34. Prader-Willi Syndrome/ (4459)
35. Rett Syndrome/ (3939)
36. Smith Magenis Syndrome/ (483)
37. Williams Beuren Syndrome/ (2672)
38. (ADHD or attention deficit).ti,ab. (32,439)
39. angelman syndrome.ti,ab. (1374)
40. (autism or autistic or asperger$).ti,ab. (39,494)
41. cerebral palsy.ti,ab. (22,786)
42. conduct disorder$.ti,ab. (4786)
43. (epilepsy or epileptic).ti,ab. (138,577)
44. Down$ syndrome.ti,ab. (23,196)
45. Fragile x syndrome.ti,ab. (4311)
46. Prader Willi Syndrome.ti,ab. (3090)
47. Prader-Willi Syndrome.ti,ab. (3090)
48. Rett syndrome.ti,ab. (3099)
49. Smith-Magenis syndrome.ti,ab. (335)
50. Williams syndrome.ti,ab. (1696)
51. (developmental adj2 (disabilit$ or delay$)).ti,ab. (18,431)
52. neurodisabilit$.ti,ab. (275)
53. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (8887)
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54. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (21)
55. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (431)
56. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (11,690)
57. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2874)
58. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or
40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or
57 (419,846)
59. 18 and 21 and 58 (10,411)
60. (animal/ or nonhuman/) not exp human/ (4,980,395)
61. 59 not 60 (10,373)
62. intellectual impairment/ (14,389)
63. (intellectual$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (13,554)
64. (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (44,139)
65. (learning adj (disability or disabled or difficult$)).ti,ab. (7378)
66. 62 or 63 or 64 or 65 (68,203)
67. 58 or 66 (462,906)
68. 18 and 21 and 67 (10,694)
69. (animal/ or nonhuman/) not exp human/ (4,980,395)
70. 68 not 69 (10,654)
71. 70 not 61 (281)
Interface: Health Management Information Centre via Ovid
Date range searched: 1979 to January 2016.
Search date: 17 March 2016.
Records identified: 4.
Search strategy
1. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (1)
2. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (4)
3. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (43)
4. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (29)
5. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem
$)).ti,ab. (2)
6. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1)
7. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (26)
8. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (262)
9. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule
$)).ti,ab. (77)
10. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare
$).ti,ab. (202)
11. (sleep-wak$ or night-wak$).ti,ab. (14)
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12. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (1)
13. (narcolepsy or nocturnal hyperkinesia).ti,ab. (4)
14. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (36,281)
15. (ADHD or attention deficit).ti,ab. (200)
16. angelman syndrome.ti,ab. (0)
17. (autism or autistic or asperger$).ti,ab. (554)
18. cerebral palsy.ti,ab. (145)
19. conduct disorder$.ti,ab. (85)
20. (epilepsy or epileptic).ti,ab. (373)
21. Down$ syndrome.ti,ab. (255)
22. Fragile x syndrome.ti,ab. (12)
23. Prader Willi Syndrome.ti,ab. (3)
24. Prader-Willi Syndrome.ti,ab. (3)
25. Rett syndrome.ti,ab. (5)
26. Smith-Magenis syndrome.ti,ab. (0)
27. Williams syndrome.ti,ab. (0)
28. (developmental adj2 (disabilit$ or delay$)).ti,ab. (101)
29. neurodisabilit$.ti,ab. (13)
30. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (31)
31. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
32. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
33. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (24)
34. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (7)
35. or/1-13 (559)
36. or/15-34 (1680)
37. 14 and 35 and 36 (10)
38. (intellectual$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (318)
39. (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (2397)
40. (learning adj (disability or disabled or difficult$)).ti,ab. (2394)
41. 38 or 39 or 40 (4883)
42. 36 or 41 (6387)
43. 14 and 35 and 42 (14)
44. 43 not 37 (4)
Interface: MEDLINE via Ovid Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Search date: 17 March 2016.
Records identified: 220.
Search strategy
1. exp Sleep Wake Disorders/ (68,198)
2. Sleep/ (41,721)
3. Somnambulism/ (563)
4. Narcolepsy/ (3053)
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5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (182)
6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (149)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (1593)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1872)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (1051)
10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (819)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (15,445)
12. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (35,005)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule$)).
ti,ab. (8934)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (17,638)
15. (sleep-wak$ or night-wak$).ti,ab. (7799)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (668)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (3509)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (126,691)
19. exp Infant/ or exp Child/ or Adolescent/ (3,049,474)
20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (1,619,190)
21. 19 or 20 (3,417,108)
22. exp Child Development Disorders, Pervasive/ (23,981)
23. Developmental Disabilities/ (16,408)
24. Angelman Syndrome/ (1005)
25. exp “attention deficit and disruptive behavior disorders”/ or attention deficit disorder with
hyperactivity/ or asperger syndrome/ or autistic disorder/ (42,816)
26. Conduct Disorder/ (2671)
27. exp Epilepsy/ (138,933)
28. Cerebral Palsy/ (16,993)
29. Down Syndrome/ (21,762)
30. Fragile X Syndrome/ (4312)
31. Prader-Willi Syndrome/ (2429)
32. Rett Syndrome/ (2027)
33. Smith-Magenis Syndrome/ (115)
34. Williams Syndrome/ (1394)
35. (ADHD or attention deficit).ti,ab. (23,416)
36. angelman syndrome.ti,ab. (1121)
37. (autism or autistic or asperger$).ti,ab. (29,748)
38. cerebral palsy.ti,ab. (16,486)
39. conduct disorder$.ti,ab. (3715)
40. (epilepsy or epileptic).ti,ab. (93,799)
41. Down$ syndrome.ti,ab. (18,660)
42. Fragile x syndrome.ti,ab. (3664)
43. Prader Willi Syndrome.ti,ab. (2435)
44. Prader-Willi Syndrome.ti,ab. (2435)
DOI: 10.3310/hta22600 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 60
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Beresford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
45. Rett syndrome.ti,ab. (2537)
46. Smith-Magenis syndrome.ti,ab. (286)
47. Williams syndrome.ti,ab. (1389)
48. (developmental adj2 (disabilit$ or delay$)).ti,ab. (13,253)
49. neurodisabilit$.ti,ab. (143)
50. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (6630)
51. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (11)
52. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (304)
53. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (8556)
54. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2050)
55. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 (307,168)
56. 18 and 21 and 55 (4385)
57. Intellectual Disability/ (49,399)
58. (intellectual$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (9558)
59. (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (34,226)
60. (learning adj (disability or disabled or difficult$)).ti,ab. (5309)
61. or/57-60 (74,629)
62. 55 or 61 (359,076)
63. 18 and 21 and 62 (4605)
64. 63 not 56 (220)
Interface: PsycINFO via Ovid
Date range searched: 1806 to week 2 March 2016.
Search date: 17 March 2016.
Records identified: 135.
Search strategy
1. exp Sleep Disorders/ (12,601)
2. Sleep/ (17,435)
3. Sleepwalking/ (384)
4. Narcolepsy/ (1260)
5. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (186)
6. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (155)
7. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (978)
8. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (1173)
9. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (402)
10. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (359)
11. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (8660)
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12. (sleep$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (18,021)
13. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule
$)).ti,ab. (5781)
14. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (12,168)
15. (sleep-wak$ or night-wak$).ti,ab. (4347)
16. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (751)
17. (narcolepsy or nocturnal hyperkinesia).ti,ab. (1850)
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (44,891)
19. (childhood birth 12 yrs or adolescence 13 17 yrs).ag. (660,440)
20. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (764,560)
21. 19 or 20 (954,409)
22. “3250”.cc. (35,699)
23. exp Pervasive Developmental Disorders/ (701)
24. exp Developmental Disabilities/ (12,490)
25. Neurodevelopmental Disorders/ (1401)
26. Attention Deficit Disorder/ (5017)
27. “Attention Deficit Disorder with Hyperactivity”/ (16,484)
28. exp Autism/ (0)
29. Aspergers Syndrome/ (0)
30. Conduct Disorder/ (3766)
31. exp Epilepsy/ (22,533)
32. Cerebral Palsy/ (4159)
33. Down’s Syndrome/ (5416)
34. Fragile X Syndrome/ (1379)
35. Prader Willi Syndrome/ (454)
36. Rett Syndrome/ (701)
37. Williams Syndrome/ (853)
38. (ADHD or attention deficit).ti,ab. (26,638)
39. angelman syndrome.ti,ab. (269)
40. (autism or autistic or asperger$).ti,ab. (37,492)
41. cerebral palsy.ti,ab. (5404)
42. conduct disorder$.ti,ab. (6208)
43. (epilepsy or epileptic).ti,ab. (30,119)
44. Down$ syndrome.ti,ab. (6310)
45. Fragile x syndrome.ti,ab. (1506)
46. Prader Willi Syndrome.ti,ab. (572)
47. Prader-Willi Syndrome.ti,ab. (572)
48. Rett syndrome.ti,ab. (891)
49. Smith-Magenis syndrome.ti,ab. (75)
50. Williams syndrome.ti,ab. (998)
51. (developmental adj2 (disabilit$ or delay$)).ti,ab. (10,871)
52. neurodisabilit$.ti,ab. (66)
53. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (3656)
54. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (5)
55. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (115)
56. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (5141)
57. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (2044)
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58. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or
56 or 57 (136,113)
59. 18 and 21 and 58 (1739)
60. exp intellectual development disorder/ (40,609)
61. (intellectual$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (10,964)
62. (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (28,202)
63. (learning adj (disability or disabled or difficult$)).ti,ab. (14,016)
64. 60 or 61 or 62 or 63 (65,071)
65. 58 or 64 (183,477)
66. 18 and 21 and 65 (1874)
67. 66 not 59 (135)
Interface: Science Citation Index via Web of Science
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 113.
Search strategy
Set Results
#17 113 #16 not #13
Indexes=SCI-EXPANDED Timespan=All years
#16 2987 #15 AND #9
Indexes=SCI-EXPANDED Timespan=All years
#15 257,021 #14 OR #11 OR #10
Indexes=SCI-EXPANDED Timespan=All years
#14 45,206 TOPIC: (intellectual* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*)) OR TOPIC:
(mental* NEAR/2 (disabilit* or disabled or deficit* or handicap* or retard*)) OR TOPIC: (learning
NEAR/2 (disability or disabled or difficult*))
Indexes=SCI-EXPANDED Timespan=All years
#13 2874 #12 AND #9
Indexes=SCI-EXPANDED Timespan=All years
#12 227,721 #11 OR #10
Indexes=SCI-EXPANDED Timespan=All years
#11 31,704 TOPIC: (developmental NEAR/2 (disabilit* or delay*)) OR TOPIC: (neurodisabilit*) OR TOPIC:
(neurodevelopment* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuromotor* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuropsychiatric* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*)) OR
TOPIC: (neuropsychol* NEAR/3 (delay* or disabilit* or disease* or disorder* or dysfunction*))
Indexes=SCI-EXPANDED Timespan=All years
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Set Results
#10 205,587 TOPIC: (ADHD or “attention deficit”) OR TOPIC: (“angelman syndrome”) OR TOPIC: (autism or
autistic or asperger*) OR TOPIC: (“cerebral palsy”)OR TOPIC: (“conduct disorder*”) OR TOPIC:
(epilepsy or epilepti) OR TOPIC: (“Down* syndrome”) OR TOPIC: (“Fragile x syndrome”) OR TOPIC:
(“Prader Willi Syndrome”) OR TOPIC: (“Rett syndrome”) OR TOPIC: (“Smith-Magenis syndrome”) OR
TOPIC: (“Williams syndrome”)
Indexes=SCI-EXPANDED Timespan=All years
#9 12,558 #8 AND #7
Indexes=SCI-EXPANDED Timespan=All years
#8 1,509,601 TOPIC: (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or
schoolchild* or teens or teenager* or toddler* or youth or youths or “young people” or “young
person*”)
Indexes=SCI-EXPANDED Timespan=All years
#7 76,873 #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED Timespan=All years
#6 36,970 TS=(sleep* NEAR/3 (initiat* or pattern* or routine* or practice* or maintain* or intervention* or
schedule*)) OR TS=(sleepless* or insomnia* or parasomnia* or “night terror*” or nightterror* or
“night mare*” or nightmare*) OR TS=(sleep-wak* or night-wak*) OR TS=(sleepwalk* or sleep-walk*
or “sleep walk*” or somnambulism) OR TS=(narcolepsy or “nocturnal hyperkinesia”)
Indexes=SCI-EXPANDED Timespan=All years
#5 48,375 TS=(nocturnal* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(nocturnal* NEAR/3 (settle* or settling or wake* or awake or wakeful* or
waking* or awaking* or awakening* or wakening*)) OR TS=(sleep* NEAR/3 (settle* or settling or
wake* or awake or wakeful* or waking* or awaking* or awakening* or wakening*)) OR TS=(sleep*
NEAR/3 (dysfunction* or disorder or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*))
Indexes=SCI-EXPANDED Timespan=All years
#4 3897 TS=(“bed time*” NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb* or delay* or
problem*)) OR TS=(bedtime* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or disturb*
or delay* or problem*)) OR TS=(night* NEAR/3 (dysfunction* or disorder* or difficult* or disrupt* or
disturb* or delay* or problem*)) OR TS=(night* NEAR/3 (settle* or settling or wake* or awake or
wakeful* or waking* or awaking* or awakening* or wakening*))
Indexes=SCI-EXPANDED Timespan=All years
#3 4952 TS=(narcolepsy)
Indexes=SCI-EXPANDED Timespan=All years
#2 299 TS=(somnambulism)
Indexes=SCI-EXPANDED Timespan=All years
#1 33,931 TS=(sleep disorder*)
Indexes=SCI-EXPANDED Timespan=All years
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Applied Social Sciences Index and Abstract via Proquest
Date range searched: no restriction.
Search date: 17 March 2016.
Records identified: 12.
Search strategy
1. ((bed time or bedtime$) adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$
or problem$)).ti,ab. (2)
2. ((bed time$ or bedtime$) adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or
intervention$ or schedule$)).ti,ab. (12)
3. (night$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).ti,
ab. (33)
4. (night$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (44)
5. (nocturnal$ adj3 (dysfunction$ or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or problem$)).
ti,ab. (4)
6. (nocturnal$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (7)
7. (sleep$ adj3 (settle$1 or settling or wake$1 or awake or wakeful$ or waking$ or awaking$ or
awakening$ or wakening$)).ti,ab. (67)
8. (sleep$ adj3 (dysfunction$ or disorder or disorder$ or difficult$ or disrupt$ or disturb$ or delay$ or
problem$)).ti,ab. (527)
9. (sleep$ adj3 (initiat$ or pattern$ or routine$ or practice$ or maintain$ or intervention$ or schedule$)).ti,
ab. (260)
10. (sleepless$ or insomnia$ or parasomnia$ or night terror$ or nightterror$ or night mare$ or nightmare$).
ti,ab. (258)
11. (sleep-wak$ or night-wak$).ti,ab. (41)
12. (sleepwalk$ or sleep-walk$ or sleep walk$ or somnambulism).ti,ab. (13)
13. (narcolepsy or nocturnal hyperkinesia).ti,ab. (5)
14. (ADHD or attention deficit).ti,ab. (941)
15. angelman syndrome.ti,ab. (8)
16. (autism or autistic or asperger$).ti,ab. (2638)
17. cerebral palsy.ti,ab. (344)
18. conduct disorder$.ti,ab. (431)
19. (epilepsy or epileptic).ti,ab. (292)
20. Down$ syndrome.ti,ab. (509)
21. Fragile x syndrome.ti,ab. (49)
22. Prader Willi Syndrome.ti,ab. (32)
23. Prader-Willi Syndrome.ti,ab. (32)
24. Rett syndrome.ti,ab. (20)
25. Smith-Magenis syndrome.ti,ab. (3)
26. Williams syndrome.ti,ab. (12)
27. (developmental adj2 (disabilit$ or delay$)).ti,ab. (590)
28. neurodisabilit$.ti,ab. (19)
29. (neurodevelopment$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (64)
30. (neuro-motor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
31. (neuromotor$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (0)
32. (neuropsychiatric$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (32)
33. (neuropsychol$ adj3 (delay$ or disabilit$ or disease$ or disorder$ or dysfunction$)).ti,ab. (12)
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34. or/1-13 (993)
35. or/14-33 (5507)
36. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenager$ or toddler$ or youth or youths or young people or young person$).ti,ab. (139,979)
37. 34 and 35 and 36 (48)
38. (intellectual$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (2135)
39. (mental$ adj (disabilit$ or disabled or deficit$ or handicap$ or retard$)).ti,ab. (1252)
40. (learning adj (disability or disabled or difficult$)).ti,ab. (5838)
41. 35 or 38 or 39 or 40 (13,791)
42. 34 and 36 and 41 (60)
43. 42 not 37 (12)
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Appendix 3 The data extraction variables used
for the study results
TABLE 30 Data extraction variables for study results (Microsoft Excel® 2010, Microsoft Corporation, Redmond,
WA, USA)
Variable Description
Study Author, date
N_Treat Number of participants in treatment arm
N_Treat2 Number of participants in second treatment arm (if applicable)
N_Treat3 Number of participants in third treatment arm (if applicable)
N_Control Number of participants in control arm
Followup Baseline ‘0’
Followup1 Final follow-up point for which subsequent data are being extracted (e.g. 12 weeks,
10 days)
Mean0_combined Baseline mean score for crossover trials
Mean0_treat Baseline mean score for treatment arm
LowerCI0_treat Lower CI for baseline mean score for treatment arm
UpperCI0_treat Upper CI for baseline mean score for treatment arm
SD0_combined SD for baseline mean score for crossover trials
SD0_treat SD for baseline mean score for treatment arm
SE0_treat SE for baseline mean score for treatment arm
Median0_treat Baseline median score for treatment arm
Min0_treat Baseline minimum score for treatment arm
Max0_treat Baseline maximum score for treatment arm
Range0_treat Baseline range score for treatment arm
Q250_treat Baseline lower quartile for treatment arm
Q750_treat Baseline upper quartile for treatment arm
IQR0_treat Baseline interquartile range for treatment arm
Mean0_plac Baseline mean score for control/placebo arm
LowerCI0_ plac Lower CI for baseline mean score for control/placebo arm
UpperCI0_ plac Upper CI for baseline mean score for control/placebo arm
SD0_ plac SD for baseline mean score for control/placebo arm
SE0_ plac SE for baseline mean score for control/placebo arm
Median0_ plac Baseline median score for control/placebo arm
Min0_ plac Baseline minimum score for control/placebo arm
Max0_ plac Baseline maximum score for control/placebo arm
Range0_ plac Baseline range score for control/placebo arm
Q250_ plac Baseline lower quartile for control/placebo arm
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TABLE 30 Data extraction variables for study results (Microsoft Excel® 2010, Microsoft Corporation, Redmond,
WA, USA) (continued )
Variable Description
Q750_ plac Baseline upper quartile for control/placebo arm
IQR0_ plac Baseline interquartile range for control/placebo arm
Mean1_treat Follow-up mean score for treatment arm
LowerCI1_treat Lower CI for follow-up mean score for treatment arm
UpperCI1_treat Upper CI for follow-up mean score for treatment arm
SD1_treat SD for follow-up mean score for treatment arm
SE1_treat SE for follow-up mean score for treatment arm
Median1_treat Follow-up mean median score for treatment arm
Min1_treat Follow-up mean minimum score for treatment arm
Max1_treat Follow-up mean maximum score for treatment arm
Range1_treat Follow-up mean range score for treatment arm
Q251_treat Follow-up mean lower quartile for treatment arm
Q751_treat Follow-up mean upper quartile for treatment arm
IQR1_treat Follow-up mean interquartile range for treatment arm
Mean1_ plac Follow-up mean score for control/placebo arm
LowerCI1_ plac Lower CI for follow-up mean score for control/placebo arm
UpperCI1_ plac Upper CI for follow-up mean score for control/placebo arm
SD1_ plac SD for follow-up mean score for control/placebo arm
SE1_ plac SE for follow-up mean score for control/placebo arm
Median1_ plac Follow-up mean median score for control/placebo arm
Min1_ plac Follow-up mean minimum score for control/placebo arm
Max1_ plac Follow-up mean maximum score for control/placebo arm
Range1_ plac Follow-up mean range score for control/placebo arm
Q251_ plac Follow-up mean lower quartile for control/placebo arm
Q751_ plac Follow-up mean upper quartile for control/placebo arm
IQR1_ plac Follow-up mean interquartile range for control/placebo arm
TimeEffect_F ANOVA f-value for time effect
TimeEffect_P ANOVA p-value for time effect
GroupEffect_F ANOVA f-value for group effect
GroupEffect_P ANOVA p-value for group effect
GroupTimeEffect_F ANOVA f-value for interaction effect
GroupTimeEffect_P ANOVA p-value for interaction effect
ChangeBL1_Mean_Treat Mean change from baseline to follow-up for treatment arm
ChangeBL1_SD_Treat SD of mean change from baseline to follow-up for treatment arm
ChangeBL1_SE_Treat SE of mean change from baseline to follow-up for treatment arm
ChangeBL1_range_Treat Range score in change from baseline to follow-up for treatment arm
ChangeBL1_LowerCI_Treat Lower CI in change value from baseline to follow-up for treatment arm
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TABLE 30 Data extraction variables for study results (Microsoft Excel® 2010, Microsoft Corporation, Redmond,
WA, USA) (continued )
Variable Description
ChangeBL1_UpperCI_Treat Upper CI in change value from baseline to follow-up for treatment arm
ChangeBL1_P_Treat p-value for change from baseline to follow-up for treatment arm
ChangeBL1_%_Treat Percentage change from baseline to follow-up for treatment arm
ChangeBL1_Mean_plac Mean change from baseline to follow-up for control/placebo arm
ChangeBL1_SD_ plac SD of mean change from baseline to follow-up for control/placebo arm
ChangeBL1_SE_ plac SE of mean change from baseline to follow-up for control/placebo arm
ChangeBL1_range_ plac Range score in change from baseline to follow-up for control/placebo arm
ChangeBL1_LowerCI_ plac Lower CI in change value from baseline to follow-up for control/placebo arm
ChangeBL1_UpperCI_ plac Upper CI in change value from baseline to follow-up for control/placebo arm
ChangeBL1_P_ plac p-value for change from baseline to follow-up for control/placebo arm
ChangeBL1_%_ plac Percentage change from baseline to follow-up for control/placebo arm
Diff_Treat_Plac Raw value/score of the difference between the treatment and control/placebo arm
Diff_Treat_Plac_mean MD between the treatment and control/placebo arm
Diff_Treat_Plac_SD SD of the MD between the treatment and control/placebo arm
Diff_Treat_Plac_test_statistic
(DF)
Test statistic of the difference between the treatment and control/placebo arm
Diff_Treat_Plac_ES Effect size of the difference between the treatment and control/placebo arm
Diff_Treat_Plac_P p-value of the difference between the treatment and control/placebo arm
CarryOverEffect_P Carry-over effect for crossover trials
Period_effect_P Period effect for crossover trials
Period_T-P_Mean Mean period effect in order of treatment to control/placebo for crossover trials
Period_T-P_SD SD of the mean period effect in order of treatment to control/placebo for crossover trials
Period_P-T_Mean Mean period effect in order of control/placebo to treatment for crossover trials
Period_P-T_SD SD of the mean period effect in order of control/placebo to treatment for crossover trials
Period_diff_P p-value for period effect
DiffChange_Mean Difference in mean change from baseline to follow-up between the treatment and control/
placebo arm
DiffChange_SD SD of the difference in mean change from baseline to follow-up between the treatment
and control/placebo arm
DiffChange_SE SE of the difference in mean change from baseline to follow-up between the treatment and
control/placebo arm
DiffChange_LowerCI Lower CI of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
DiffChange_UpperCI Upper CI of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
DiffChange_P p-value of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
DiffChange_PES Effect size of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
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TABLE 30 Data extraction variables for study results (Microsoft Excel® 2010, Microsoft Corporation, Redmond,
WA, USA) (continued )
Variable Description
AdjustedDiff_Mean Adjusted difference in mean change from baseline to follow-up between the treatment and
control/placebo arm
AdjustedDiff_SD Adjusted SD of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
AdjustedDiff_SE Adjusted SE of the difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
AdjustedDiff_LowerCI Adjusted lower CI of the difference in mean change from baseline to follow-up between
the treatment and control/placebo arm
AdjustedDiff_UpperCI Adjusted upper CI of the difference in mean change from baseline to follow-up between
the treatment and control/placebo arm
AdjustedDiff_P p-value of the adjusted difference in mean change from baseline to follow-up between the
treatment and control/placebo arm
Notes Any additional notes of relevance
ANOVA, analysis of variance.
Note
Each variable was listed as the column heading in a spreadsheet, with data for each study extracted on each row
underneath. One spreadsheet was used for each outcome reported.
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Appendix 4 List of papers excluded after full-text
review and reasons for exclusions
TABLE 31 List of papers excluded after full-text review and reasons for exclusion
Reference Reason for exclusion
Records identified from trial registeries
ISRCTN05534585, The use of MElatonin in children with Neuro-developmental Disorders
and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study
Already included as
Appleton et al.48
ISRCTN92655217, Snuggledown – Use of sensory blankets for children with autistic
spectrum disorder
Already included as Gringras
et al.36
NCT01322022, Treatment of sleep disturbances in young children with autism. 2009 Already included as Johnson
et al.107
ISRCTN84194243, Development of effective primary care treatment of severe sleep
disorders in children with a learning disability; a randomised controlled trial
Already included as
Montgomery et al.49
ISRCTN77884120, Melatonin treatment for sleep problems in children with autism:
a randomised controlled crossover trial
Already included as
Wright et al.106
2007-004664-46, Influence of methylphenidate on sleep and circadian rhythm in children
with Attention-Deficit/Hyperactivity Disorder (ADHD) – MELMET
Intervention
2011-003313-42, Agomelatine efficacy of the drug to improve sleep problems in autistic
people
Intervention
ISRCTN31542578, A blinded randomised cross-over study of the effect of melatonin
treatment of sleep disturbances on hypothalamic–pituitary-gonadal axis and leptin in
pubertal children
Intervention
NCT00393042, Sleep and tolerability study: comparing the effects of Adderall XR and
Focalin XR
Intervention
NCT00695136, The effect of Donepezil [Aricept (Registered Trademark)] on REM sleep in
children with autism
Intervention
NCT00745030, Efficacy and tolerability of Ramelteon in patients with rapid eye movement
(REM) behavior disorder and Parkinsonism
Intervention
NCT00807222, Effect of Vyvanse on sleep in children aged 6–12 years with attention
deficit hyperactivity disorder (ADHD)
Intervention
NCT00989950, Study of the effect of individualizing Daytrana wear-times on sleep in
children with ADHD
Intervention
NCT01156051, Effect of Guanfacine extended-release on attention deficit hyperactivity
disorder (ADHD)-associated insomnia
Intervention
NCT01887132, A trial of the drug Donepezil for sleep enhancement and behavioral
change in children with autism
Intervention
NCT02231008, Evaluating the effects of Tasimelteon vs Placebo on sleep disturbances in
SMS
Intervention
NCT02487082, Pilot study of sleep therapy and biomarkers in children with autism
spectrum disorders
Intervention
NCT02638168, Effects of evening dose of immediate release methylphenidate on sleep in
children with ADHD
Intervention
NCT00152750, Study of Clonidine on sleep architecture in children with Tourette’s
Syndrome (TS) and comorbid ADHD
Outcome
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
NCT01508793, Enhancing sleep duration: effects on children’s eating and activity
behaviors
Outcome
NCT01903681, Assessment of the pharmacokinetics of Circadin® in children with
neurodevelopmental disorders and sleep disturbances
Outcome
NCT02132273, Use of an educational story to prepare children with developmental
disabilities for sleep study
Outcome
IRCT2015062222865N1, The effect of aromatherapy with Rosa Damascena on sleep
quality of children
Population
NCT00005753, Pharmacological and behavioral treatment of insomnia Population
NCT00133055, Parenting matters: helping parents with young children Population
NCT00877162, The rocky sleep study Population
NCT02195401, The effects of a clean room sleeping environment on elemental and
chemical concentrations in children with autism
Population
NCT02398214, A sleep hygiene-based intervention program for infants and toddlers Population
NCT02648568, Does hypnosis improve severe sleepwalking? Population
NTR4045, Effects of melatonin treatment, light therapy, and sleep improvement in children
with sleep onset problems
Population
NCT00691080, Understanding sleep problems in children with autism spectrum disorder Study design
Records identified from databases
Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for
children with autistic spectrum disorder. J Altern Complement Med 2004;10:1033–9
Intervention
Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR. Placebo-controlled
evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts
(Adderall): efficacy rate and side effects. Pediatrics 2001;107:E10
Intervention
Allen KD, Kuhn BR, DeHaai KA, Wallace DP. Evaluation of a behavioral treatment package
to reduce sleep problems in children with Angelman Syndrome. Res Dev Disabil
2013;34:676–86
Study design (before-and-after
study with ≤ 10 participants)
Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with
attention deficit hyperactivity disorder. Pediatr Neurol 2011;45:381–6
Intervention
Askenasi A. O251. Effect of transdermal methylphenidate wear times on sleep in children
with ADHD. 22nd meeting of the European Neurological Society, 9–12 June 2012, Prague,
Czech Republic. J Neurol 2012;259:S33–34
Intervention
Barlow J, Cullen L. Coming together through touch: the experiences of parents of children
with disabilities learning the principles of massage. Early Child Dev Care 2000;161:93–106
Intervention
Barlow J, Powell L, Cheshire A. The Training and Support Programme (involving basic
massage) for parents of children with cerebral palsy: an implementation study. J Bodyw
Mov Ther 2007;11:44–53
Intervention
Becke SP, Froehlich TE, Epstein JN. Effects of methylphenidate on sleep functioning in
children with attention-deficit/hyperactivity disorder. J Dev Behav Pediatr 2016;37:395–404
Intervention
Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem
for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in
children 6 to 17 years of age. Pediatrics 2009;123:e770–6
Intervention
Bovet-du Bois N. [Neuroleptic treatment in child psychiatry: analysis of a series of 100 cases
treated with thioridazine.] Schweiz Rundsch Med Prax 1973;62:1556–64
Intervention
Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to
melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res
2010;54:547–55
Intervention
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Brady A, Mpetha K, Humphreys S, Carney AM. Developing a sleep service for children with
learning disabilities or autistic spectrum disorders aged 0–5: setting up the service and
lessons from practice. Clinical Psychology Forum 2011;222:31–5
Intervention
Briault M, Labrosse M, Verreault M, Berthiaume C, Lageix P, Turgeon L, Godbout R.
Sleep in children with attention deficit disorders: effects of comorbid anxiety and response
to treatment. 23rd Annual Meeting of the Associated-Professional-Sleep-Societies,
6–11 June 2009, Seattle, WA, USA. Sleep 2009;32:A65
Intervention
Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, et al. An open
label trial of donepezil for enhancement of rapid eye movement sleep in young children
with autism spectrum disorders. J Child Adolesc Psychopharmacol 2011;21:353–7
Intervention
Bussing R, Mason D, Garvan CW, Gurnani T, Koro-Ljungberg M, Noguchi K, Albarracin D.
Willingness to use ADHD self-management: mixed methods study of perceptions by
adolescents and parents. J Child Fam Stud 2016;25:562–73
Intervention
Campbell M, Perry R, Polonsky BB, Deutsch SI, Palij M, Lukashok D. An open study of
fenfluramine in hospitalized young autistic children. J Autism Dev Disord 1986;16:495–506
Intervention
Campbell M, Deutsch SI, Perry R, Wolsky BB, Palij M. Short-term efficacy and safety
of fenfluramine in hospitalized preschool-age autistic children: an open study.
Psychopharmacol Bull 1986;22:141–7
Intervention
Campbell M, Small AM, Palij M, Perry R, Polonsky BB, Lukashok D, Anderson LT.
The efficacy and safety of fenfluramine in autistic children: preliminary analysis of a
double-blind study. Psychopharmacol Bull 1987;23:123–7
Intervention
Chen XQ, Zhang WN, Yang ZX, Zhao M, Cai FC, Huang SP, et al. Efficacy of levetiracetam
in electrical status epilepticus during sleep of children: a multicenter experience. Pediatr
Neurol 2014;50:243–9
Intervention
Cheng Song J, Hiscock H, Scibberras E, Schuster T. Behavioural sleep problems in children
with ADHD: cross–sectional associations with parenting and sleep hygiene. Sleep Biologic
Rhythms 2015;13(Suppl. 1):1–98
Intervention
Chung I, Han CH, Kim HW, Cho SC. P.7.c.008 The effect of prolonged-release
methylphenidate on the sleep of children with attention-deficit/hyperactivity disorders.
Eur Neuropsychopharmacol 2010;20(Suppl. 3):624–5
Intervention
Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS
methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder.
Int J Neuropsychopharmacol 2010;13:184
Intervention
Clonidine for treatment of attention-deficit/hyperactivity disorder. Med Lett Drugs Ther
1996;38:109–10
Intervention
Cocchi R. Drug therapies for sleep troubles, hyperactivity and aggression in young adult
autistics. Ital J Intellective Impairment 1995;8:169–74
Intervention
Cohen-Zion M. Sleep and circadian rhythms in children with attention deficit-hyperactivity
disorder: before and after stimulant treatment. San Diego, CA: University of California,
San Diego and San Diego State University; 2005
Intervention
De Leersnyder H, de Blois M-C, Vekemans M, Sidi D, Villain E, Kindermans C, Munnich A.
β1-adrenergic antagonists improve sleep and behavioural disturbances in a circadian
disorder, Smith–Magenis syndrome. J Med Genet 2001;38:586–90
Intervention
DeLeon IG, Fisher WW, Marhefka JM. Decreasing self-injurious behaviour associated with
awakening in a child with autism and developmental delays. Behav Interv 2004;19:111–19
Intervention
Duncan B, Barton L, Edmonds D, Blashill BM. Parental perceptions of the therapeutic effect
from osteopathic manipulation or acupuncture in children with spastic cerebral palsy.
Clin Pediatr 2004;43:349–53
Intervention
Ediberidze T, Maisuradze L, Kasradze S. Influence of anticonvulsants on sleep difficulties in
children with epileptic seizures of genetic aetiology (ESGE)-a questionnaire based study.
J Sleep Res 2016;25:229
Intervention
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Rugino T. Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity
Disorder (ADHD)-Associated Insomnia. Children’s Specialised Hospital; 2010.
URL: https://clinicaltrials.gov/ct2/show/NCT01156051 (accessed 26 July 2018)
Intervention
Efron D, Lycett K, Sciberras E. Use of sleep medication in children with ADHD. Sleep Med
2014;15:472–5
Intervention
Elbhrawy S, et al. Polysomnographic based study of sleep in juvenile myoclonic epilepsy
patients. Epilepsia 2016;57(Suppl. 2):43
Intervention
Esmaeli L, Abedi MR, Najafi MR, Aminjafari A, Afsar F, Moghtadaei M. Effectiveness of
emotion regulation on anxiety, insomnia and social dysfunction of epileptic adolescent
girls. Abstracts of 5th International Congress Of Child and Adolescent Psychiatry,
8–11 October 2012, Tehran, Iran. Iran J Psychiatry 2012;1:3
Intervention
Faber S, Zinn GM, Boggess A, Fahrenholz T, Kern JC, Kingston HM. A cleanroom sleeping
environment’s impact on markers of oxidative stress, immune dysregulation, and behavior
in children with autism spectrum disorders. BMC Complement Altern Med 2015;15:71
Intervention
Feinberg I, Hibi S, Braun M, Cavness C, Westerman G, Small A. Sleep amphetamine effects
in MBDS and normal subjects. Arch Gen Psychiatry 1974;31:723–31
Intervention
Fletcher F, Foster-Owens M, Conduit R, Cornish K. The impact of sleep hygiene on sleep
onset issues in children with high functioning autism and Asperger syndrome. Sleep Biol
Rhythms 11:12
Intervention
Fletcher, Rinehart N, Conduit R, Rajaratnam S, Thomas D, Cornish K. Targeting sleep
problems and anxiety in children with high functioning autism. Sleep Biol Rhythms
2012;10:63
Intervention
Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with
attention deficit disorder. Am J Psychiatry 1984;141:906–8
Intervention
Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of attention deficit
disorder in adolescents. Psychopharmacol Bull 1985;21:144–5
Intervention
Giblin JM, Strobel AL. Effect of lisdexamfetamine dimesylate on sleep in children with
ADHD. J Atten Disord 2011;15:491–8
Intervention
Goldman SE, Adkins KW, Calcutt MW, Carter MD, Goodpaster RL, Wang L, et al.
Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic
profiles in relation to sleep. J Autism Dev Disord 2014;44:2525–35
Intervention
Grubar JC, Gigli GL, Colognola RM, Ferri R, Musumeci SA, Bergonzi P. Sleep patterns
of Down’s syndrome children: effects of butoctamide hydrogen succinate (BAHS)
administration. Psychopharmacology 1986;90:119–22
Intervention
Gruber R, Grizenko N, Schwartz G, Ben Amor L, Gauthier J, de Guzman R, Joober R. Sleep
and COMT polymorphism in ADHD children: preliminary actigraphic data. J Am Acad Child
Adolesc Psychiatry 2006;45:982–9
Intervention
Gupta M, Aneja S, Kohli K. Add-on melatonin improves quality of life in epileptic children
on valproate monotherapy: a randomised, double-blind, placebo-controlled trial. Epilepsy
Behav 2004;5:316–21
Intervention
Hagerman RJ, Riddle JE, Roberts LS, Breese K, Fulton M. Survey of the efficacy of clonidine
in fragile X syndrome. Dev Brain Dysfunc 1995;8:336–44
Intervention
Hallböök T, Lundgren J, Köhler S, Blennow G, Strömblad LG, Rosén I. Beneficial effects on
sleep of vagus nerve stimulation in children with therapy resistant epilepsy. Eur J Paediatr
Neurol 2005;9:399–407
Intervention
Hallböök T, Lundgren J, Rosén I. Ketogenic diet improves sleep quality in children with
therapy-resistant epilepsy. Epilepsia 2007;48:59–65
Intervention
Head TK. Evaluation of medication effects on academic performance, sleep, and core
ADHD symptoms in children. Kalamazoo, MI: Western Michigan University; 2015
Intervention
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Henderson JA, Barry TD, Bader SH, Jordan SS. The relation among sleep, routines, and
externalising behaviour in children with an autism spectrum disorder. Res Autism Spectr
Disord 2011;5:758–67
Intervention
Hewitt K. Behavioural approaches to sleeplessness. Br J Learning Disabil 1985;13:112–14 Study design
Honomichl RD, Goodlin-Jones BL, Burnham MM, Hansen RL, Anders TF. Secretin and sleep
in children with autism. Child Psychiatry Hum Dev 2002;33:107–23
Intervention
Hoshino K. Effectiveness of low dose of L-dopamine in children with autism and
attention-deficithyperactivity disorder. Dev Med Child Neurol 2012;54:5–212
Intervention
Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit
disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.
J Am Acad Child Psychiatry 1985;24:617–29
Intervention
Hunt RD, Minderaa RB, Cohen DJ. The therapeutic effect of clonidine in attention
deficit disorder with hyperactivity: a comparison with placebo and methylphenidate.
Psychopharmacol Bull 1986;22:229–36
Intervention
Hvolby A. Does treatment of ADHD sleeping problems improve attention, hyperactivity and
impulsiveness in children with attention deficit hyperactivity disorder? Eur Child Adolesc
Psychiatry 2013;22:S87–323
Intervention
Laboni A, Gibbons J, Hamilton J, Narang I. Sleep characteristics of prepubescent
children with Prader–Willi syndrome before and after growth hormone treatment.
Sleep 2009;32:A113
Intervention
Jan JE, Connolly MB, Hamilton D, Freeman RD, Laudon M. Melatonin treatment of
non-epileptic myoclonus in children. Dev Med Child Neurol 1999;41:255–9
Intervention
Kent JD, Joseph C, Blader HS, Koplewicz HA, Foley CA. Effects of late-afternoon
methylphenidate administration on behaviour and sleep in attention-deficit hyperactivity
disorder. Pediatrics 1995;96:320–5
Intervention
Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS
methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder.
Int Clin Psychopharmacol 2010;25:107–15
Intervention
Konafel E, Lecendreuz M, Bouvard MP, Mouren-Simeoni MC. Effects of vesperal
methylphenidate (MPH) administration on diurnal and nocturnal activity in ADHD children:
an actigraphic study. Amer Acad Sleep Med 2001:A215
Intervention
Liboni F, Palagini L, Mandredi A, Tacchi A, Ricci F, Mauri M, et al. Effects of six-months
methylphenidate treatment on sleep disturbances in children with attention-deficit/
hyperactivity disorder. A pilot study. JOURNAL OF, 2014;23:322–2
Intervention
Lyon MR, Kapoor MP, Juneja LR. The effects of L-theanine (Suntheanine) on objective
sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomised,
double-blind, placebo-controlled clinical trial. Altern Med Rev 2011;16:348–54
Intervention
Malow BA, MacDonald LL, Fawkes DB, Alder ML, Katz T. Teaching children with autism
spectrum disorder how to sleep better: a pilot educational program for parents. Clin Pract
Paediat Psychol 2016;4:125
Study design (before-and-
after study with
≤ 10 participants)
Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep difficulties
and medications in children with autism spectrum disorders: a registry study. Pediatrics
2016;137(Suppl. 2):98–104
Intervention
Miyamoto A, Fukuda I, Tanaka H, Oka R, Araki A, Cho K. [Treatment with ramelteon for
sleep disturbance in severely disabled children and young adults.] No To Hattatsu
2013;45:440–4
Intervention
Mostafavi S-A, Mohammadi MR, Hosseinzadeh P, Eshraghian MR, Akhondzadeh R,
Hosseinzadeh-Attar MJ, et al. Dietary intake, growth and development of children with
ADHD in a randomised clinical trial of Ritalin and Melatonin co-administration: Through
circadian cycle modification or appetite enhancement? Iran J Psychiatry 2012;7:114–19
Intervention
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Nayak C, Sinha S, Ramachandraiah CT, Nagappa M, Thennarasu K, Taly AB, Satishchandra P.
Differential improvement of the sleep quality among patients with juvenile myoclonic
epilepsy with valproic acid: A longitudinal sleep questionnaire-based study. Ann Indian Acad
Neurol 2015;18:403–7
Intervention
Long Y, Tan J, Nie Y, Lu Y, Mei X, Tu C. Hyperbaric oxygen therapy is safe and effective for
the treatment of sleep disorders in children with cerebral palsy. Neurol Res 2017;39:239–47
Intervention
Ornitz EM, Forsythe AB, de la Peña A. Effect of vestibular and auditory stimulation on the
REMs of REM sleep in autistic children. Arch Gen Psychiatry 1973;29:786–91
Intervention
Owens J, Weiss M, Nordbrock E, Mattingly G, Wigal S, Greenhill LL, et al. Effect of
aptensio XR (methylphenidate HCl extended-release) capsules on sleep in children with
attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2016;26:873–81
Intervention
Petre-Quadens O, De Greef A. Effects of 5-HTP on sleep in Mongol children. Preliminary
results. J Neurol Sci 1971;13:115–19
Intervention
Larsen S, Harrington K, Hicks S. The LENS (Low Energy Neurofeedback System): a clinical
outcomes study on one hundred patients at Stone Mountain Centre, New York.
J Neurother 2006;10:69–78
Intervention
Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH. Continuous intrathecal baclofen therapy
in children with cerebral palsy – when does improvement emerge? Acta Paediatr
2010;99:1661–5
Intervention
Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in
children. J Child Neurol 2013;28:1618–21
Intervention
Robinson AM, Richdale AL. Sleep problems in children with an intellectual disability:
parental perceptions of sleep problems, and views of treatment effectiveness. Child Care
Health Dev 2004;30:139–50
Intervention
Rogozea R, Florea-Ciocoiu V. Orienting reaction in patients with night terrors. Biol Psychiatry
1985;20:894–905
Intervention
Rugino TA. Effect on primary sleep disorders when children with ADHD are administered
Guanfacine extended release. J Atten Disord 2014;22:14–24
Intervention
Binay Safer V, Ozbudak Demir S, Ozkan E, Demircioglu Guneri F. Effects of botulinum toxin
serotype A on sleep problems in children with cerebral palsy and on mothers sleep quality
and depression. Neurosciences 2016;21:331–7
Intervention
Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and
methylphenidate on sleep in children with ADHD. Sleep 2006;29:1573–85
Intervention
Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia
associated with attention-deficit/hyperactivity disorder. Pediatrics 2014;134:e1095–103
Intervention
Sangal RB, Owens J, Allen A, Kelsey D, Sutton V, Schuh K. Effects of atomoxetine and
methylphenidate on sleep in children with attention-deficit/hyperactivity disorder. Int J
Neuropsychopharmacol 2004;7
Intervention
Schelleman M, Richdale A. The relative and combined effects of a diet and a behavioural
intervention for behaviour and sleep problems in children with significant challenging
behaviours. Sleep Biol Rhythms 2010;8:A7
Intervention
Shah T, Tse A, Gill H, Wong I, Sutcliffe A, Gringras P, et al. Administration of melatonin
mixed with soft food and liquids for children with neurodevelopmental difficulties.
Dev Med Child Neurol 2008;50:845–9
Intervention
Sherwin I, Hooge JP. Comparative effectiveness of natural sleep and methohexital.
Provocative tests in electroencephalography. Neurology 1973;23:973–6
Intervention
Smits MG. Clinical experiences of DLMO measurements in insomnia patients at the
Gelderse Vallei Hospital Sleep Centre. J Sleep Res 2010;19:97
Intervention
Strawn JR, McReynolds D. An evidence-based approach to treating paediatric anxiety
disorders. Current Psychiatry 2012;11:16–21
Intervention
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Reference Reason for exclusion
Tai A, Horne R, Davey M, Nixon G. The effects of growth hormone on sleep parameters in
children with Prader–Willi syndrome. Sleep Biol Rhythms 2009;7:A56
Intervention
Tajima S, Matsuzawa S, Takai K, Kawakami M, Nakashima M, Miike T. Poster presentations 1.
Sleep Biol Rhythms 2011;9:254–342
Intervention
Tatsumi Y, Mohri I, Shimizu S, Tachibana M, Ohno Y, Taniike M. Daytime physical activity
and sleep in pre-schoolers with developmental disorders. J Paediatr Child Health
2015;51:396–402
Intervention
Tilford JM, Payakachat N, Kuhlthau KA, Pyne JM, Kovacs E, Bellando J, et al. Treatment for
sleep problems in children with autism and caregiver spillover effects. J Autism Dev Disord
2015;45:3613–23
Intervention
Tirosh E, Sadeh A, Munvez R, Lavie P. Effects of methylphenidate on sleep in children
with attention-deficit hyperactivity disorder: an activity monitor study. Am J Dis Child
1993;147:1313–15
Intervention
Tizard B. A controlled study of all-night sleep in overactive imbecile children. Am J Ment
Defic 1968;73:209–13
Intervention
Valdizan JR, Almarcegui C, Brualla J, Alejos MV, Chulilla JL, Dolz I. The influence of
gabapentin on sleep in children with secondarily generalised partial epilepsy. Rev Neurol
1999;29:718–21
Intervention
De Weerd A, Van Den Bosschhe R. Sleep in very young children with Prader Willi syndrome
before and during growth hormone substitution. J Sleep Res 2010;19:29
Intervention
Van der Heijden KB, Smits MG, Gunning WB. Sleep hygiene and actigraphically evaluated
sleep characteristics in children with ADHD and chronic sleep onset insomnia. J Sleep Res
2006;15:55–62
Intervention
Verrillo E, Bruni O, Franco P, Ferri R, Thiriez G, Pavone M, et al. Analysis of NREM sleep in
children with Prader–Willi syndrome and the effect of growth hormone treatment. Sleep
Med 2009;10:646–50
Intervention
Verrillo E, Bizzarri C, Bruni O, Ferri R, Pavone M, Cappa M, Cutrera R. Effects of
replacement therapy on sleep architecture in children with growth hormone deficiency.
Sleep Med 2012;13:496–502
Intervention
Wachob D, Lorenzi DG. Brief report: influence of physical activity on sleep quality in
children with autism. J Autism Dev Disord 2015;45:2641–6
Intervention
Wang L, Liu Y. Behaviour improvement by diet and environmental interventions in brain
injured children. CRTER 2007;11:5983–5
Intervention
Wehmeier PM, Dittman RW, Schacht A, Helsbery K, Lehmkuhl G. Morning and evening
behaviour in children and adolescents treated with atomoxetine once daily for attention-
deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies.
Child Adolesc Psychiatry Ment Health 2009;3:5
Intervention
Williams G, Sears L, Allard A. Parent perceptions of efficacy for strategies used to facilitate
sleep in children with autism. J Dev Phys Disabil 2006;18:25–33
Intervention
Vol’f MSh, Prokudin VN, Iurkova IA. [The place of nitrazepam in the complex treatment of
epilepsy.] Zh Nevropatol Psikhiatr Im S S Korsakova 1973;73:1714–18
Intervention
Wyatt K, Edwards V, Franck L, Britten N, Creanor S, Maddick A, Logan S. Cranial
osteopathy for children with cerebral palsy: a randomised controlled trial. Arch Dis Child
2011;96:505–12
Intervention
Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D. Treatment of hyperactive
children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry
1985;42:962–6
Intervention
Zametkin AJ, Reeves JC, Webster L, Werry JS. Promethazine treatment of children with
Attention Deficit Disorder with Hyperactivity – ineffective and unpleasant. J Am Acad Child
Psychiatry 1986;25:854–6
Intervention
continued
DOI: 10.3310/hta22600 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 60
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Beresford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
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Reference Reason for exclusion
Zandieh S, Khatwa U, Zarowski M, Kothare S. Utility of the maintenance of wakefulness
test (MWT) in assessing treatment efficacy & optimising management in children with
narcolepsy. 2012;35:A391
Intervention
Zhou JY, Tang XD, Huang LL, Zhong ZQ, Lei F, Zhou D. The acute effects of levetiracetam
on nocturnal sleep and daytime sleepiness in patients with partial epilepsy. J Clin Neurosci
2012;19:956–60
Intervention
Beriault M, Turgeon L, Labrosse M, Berthiaume C, Verreault M, Berthiaume C, Godbout R.
Comorbidity of ADHD and anxiety disorders in school-age children: impact on sleep and
response to a cognitive-behavioural treatment. J Atten Disord 2015;22:22
Outcome
Borusiak P, Bast T, Kluger G, Weidenfeld A, Langer T, Jenke ACW, Wiegand G.
A longitudinal, randomized, and prospective study of nocturnal monitoring in children
and adolescents with epilepsy: Effects on quality of life and sleep. Epilepsy Behav
2016;61:192–8
Outcome
Bartlet L, Beaumont J. Treating the sleep disorders of children with disabilities and illness:
a one-year project. Clin Child Psychol Psychiatry 1998;3:591–612
Population
Bazil CW, Dave J, Cole J, Stalvey J, Drake E. Pregabalin increases slow-wave sleep and
may improve attention in patients with partial epilepsy and insomnia. Epilepsy Behav
2012;23:422–5
Population
Braam W, Didden R, Maas AP, Korzilius H, Smits MG, Curfs LM. Melatonin decreases
daytime challenging behaviour in persons with intellectual disability and chronic insomnia.
J Intellect Disabil Res 2010;54:52–9
Population
Braam W, Didden R, Smits M, Curfs L. Melatonin treatment in individuals with intellectual
disability and chronic insomnia: a randomised placebo-controlled study. J Intellect Disabil
Res 2008;52:256–64
Population
Brand S, Jossen S, Holsboer-Trachsler E, Pühse U, Gerber M. Impact of aerobic exercise
on sleep and motor skills in children with autism spectrum disorders – a pilot study.
Neuropsychiatr Dis Treat 2015;11:1911–20
Population
Burke RV, Kuhn BR, Peterson JL. Brief report: a ‘storybook’ ending to children’s bedtime
problems – the use of a rewarding social story to reduce bedtime resistance and frequent
night waking. J Pediatr Psychol 2004;29:389–96
Population
Chang YS, Lin MH, Lee JH, Lee PL, Dai YS, Chu KH, et al., Melatonin supplementation for
children with atopic dermatitis and sleep disturbance a randomised clinical trial. JAMA
Pediatrics 2016;170:35–42
Population
Coppola G, Iervolino G, Mastrosimone M, La Torre G, Ruiu F, Pascotto A. Melatonin in
wake-sleep disorders in children, adolescents and young adults with mental retardation
with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain Dev
2004;26:373–6
Population
Corkum P, Lingley-Pottie P, Davidson F, McGrath P, Chambers CT, Mullane J, et al. Better
nights/better days – distance intervention for insomnia in school-aged children with/
without ADHD: a randomised controlled trial. J Paediatr Psychology 2016;41:701–13
Population
Cronin S, Gose L, Gottschlich MM, Kagan RJ. Retrospective examination of the
effectiveness of zolpidem for sleep in paediatric burn patients with a known history of
attention deficit/hyperactivity disorder. J Burn Care Res 2012;1:S117
Population
Cronin SD, Gottschlich MM, Gose LM, Kagan RJ. Zolpidem and sleep in pediatric burn
patients with attention deficit/hyperactivity disorder. Pediatr Nurs 2015;41:132–4, 140
Population
Bruin EJ, Bogels SM, Oort FJ, Meijer A. Improvements of adolescent psychopathology after
insomnia treatment: results from a randomised controlled trial over 1 year. J Sleep Res
2016;25:91
Population
De Cock VC, Diene G, Molinas C, Masson VD, Kieffer I, Mimoun E, et al. Efficacy of
modafinil on excessive daytime sleepiness in Prader–Willi syndrome. Am J Med Genet A
2011;155A:1552–7
Population
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Reference Reason for exclusion
Einfeld SL, Smith E, McGregor IS, Steinbeck K, Taffe J, Rice LJ, et al. A double-blind
randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med
Genet A 2014;164A:2232–9
Population
Freeman KA. Treating bedtime resistance with the bedtime pass: a systematic replication
and component analysis with 3-year-olds. J Appl Behav Anal 2006;39:423–8
Population
Gigli GL, Grubar JC, Colognola RM, Amata MT, Pollicina C, Ferri R, et al. Butoctamide
hydrogen succinate and intensive learning sessions: effects on night sleep of Down’s
syndrome patients. Sleep 1987;10:563–9
Population
Gupta M, Gupta YK, Aneja S, Kohli K. Effects of add-on melatonin on sleep in epileptic
children on carbamazepine monotherapy: a randomised placebo controlled trial. Sleep Biol
Rhythms 2004;2:215–19
Population
Gupta M, Aneja S, Kohli K. Add-on melatonin improves sleep behaviour in children with
epilepsy: randomised, double-blind, placebo-controlled trial. J Child Neurol 2005;20:112–15
Population
Holsboer-Trachsler E. Aerobic exercise and skill training improved objective sleep and motor
skills in children suffering from autism spectrum disorder (ASD) – a pilot study. Biol
Psychiatry 2015;77:10010–1710
Population
Hvolby A, Bilenberg N. Use of Ball Blanket in attention-deficit/hyperactivity disorder
sleeping problems. Nord J Psychiatry 2011;65:89–94
Population
Ishizaki A, Sugama M, Takeuchi N. [Usefulness of melatonin for developmental sleep
and emotional/behaviour disorders–studies of melatonin trial on 50 patients with
developmental disorders.] No To Hattatsu 1999;31:428–37
Population
Ivanenko A, Crabtree VM, Tauman R, Gozal D. Melatonin in children and adolescents with
insomnia: a retrospective study. Clin Pediatr 2003;42:51–8
Population
Keshavarzi Z, Bajoghli H, Mohamadi MR, Salmanian M, Kirov R, Gerber M, et al. In a
randomised case – control trial with 10-years olds suffering from attention deficit/
hyperactivity disorder (ADHD) sleep and psychological functioning improved during a
12-week sleep-training program. World J Biol Psychiatry 2014;15:609–19
Population
Ledet D, Aplin-Kalisz C, Filter M, Dycus P. A pilot study to assess a teaching intervention to
improve sleep-wake disturbances in parents of children diagnosed with epilepsy. J Neurosci
Nurs 2016;48:2–14
Population
McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous
melatonin treatment. Dev Med Child Neurol 1998;40:186–92
Population
Merrifield R. Evaluation of a health visitor-led sleep and behaviour clinic. Community Pract
2005;78:283–8
Population
Mila M, Cecilia A, Gracia A, Antonio M, Oscar T, Patricio P. Evaluation of oral iron
supplementation in paediatric maintenance insomnia. Sleep Med 2013;14:e207–8
Population
Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum
disorders. Brain Dev 2008;30:454–60
Population
Mohammadi MR, Mostafavi SA, Keshavarz SA, Eshraghian MR, Hosseinzadeh P,
Hosseinzadeh-Attar MJ, et al. Melatonin effects in methylphenidate treated children with
attention deficit hyperactivity disorder: a randomised double blind clinical trial. Iran J
Psychiatry 2012;7:87–92
Population
Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Fatty acids and sleep
in UK children: subjective and pilot objective sleep results from the DOLAB study – a
randomised controlled trial. J Sleep Res 2014;23:364–88
Population
O’Callaghan FJ, Clarke AA, Hancock E, Hunt A, Osborne JP. Use of melatonin to treat sleep
disorders in tuberous sclerosis. Dev Med Child Neurol 1999;41:123–6
Population
O’Connell A, Vannan K. Sleepwise: addressing sleep disturbance in young children with
developmental delay. Aust Occup Ther J 2008;55:212–14
Population
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Reference Reason for exclusion
Paasch V, et al. Preparing children with autism spectrum disorders for overnight sleep
studies: a case series. Clin Pract Pediatr Psychol 2016;4:153–63
Population
Pelsser LM, Frankena K, Buitelaar JK, Rommelse NN. Effects of food on physical and sleep
complaints in children with ADHD: a randomised controlled pilot study. Eur J Pediatr
2010;169:1129–38
Population
Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances
associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases.
J Am Acad Child Adolesc Psychiatry 1996;35:599–605
Population
Ross C, Davies P, Whitehouse W. Melatonin treatment for sleep disorders in children
with neurodevelopmental disorders: an observational study. Dev Med Child Neurol
2002;44:339–44
Population
Schlarb AA, Brandhorst I, Hautzinger M. [Mini-KiSS – a multimodal group therapy
intervention for parents of young children with sleep disorders: a pilot study.] Z Kinder
Jugendpsychiatr Psychother 2011;39:197–206
Population
Schroder C, Schmidt C, Kilic-huck U, Danion-Grilliat A, Bourgin P. Impact of long-term
melatonin treatment for sleep disturbances in a child psychiatric population. Eur Child
Adolesc Psychiatry 2015;24:1–303
Population
Silva LM, Scalock M, Ayres R, Bunse C, Budden S. Qigong massage treatment for sensory
and self-regulation problems in young children with autism: a randomised controlled trial.
Am J Occupation Ther 2009;63:423–32
Population
Simcock G. Sleep problems: assessing behavioural approaches. Community Pract
1999;72:128–30
Population
Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for
chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child
Neurol 2001;16:86–92
Population
Smits MG, van der Heijden KR, Meijer A, Coenen AM, Kerkhof GA. Melatonin improves
health status and sleep in children with idiopathic chronic sleep-onset insomnia: a
randomised placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003;42:1286–93
Population
Stores R, Stores G. Evaluation of brief group-administered instruction for parents to prevent
or minimise sleep problems in young children with Down syndrome. J Appl Res Intellect
Disabil 2004;17:61–70
Population
Szeinberg A, Borodkin K, Dagan Y. Melatonin treatment in adolescents with delayed sleep
phase syndrome. Clin Pediatr 2006;45:809–18
Population
Van Maanen A, Meijer AM, Smits MG, Oort FJ. Termination of short term melatonin
treatment in children with delayed Dim Light Melatonin Onset: effects on sleep, health,
behaviour problems, and parenting stress. Sleep Med 2011;12:875–9
Population
Ward F, Nanjappa M, Hinder SA, Roy M. Use of melatonin for sleep disturbance in a large
intellectual disability psychiatry service. Int J Developmental Disabil 2015;61:182–7
Population
Williams TI. Evaluating effects of aromatherapy massage on sleep in children with autism:
a pilot study. Evid Based Complement Alternat Med 2006;3:373–7
Population
Abdollahian E, Mohareri F. Evaluation of the effect of melatonin on improvement of
sleep quality in children with attention deficit/hyperactivity disorder whom received ritalin.
Eur Psychiatry 2015;30(Suppl. 1):584
Study design
Catherall C, Williams-Jones A. Managing sleep problems in children. Learning Disability
Practice 2011;14:14–19
Study design
Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children
with autism spectrum disorders. J Child Neurol 2008;23:482–5
Study design
Anonymous. Does melatonin improve sleep in children with neurodevelopmental disorders?
DTB 2013;51:4
Study design
Anonymous. Melatonin for primary insomnia? DTB 2009;47:74–7 Study design
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Anonymous. Melatonin improves sleep in children with ADHD and chronic insomnia:
no effect found on behaviour, cognition or quality of life. CABL 2007;23:1–7
Study design
Anonymous. Neurodevelopmental disorders: No evidence for efficiency of weighted
blankets in improving sleep in children with autism spectrum disorder. Nat Rev Neurol
2014;10:428
Study design
Arns M, Kenemans JL. Neurofeedback in ADHD and insomnia: vigilance stabilisation
through sleep spindles and circadian networks. Neurosci Biobehav Rev 2014;44:183–94
Study design
Ayyash HF, Preece P, Morton R, Cortese S. Melatonin for sleep disturbance in children with
neurodevelopmental disorders: prospective observational naturalistic study. Expert Rev
Neurother 2015;15:711–17
Study design
Behavioural Interventions To Improve Sleep Disturbance in Typically Developing Children
May be Effective for Children with Autism Spectrum Disorder. Clinician’s Research Digest:
Adult Populations. 2012;30:6
Study design
Bourdon GG. Treating insomnia in children with ADHD . . . ‘towards a psychology of
understanding: attention-deficit/hyperactivity disorder’. JAAPA 1998;11:76
Study design
Bouvier M, Claustrat B, Franco P. Melatonin treatment in autism spectrum disorders (ASD):
preliminary results. J Sleep Res 2012;236
Study design
Brown LW. Looking beyond the polysomnograph in ADHD. Sleep 2006;29:745–6 Study design
Christodulu KV, Durand VM. Reducing bedtime disturbance and night waking using
positive bedtime routines and sleep restriction. Focus Autism Other Dev Disabli
2004;19:130–9
Study design
Christodulu KV. Reducing bedtime disturbances and night waking using positive bedtime
routines and sleep restriction. Diss Abstr Int 2000;3:130–9
Study design
Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo
syndrome. Dev Med Child Neurol 1996;38:538–44
Study design
Cortese S, Brown TE, Corkum P, Gruber R, O’Brien LM. First step in sleep problems in
ADHD is promoting healthy sleep habits. CABL Update 2013;15:8
Study design
Damiani JM, Sweet BV, Sohoni P. Melatonin: an option for managing sleep disorders in
children with autism spectrum disorder. Am J Health Syst Pharm 2014;71:95–101
Study design
De Leersnyder H, Bresson JL, de Blois MC, Souberbielle JC, Mogenet A, Delhotal-Landes B,
et al. Beta 1-adrenergic antagonists and melatonin reset the clock and restore sleep in a
circadian disorder, Smith–Magenis syndrome. J Med Genet 2003;40:74–8
Study design
De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with
neurodevelopmental disorders. Pediatr Neurol 2011;45:23–6
Study design
Didden R, Curfs LM, van Driel S, de Moor JM. Sleep problems in children and young adults
with developmental disabilities: home-based functional assessment and treatment. J Behav
Ther Exp Psychiatry 2002;33:49–58
Study design
Didden R, de Moor JMH, Curfs LMG, Behavioural treatment of sleep problems in three
children with developmental disabilities. BJDD 2004;50:13–19
Study design
Doan RJ. Risperidone for insomnia in PDDs. Can J Psychiatry 1998;43:1050–1 Study design
Does melatonin improve sleep in children with neurodevelopmental disorders? Drug Ther
Bull 2013;51:4
Study design
Durand VM, Christodulu KV. Description of a sleep-restriction program to reduce bedtime
disturbances and night waking. J Posit Behav Interv 2004;6:83–91
Study design
Durand VM, Gernert-Dott P, Mapstone E. Treatment of sleep disorders in children with
developmental disabilities. Res Pract Persons Severe Disabl 1996;21:114–22
Study design
Durand VM. Treating sleep terrors in children with autism. J Posit Behav Interv
2002;4:66–72
Study design
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Duwez M, Rouby A, Renou M, Chanoine S, Sabourdy C, Vercueil L, et al. Effectiveness
and safety of oral melatonin premedication in sleep EEG in paediatrics. Int J Clin Pharm
2016;38:580–1
Study design
Efron D, Lycett K, Sciberras E. Response to: sleep medication in patients with
attention-deficit/hyperactivity disorder. Sleep Med 2015;16:208
Study design
Elkhayat HA, Hassanein SM, Tomoum HY, Abd-Elhamid IA, Asaad T, Elwakkad AS.
Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol
2010;42:249–54
Study design
Esbensen AJ, Beebe DW, Byars KC, Hoffman EK. Use of sleep evaluations and treatments
in children with Down syndrome. J Dev Behav Pediatr 2016;37:629–36
Study design
Espie CA, Wilson A. Improving sleep-wake schedules among people with mental
handicaps: some preliminary case material. Behav Cogn Psychother 1993;21:51–5
Study design
Fauteck J, Schmidt H, Lerchl A, Kurlemann G, Wittkowski W. Melatonin in epilepsy: first
results of replacement therapy and first clinical results. Biol Signals Recept 1999;8:105–10
Study design
Gee BM, Peterson T, Buck A, Lloyd K. Improving sleep quality using weighted blankets
among young children with an autism spectrum disorder. Int J Ther Rehabil
2016;23:173–81
Study design
Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release
melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord
2006;36:741–52
Study design
Giannotti F, Cortesi F, Antonella C, Bernabei P. Long-term melatonin treatment for sleep
disorders in autistic children. A two-year follow-up study. Amer Acad Sleep Med
2004:94–4
Study design
Greydanus DE. Causes and management of sleep problems in children with developmental
disabilities. Child Care Health Dev 2010;36:29
Study design
Gupta R, Hutchins J. Melatonin: a panacea for desperate parents? (Hype or truth). Arch Dis
Child 2005;90:986–7
Study design
Hart-Santora D, Hart LL. Clonidine in attention deficit hyperactivity disorder. Ann
Pharmacother 1992;26:37–9
Study design
Hätönen T, Kirveskari E, Heiskala H, Sainio K, Laakso ML, Santavuori P. Melatonin
ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor
activity rhythms recorded by wrist actigraphy. Mol Genet Metab 1999;66:401–6
Study design
Herrmann S. Counting sheep: sleep disorders in children with autism spectrum disorders.
J Pediatr Health Care 2016;30:143–54
Study design
Hodoba D, Schmidt D. Biperiden for treatment of somnambulism in adolescents and adults
with or without epilepsy: clinical observations. Epilepsy Behav 2012;25:517–28
Study design
Howlin P. A brief report on the elimination of long term sleeping problems in a 6-year-old
autistic boy. Behav Cogn Psychother 1984;12:257–60
Study design
Hvolby A, Bilenberg N. Use of ball blanket in attention deficit hyperactivity disorder
sleeping problems. Eur Child Adolesc Psychiatry 2011;20:7–223
Study design
Hylkema T, Vlaskamp C. Significant improvement in sleep in people with intellectual
disabilities living in residential settings by non-pharmaceutical interventions. J Intellect
Disabil Res 2009;53:695–703
Study design
Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in
children with neurodevelopmental disorders – a case series. Eur Child Adolesc Psychiatry
2005;14:34–40
Study design
Itoh M, Hayashi M, Hasegawa T, Shimohira M, Kohyama J. Systemic growth hormone
corrects sleep disturbance in Smith–Magenis syndrome. Brain Dev 2004;26:484–6
Study design
Jan JE, Espezel H. Melatonin treatment of chronic sleep disorders. Dev Med Child Neurol
1995;37:279–80
Study design
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Jan JE, O’Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders.
J Pineal Res 1996;21:193–9
Study design
Jan JE, Espezel H, Goulden KJ. Melatonin in sleep disorders of children with
neurodevelopmental disabilities. Melatonin in psychiatric and neoplastic disorders. Progress
Psychiatry 1998;55:169–88
Study design
Jan JE, Freeman RD, Fast DK. Melatonin treatment of sleep–wake cycle disorders in children
and adolescents. Dev Med Child Neurol 1999;41:491–500
Study design
Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med
Child Neurol 1994;36:97–107
Study design
Jan MM. Melatonin for the treatment of handicapped children with severe sleep disorders.
Pediatr Neurol 2000;23:229–32
Study design
Jin CS, Hanley GP, Beaulieu L. An individualized and comprehensive approach to treating
sleep problems in young children. J Appl Behav Anal 2013;46:161–80
Study design
Kawabe K, Horiuchi F, Oka Y, Ueno S. The melatonin receptor agonist ramelteon
effectively treats insomnia and behavioural symptoms in autistic disorder. Case Rep
Psychiatry 2014;2014:561071
Study design
Knight R, Johnson M. Using a behavioural treatment package for sleep problems in
children with autism spectrum disorders. Child Fam Behav Ther 2014;36:204–21
Study design
Konishi T, Masuko K, Naganuma Y, Hongou K, Yagi S. Flunitrazepam for sleep disturbance
in children with intractable epilepsy. Brain Dev 1995;17:69–72
Study design
Lerchl A, Reiter RJ. Treatment of sleep disorders with melatonin. BMJ 2012;345:e6968 Study design
Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, Burnette C.
Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability,
and outcomes. J Autism Dev Disord 2012;42:1729–37
Study design
Malow BA, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, Burnette C. Erratum
to: Melatonin for sleep in children with autism: a controlled trial examining dose,
tolerability, and outcomes. J Autism Dev Disord 2012;42:1738
Study design
Malow BA, Adkins KW, McGrew SG, Surdyka K, Goldman SE, Wofford D. Impact of
supplemental melatonin on sleep and behaviour in children with autism spectrum
disorders. 2009;32:A64
Study design
Malow BA, Adkins K, Goldman SE, McGrew SG, Burnette C, Wofford D, et al.
Supplemental melatonin decreases sleep latency in children with autism. Amer Acad Sleep
Med 2011:A267
Study design
Malow BA, Adkins KW, McGrew SG, Surdyka K, Wofford D. Supplemental melatonin
improves sleep in children with autism spectrum disorders. Ann Neurol 2009;66:S31
Study design
McArthur I, Maisey J, Zuberi SM. Does slow release melatonin (SR) prevent recurrent night
wakenings in children with neurodisability? Amer Academy Sleep 2003;26:A122–3
Study design
McArthur I, Maisey J, Zuberi SM. Impact of a nurse led sleep clinic on the use and
evaluation of melatonin FR (Fast release) for sleep problems in children with neurodisability.
Amer Academy Sleep 2003;126:A123
Study design
McLay LLK, France K. Empirical research evaluating non-traditional approaches to
managing sleep problems in children with autism. Dev Neurorehabil 2014;19:123–34
Study design
Melatonin for insomnia in ADHD. Nurses’ Drug Alert. AJN 2010;34:3–4 Study design
The Brown University Child and Adolescent Behaviour Letter (CABL) 2007;23:1–7.
URL: https://onlinelibrary.wiley.com/doi/epdf/10.1002/cbl.20043 (accessed 26 July 2018)
Study design
Miyamoto A, Oki J, Takahashi S, Okuno A. Serum melatonin kinetics and long-term
melatonin treatment for sleep disorders in Rett syndrome. Brain Dev 1999;21:59–62
Study design
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Moon EC, Corkum P, Smith IM. Case study: a case-series evaluation of a behavioural sleep
intervention for three children with autism and primary insomnia. J Pediatr Psychol
2011;36:47–54
Study design
Moore P. The use of social stories in a psychology service for children with learning
disabilities: a case study of a sleep problem. Br J Learn Disabil 2004;32:133–8
Study design
Mullane J, Corkum P. Case series: evaluation of a behavioral sleep intervention for three
children with attention-deficit/hyperactivity disorder and dyssomnia. J Atten Disord
2006;10:217–27
Study design
Nakano T, Koyama E, Taniike M, Unase K. Application of an infrared sensor to
home-monitoring of rest-activity patterns in a child with sleep disturbance. Sleep Biol
Rhythms 2003;1:173–4
Study design
Narasingharao K, Pradhan B, Navaneetham J. Sleep Disorder, Gastrointestinal Problems and
Behaviour Problems Seen in Autism Spectrum Disorder Children and Yoga as Therapy:
A Descriptive Review. J Clin Diagn Res 2016;10:VE01–3
Study design
Niederhofer H, Staffen W, Mair A, Pittschieler K. Brief report: melatonin facilitates sleep in
individuals with mental retardation and insomnia. J Autism Dev Disord 2003;33:469–72
Study design
Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness
of melatonin in the treatment of sleep disturbances in children with Asperger disorder.
J Child Adolesc Psychopharmacol 2003;13:83–95
Study design
Palm L, Blennow G, Wetterberg L. Long-term melatonin treatment in blind children
and young adults with circadian sleep-wake disturbances. Dev Med Child Neurol
1997;39:319–25
Study design
Piazza CC, Fisher W. A faded bedtime with response cost protocol for treatment of
multiple sleep problems in children. J Appl Behav Anal 1991;24:129–40
Study design
Piazza CC, Fisher WW. Bedtime fading in the treatment of pediatric insomnia. J Behav Ther
Exp Psychiatry 1991;22:53–6
Study design
Piazza CC, Hagopian LP, Hughes CR, Fisher WW. Using chronotherapy to treat severe sleep
problems: a case study. Am J Ment Retard 1998;102:358–66
Study design
Piazza CC, Fisher W, Moser H. Behavioral treatment of sleep dysfunction in patients with
the Rett syndrome. Brain Dev 1991;13:232–7
Study design
Pillar G, Shahar E, Peled N, Ravid S, Lavie P, Etzioni A. Melatonin improves sleep-wake
patterns in psychomotor retarded children. Pediatr Neurol 2000;23:225–8
Study design
Pillar G, Etzioni A, Shahar E, Lavie P. Melatonin treatment in an institutionalised child with
psychomotor retardation and an irregular sleep-wake pattern. Arch Dis Child 1998;79:63–4
Study design
Reeve A, Miers S. Managing sleep problems in children with special needs. Health Visit
1994;67:230–1
Study design
Richdale AL. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child
Neurol 1999;41:60–6
Study design
Richdale AL. Treatment of sleep problems in children with autism. J Intellect Disabil Res
2000;44:441–1
Study design
Ross C, Morris B, Whitehouse W. Melatonin treatment of sleep-wake cycle disorders in
children and adolescents. Dev Med Child Neurol 1999;41:850
Study design
Rukovets O. Mending Children’s sleep habits, improving family relations. Neurol Today
2012;12:37
Study design
Scott J. Melatonin an effective treatment for sleep problems in children with autism. Foods
Matter (USA) 2009:15
Study design
Snowden S. Question 1. Does melatonin improve sleep pattern in children with attention
deficit hyperactivity disorder? Arch Dis Child 2009;94:321–2
Study design
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TABLE 31 List of papers excluded after full-text review and reasons for exclusion (continued )
Reference Reason for exclusion
Stevinson C. Valerian may improve sleep of children with intellectual deficits. Focus Altern
Complement Ther 2002;7:347–8
Study design
Summers JA, Lynch PS, Harris JC, Burke JC, Allison DB, Sandler L. A combined behavioural/
pharmacological treatment of sleep–wake schedule disorder in Angelman syndrome.
J Dev Behav Pediatr 1992;13:284–7
Study design
Thackeray EJ, Richdale AL. The behavioural treatment of sleep difficulties in children with
an intellectual disability. Behav Interv 2002;17:211–31
Study design
Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG. Melatonin for treatment of
sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary
open label study. Eur J Pediatr 2003;162:554–5
Study design
Top tips. Learning Disability Today. 2013;13:20 Study design
Toussaint FS, Baverstock AC. An audit of melatonin use and parental satisfaction in a
district general hospital. Arch Dis Child 2012;97(Suppl. 1):A128
Study design
Uberos J, Augustin-Morales MC, Molina Carballo A, Florido J, Narbona E, Munoz-Hoyos A.
Normalisation of the sleep-wake pattern and melatonin and 6-sulphatoxy-melatonin levels
after a therapeutic trial with melatonin in children with severe epilepsy. J Pineal Res
2011;50:192–6
Study design
Wassmer E, Carter PF, Quinn E, McLean N, Welsh G, Seri S, Whitehouse WP. Melatonin is
useful for recording sleep EEGs: a prospective audit of outcome. Dev Med Child Neurol
2001;43:735–8
Study design
Waters F. Natural alternative offers hope on sleep disorders: the National Network for
Learning Disability Nurses held its annual conference in Pontypridd last week. Nurs Stand
2004;18:9–10
Study design
Weiskop S, Matthews J, Richdale A. Treatment of sleep problems in a 5-year-old boy with
autism using behavioural principles. Autism 2001;5:209–21
Study design
Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate
and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry
1999;38:614–19
Study design
Yamashita Y, Matsuishi T, Murakami Y, Kato H. Sleep disorder in Rett syndrome and
melatonin treatment. Brain Dev 1999;21:570
Study design
Zhdanova IV, Wurtman RJ, Wagstaff J. Effects of a low dose of melatonin on sleep in
children with Angelman syndrome. J Pediatr Endocrinol Metab 1999;12:57–67
Study design
Zolpidem not effective for ADHD-associated insomnia. CABL Update 2009;11:7 Study design
Zotter H, Kerbl R, Millner M, Kurz R. Methylphenidate and melatonin for sleep disorder
with optic glioma. J Am Acad Child Adolesc Psychiatry 2001;40:992–3
Study design
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Appendix 5 Study details for pharmacological
interventions
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TABLE 32 Study details for pharmacological interventions
Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Melatonin vs. placebo
Parallel trials
Appleton et al.48
Associated publications:
Gringras et al.108 and
Appleton et al.48,109
UK
Melatonin: capsules, starting dose of
0.5 mg, taken 45 minutes before
bedtime for 12 weeks. Dose could be
raised to 2, 6 and 12mg in the first
4 weeks, then maintained
Placebo: capsule-matching placebo,
starting dose of 0.5 mg. Dose could be
escalated through 2mg and 6mg to
12mg in the first 4 weeks, then
maintained
N = 146
Melatonin (n= 70): 106.0 months
(34.8 months), range 44–181 months
70% male
DD, 19%; DD and epilepsy, 11%; DD
and ASD, 43%; DD, ASD and epilepsy,
0; DD and ‘other’, 27%
Placebo (n = 76): 100.7 months
(37.4 months), range 37–186 months
63% male
DD, 9%; DD and epilepsy, 7%; DD and
ASD, 39%; DD, ASD and epilepsy, 3%;
DD and ‘other’, 38%
Sleep disturbance
l Sleep initiation: not falling asleep within 1 hour of
‘lights off’ or ‘snuggling down to sleep’ in 3 out of
5 nights and/or < 6 hours
l Sleep maintenance: continuous sleep in 3 out of
5 nights
Prior interventions
l Prior to randomisation, research nurses introduced
eligible participants to a behaviour therapy advice
booklet and children’s sleep was monitored using
parent-completed sleep diaries and actigraphy.
Only children whose sleep problems persisted
were randomised
Low
Cortesi et al.110
Italy
Melatonin: controlled release, dose
3 mg, taken at 9 p.m. for 12 weeks
CBT: 4 sessions, weekly individual
sessions
Melatonin and CBT: as above
N = 160
Melatonin (n= 40): 6.8 years
(0.9 years)
82% male
ASD, 100%
Sleep disturbance
l Sleep initiation: mixed sleep onset
l Sleep maintenance: maintenance insomnia
Prior interventions
High
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Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Placebo: identical placebo tablet (same
appearance smell and flavour to active
treatment), dose 3 mg, taken at 9 p.m.
for 12 weeks
Melatonin and CBT (n= 40): 6.4 years
(1.1 years)
80% male
ASD, 100%
CBT (n = 40): 7.1 years (0.7 years)
83% male
ASD, 100%
Placebo (n = 40): 6.3 years (1.2 years)
84% male
ASD, 100%
l None reported
Van der Heijden et al.111
Associated publications:
Hoebert et al.112
The Netherlands
Melatonin: fast release, 3 mg
(if < 40 kg), 6 mg (if > 40 kg) at 19.00,
4 weeks
Control: identical appearing placebo at
19.00, 4 weeks
N = 107
Melatonin (n= 54): 9.1 years (2.3 years)
66% male
ADHD subtype: ADHD-C, 77%;
ADHD-I, 17%; ADHD-HI, 4%
Placebo (n = 53): 9.3 years (1.8 years)
83% male
ADHD subtype: ADHD-C, 69%;
ADHD-I, 25%; ADHD-HI, 4%
Sleep disturbance
l Sleep initiation: sleep onset insomnia
Prior interventions
l None reported
Unclear
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TABLE 32 Study details for pharmacological interventions (continued )
Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Crossover trials
Camfield et al.113
Individualised ‘N of 1
crossover trial’
Canada
Melatonin: capsules 0.5 mg for three
cases and 1.0 mg for three cases, taken
at 18.00, given for 1 week
Placebo: capsules, identical-looking to
intervention, given for 1 week
Ten-week trial in which, for each of the
five 2-week intervals, the child was
randomised to receive daily placebo or
melatonin for the first week with the
alternate agent given in the second
week
N = 6
7.3 years, range 3–13 years
67% male
Congenital optic nerve hypoplasia:
17%; moderate spastic quadriplegia
17%; schizencephaly, spastic diplegia
and severe learning disabilities, 17%;
moderate learning disabilities and
severe athetoid cerebral palsy, 17%;
developmental disorder with extreme
hyperactivity and moderate to severe
learning disabilities, 17%; autosomal
recessive disorder with cerebellar
hypoplasia and tapetoretinal
degeneration but with stable moderate
to severe learning disabilities, 17%
Sleep disturbance
l Sleep initiation: delayed sleep phase
l Sleep maintenance: disrupted and fragmented
sleep
Prior interventions
l All parents reported attempting behavioural
approaches to nocturnal awakenings and at least
one hypnotic agent, without success
High
Dodge and Wilson114
Associated publications:
Hoebert et al.112
USA
Melatonin: capsules, dose 5 mg, taken
at 20.00 for 2 weeks
Placebo: capsule and filler packaged to
be identical to the melatonin capsules,
dose 5 mg, taken at 20.00 for 2 weeks
Washout period of 1 week
N = 36
89 months, range 13 months to
15 years
Gender: not reported
Cerebral palsy, 75%; autism, 10%;
genetic syndrome, 10%; learning
disabilities, 5%
Sleep disturbance
l ‘Chronic sleep problems’
Prior interventions
l Individuals were excluded if behavioural
interventions had not been ‘adequately tried’
Unclear
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Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Garstang and Wallis69
UK
Melatonin: dose 5 mg, for 4 weeks
(type of dose not reported)
Placebo: capsule, dose not reported,
for 4 weeks
Washout period of 1 week
N = 11
8.6 years (3.1 years), range 5–15 years
64% male
All ASD plus: mild LD, 27%; moderate
LD, 18%; severe LD, 9%; dyspraxia,
18%; no other diagnoses, 27%
Sleep disturbance
l Sleep initiation: sleep latency of at least 1 hour
after bedtime
l Sleep maintenance: night awakenings requiring
parental attention, present for 4 nights/week or
more in previous 6 months
Prior interventions
l There had to be a failure of behavioural
management techniques to be included. All
parents received a standard advice leaflet about
establishing good sleep hygiene measures
High
Jain et al.115
Associated publications:
Jain et al.116
USA
Melatonin: sustained release, tablet
form, dose 9 mg, taken 30 minutes
before bedtime for 4 weeks
Placebo: tablet form, the same
appearance as melatonin tablets, dose
not reported
Washout period of 1 week
N = 11
8.4 years (1.3 years)
70% male
Epilepsy type: focal, 70%; generalised,
20%; undetermined, 10%
Sleep disturbance
l A score of ≥ 30 on Sleep Behaviour Questionnaire
subscales: sleep fragmentation, parasomnia and
daytime drowsiness
Prior interventions
l None reported
High
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TABLE 32 Study details for pharmacological interventions (continued )
Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Wasdell et al.117
Associated publications:
Carr et al.118
Canada
Melatonin: controlled release, capsules,
dose 5 mg, taken 20–30 minutes
before bedtime for 10 days
Placebo: identical capsules to
melatonin, dose 5 mg, 20–30 minutes
before bedtime for 10 days
‘Placebo washout’ period of 3–5 days
N = 51
7.4 years, range 2.1–17.8 years; 62%
Severe intellectual loss, 64%; cerebral
palsy, 52%; epilepsy, 46%; visual
impairment, 40%; lack of mobility,
36%; ASD, 32%
Sleep disturbance
l Sleep initiation: chronic delayed sleep syndrome
l Sleep maintenance: impaired sleep maintenance
Prior interventions
l Prior to randomisation, a paediatric nurse
supervised caregivers, while participants received
sleep hygiene tailored to their age, development
and individual disabilities. Only children whose
sleep problems persisted were randomised
Unclear
Weiss et al.70
Canada
Melatonin: short acting, dose 5 mg,
taken 20 minutes before bedtime for
10 days
Placebo: dose X mg for 10 days
The 10-day treatment phases were
separated by a ‘placebo washout’
period of 5 days
N = 23
10.29 years, range 6.5–14.7 years
91% male
All ADHD. Subtype: inattentive, 4%;
ADHD-C, 96%
Sleep disturbance
l Sleep initiation: initial insomnia of > 60 minutes
Prior interventions
l At the start of the study children received a sleep
hygiene intervention. Only children who continued
to have initial insomnia for > 60 minutes were
randomised
Unclear
Wirojanan et al.119
USA
Melatonin: dose 3 mg, taken
30 minutes prior to bedtime for
2 weeks
Placebo: dose 3 mg, taken 30 minutes
before bedtime for 2 weeks
No washout period
N = 18
5.5 years (3.6 years), range
2–15.3 years
92% male
Fragile X syndrome + ASD, 25%; fragile
X syndrome, 25%; ASD, 42%; fragile X
syndrome permutation, 8%
Sleep disturbance
l ‘Sleep problem’
Prior interventions
l None reported
Unclear
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Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Wright et al.106
UK
Melatonin: standard release melatonin,
dose 2 mg, taken 30–40 minutes
before bedtime. Dose increased by
2 mg every 3 nights to a maximum of
10mg. Taken for 3 months
Placebo: capsules identical to melatonin,
dose 2mg, taken 30–40 minutes before
bedtime. Dose increased by 2mg every
three nights to a maximum of 10mg.
Taken for 3 months
Washout period of 1 month
N = 20
9.0 years (2.9 years), range 4–16 years
80% male
Autism, 70%; atypical autism, 20%;
Asperger syndrome, 10%
Sleep disturbance
l Sleep initiation: sleep latency
l Sleep maintenance: excessive night waking or
reduced TST
Prior interventions
l Children were only invited to participate if behaviour
management with parenting support had been
provided by an experienced clinician and was not
successful. Previous interventions were discussed to
ensure all participants had been offered adequate
behaviour management and parenting support. If
participants had not received behaviour management
and support, they were referred to the learning
disability Child and Adolescent Mental Health Services
team. Families that had received appropriate support
received a refresher session. Sleep diaries were
completed for 1 month and only those who had
persistent sleep problems were randomised
Unclear
Melatonin vs. melatonin
Crossover trials
Hancock et al.120
UK
Melatonin: 1 × 5mg plus 1 × 5 mg
placebo, 30 minutes before bedtime for
2 weeks
Melatonin: 2 × 5mg of melatonin
(10 mg in total), taken 30 minutes
before bedtime for 2 weeks
Washout period of 2 weeks
N = 8
12.1 years (10.0 years), range
1.5–31 years
57% male
All tuberous sclerosis
Of participants aged < 19 years
6.9 years (4 years), range 1.5–11 years;
40%
All tuberous sclerosis
Sleep disturbance
l Quine sleep index score of at least 6
(of a possible 8)
Prior interventions
l None reported
High
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
0
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
8
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
B
e
re
sfo
rd
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
1
8
3
TABLE 32 Study details for pharmacological interventions (continued )
Study details and
study design Trial treatments
Participant characteristics: number
randomised, mean age (SD);
% male, % diagnosis Type of sleep disturbance/prior interventions
Risk of bias
(low, unclear
or high)
Jan et al.121
Canada
Melatonin: sustained-release melatonin,
variable doses from 2–10mg, taken
30 minutes before bedtime, 11 days
Control: fast-release melatonin, variable
does from 2–10mg, taken for 11 days
No washout period
N = 16
Age range: 4–21 years
N = 15 eligible participants (under
18 years)
9.3 years, range 4–16 years
Gender: not reported
Multidisabled but not reported
separately for RCT
Sleep disturbance
l ‘Chronic sleep–wake disorders’
Prior interventions
l None reported
High
ADHD-C, attention deficit hyperactivity disorder – combined type; ADHD-I, attention deficit hyperactivity disorder – inattentive type; ADHD-HI, attention deficit hyperactivity disorder –
hyperactive impulsive type; CBT, cognitive–behavioural therapy; DD, developmental delay; LD, learning disability.
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Appendix 6 Study quality: studies evaluating
melatonin
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TABLE 33 Summary of quality assessment using the Cochrane risk of bias for RCTs tool62,a
Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Melatonin vs. placebo
Parallel trials
Appleton
et al.
48
Yes
Computer-generated
sequence
Yes
Pharmacy led
Yes
Similar numbers lost in each arm
for similar reasons. Data analysed
on intention-to-treat basis
Yes
Protocol available, amendments
detailed, all outcomes reported
Yes
No other bias obvious
N/A
Cortesi
et al.
110
Yes
Computer-generated
sequence
Unclear
Allocation was done by
someone independent of
treatment personnel and
via computer, but it is
not clear if the allocation
was concealed to the
independent person (e.g.
via opaque envelopes)
Yes
Doubleblinding,using
identicalcapsulesandcentral
allocation. Intwocases
participantswereunblinded
inordertotreatserious
adverseevents
Unclear
Authorsarguethat
researchersandparticipants
didnotknowwhicharm
theywere in(therewerefour
arms intotal).Althoughthis
isplausibleforthemelatonin
onlyandplacebo-onlyarms,
inwhichthecapsuleswere
identical, it is lessplausible
forthemelatonincombined
withCBTandtheCBTonly,
astheywouldobviously
know iftheywerereceiving
CBT.Similarly,theprincipal
investigators(PIs)observed
tapesoftheCBTfor
adherencetoprotocol,so
theywouldknowat least
whowasreceivingCBT(even
iftheycouldnotknow if
theywerereceivingthisalone
orwithPHODWRQLQ),sothis is
inagreementwiththeabove
judgement
No
None were lost to follow-up
but 16 dropped out owing to
difficulties in administering
medication, non-compliance
and lack of improvement. An
additional 10 were excluded
from analysis owing to missing
actigraphy data. The final analysis
excluded all above. There were no
details of the potential implications
of missing data/dropouts. All six
dropouts in placebo group were
because of lack of improvement;
none of the dropouts in the other
groups were for this reason
Unclear
No protocol is referenced in the
paper and one was not found on
searching. The study reports
outcomes that one would expect.
However, table 3 reports two
outcomes that are not referred
to anywhere else in the paper
(Naptime and Bedtime). It is not
clear what they are
In the methods section, the paper
only states what the primary
outcomes were and so it is
presumed that Naptime and
Bedtime are secondary, but this is
not stated so there is a low degree
of selective reporting, as the
authors state that groups and
clinicians were unaware of what
they were receiving and both
groups were treated as per an
identical protocol
Yes N/A
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Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Van der
Heijden
et al.
111
Unclear
Randomisation in blocks
of four to keep number
in each treatment group
closely balanced. No
details of how sequence
generated
Yes
Central allocation.
Performed by a hospital
pharmacist who was not
connected to study
Yes
Reported as double-blind
and the placebo tablets
looked identical to
intervention tablets.
Investigators and participants
unware of allocation. Code
broken after all treatment
completed and data
recorded
Yes
No loss to follow-up. One child in
placebo group and one in the
melatonin group were withdrawn
prior to treatment because they
started other treatment without
permission
Unclear
Protocol available on the
International Standard Randomised
Controlled Trial Number website
(although it says it was
retrospectively registered).
Outcomes listed on trial record are:
(primary) sleep onset, latency, total
sleep duration (acting and sleep
log) and Dim Light Melatonin
Onset and (secondary) sustained
attention and response inhibition,
severity of ADHD symptoms,
quality of life and side effects.
The study paper reports these
outcomes but also reports that
difficulty falling asleep (rated in
severity) was a primary outcome
(p. 235). CBCL (behavioural
problems) was also reported
(which may be the measure of
ADHD severity listed in protocol
but this is not clear)
An additional file that includes all
raw data for study outcomes is
available
Yes
The number of missing
data on behaviour and
quality-of-life measures
was large but authors
suggest that the risk of
bias in the analysis is
small because the missing
data are equal in both
groups
N/A
Crossover trials
Camfield
et al.
113
Unclear
No details are provided
in the paper
Unclear
No details are provided
in the paper
Unclear
Participants were blinded,
although not clear how. Not
clear if researchers blinded at
analysis
Yes
No loss to follow-up and data
presented for all six participants
Unclear
No protocol is referenced in the
paper and one was not found
on searching. Three outcome
measures are used: average hours
of sleep per 24 hours, number of
awakenings between 9 p.m. and
7 p.m. per day and number of
nights with no arousals from
8 p.m. to 7 a.m. The reported
‘nights without awakening’ was
10 p.m. to 7 a.m. rather than
9 p.m. to 7a.m. Not clear whether
this was a typo or the outcome
measure changed
No
Small sample and only
descriptive data are
reported
continued
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TABLE 33 Summary of quality assessment using the Cochrane risk of bias for RCTs tool62,a (continued )
Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Dodge
and
Wilson
114
Unclear
Randomisation
performed by pharmacy
personal but sequence
generation not described
Unclear
Randomisation and
packaging of capsules
done by research
pharmacy personal but
it is not clear if these
research pharmacy
personal were part of
research team, and
no detail is provided
about whether or not
allocation was concealed
Yes
Identical packaging. Parents
asked to guess which
treatment their children were
on prior to unblinding.
Randomisation by research
pharmacists, not study team
Unclear
No flow chart. In total, 20 out of 36
participants who enrolled completed
the study but it was not clear how
missing data were addressed. Losses
to follow-up were reported as having
no significant difference on age,
primary diagnosis, epilepsy or vision
impairment compared with those
completing study. Non-completion
was because of lost sleep logs
(n=1), lost medication (n=2),
changed mind about participating
(n=4), intercurrent illness (n=2),
family emergency (n=1), family lost
to follow-up (n=3) and medication
not working (n=2)
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without
protocol, it is difficult to be certain
Unclear
Details of sample
characteristics between
treatment and placebo at
baseline are not reported,
making the comparability
unclear
N/A
Garstang
and
Wallis
69
Yes
Random numbers table
Yes
Pharmacy led
Unclear
Reported as double blind
but there were few details
as to how this was achieved.
There was no reference to
treatment and placebo
capsules being identical
No
Dropouts: after drugs recall
following empty placebo capsules,
n= 3; owing to a house move,
n= 1; and on the start of a child
protection enquiry, n= 1. No
detail on whether last two were
receiving placebo or melatonin.
Data were analysed for trial
completers only
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without a
protocol, it is difficult to be certain
No
There was an assumption
that the child was asleep
(and logged as asleep)
if parents were not
disturbed. Child could
have been awake but did
not disturb the parent.
There was also a drugs
recall and the trial was
stopped early, so it is not
clear if and how this
affected subsequent
procedure and blinding
of treatment
Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Yes
Can it be assumed that the
trial was not biased from
carry-over effects?
Washout period used, but
no analysis of carry-over
effect
Are unbiased data
available?
There does not appear to be
any analysis of difference
between the treatment and
control groups
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Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Jain
et al.
115
Yes
Computer-randomised
number generator
Yes
Pharmacy led
No
The appearance of capsules
was identical but the
statistician and pharmacist
were unblinded
Unclear
In total, 1 out of 11 did not
complete the study owing to
being unable to swallow the
capsules
The limitations section states that
there were some secondary
outcome data lost for two
participants and that this may
have had an impact on the results.
It is not clear what the missing
data or impacts were
No
Protocol is available on clinical
trials register. Outcomes listed on
register include: (primary) sleep
efficiency and improved lapse time
on psychomotor vigilance task
and (secondary) improvement
in eleptiform discharges on
electroencephalography and seizure
frequency. However, in the paper,
more outcomes are reported. The
primary outcomes in the paper
are SOL and wakefulness. Twenty
secondary outcomes are listed,
including the one listed as primary
(sleep efficiency) on the trials register
Yes Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Yes
Can it be assumed that the
trial was not biased from
carry-over effects?
Carry-over effects observed
for two REM variables and
so adjusted analysis
Are unbiased data available?
When carry-over effects are
not observed, authors report
using Wilcoxon rank-sum test
and two sample tests
continued
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TABLE 33 Summary of quality assessment using the Cochrane risk of bias for RCTs tool62,a (continued )
Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Wasdell
et al.
117
Unclear
Blocked randomisation
method led by pharmacy,
‘in which every four
patients had equal
probability of receiving
either of the two
treatment sequences’
(p. 58). However, no
detail given on how the
randomisation sequence
was generated
Yes
Pharmacy led
Yes
Patients, caregivers, the study
investigator and clinical
staff were blinded to the
medication randomisation.
Unblinding occurred at the
end of the study
Yes
Overall, 50 out of 51 randomised
participants completed trial. One
withdrew owing to illness. Only
the 50 who completed the trial
were included in the analysis
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without a
protocol, it is difficult to be certain
Yes Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Yes
Can it be assumed that the
trial was not biased from
carry-over effects?
Washout period used and
authors undertook analysis
to test for carry-over effect
and report that there were
none
Are unbiased data
available?
Yes. Paired t-test used
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Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Weiss
et al.
70
Unclear
No details are provided
Yes
Pharmacy led
Unclear
Authors state that all
participants and study
personal blinded to the
order of treatment during
randomisation phase. This
implies that blinding may
not have extended after
randomisation (e.g. at data
collection and analysis).
However, no further detail
is given so it is difficult to
judge this
Yes
3/22 discontinued because of
protocol violations but outcomes
unchanged whether included or
not (were excluded in results
presented in paper)
Unclear
No protocol referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without
protocol, it is difficult to be certain.
Furthermore, CADS-P was not
reported, other than that no
significant change was observed;
therefore, the data cannot be
included in a meta-analysis
Yes Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Not clear
Can it be assumed that the
trial was not biased from
carry-over effects?
Washout period used and
authors undertook analysis
to test for carry-over effect
and report there were none
Are unbiased data
available?
Yes. Paired analysis used
continued
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TABLE 33 Summary of quality assessment using the Cochrane risk of bias for RCTs tool62,a (continued )
Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Wirojanan
et al.
119
Unclear
No details are provided
Unclear
Authors say that the
allocation was concealed
but do not say how
Yes
Authors say that assignment
to the treatment condition
was concealed until the end
of the study. Allocation key
with investigator (locked in
file) until the end of the
study
Yes
In total, 12 out of 18 participants
completed trial. No details of
characteristics of the six who did
not complete. Reasons were sleep
diaries not completed/actigraphy
data not readable (n= 2 placebo,
n= 1 melatonin); actigraphy watch
not worn during first treatment
phase (melatonin) (n= 1);
actigraphy watch taken off in first
phase (placebo) (n= 1); study
protocol not followed (n= 1). Data
only from the 12 were analysed
Missing output data dealt with by
complete-case analysis and last
observation carried forward
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without a
protocol, it is difficult to be certain
Unclear
Authors report that
normality assumption for
parametric paired test
was violated owing to
highly skewed data and
presence of outliers.
The authors present
both parametric and
non-parametric analyses.
The authors imply in the
discussion that some
families may have been
practising sleep hygiene,
with variability in this.
There is no further
information about this
but the implication is that
this was possible and not
minimised or controlled.
Without any further
information (e.g. how
many families practised
sleep hygiene), it is
difficult to judge whether
or not this has introduced
bias
Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
No
Can it be assumed that the
trial was not biased from
carry-over effects?
No. No washout period was
used between crossover.
The authors say that this is
because of the half-life of
melatonin but is this
conclusive? Different studies
have used different
approaches – some having a
washout period and others
not. It is not clear or certain
if this could present a bias
Are unbiased data
available?
Paired t-tests used,
both parametric and
non-parametric
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Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Wright
et al.
106
Unclear
No details are provided
Yes
Remote pharmacy led
Yes
Double-blind randomisation
was undertaken by someone
with no contact with the
research team and the
capsules were identical
Yes
There were four withdrawals (three
in melatonin first, one in placebo
first, but two while taking melatonin
and two while taking placebo).
Reasons: too difficult for parents to
administer medication, n=1;
parents unable to complete sleep
diary questionnaire measures, n=1;
very significant sleep benefits early
in first arm, n=1; and apparent
ineffectiveness of medication, n=1.
The last completed one arm of trial
and so data were included in some
of analyses. This participant was in
melatonin arm first and another
clinician prescribed another drug
Only one withdrawal (early very
significant effects) was likely to be
related to the true outcome
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without a
protocol, it is difficult to be certain
Yes Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
No
Can it be assumed that the
trial was not biased from
carry-over effects?
A washout period of
1 month used
Are unbiased data
available?
Paired t-tests were used
Melatonin vs. melatonin
Crossover trials
Hancock
et al.
120
Unclear
The hospital pharmacy
led randomisation but it
is not clear how the
sequence was generated
The pharmacy
department generated
random numbers that
determined whether
individuals started with
5mg or 10mg of
melatonin. This is
assessed as LOW risk/Yes
Yes
Pharmacy led
Yes
The study was double blind,
identical capsules were used
and unblinding occurred
after completion of trial
Unclear
In total, one out of eight sets of
data was lost in the mail. There
are no details of lost patient
characteristics and the implications
of this
There is no detail of how other
missing data are dealt with
Unclear
No protocol was referenced in the
paper and one was not found
after searching. The outcomes
reported are those that are
expected. However, without a
protocol, it is difficult to be certain
No
It had a small sample,
but it is a pilot study
Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Yes
Can it be assumed that the
trial was not biased from
carry-over effects?
A washout period used but
no analysis of carry-over effect
Are unbiased data available?
Paired t-tests used
continued
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TABLE 33 Summary of quality assessment using the Cochrane risk of bias for RCTs tool62,a (continued )
Study
Domain
1: adequate sequence
generation?
2: allocation
concealment? 3: blinding?
4: incomplete outcome data
addressed? 5: free of selective reporting? 6: free of other bias?
Additional questions for
crossover trials
Jan
et al.
121
Unclear
No details are provided
in the paper
Unclear
No details are provided
in the paper
Unclear
Paper reports that both
investigators and caregivers
were blinded but no detail
is given as to how
(e.g. identical packs)
Yes
No loss to follow-up
No
No protocol was referenced and
one was not found after searching.
However, the only outcome
reported is changes in sleep
pattern, which is reported as
whether or not there was a
response to treatment (with little
detail on what exactly was
measured). There are no data
presented regarding what this
response was and it is, thus, rather
vague. Perhaps this is because it
was a dose-finding RCT, but even
so, the lack of detail on the
outcome makes the reporting
appear selective and lacks
transparency
No
Participants had already
been treated with
another form of
melatonin. It is not clear
how the 16 participants
were selected; for
example, whether or not
they fit eligibility criteria
Was use of a crossover
design appropriate?
Yes
Is it clear that the order of
receiving treatments was
randomised?
Yes
Can it be assumed that the
trial was not biased from
carry-over effects?
No, as there was no
washout period between
crossover. There was no
analysis of carry-over effect
Are unbiased data
available?
No. The type of analysis
used was not clear
CADS-P, Conners Attention Deficit Scale Parent version; CBT, cognitive–behavioural therapy; N/A, not applicable; REM, rapid eye movement.
a Yes, low risk of bias; unclear, unclear risk of bias; no, high risk of bias.
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Appendix 7 Child sleep-related outcomes in trials
comparing melatonin with placebo
TABLE 34 Child sleep-related outcomes in trials comparing melatonin with placebo
Study
Child sleep-related
outcome assessed
Method of
assessmenta Definitionsb
Global measures and composite scores
Appleton et al.48 Sleep efficiency Actigraphy Number of minutes spent sleeping in bed/total
number of minutes spent in bed × 100
TST Actigraphy, sleep diary The amount of time between the time that the
child went to sleep and the time that the child
woke up the following morning minus any
night-time awakenings
Camfield et al.113 TST Sleep diary Average sleep per day
Cortesi et al.110 CSHQ CSHQ (total score and
subscales)
A 33-item parent questionnaire that includes
items relating to a number of key sleep domains,
which are grouped into the following subscales:
bedtime resistance, sleep onset delay, sleep
duration, sleep anxiety, night wakings,
parasomnias, sleep disordered breathing and
daytime sleepiness. The authors provide a
reference
Sleep efficiency Actigraphy No definition provided, other than that ‘these
variables were averaged over 7 nights for each
assessment phase’110
TST Actigraphyc No definition provided, other than that ‘these
variables were averaged over 7 nights for each
assessment phase’110
WASO Actigraphyc Inclusion criteria defined WASO as wake after
sleep onset > 30 minutes that occurred on ≥ 3
nights a week
Van der Heijden
et al.111
Sleep efficiency Actigraphyc Percentage of time spent asleep in the period
from lights out until the time of leaving bed
TST Actigraphyc Actual amount of sleep, calculated as the period
from sleep onset to wake up time minus
estimated time awake in the period from sleep
onset until awake time
Dodge and
Wilson114
TST Sleep log Duration of sleep
Garstang and
Wallis69
TST Sleep chart No definition provided
Jain et al.115 Sleep efficiency Polysomnography,
actigraphyd
‘The American Academy of Sleep Medicine
standard definition was used’115
TST Polysomnography,
actigraphy, sleep diary
‘The American Academy of Sleep Medicine
standard definition was used’115
WASO Polysomnography,
actigraphyd
The sum of wake time in minutes from sleep
onset to the final awakening
continued
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TABLE 34 Child sleep-related outcomes in trials comparing melatonin with placebo (continued )
Study
Child sleep-related
outcome assessed
Method of
assessmenta Definitionsb
Sleep Behaviour
Questionnaire
Sleep Behaviour
Questionnaire
Sensory Behaviour Questionnaire includes a set of
six questions related to sleep–wake habits and a
29-item Likert-type rating scale. The subscales
include parasomnias, parent/child interaction,
sleep fragmentation, daytime drowsiness and
bedtime difficulties. The Sensory Behaviour
Questionnaire total score is considered a global
index of sleep problems, with higher scores
representing more sleep problems
Wasdell et al.117 Sleep efficiency Actigraphy, somnolog No definition provided
TST Actigraphy, somnolog For somnolog-measured TST: ‘Total night-time
sleep as recorded on care-giver completed
somnologs which provided a running record of
the time when the child was asleep or awake
during the relevant measurement period’117
Longest sleep episode Somnolog, actigraphy No definition provided
Weiss et al.70 TST Actigraphy, somnolog Total sleep duration
Wirojanan et al.119 TST Actigraphyc The time from sleep onset to wake-up time
minus the time awake during the night
Wright et al.106 TST Sleep diary No definition provided
Sleep initiation
Appleton et al.48 SOL Actigraphy, sleep diary The time taken to fall asleep; the number of
minutes between lights out/‘snuggle down’ time
and sleep start time
Cortesi et al.110 SOL Actigraphyc Inclusion criteria defined SOL as mixed sleep
onset and maintenance insomnia
Bedtime Actigraphyc No definition provided
Van der Heijden
et al.111
Difficulty falling
asleep
Sleep log Averaged score (over seven days) on an item
asking parents how difficult it was for the child
to fall asleep in the evening (1= not difficult;
5= very difficult)
Sleep onset Actigraphyc Start of a period of at least 10 minutes of
consecutively recorded immobile actigraphy data
following lights out
SOL Actigraphyc Time from lights out until sleep onset
Dodge and
Wilson114
SOL Sleep log Time taken to fall asleep
Garstang and
Wallis69
SOL Sleep chart No definition provided
Jain et al.115 SOL Polysomnography,
actigraphy (data not
reported)
The time in minutes from lights out to sleep
onset
Bedtime Sleep diary No definition provided
Wasdell et al.117 SOL Actigraphy, somnolog No definition provided
Weiss et al.70 SOL Actigraphy, somnolog The amount of time between when the child was
put to bed and when he or she fell asleep
Wirojanan et al.119 SOL Actigraphyc The time from bedtime to sleep onset time
Sleep onset Actigraphyc The clock time that the child fell asleep
Wright et al.106 SOL Sleep diary Time from start of bedtime routine to sleep
Sleep latency Sleep diary Time from drug to sleep
APPENDIX 7
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TABLE 34 Child sleep-related outcomes in trials comparing melatonin with placebo (continued )
Study
Child sleep-related
outcome assessed
Method of
assessmenta Definitionsb
Sleep maintenance
Camfield et al.113 Number of night
wakings
Sleep diary Total number of awakenings between 9.00 p.m.
and 7.00 a.m. per day/the number of days of
complete data
Nights without
awakening
Sleep diary Nights without awakening between 10.00 p.m.
and 7.00 a.m. per day/the number of days of
complete data
Van der Heijden
et al.111
Wake time Actigraphy Last epoch of actigraphically assessed immobility
before the start of a 10-minute consecutive
period of activity around the time of leaving bed
Non-specified
night-time sleep
disturbance: moving
time
Actigraphy Percentage of time spent moving during the
assumed sleep period
Dodge and
Wilson114
Number of night
wakings
Sleep log No definition provided
Garstang and
Wallis69
Number of night
wakings
Sleep chart No definition provided
Jain et al.115 Wake time Sleep diary No definition provided
Wasdell et al.117 Number of night
wakings
Actigraphy, somnolog No definition provided
Wirojanan et al.119 Number of night
wakings
Actigraphyc No definition provided
Wright et al.106 Number of night
wakings
Sleep diary No definition provided
Sleep scheduling
Cortesi et al.110 Naptime Actigraphyc No definition provided
Other outcomes
Van der Heijden
et al.111
Interdaily stability Actigraphy Degree of resemblance between the activity
patterns on individual days (range from 0 to 1,
higher values indicating more stable rhythms)
Interdaily variability Actigraphy Fragmentation of periods of rest (or sleep) and
activity (or wakefulness) (range from 0 to 2,
with higher values indicating more fragmented
rhythms)
L5 (average activity
during the least active
5 hours)
Actigraphy Average activity during the least active 5-hour
period in the average 24-hour activity rhythm
Jain et al.115 Arousal Arousal index American Academy of Sleep Medicine standard
definitions were used for arousal index. The
authors provide a reference
Percentage of sleep
stages
Sleep diary American Academy of Sleep Medicine standard
definitions were used for percentage of sleep
stages (N1, N2, N3 or REM %). The authors
provide a reference
REM, rapid eye movement.
a Various terms used for sleep diaries (logs, charts, somnologs).
b As defined by study author.
c Only reports actigraphy data; however, a sleep diary/log was used to provide verification.
d Only reports polysomnography data.
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Appendix 8 Child sleep-related outcomes in trials
comparing melatonin with melatonin
TABLE 35 Child sleep-related outcomes in trials comparing melatonin with melatonin
Study
Child sleep-related outcome
assessed
Method of
assessmenta Definitionsb
Global measures and composite scores
Hancock et al.120 TST Sleep diary No definition provided
Jan et al.121 Changes in sleep pattern Sleep charts and
parental history
Based on sleep onset, the number of
awakenings, duration of sleep and how the
children behaved the following day
Sleep initiation
Hancock et al.120 Bedtime settling: SOL Sleep diary Time taken to fall asleep
Sleep maintenance
Hancock et al.120 Night waking: number of night
wakings
Sleep diary The mean number of awakenings each night
a Various terms used for sleep diaries (logs, charts, somnologs).
b As defined by study author.
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Appendix 9 Study details for non-pharmacological
interventions
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TABLE 36 Study details for non-pharmacological interventions
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Parent-directed comprehensive tailored interventions
Parallel trials
Beresford et al.21
Associated publications:
Beresford et al.136
UK
Intervention: two face-to-face sessions for the
assessment and development of a sleep
management strategy and parent training were
given. Parents were supported to implement the
strategy via telephone calls
Control: the usual approach. As for the intervention
but implementation support was delivered via home
visits
N= 13
Home visits (n= 6):
l 2.67 years (0.82 years)
l 100% male
l ASC, 50%; LD, 16.7%; physical or
sensory disability, 16.7%; unknown/
awaiting diagnosis, 16.7%
Telephone support (n= 7):
l 2.86 years (1.07 years)
l 71% male
l ASC, 71%; LD, 14%; and physical or
sensory disability, 14%
Sleep disturbance
l Sleep initiation: bedtime resistance,
sleep anxiety
l Sleep maintenance: night wakings
Prior interventions
l Not reported
High
Hiscock et al.138
Associated publications:
Papadopoulos et al.139
Australia
Intervention: one session was given for the
assessment and development of a sleep
management strategy and parent training. Parents
were supported to implement the strategy via one
face-to-face session and one telephone call
Control: usual care
N= 244
Behavioural programme (n= 122):
l 10.3 years (1.8 years)
l 84% male
l ADHD, 100%; LD, 34%; autism
spectrum or Asperger syndrome,
23%
Usual care (n= 122):
l 9.9 years (2.1 years)
l 86% male
l ADHD, 100%; LD, 34%; and autism
spectrum or Asperger syndrome, 27%
Sleep disturbance
l ‘Moderate/severe sleep
problems’ including:
¢ Sleep initiation: sleep onset
association disorder, limit setting
disorder, delayed sleep phase,
idiopathic or psychophysiological
insomnia
Prior interventions
l None reported: an exclusion criterion
was if children were already
receiving specialist sleep input
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Johnson et al.107
Associated publications:
Turner140
USA
Intervention: one session for assessment and the
development of sleep management strategy was
given; there were five sessions for training the
parent in the strategy. Implementation support was
delivered via one face-to-face session
Control: non-sleep-related parent education
delivered in an identical manner to the intervention
group
N= 40
Behavioural parent training programme
(n = 20, data on n = 15):
l 3.51 years (0.98 years)
l 73% male
l Autism, 80%; and ASD, 20%
Non-sleep-related parent education
(n = 20, data on n = 18):
l 3.6 years (1.12 years)
l 83% male
l Autism, 94%; and ASD, 6%
Sleep disturbance
l Sleep initiation: bedtime resistance,
delayed sleep onset and sleep
association problems
l Sleep maintenance: night-time
wakings, morning waking before
5:00 a.m. and when the child
disturbed the parent or entered the
parents’ bedroom
Prior interventions
l Not reported, but exclusion criteria
included children using sleep
supplements
High
Moss et al.124
Associated publications:
O’Connell et al.141,142
Australia
Intervention: two parent training workshops,
followed by a home visit for the assessment and
development of a sleep management strategy were
given. Implementation support was delivered via
one home visit followed by telephone calls as
needed
Control: waiting list control
N= 26
Intervention and control not reported
separately
l Overall 11.74 years (2.53 years)
l Gender: not reported
l ASD, 58%; Angelman, Down and
other syndromes, 19%; intellectual
disability and global developmental
delay, 11%; blindness, 4%; and
unspecified, 8%
Sleep disturbance
l Sleep initiation: settling
l Sleep maintenance: problems with
night waking, sleep duration/
regularity, co-sleeping and early
waking
l Sleep scheduling: excessing
daytime sleepiness
l Other: snoring
Prior interventions
l One child taking melatonin,
although it is not clear if this is
for sleep
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Sciberras et al.125
Associated publications:
Sciberras et al.,143 Fulton
et al.144 and Sciberras
and Rinehart145
Australia
Intervention: two sessions for the assessment and
development of a sleep management strategy
and training parents in the strategy were given.
Implementation support was delivered via a single
telephone call followed by further face-to-face
session if needed
Control: a single session for the assessment and
development of a sleep management strategy
and training parents in the strategy was given.
No implementation support was given
N= 27
Extended behavioural programme
(n = 14):
l 12.1 years (2.2 years)
l 71% male
l ADHD, 100%
Brief behavioural programme (n= 13):
l 10.9 years (2.5 years)
l 77% male
l ADHD, 100%
Sleep disturbance
l ‘Moderate/severe sleep problem’
including:
¢ Sleep initiation – delayed sleep
phase, limit setting disorder,
anxiety, sleep onset association
disorder, insomnia
Prior interventions
l Not reported
High
Before-and-after studies
Austin et al.123
Australia
Two parent training workshops were given,
followed by a home visit for the assessment and
development of sleep management strategy,
followed by a third workshop. Implementation
support was delivered via one face-to-face session
and a telephone call
N= 8
3.9 years
100% male
Pervasive developmental disorder:
l 38% male
l ASD, 50%; and unknown, 12%
Sleep disturbance
l Sleep initiation: bedtime resistance.
Duration of sleep problems ranged
from 4 months to 2 years
l Sleep maintenance: night waking,
co-sleeping, early waking, irregular
sleep–wake cycle
Prior interventions
l Not reported
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Beresford et al.21
Associated publications:
Beresford et al.136 and
Stuttard et al.45,137
UK
Two sessions were given for the assessment and
development of sleep management strategy and
training the parents in the strategy. Implementation
support was delivered via fortnightly face-to-face
sessions
N= 12
2.88 years (1.25 years)
50% male
ASC, 25%; LD, 25%; and unknown/
awaiting diagnosis, 50%
Sleep disturbance
l Sleep initiation: bedtime resistance
and sleep anxiety
l Sleep maintenance: night wakings
Prior interventions
l Not reported
High
Quine and Wade146
Associated publications:
Wade and Wade147
UK
Two sessions were given for the assessment and
development of a sleep management strategy and
training parents in the strategy. Implementation
support delivered via face-to-face sessions
N= 25
Range 3–21 years
69% male
LD, 100%
Sleep disturbance
l Sleep initiation: night settling
problems usually ≥ 3 times a week
l Sleep maintenance: night waking
usually ≥ 3 times a week, limited
hours sleep usually ≥ 3 times a week
Prior interventions
l Not reported
High
Weiskop et al.126
Before-and-after study
with multiple baseline
Australia
Four sessions were given for the assessment and
development of a sleep management strategy and
training parents in the strategy. Implementation
support (via telephone calls) was delivered from
outset of intervention. It continued after training
sessions completed with face-to-face session and
further telephone calls
N= 13
l 5.1 years, range 1–9 years
l 77% male
l ASD: 46% (autism, 38%; Asperger
syndrome, 8%; and fragile X
syndrome, 54%)
Sleep disturbance
l Sleep initiation: difficulty settling and
bed refusal
l Sleep maintenance: night waking,
co-sleeping or waking early
Prior interventions
l One child was taking medication for
behaviour and sleep problems
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Parent-directed comprehensive non-tailored interventions
Parallel trials
Adkins et al.127
Associated publications:
Malow et al.148
USA
Intervention: training curriculum contained in a
booklet provided to parents
Control: no booklet provided
N= 36
Overall age 6.4 years (2.6 years)
Sleep education pamphlet (n = 18):
l 2–5 years, 50%; 6–10 years, 50%
l 56% male
l Autism, 89%; Asperger syndrome,
11%; and PDD-NOS, 0%
Control (no pamphlet) (n= 18):
l Aged 2–5 years, 33%; aged
6–10 years, 67%
l 78% male
l Autism, 72%; Asperger syndrome,
22%; and PDD-NOS, 6%
Sleep disturbance
l Sleep initiation: SOL of at least
30 minutes for ≥ 3 nights/week
Prior interventions
l Not reported
High
Montgomery et al.49
Associated publications:
Montgomery et al.49
UK
Intervention a: a training curriculum was contained
in a booklet provided to parent
Intervention b: a training curriculum (content
identical to intervention a) was delivered via a
face-to-face session
Control: there was no intervention for 6 weeks, at
which point they were re-randomised into an active
treatment group
N= 66
Overall age range: 27–101 months
64% male
Brief treatment (n = 22):
l Age: not reported
l Gender: not reported
l (Not mutually exclusive): autism,
18%; Down syndrome, 9%; global
developmental delay, 5%; epilepsy,
5%; other, 20%; no diagnosis, 46%
Sleep disturbance
Present for at least 3 months and not
because of physical problem:
l Sleep initiation: settling problems
≥ 3 times a week in which the child
takes more than 1 hour to settle and
is disturbing the parents
l Sleep maintenance: night waking
≥ 3 times a week and when the
child disturbs parents and/or goes
into parents’ room/bed
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Conventional treatment (n = 34):
l Age: not reported
l Gender: not reported
l (Not mutually exclusive): autism,
35%; Down syndrome, 15%; global
developmental delay, 10%; epilepsy,
5%; other, 20%; no diagnosis, 20%
Control (n = 26):
l Age: not reported
l Gender: not reported
l (Not mutually exclusive): autism,
42%; Down syndrome, 8%; global
developmental delay, 8%; epilepsy,
8%; other, 15%; no diagnosis, 17%
Prior interventions
l Not reported
Malow et al.128
USA
Intervention: the training curriculum was delivered
via two group-delivered sessions. Implementation
support was delivered via telephone calls
Control: training curriculum delivered via single,
face-to-face session. Implementation support was
delivered via telephone calls
N= 80
Group-delivered parent education
programme (n= 39):
l 5.9 years (2.8 years)
l 64% male
l Autism, 67%; Asperger syndrome,
13%; and PDD-NOS, 5%
Individual-delivered parent education
programme (n= 41):
l 5.6 years (2.6 years)
l 95% male
l Autism, 78%; Asperger syndrome,
27%; and PDD-NOS, 9%
Sleep disturbance
l Sleep initiation: SOL > 30 minutes
for ≥ 3 nights/week
Prior interventions
l Not reported
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Before-and-after studies
Beresford et al.21
Associated publications:
Beresford et al.136 and
Stuttard et al.45,137
UK
Group delivery of a training curriculum over four
sessions
N= 22
8.91 years (3.25 years)
50% male
ASC, 64%; LD, 27%; physical or sensory
disability, 4%; and no diagnosis, 4%
Sleep disturbance
l Sleep initiation: bedtime resistance,
sleep anxiety and night wakings
Prior interventions
l Not reported
High
Beresford et al.21
Associated publications:
Beresford et al.136 and
Stuttard et al.45,137
UK
A training curriculum delivered via a single half-day
workshop
N= 25
7 years (3.30 years)
64% male
ASC, 36%; LD, 16%; physical or sensory
disability, 16%; and ASC other, 20%
Sleep disturbance
l Sleep initiation: bedtime resistance
and sleep anxiety
l Sleep maintenance: night wakings
Prior interventions
l Not reported
High
Bramble149
Associated publications:
Bramble122
UK
A training curriculum delivered via a single session.
Implementation support was delivered via telephone
calls
N= 15
7.2 years (2.6 years)
67% male
All severe learning disability, aetiological
factor known for 60%: Down syndrome,
20%; macrocephaly, 7%; Angelman
syndrome, 7%; Smith–Magenis
syndrome, 7%; carcinuria:, 7%; perinatal
cerebral anoxia, 7%; and cerebral
leucodystrophy, 7%
Sleep disturbance
l Sleep initiation: severe night settling
(taking ≥ 1 hour to settle)
l Sleep maintenance: night waking
problems (most nights of the week
and disturbing parents during the
night). Sleep problems to be present
for at least 1 year
Prior interventions
l Previous interventions indicated but
not described other than sedatives
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Reed et al.129
Associated publications:
Reed et al.150
Canada
Group delivery of a training curriculum over three
sessions
N= 22
5.8 years (2.7 years)
82% male
ASD, 100%
Sleep disturbance
l Sleep initiation: difficulty
falling asleep
l Sleep maintenance: night wakings
and early morning wakings
Prior interventions
l Not reported
Unclear
Yu et al.151
Hong Kong
Group delivery of a training curriculum over three
sessions, supported by weekly telephone calls.
Implementation support was delivered by telephone
calls
N= 54
4.78 years (0.85 years)
79.6% male
ASD, 96%; and Asperger syndrome, 2%
Sleep disturbance
l Sleep initiation: bedtime resistance
and difficulty initiating sleep (delayed
by > 1 hour)
l Sleep maintenance: night-time
waking that disturbed parents and
early wake time (earlier than 06.00)
Prior interventions
l Not reported
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Non-comprehensive parent-directed interventions
Cluster trials
Wiggs and Stores152
Associated publications:
Wiggs and Stores153,154
UK
Intervention: a tailored intervention. There was a
single session for the assessment and development
of a sleep management strategy and training the
parent in the strategy. Implementation support was
delivered via telephone calls
Control: no intervention
N= 30
Individually tailored behavioural
programme (n= 15):
l 8.21 years (2.7 years)
l 60% male
l Unknown, 40%; unknown + autism,
27%; Down syndrome, 7%;
meningitis, 7%; microcephaly, 7%;
cerebral palsy, 7%; and CHARGE
association, 7%. In addition, 33%
had epilepsy (absence, 7%; tonic
clonic, 13%; absence and tonic
clonic, 7%; and atonic, 7%)
Control (n = 15):
l 10.77 years (3.81 years)
l 60% male
l Unknown, 27%; unknown + autism,
20%; Down syndrome, 20%;
agenesis of the corpus callosum,
7%; Sanfillipo syndrome, 7%; Ring
15 chromosome disorder, 7%; and
cerebral palsy, 13%. In addition,
40% had epilepsy (absence, 7%;
tonic clonic, 13%; tonic, 7%; tonic
clonic and complex partial, 7%;
and tonic, complex partial and
absence, 7%)
Sleep disturbance
‘Severe problems’ defined as:
l Sleep initiation: settling problems
occurring ≥ 3 times/week, taking
> 1 hour to settle and fall asleep
l Sleep maintenance: when parents
were disturbed, night waking
occurring ≥ 3 times/week; when
duration of wake was more than a
few minutes and parents were
disturbed, waking before 5 a.m.
≥ 3 times/week
Prior interventions
l Not reported
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Before-and-after study
Peppers et al.155
USA
Prescriptive sleep hygiene advice delivered in a
single session
N= 23
Prescriptive sleep hygiene intervention
(n = 23):
l Age: not reported
l 57% male
l ADHD, 87%; and ADD, 13%
Control (n = 30):
l Age: not reported
l Gender: not reported
l Diagnosis: not reported
Sleep disturbance
l A score of ≥ 42 on the sleep
assessment tool (intervention group)
l A score of ≤ 41 on the sleep
assessment tool (control group)
High
Other non-pharmacological interventions
Parallel trials
Piazza et al.157
USA
Intervention: FBRC, for 10 days. The study author
delivered the face-to-face (home visits) and booklet
intervention
Control: bedtime scheduling
N= 14
FBRC (n = 7):
l 6.7 years (2.6 years)
l Gender: not reported
l All moderate to profound
developmental disability. In addition
(not mutually exclusive): PDD, 14%;
cerebral palsy, 14%; Down
syndrome, 14%; Prada-Willi, 14%;
sleep apnoea, 14%; mixed motor
encephalopathy, 14%; autism, 29%;
and seizure disorder, 14%
Bedtime scheduling (n = 7):
l 8.3 years (3.0 years)
l Gender: not reported
Sleep disturbance
l Sleep maintenance: sleeping for at
least 10% less than what is expected
for age, including night and early
waking
l Sleep initiation: delayed sleep onset
Prior interventions
l Children were excluded if they
were receiving pharmacological
interventions for sleep. No other
previous interventions reported
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
l All moderate to profound
developmental disability. In addition
(not mutually exclusive): cerebral
palsy, 29%; seizure disorder, 71%;
Down syndrome, 14%; and
autism, 29%
Crossover trials
Francis and Dempster156
Australia
Intervention: valerian: 500mg per tablet, 30 mg per
kilogram of body weight as a single nightly dose at
least 1 hour before bedtime, taken for 2 weeks
Control: to give the same appearance and odour,
the placebo contained 25mg of whole room
V. edulis extract, taken for 2 weeks
N= 5
Age range: 7–14 years
100% male
Moderate intellectual disability, 40%;
mild to moderate intellectual disability,
20%; genetic disorder, 20%; episodic
fibril convulsions, 20%; hyperactivity and
behaviour problems, 20%; ADD, 20%;
and ADHD, 20%
Sleep disturbance
‘Significant sleep problems’ including:
l Sleep initiation: sleep initiation
l Sleep maintenance: sleep
maintenance, co-sleeping and
morning waking
Prior interventions
l Not reported
High
Gringras et al.36
Associated publications:
Gringras et al.36
UK
Intervention: a weighted blanket. The blanket
weight was 2.25 kg (small) or 4.5 kg (large).
Blankets used for 12–16 days and were given by
researchers at home/clinic visits
Control: a placebo blanket
N= 73
Intervention + control (n= 36):
l 8.7 years (3.3 years)
l 78% male
l Autism: 22%; Asperger syndrome:
44%; and ASD: 22%
Control and intervention (n= 37):
l 9.9 years (2.8 years)
l 70% male
l Autism, 35%; Asperger syndrome,
46%; and ASD, 14%
Sleep disturbance
l Sleep initiation: delayed sleep onset
and/or
l Sleep maintenance: poor sleep
maintenance
Prior interventions
l Not reported
High
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Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Before-and-after studies
Guilleminault et al.158
USA
Light therapy+ behavioural programme. Light
exposure was given daily at 07.00 and 12.00 for
45 minutes (the overall treatment duration, setting
and practitioner unclear)
N= 142.9 years, range 9 months to
4 years
57% male
Moderate to severe learning disabilities,
100%
Sleep disturbance
l Sleep maintenance: nocturnal
sleep disturbances
l Other: ‘lack of sleep consolidation’
Prior interventions
l Sleep medications not otherwise
detailed. Eight children had attended
sleep clinics and centres for
treatment. Behavioural treatment
had been implemented with some of
the children
High
Oriel et al.159
A–B–A withdrawal
design
USA
An aquatic exercise programme. 60 minutes of
aquatic exercise was undertaken two times per
week
N= 8
8.88 years, range 6–11 years
63% male
ASD, 100%
Sleep disturbance
l Parent/guardian report of sleep
dysfunction
Prior interventions
l Children who had complex medical
comorbidity in addition to ASD, or
any other developmental disorders
were excluded
High
continued
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TABLE 36 Study details for non-pharmacological interventions (continued )
Study details and
study design Intervention details
Participant characteristics: number
randomised (N), mean age (SD);
% male; % diagnosis
Type of sleep disturbance/prior sleep
interventions
Risk of bias
(low, unclear
or high)
Yehuda et al.160
Controlled before-and-
after study
Israel
Intervention: essential fatty acids supplement that
comprised 90 g of α-linolenic and 360 g of linoleic
acid in mineral oil. Two capsules per day for
10 weeks
Control: placebo (and healthy control group)
N= 78
Essential fatty acid supplement (n= 40):
l Age range (across intervention and
control): 9–12 years
l 100% male
l ADHD: 100%
ADHD control (n= 38):
l 100% male
l ADHD: 100%
Healthy control (n = 22):
l 22% male
Sleep disturbance
‘Sleep deprived’
Prior interventions
Not reported
Unclear
Yu and Hong161
China
Acupuncture and ear-point taping. Two courses
of acupuncture treatment were given once every
other day, three times a week, with 36 sessions
constituting one course. Ear-point taping was given
three times a week, with 36 sessions constituting
one course. Two courses were required
N= 30
6.9 years (3.1 years)
77% male
Learning disabilities, 100%
Sleep disturbance
Sleep restlessness including:
l Sleep initiation: sleep ‘starting’,
circadian rhythm derangement
l Sleep maintenance: sleep ‘keeping’
l Other: abnormal sleep state
(including apnoea)
Prior interventions
l Not reported
High
ADD, attention deficit disorder; CHARGE, coloboma, heart defects, atresia choanae (also known as choanal atresia), growth retardation, genital abnormalities, and ear abnormalities;
FBRC, faded bedtime with response cost; LD, learning disability; PDD, Pervasive Developmental Disorder; PDD-NOS, Pervasive Developmental Disorder Not Otherwise Specified.
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TABLE 37 Intervention and control details: non-pharmacological studies
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Tailored interventions
Study objective: evaluation of intervention clinical effectiveness
Parallel trials
Hiscock et al.
138
Individual (face to face
and telephone)
Intervention:
l 1 × face-to-face
session
Implementation support:
l 1 × face-to-face
session
l 1 × telephone call:
offered 2 weeks
after the second
face-to-face session
Control:
l Usual care
Intervention:
l Intervention period:
4 weeks
l Face-to-face sessions
(n= 2): duration
not reported
l Telephone calls
(n= 1): duration of
calls not reported
Intervention:
l Session 1: assessment; identification
of parent goals; sleep education
(normal sleep, sleep cycles and sleep
hygiene strategies); formulation of a
behavioural sleep management plan
tailored to the child’s sleep problem
l Session 2: review of the sleep diary;
reinforcement of the management
plan created in Session 1; ‘trouble
shoot any problems’
l Telephone call: review of sleep
diary; reinforce management plan
created in Session 1; trouble shoot
any problems
N/A ADHD Paediatrican’s
office, hospital
clinic or home
Psychologist or
consultant paediatrician
Johnson et al.
107
Individual (face to face) Intervention:
l 4 × face-to-face
sessions
Implementation support:
l 1 × face-to-face
session
Control:
l Non-sleep-related
parent education
Intervention:
l Intervention period:
unclear
l Face-to-face sessions
(n= 5) at 1–1.5 hours;
the spacing of the
sessions was not
reported
Control:
l Intervention period:
unclear
l Face-to-face sessions
(n=5) at 1–1.5 hours;
the spacing of the
sessions was not
reported
Intervention:
l Session 1: basic behavioural
principles
l Session 2: addressing prevention
techniques and bedtime routines
l Session 3: addressing reinforcement
and extinction procedures for
bedtime struggles, night
awakenings and early morning
awakenings
l Session 4: addressing delayed sleep
onset and sleep association
procedures
l Session 5: booster and maintenance
session
N/A ADHD Clinic Masters-level doctoral
students or senior
behavioural analyst
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Session content tailored to the family’s
specific needs and ‘a cumulative bedtime
and sleep intervention plan developed’,
modified as needed over the intervention
period
[A detailed overview of the sessions and
content of the control were provided in
the paper]
Moss et al.
124
Group and individual
(face to face and
telephone)
Intervention:
232
l 2 ×workshops
(group size 5–7)
Published as
The Sleepwise
Program
232
l 1 × face-to-face
session
Implementation support:
l 1 × face-to-face
session
l Telephone calls
provided on a
needs basis
Control:
l Waiting list
Intervention:
l Intervention
period: unclear
l Workshops (n= 2) at
3 hours
l Face-to-face sessions
(n= 2): duration
not reported
l Telephone calls:
duration of calls not
reported. Provided on
a ‘needs basis’
Intervention:
l Workshop 1: on typical sleep, the
nature of sleep and factors affecting
sleep, positive sleep practices, types
of sleep disturbance; a sleep diary
was completed for homework
l Workshop 2: on managing sleep
disturbance and developing a
sleep plan
l Face-to-face session 1: sleep
interview (i.e. assessment),
observation of child’s sleep
environment and problem-solving
for the sleep plan; the sleep plan
was produced
l Face-to-face session 2:
implementation of sleep plan
l Telephone calls: ongoing support
regarding implementation of sleep
plan
[A detailed overview of workshop
content is provided in the paper]
N/A No Workshop:
not stated
Face-to-face
sessions:
home
Allied health workers
continued
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Before-and-after studies
Austin et al.
123
Group and individual
(face to face and
telephone)
Intervention:
232
l Published as
The Sleepwise
Program
232
l 2 ×workshops
(group size 6)
l 1 × face-to-face
session
l 1 ×workshop
l Implementation
support: weekly
telephone calls
Intervention period:
15 weeks
Workshops (n= 3) at
3 hours each
Face-to-face sessions
(n= 1): at ≈2 hours
(Workshops 1 and 2 were
2 weeks apart; the face-
to-face session was a
week later; and workshop
3 was a week after that)
Telephone calls: duration
of calls not reported;
delivered weekly for
6 weeks
l Workshop 1: on typical sleep, the
development of sleep, sleep cycles,
nature of sleep, factors influencing
children’s sleep patterns, need for
sleep and positive sleep practices
l Workshop 2: on causes of sleep
disturbance, prevalence of sleep
disturbance, types of sleep
disturbance disorders and
preparation for starting a sleep plan
l Face-to-face session 1: sleep
interview (i.e. comprehensive sleep
assessment) and observation of
child’s bedroom environment
l Workshop 3: positive sleep
practices, establishing a bedtime
routine, sensory, behavioural and
communication approaches, positive
reinforcement, goal-setting and the
development of a sleep plan
l Telephone calls: provide ongoing
support as parents implement the
sleep plan
N/A No Workshops:
not stated
Face-to-face
session: home
Psychologist or
manager of early
intervention centre
Beresford et al.
21
Individual (face to face) 2 × face-to-face sessions
Implementation support:
face-to-face sessions –
number determined by
progress
Intervention period:
variable, usually
12–16 weeks
Face-to-face sessions
(n= variable): duration not
reported
l Sessions 1 and 2: assessment, home
visit sleep strategy created and
parent education and training in
sleep strategy
l Sessions 3 onwards: supporting
implementation of sleep strategy
The number of sessions is directed by
progress towards the outcomes
N/A No Community
centre and
home
Community-based
disability link workers
A
P
P
E
N
D
IX
1
0
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
1
8
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Quine and Wade
146
Individual (face to face) 2 × face-to-face sessions
Implementation support:
face-to-face sessions –
number determined by
progress
Intervention period:
variable, 6–28 weeks
Face-to-face sessions
(n= variable): duration not
reported. They took place
weekly, but after session
3, the authors sought to
increase the spacing of
the sessions
l Session 1: assessment and
parent education
l Session 2: (sleep) training
programme devised and parents
trained in implementation
l Session 3 onwards: supporting the
implementation of the sleep
strategy
The number of sessions is directed by
progress towards the outcomes
N/A No Home Health professional:
health visitor,
community nurse or
district nurse, school
nurse
Weiksop et al.
126
Individual (face to face
and telephone)
4 × face-to-face sessions
Implementation support:
1 × face-to-face session
Telephone calls weekly
after session 4,
diminishing in intensity
after session 5
Intervention period:
minimum 7 weeks
Face-to-face session 1:
duration not reported
Face-to-face sessions 2–4:
duration not reported;
consecutive weeks
Face-to-face session 5:
duration not reported;
delivered 5 weeks after
session 4
l Session 1: assessment
l Session 2: goal-setting, parent
education and creation of sleep
hygiene/bedtime routine strategy
l Session 3: parent education
(supporting consistent parenting
and positive problem-solving)
l Session 4: training in three extinction
techniques, and the parent chooses
the specific technique that they will
implement – further training is given
in chosen technique
l Session 5: review of progress
N/A No Home and
clinic
‘Therapist’
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Study objective: comparative evaluation of modes of delivering implementation support [home visit (arm a) vs. telephone call (arm b)]
Parallel trial
Beresford et al.
21
Arm A: individual
(face to face)
Arm B: individual (face
to face and telephone)
Arm A:
l 1 × face-to-face
session
l Implementation
support: face-to-face
sessions
approximately
weekly over a 6- to
8-week period;
number determined
by progress
Arm B:
l 1 × face-to-face
session
l Implementation
support:
telephone calls
approximately
weekly
Arm A:
l Intervention period:
variable, ≈10 weeks
l Face-to-face sessions
(n= 1+ variable):
duration of sessions
not reported;
implementation
support sessions
were delivered
approximately
weekly, over a 6- to
8-week period
Arm B:
l Intervention period:
variable, ≈10 weeks
l Face-to-face session
(n= 1): duration of
session not reported
l Telephone calls
(n= variable):
duration of calls not
reported; delivered
approximately weekly,
over a 6- to 8-week
period
l Session 1 (arms A and B):
comprehensive sleep assessment,
development of sleep management
strategy and parent education and
training in strategy
l Sessions 2 onwards (arm A only):
support with implementation of
sleep strategy
l Telephone calls (arm B only):
support with implementation of
sleep strategy
N/A No Home Specialist health visitors
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Study objective: comparative evaluation of intervention intensity (brief vs. extended)
Parallel trial
Sciberras et al.
143
Brief intervention:
individual (face to face)
Extended intervention:
individual (face to face
and telephone)
Brief intervention:
l 1 × face-to-face
session
Extended intervention:
l 2 × face-to-face
sessions
Implementation support:
l 1 × telephone call
l Further face-to-face
session if required
Brief intervention:
l Intervention period:
a single face-to-face
session
l Face-to-face session
(n= 1) at 45 minutes
Extended intervention:
l Intervention period:
4 weeks
l Face-to-face sessions
(n= 2) at 45 minutes,
1 week apart
l Telephone call
(n= 1): duration not
reported; delivered
2 weeks later
Brief and extended intervention:
l Described as ‘a behavioral sleep
program’
143
(p. 933). The content of
the written material used and
developed to supplement sessions
suggests that the face-to-face
session(s) covered: ‘normal sleep,
healthy sleep hygiene practices and
standard clinical strategies for
managing sleep problems’
143
(p. 933)
Extended only:
l Telephone call: described as a
‘follow-up call’
143
(p. 933)
N/A ADHD Hospital Paediatric trainee or
child psychologist
Non-tailored interventions
Study objective: evaluation of intervention effectiveness
Parallel trial
Adkins et al.
127
Written material Intervention:
l Provision of a
‘sleep education
pamphlet’ to parents
(four pages)
Implementation support:
l None
Control:
l No pamphlet
N/A Intervention:
l The topics covered in the pamphlet
were ‘providing a comfortable sleep
setting; establishing regular bedtime
habits; keeping a regular schedule;
teaching your child to fall asleep
alone; avoiding naps (in children
who have outgrown the need for a
daytime nap); encouraging daytime
activities that promote a better
sleep/wake schedule.’
127
(p. S140)
N/A ADHD N/A N/A
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Before-and-after studies
Beresford et al.
21
Group 4 ×workshops
(maximum group size 8)
Implementation support:
none except that
included in workshop
curriculum
Intervention period:
5 weeks
Workshops (n= 4) at
3 hours; delivered over a
5-week period
Workshop 1: ‘children’s sleep;
behavioural approaches to behaviour
management; positive and negative
reinforcers; communication’
21
Workshop 2: ‘sleep routines; structuring
bedtime; using reinforcers to manage
behaviour; planning bedtime routines:
bedroom environment’
21
Workshop 3: ‘principles of behavioural
analysis then applied to children’s sleep
problems’
21
Workshop 4: ‘specific strategies to
manage sleep problem behaviours; the
use of medication’
21
Yes No Community
setting
Staff based in Learning
Disability Child Mental
Health Service
Beresford et al.
21
Group 1 ×workshop (maximum
group size 20).
233
(www.
scope.org.uk/support/
services-directory/sleep-
solutions-training-for-
families; accessed
20 April 2016)
Implementation support:
none
Intervention period: a
single face-to-face session
Face-to-face session (n= 1)
at 5 hours
Workshop topics: ‘the impact of sleep
disorders; your existing routine; the
bedroom environment; does your child’s
impairment matter?; techniques, tips and
resources; making a change, when the
time is right’
21
No No Community
setting
Staff trained in
managing sleep
disturbance and
working for Scope UK
(a UK charity for
children with cerebral
palsy and their families)
Bramble
149
Individual (face to face
and telephone)
1 × face-to-face session
Implementation support:
telephone calls delivered
on 3 consecutive days
after the face-to-face
session, with additional
calls arranged, if
necessary, for up to
2 weeks
Intervention period: up to
2 weeks
Face-to-face session
(n= 1): duration not
reported
Telephone calls
(n= variable): duration not
reported. Delivered 3
consecutive days after
face-to-face session, with
additional calls arranged if
necessary for up to 2 weeks
Session 1: education in children’s sleep and
behaviour modification based on the
following principles: ‘setting regular bed and
wake times; establishing routines; setting
appropriate mood for sleep; rapid settling of
child at bedtime; parental withdrawal after
settling; ignoring protestations; returning
child to room with minimal contact;
rewarding and praising improved morning
and night-time behaviour’
149
(p. 544)
The content of the session was subject to
minimal adaptation only in specific cases
N/A No Clinic or home Consultant psychiatrist
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Telephone calls: provided support to parents
as they changed the ways that they
managed sleep disturbance
Reed et al.
129
Group 3 ×workshops (group
size 3–5)
Implementation support:
none except that
included in workshop
curriculum
Intervention period:
3 weeks
Workshops (n= 3):
at 2 hours; delivered over
consecutive weeks
Workshop 1: establishing daytime and
night-time habits and the child’s bedtime
routine
Workshop 2: minimising night wakings
and early morning awakenings
Workshop 3: addressing individualized
sleep concerns
129
(pp. 939–40)
[A detailed overview of the workshop
content is provided in the paper]
Yes ASD Not reported Neurology sleep
specialist, with
assistance from a
nurse educator and
educational consultant
Yu et al.
151
Group and individual
(telephone)
3 ×workshops
(maximum group size 8)
Implementation support:
telephone calls weekly
for the entire
intervention period
Intervention period:
7 weeks
Workshops (n= 3):
duration not reported;
delivered over consecutive
weeks
Telephone calls (n= 7):
weekly for entire
intervention period;
duration of calls not
reported
Workshop 1: ASD and sleep; impacts;
sleep hygiene
Workshop 2: promoting sleep –
behavioural approaches
Workshop 3: other concerns; sleep
medication for sleep problems
Telephone calls: offer parents immediate
support post workshop, answer enquiries
and gain feedback
Yes ASD Not reported Trained research nurse
continued
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Study objective: comparative evaluation of mode of intervention delivery vs. no intervention
Parallel trial
Montgomery et al.
49
Arm A: written
material
Arm B: individual
(face to face)
Arm A:
l Provision of a
14-page easy-to-
read, illustrated
booklet
l Implementation
support: none
Arm B:
l 1 × face-to-face
session delivering
same material as
covered in booked
(conventional
approach)
l Implementation
support: none
Arm C (control):
l No intervention
Arm A:
l Intervention period:
N/A
Arm B:
l Intervention period:
a single face-to-face
session
l Face-to-face session
(n= 1): at 90 minutes
Arms A and B:
l Topics covered: ‘normal sleep;
introduction to behavioural techniques
in general; monitoring behaviour;
good sleep habits; specific techniques
for changing undesirable behaviour’
49
(p. 126)
[A detailed overview of content provided
in paper]
N/A No Arm A:
l Home
Arm B:
l Home
Arms A and B:
l Member of
research team
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Study objective: comparative evaluation of alternative modes of intervention delivery
Parallel trial
Malow et al.
128
Arm A: group and
individual (telephone)
Arm B: individual (face
to face and telephone)
Arm A:
l 1 ×workshop
(group size 2–4)
l 1 × telephone call
l 1 ×workshop
l 1 × telephone call
l Implementation
support: telephone
calls – delivered
after each workshop
Arm B:
l 1 × face-to-face
session
l Implementation
support: telephone
calls: within 2 weeks
of receiving the
face-to-face session
Arm A:
l Intervention
period: unclear
l Workshops (n= 2):
at 2 hours
l Telephone calls
(n= 2): duration not
reported; calls
delivered after each
workshop
Arm B:
l Intervention period:
2 weeks
l Face-to-face session
(n= 1) at 1 hour
l Telephone calls
(n= 2): duration not
reported; delivered
within 2 weeks of
face-to-face session
and 1 week apart
Arms A and B:
l ‘Major areas covered in sessions
were: sleep hygiene (including
daytime and evening habits and the
sleep environment); sleep amount/
timing/regularity; bedtime routine;
strategies related to minimizing
bedtime resistance, night wakings,
co-sleeping (including graduated
extinction, bedtime pass)’
128
(pp. 219–220)
l Telephone calls: described as
‘educational phone calls . . . to
review questions and answer any
questions parents may have’
128
(p. 220)
[A detailed overview of content provided
in paper. Same curriculum as Reed et al.
129
but aspects of intervention delivery differ]
Group delivery
only: were parents
supported to apply
learning to their
own child?’: Yes
ADHD Arm A:
l Not
reported
Arm B:
l Not
reported
Arms A and B:
l ‘Trained
educators’
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Non-comprehensive parent-directed interventions
Tailored intervention: content restricted to behavioural principles of managing problem behaviour
Study objective: evaluation of intervention clinical effectiveness (intervention vs. attention control)
Parallel trial
Wiggs and Stores
152
Intervention: individual
(face to face and
telephone)
Attention control:
individual (face to face)
Intervention:
l 1 × face-to-face
session
l Implementation
support: telephone
calls at least weekly
Attention control:
l 1 × face-to-face
session
l Implementation
support: none
Intervention:
l Intervention period:
variable, up to
3 months
l Face-to-face session
(n= 1) at 1–2.5 hours
l Telephone calls:
l (n= variable); at least
weekly, and for up to
3 months
l Duration of call not
reported
Attention control:
l Intervention period:
single face-to-face
session
l Face-to-face session
(n= 1) at 1–2.5 hours
Intervention:
l Face-to-face session: ‘functional
assessment of problem;
identification of parents’ aims of
treatment, discussion of possible
mechanisms maintaining settling
and waking problems; discussion of
therapeutic techniques . . . practical
application; identification and
anticipation of particular problems
with intervention; identification of
targets for first stage’
152
l Telephone calls: to monitor
progress, encourage, discuss any
problems and amend programme as
necessary. Parents also told could
telephone researcher at any time
(this rarely happened)’
152
(p. 121)
Attention control:
l Content not described
N/A No Both arms:
l Home
‘The researcher’
A
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Tailored intervention: content restricted to sleep hygiene
Before-and-after study
Peppers
155
Individual (face to face) Intervention:
l 1 × face-to-face
session
l Implementation
support: none
Intervention period: a
single face-to-face session
Face-to-face session
(n= 1): duration not
reported
Session content:
1. The parent/caregiver and child view
6-minute standardised sleep hygiene
video (see p. e44 for content)
2. Opportunity to discuss the video and
key aspects of the sleep hygiene routine
with practitioner
3. Development of a patient specific
sleep hygiene routine, then embedded
in the electronic health record for
documentation
4. Provision of a written copy of the
patient specific sleep hygiene routine’
155
(p. e46)
N/A ADHD Clinic Physician or nurse
practitioner
Other non-pharmacological interventions
Parallel trials
Piazza et al.
157
Individual (face to face) Intervention:
l Faded bedtime and
response costs
Control:
l Bedtime scheduling
‘Average treatment length
8 weeks’
Faded bedtime with response cost
involved establishing a bedtime in which
it was likely that the child would fall
asleep within 15 minutes. Response cost
involved keeping the child awake for
1 hour if they did not fall asleep within
15 minutes of bedtime
Bedtime reduced by half an hour each
night, if the child fell asleep within
15 minutes of bedtime the previous
night. Bedtime increased by half an hour
if the child did not fall asleep within
15 minutes the previous night
N/A No Hospital Not specified
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TABLE 37 Intervention and control details: non-pharmacological studies (continued )
Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Crossover trials
Francis and
Dempster
156
Individual (face to face) Intervention:
l Valerian tablet
Control:
l Placebo tablet
Treatment A: 2 weeks
Washout period 1: 1 week
Treatment B: 2 weeks
Washout period 2: 1 week
Intervention:
l Valerian tablet. 500mg per tablet.
30mg per kilogram of body weight
as a single nightly dose 1 hour
before bedtime, taken for 2 weeks
Control:
l To give the same appearance and
odour, the placebo tablet contained
25mg of whole room V. edulis extract
N/A No Tablets
administered
at home
Parent administered
tablets to child
Gringas et al.
36
Not explicitly stated,
reasons for using
weighted blankets
‘the deep pressure and
more consistent
sensory input provided
by weighted items
reduces the body’s
physiological level of
arousal and stress,
which might improve
sleep’
Intervention:
l Weighted blanket
and additional
clinic/home visit
Control:
l Placebo blanket
At baseline, participants
received a weighted
blanket, which was
used for 12–16 days
At 2-week follow-up,
the initial blanket was
removed and the
alternative blanket was
provided and used for
12–16 days
Intervention:
l During a home or clinic visit,
children were given a weighted
blanket at baseline and it was used
for 12–16 days. Blankets weighed
2.25 kg (small) or 4.5 kg (large).
Additional clinic/home visit
Control:
l During a home or clinic visit,
children were given a control
blanket at baseline and it was used
for 12–16 days. Blankets weighed
2.25 kg (small) or 4.5 kg (large)
N/A No Blankets
received at
home or clinic
Visits were at
home or in a
clinic. Blankets
used at child’s
home
Researchers
Before-and-after studies
Guilleminault et al.
158
Individual Intervention:
l Light therapy and
behavioural
programme
Overall treatment
duration: unclear
Light exposure duration:
daily at 7 a.m. and
12 a.m. for 45 minutes
Light therapy and behavioural programme
Children were exposed to bright light
(sunlight or artificial)
A behavioural programme was also
implemented and involved scheduled
parent child interaction, scheduled naps
for younger children, avoidance of naps
for older children, scheduled lunch and
scheduled sleep time
N/A No Unclear Unclear
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Study
Mode of delivery:
active arm(s)
Intervention overview:
the chronological
order of delivery
The intervention period;
the duration of each
parent–practitioner
contact; intensity Content of the intervention
Group delivery
only: were parents
supported to
apply learning to
their own child?
For a
specific
ND? Location Who delivered it?
Oriel et al.
159
Group Intervention:
l Aquatic exercise
programme
Intervention: 60 minutes
of aquatic exercise two
times per week
Aquatic exercise programme:
l During all three phases of the study,
the researchers made telephone
calls to the parents/guardians
questioning them about their child’s
previous night of sleep (two times
per week)
l The programme consisted of warm-up
exercises, upper and lower extremity
circuits, cardiovascular exercises, a
game, which included red light–green
light, keep away or sharks and
minnows; free swim in which the
participants were given the
opportunity to play with toys and cool-
down. Participants were continuously
encouraged to remain active
throughout the entire session
No No Not specified It is not clear who
delivered exercise
programme – each
participant was paired
with a researcher or
volunteer
Yehuda et al.
160
Individual Intervention:
l Essential fatty acids
supplement
Control:
l placebo (and a
healthy control
group)
Two capsules per day for
10 weeks
Intervention:
l Essential fatty acid supplement, which
comprised 90g of α-linolenic and
360 g of linoleic acid in mineral oil
Control:
l A placebo, which was mineral oil in
an identical capsule
No No Not specified Not specified
Yu and Hong
161
Individual Intervention:
l Acupuncture and
ear-point taping
Two courses of
acupuncture treatment
were given once every
other day, three times a
week, with 36 sessions’
constituting one course
Ear-point taping was given
three times a week with
36 sessions constituting
one course. Two courses
were required
See full paper for technical details of
acupuncture and ear-point taping
No No Not specified Not specified
N/A, not applicable.
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Appendix 11 Child-related outcomes for studies
evaluating parent-directed tailored interventions
TABLE 38 Child-related outcomes for studies evaluating parent-directed tailored interventions
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Global measures and composite scores
Austin
et al.123
CSHQ CSHQ (total score) The CSHQ was used to measure overall total sleep
disturbance in children aged 4–12 years. Subscales include
bedtime resistance, sleep onset delay, sleep duration, sleep
anxiety, night wakings, parasomnias, sleep disordered
breathing and daytime sleepiness. There were 33 items rated
on a three-point Likert scale. The authors provide a reference
Beresford
et al.21
CSHQ CSHQ (total score and
subscales)
The CSHQ was used to assess the severity of sleep
problems in children aged 4–10 years. Parent reported.
Subscales include bedtime resistance, sleep onset
delay, sleep duration, sleep anxiety, night wakings,
parasomnias, sleep disordered breathing and daytime
sleepiness. The authors provide a reference
Parent-set child sleep
goal(s)
Parent-set child sleep
goal(s)
A 10-point scale captured progress towards goals.
Parents identified up to three goals during session 1.
The authors provide a reference
Beresford
et al.21
CSHQ CSHQ (total score and
subscales)
The CSHQ was used to assess the severity of sleep
problems in children aged 4–10 years. Parent reported.
Subscales include bedtime resistance, sleep onset
delay, sleep duration, sleep anxiety, night wakings,
parasomnias, sleep disordered breathing and daytime
sleepiness. The authors provide a reference
Parent-set child sleep
goal(s)
Parent-set child sleep
goals
A 10-point scale captured progress towards goals.
Parents identified up to three goals during session 1.
The authors provide a reference
Hiscock
et al.138
CSHQ CSHQ (total score) The CSHQ was used, a validated 33-item parent-reported
measure of difficulties initiating and maintaining sleep
over the past week. The maximum total score was 99.
The authors provide a reference
Sleep efficiency Actigraphy The ratio of time asleep to time spent in bed
TST Actigraphy The duration of night-time sleep
Johnson,
et al.107
Composite sleep
index (bedtime
resistance, night
waking, early waking,
sleeping in places
other than bed)
Composite sleep index
of the modified version
of the Simonds and
Parraga Sleep
Questionnaire
A modified version of the Simon and Parraga Sleep
Questionnaire completed by child’s primary caregiver. The
Total Composite Sleep Index score ranged from 0 to 12.
It was calculated by assigning a score to the frequency
of targeted sleep problems: bedtime resistance, night
awakening, early awakening and sleeping in places other
than bed. Additional scores were assigned to the duration of
sleep latency and night awakenings. To calculate frequency,
scores were as follows: 1= problems occurring once or twice
a week and 2= problems occurring more than several times a
week. To calculate duration, scores were as follows: 1= sleep
latency lasting up to 1 hour and 2= over 1 hour. For night
awakenings, scores were as follows: 1= awakenings lasting a
few minutes and 2= lasted longer than a few minutes. The
authors provide a reference for the Simond and Parraga Sleep
Questionnaire
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TABLE 38 Child-related outcomes for studies evaluating parent-directed tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Sleep efficiency Actigraphy and sleep
diary (to verify
actigraphy)
Percentage of time sleeping while in bed and lights off
TST Actigraphy and sleep
diary (to verify
actigraphy)
No definition provided
Moss
et al.124
CSHQ CSHQ total score and
subscales
‘A comprehensive parent-report sleep screening instrument
designed for school-aged children’ was used to identify
behaviourally and medically based sleep problems. It
consists of a total score and eight subscale scores. The
CSHQ includes additional questions relating to hours of
daily sleep and length of night waking. Participants only
completed the questions that were used to calculate total
and subscale scores. The authors provide a reference
Sleep goals Goal Attainment Scale Families defined individual child sleep goals in conjunction
with the facilitator to obtain an objective measure of sleep
disturbance change. There were five levels of possible
outcome levels: 0%, 25%, 50%, 75% and 100%. The
child’s current sleep pattern was outlined as 0%. ‘For
example: If the child did not settle to sleep in less than
30 minutes on any night in the week, a parent report of
100% level of success would have been achieved when
the child settled to sleep in less than 30 minutes, 6 nights
a week.’ No reference was provided
Sciberras
et al.125
CSHQ CSHQ The CSHQ was used to measure caregiver report of sleep
problems and three items from the CSHQ were used to
screen children for sleep apnoea. The authors provide a
reference but no further details are provided
Weiskop
et al.126
TST Sleep diary The average duration of night-time sleep per week.
The length of night wakings was subtracted if these
data were available
Child’s sleep
behaviour goals
GAS The GAS was used to assess the clinical significance of
any changes in child’s sleep behaviour and to provide a
quantifiable measure of intervention success. The GAS
was based on parent-stated goals: a separate GAS was
developed for each sleep behaviour identified by parents
as a goal for behaviour change. For each behaviour,
0% success was set as the baseline rate of that behaviour.
The parents and therapists decided what total success
(100%) meant before the intervention. This did not have
to mean elimination of the sleep problem but related to
the level of improvement that the parents thought would
make a difference to their lives and was developmentally
appropriate. Post intervention, the change in each
behaviour was expressed as a percentage of success over
baseline. The authors provide a reference
Sleep initiation
Austin
et al.123
Bedtime settling:
bedtime resistance,
bedtime routine and
SOL
Sleep diary No definition provided
Johnson
et al.107
Bedtime settling: SOL Actigraphy, sleep diary
(to verify actigraphy)
Time from lights off to sleep onset
APPENDIX 11
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TABLE 38 Child-related outcomes for studies evaluating parent-directed tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Quine
and
Wade146
Bedtime settling: child
settling
Parent report –
Behaviour Screening
Questionnaire
Settling was assessed using the behaviour screening
questionnaire. Severe settling problem=≥ 3 times per week.
Mild settling problem= once or twice a week. The authors
provide a reference for the Behaviour Screening Questionnaire
and a detailed description of the questionnaire is provided in
an appendix to the Quine and Wade report
Weiskop
et al.126
Bedtime settling:
Number of pre-
sleep disturbances/
week
Sleep diary Pre-sleep disturbance was defined as any disruption
occurring between the time that the child was put to bed
and the time of sleep onset, for example crying, leaving
the room or calling out
Number of nights
that child fell
asleep in own bed
Sleep diary No further definition provided
SOL Sleep diary Average sleep latency per week. Sleep latency was
considered as the number of minutes between first being
settled to bed and sleep onset
Sleep maintenance
Austin
et al.123
Night waking Sleep diary No definition provided
Waking time Sleep diary No definition provided
Non-specified
sleep disturbance:
co-sleeping and
severity of child’s
sleep disturbance
Sleep disturbance
index
A parent-reported scale of 0–2 with a total maximum
score of 8. Parents reported on the severity of their child’s
sleep. The index focusses on difficulties settling the child
to sleep, night-time wakening, parent’s attendance to the
child during the night and parental sleep loss through
co-sleeping
Hiscock
et al.138
Night waking: WASO
Actigraphy No definition was provided
Non-specified
night-time sleep
disturbance: sleep
problems
Primary caregiver
report of child sleep
problems over past
4 weeks
Sleep problems were rated as none, mild, moderate or
severe
Quine
and
Wade146
Waking time: number
of night wakings and
sleeping in parent’s
bed
Parent reported-
behaviour screening
questionnaire
It was classified as a severe waking problem if it occurs
> 3 times per week and the child wakes for more than a
few minutes, disturbs parents or goes into the parents’
room or bed. The authors provide a reference for the
behaviour screening questionnaire and a detailed description
of the questionnaire is provided in an appendix to the Quine
and Wade report
Sciberras
et al.125
Non-specified
night-time sleep
disturbance: sleep
problems
CSHQ and caregiver
report
The CSHQ was used to measure care-giver report of sleep
problems and three items from the CSHQ were used to
screen children for sleep apnoea. The authors provide a
reference but no further details are provided
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TABLE 38 Child-related outcomes for studies evaluating parent-directed tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Weiskop
et al.126
Night waking:
Number of night
wakings
Sleep diary Number of night wakings per week that parents were
aware of
Non-specified
night-time sleep
disturbance: number
of nights/week that
child co-slept
Sleep diary Co-sleeping was not coded when the parents only lay with
the child until they fell asleep at bedtime
Sleep scheduling
Austin
et al.123
Napping Sleep diary No definition provided
Child-related quality of life, daytime behaviour and cognition
Austin
et al.123
Behavioural and
emotional
disturbance
Developmental
Behaviour Checklist –
parent version
Used to assess behavioural and emotional disturbance in
children with developmental and intellectual disabilities.
96 items are grouped into the following subscales:
disruptive/antisocial, self-absorbed, communication
disturbance, anxiety and social relating. Subscales are
combined to determine a total behaviour problem score.
The authors provide a reference
Hiscock
et al.138
Child-related quality
of life
PedsQL The PedsQL version 4.0 was used for parent proxy report.
It is a validated 23-item measure of quality of life for
children aged 2–18 years. Items were rated on a 5-point
scale. 15 items contributed to a psychosocial health
summary score. Scores ranged from 0 to 100. The authors
provide a reference
Child daytime
behaviour and
cognition
ADHD symptoms ADHD Rating Scale IV
(parent and teacher
reported)
The ADHD Rating Scale IV parent- and teacher-reported
versions. It is a validated 18-item measure of ADHD
symptoms rated on 4-point scale. Nine items assess
inattentive symptoms and nine assess hyperactive
symptoms. The authors provide a reference
Daily functioning Daily parent rating of
evening and morning
behaviour
A 11-item parent-reported measure of core ADHD
symptoms and behavioural problems on a 4-point scale.
Scores ranged from 0 to 33. The authors provide a
reference
Behaviour Strengths and
difficulties
questionnaire
Parent and teacher versions. It is a validated 25-item
measure of behavioural and emotional problems for
children aged 4–16 years. Items rated on 3-point scale,
with 20-item total problem score from 0 to 40. The
authors provide a reference
Working memory Working memory test
battery for children
Three subtests from the working memory test battery for
children assessing the central executive working memory
domain: backwards digital recall, counting recall and
listening recall. These subsets provide a central executive
composite. The authors provide a reference
Moss
et al.124
Child daytime
behaviour and
cognition
Developmental
Behaviour Checklist –
Parent Version
Developmental Behaviour Checklist is used to measure the
behavioural and emotional problems of children with
developmental and intellectual disabilities aged 4–18 years.
The checklist includes five subscales: disruptive/antisocial,
self-absorbed, communication disturbance, anxiety and
societal relating and a total score. The authors provide a
reference
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TABLE 38 Child-related outcomes for studies evaluating parent-directed tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Quine
and
Wade146
Child daytime
behaviour and
cognition
Daytime behaviour
(BPI)
The BPI is an adaptation of the Behaviour Screening
Questionnaire that includes a wider range of sleep problems
that are deemed more appropriate for children with severe
learning difficulties. A reference is provided as is a more
detailed description of the Index and the Behaviour
Screening Questionnaire in an appendix to the report
Sciberras
et al.125
Child related quality
of life
PedsQL Health-related quality of life was measured using PedsQL
(version 4.0), psychosocial health summary score. The
authors provide a reference
Child daytime
behaviour and
cognition
ADHD Rating Scale IV ADHD symptom severity was measured using the ADHD
Rating Scale IV. The authors provide a reference
Daily parent rating on
the Evening and
Morning Behaviour
Scale
The Evening and
Morning Behaviour
Scale
Daily functioning was measured via daily parent rating on
the Evening and Morning Behaviour Scale. The authors
provide a reference
School attendance Number of days
missed or late for
school over previous
6 months
No further definition provided. The authors provide a
reference
Other child-related sleep outcomes
Austin
et al.123
Meal times Sleep diary No definition provided
Hiscock
et al.138
School attendance Parent report of child’s
school attendance
Parent report of whether or not their child had missed or
been late for school over the preceding 3 months
Sleep help Parent report of other
professional help
sought for their child’s
sleep – for example,
general practitioner or
psychologist
Parent report of other professional help sought for their
child’s sleep
GAS, Goal Attainment Score.
a As defined by study authors.
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Appendix 12 Parent sleep-related outcomes
for studies evaluating parent-directed tailored
interventions
TABLE 39 Parent sleep-related outcomes for studies evaluating parent-directed tailored interventions
Study
Parent sleep-related
outcome assessed
Method of
assessment Definitionsa
Parent-carer-related quality of life
Hiscock et al.138 Parental stress DASS Validated 21-item measure of adult mental health
including scales assessing depression, anxiety and
stress. Items rated on a 4-point scale. The authors
provide a reference
Moss et al.124 Parent stress Parenting Stress
Index – Short Form
The Parenting Stress Index enables a clinician or
researcher to examine the relationship of parenting
stress with child characteristics, parent characteristics
and situations that are directly related to the role of
being a parent. The index includes three subscales:
parental distress, parent–child dysfunctional
interaction and difficult child. A total stress score is
also provided. The authors provide a reference
Quine and
Wade146
Parent stress Maternal stress and
morale – the Malaise
Inventory
A 24-item binary choice questionnaire adapted from
the Cornell Medical Index. Scores of 5 or 6 were
outside the normal range and indicate stress. Scores
of ≥ 7 were considered more critical. The authors
provide a reference
Sciberras et al.125 Mental health DASS Mental health was measured via the DASS. The
authors provide a reference
Other outcomes
Hiscock et al.138 Family functioning Parent-reported
missed work
attendance
Parent report of whether or not they had missed or
been late for work over the preceding 3 months and
the number of days that they missed or were late for
work during that period
Sciberras et al.125 Parent work
attendance
Parent/caregiver
report
Number of days missed or late to work over the
previous 6 months. The authors provide a reference
a As defined by study authors.
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Appendix 13 Measures of perceived confidence
and/or efficacy and/or understanding of sleep/sleep
management for studies evaluating parent-directed
tailored interventions
TABLE 40 Measures of perceived confidence and/or efficacy and/or understanding of sleep/sleep management for
studies evaluating parent-directed tailored interventions
Study Method of assessment Definitiona
Behavioural
Beresford
et al.21
PSOC scale and satisfaction
and efficacy subscales
A 16-item scale with two subscales. Parents respond to a series of questions
about parenting, indicating their level of agreement or disagreement on a
six-point Likert scale. The satisfaction subscale measures the extent that parents
are satisfied with their role as a parent and so captures the affective dimension
of parenting competence, including the extent of parental frustration, anxiety
and motivation. The efficacy subscale measures the extent that parents feel
that they are managing the role of being a parent and captures competence,
problem-solving ability and capability in the parenting role. The authors provide
a reference
Beresford
et al.21
PSOC scale and satisfaction
and efficacy subscales
A 16-item scale with two subscales. Parents respond to a series of questions
about parenting, indicating their level of agreement or disagreement on a
six-point Likert scale. The satisfaction subscale measures the extent that parents
are satisfied with their role as a parent and so captures the affective dimension
of parenting competence, including the extent of parental frustration, anxiety
and motivation. The efficacy subscale measures the extent that parents feel
that they are managing the role of being a parent and captures competence,
problem-solving ability and capability in the parenting role. The authors provide
a reference
Quine
and
Wade146
Improvement in knowledge
of behavioural principles
using Knowledge of
Behavioural Principles as
Applied to Children test
A 50-item multiple forced-choice test designed to assess understanding of the
application of basic behavioural principles as they are applied to children,
which takes about 30 minutes. Each item presents a problem situation to
which the respondent is required to select the correct behavioural response.
Criterion response for each question was selected on the basis of learning
principles. The authors provide a reference
a As defined by study authors.
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Appendix 14 Child-related outcomes for studies
evaluating parent-directed non-tailored interventions
TABLE 41 Child-related outcomes for studies evaluating parent-directed non-tailored interventions
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Global measures and composite scores
Adkins
et al.127
Sleep efficiency Actigraphy Percentage of TST/time in bed
TST Actigraphy Actual time slept – the sum of all ‘sleep epochs’
measured in minutes within the interval between the
time set on the actogram for night-time sleep and
morning wake time
Beresford
et al.21
CSHQ and subscales CSHQ The CSHQ was used to assess the severity of sleep
problems in children aged 4–10 years. Parent
reported. Subscales include bedtime resistance, sleep
onset delay, sleep duration, sleep anxiety, night
wakings, parasomnias, sleep disordered breathing
and daytime sleepiness. The authors provide a
reference
Parent-set child sleep goals Parent-set child
sleep goals
A 10-point scale captured progress towards goals.
Parents identified up to three goals during session 1
(GAS). The authors provide a reference
Beresford
et al.21
CSHQ CSHQ The CSHQ was used to assess the severity of sleep
problems in children aged 4–10 years. Parent
reported. Subscales include bedtime resistance, sleep
onset delay, sleep duration, sleep anxiety, night
wakings, parasomnias, sleep disordered breathing
and daytime sleepiness. The authors provide a
reference
Parent-set child sleep goals Parent-set child
sleep goals
A 10-point scale captured progress towards goals.
Parents identified up to three goals during session 1
(GAS). The authors provide a reference
Malow
et al.128
CSHQ CSHQ The CSHQ is a parent-completed questionnaire
consisting of 33 questions on a 3-point scale. The
CSHQ Is used to examine sleep behaviour in toddlers,
preschool and school-aged children with a variety
of conditions. Subscales of the CSHQ measure
insomnia-related dimensions, such as bedtime
resistance, sleep anxiety, sleep onset delay, sleep
duration and night wakings. Other dimensions
include daytime sleepiness, sleep disordered
breathing and parasomnias. The authors provide a
reference
FISH FISH FISH is a quantitative scale of sleep habits, including
bedtime routine, sleep environment and parental
interactions. FISH as used was a 12-item scale – the
full version includes 22 items. The authors provide a
reference
Sleep efficiency Actigraphy and
sleep diary
Per cent of TST out of the total time in bed
continued
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TABLE 41 Child-related outcomes for studies evaluating parent-directed non-tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
TST Actigraphy Actual time slept, the sum of all sleep epochs, measured
in minutes with the interval between the time set on the
actogram for night-time sleep and morning wake time
Montgomery
et al.49
Composite Sleep
Disturbance Score
Sleep diary A Composite Sleep Disturbance Score was calculated
by summing the score on each problem. Calculated
from the sleep diary as follows: 4=minimum entry
score, representing, for example, a child with settling
problems lasting > 30 minutes at least five times
weekly and 8=maximum score, representing a child
who also wakes in the night for at least 30 minutes
> 3 nights each week. No reference provided
Reed et al.129 CSHQ CSHQ and
subscales
The CSHQ is a parent-completed questionnaire used
to examine sleep behaviour in toddlers, preschool
and school-aged children with a variety of conditions.
Subscales measured insomnia-related dimensions
including bedtime resistance, sleep anxiety, sleep
onset delay, sleep duration and night wakings.
Additional dimensions include daytime sleepiness,
sleep disordered breathing and parasomnias. A total
score is also calculated and the authors reference as
previously reported the use of a modified totals core
incorporating the insomnia domains – total of items
compromising the bedtime resistance, sleep anxiety,
sleep onset delay, sleep duration and night wakings
scales. The CSHQ was used to measure changes in
subscales and total scores after the behavioural
intervention. The authors provide a reference
FISH FISH FISH is a parent-reported questionnaire that assesses
sleep hygiene for their children. It includes giving
attention to developing a structured consistent bedtime
routine, sleep environment, daytime habits and parental
interactions at bedtime and on night wakings. Parents
rate the frequency of sleep habits over the last month
on a 5-point scale. The authors previously validated a
12-item research version of the scale. In parent
education classes, the authors used the 22-item scale
that provides a comprehensive overview of sleep habits.
The full version of the scale is provided in a table
TST (time in bed) Actigraphy No definition provided
Sleep efficiency Actigraphy No definition provided
Yu et al.151 CSHQ CSHQ The CHSQ is a sleep-screening instrument that is
widely used to identify sleep problems in children
with a range of problems, including ASD. It includes
50 questions, and each item is scored as 3 = usually
(5–7 times/week), 2= sometimes (2–4 times/week) or
1 = rarely (0–1 times/week). It produces a total score
and eight subscale scores for sleep onset delay, night
awakening, sleep duration, sleep resistance, sleep
anxiety, parasomnia, daytime sleepiness and sleep
disordered breathing, which reflect key sleep domains
that encompass the major medical and behavioural
sleep disorders. The authors provide a reference
FISH FISH FISH was developed to measure sleep hygiene and
behaviours in children with ASD. There are 22
questions and each question is scored from 1 to 5
depending on the frequency of occurrence, namely
never, rarely, sometimes, usually and always. The
authors provide a reference
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TABLE 41 Child-related outcomes for studies evaluating parent-directed non-tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Sleep initiation
Adkins
et al.127
Bedtime settling: SOL Actigraphy The number of minutes that it took for the child to
fall asleep when the parent turned the lights out and
expected them to fall asleep
Bramble149 Bedtime settling: time to
settle (SOL)
Sleep diary Mean time to settle once the child was in bed
Malow
et al.128
Bedtime settling: SOL Actigraphy and
sleep diary
The number of minutes taken for the child to fall
asleep when the parent turned the lights out and
expected the child to fall asleep
Reed et al.129 Bedtime settling:
SL Actigraphy No definition provided
Bedtime Sleep diary and
event markers
No definition provided
Sleep maintenance
Adkins
et al.127
Night waking:
WASO Actigraphy The total time that the child was awake during the
night, after the SOL was excluded. WASO was
measured as the sum of all wake epochs during the
sleep period. WASO did not include wake time in bed
before the final arising and terminal wakefulness was
not encountered
Fragmentation index Actigraphy The Fragmentation Index captures all movement
regardless of the intensity of the movement. The
Fragmentation Index is a measure of nocturnal
movement that is calculated using: (number of movile
epochs lasting four epochs+ number of immobile
epochs < 1-minute duration/number of immobile
epochs > 1-minute duration) × 100
Bramble149 Non-specified night-time
sleep disturbance: severity
of sleep problems
Parent/carer report
on VAS
Efficacy of treatment assessed by parental reports of
the severity of sleep problems using a VAS (0 = no
problems to 10= very severe problems, converted to
%). The severity of sleep problems was also rated on
a categorical scale (0 = usually sleeps and settles well
to 9 = sleep is disturbed, settles late and wakes early
most nights). These scales were derived from the
two sleep-problem items of the Wing and Goulds
Handicaps, Behaviours and Skills scale. The authors
provide a reference
Malow
et al.128
WASO Actigraphy and
sleep diary (to
confirm accuracy)
The total time that the child was awake during the
night after the SOL was excluded. WASO was
measured as the total of all wake epochs during the
sleep period
Reed et al.129 Night waking: WASO Actigraphy, sleep
diary and event
markers
No definition provided
continued
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TABLE 41 Child-related outcomes for studies evaluating parent-directed non-tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Child-related quality of life, daytime behaviour and cognition
Bramble149 Child daytime behaviour
and cognition
BPI The BPI was derived for specific use with children
with severe learning disabilities and was scored from
0 to 64. The authors provide a reference
Malow
et al.128
Child-related quality of life PedsQL (total
score)
The PedsQL is a 23-item instrument designed for
children aged 2–18 years. PedsQL includes four
domains of functioning: physical, emotional, social
and school. Each domain has a subscore and a total
score and a psychosocial health summary score.
The authors provide a reference
Child daytime behaviour
and cognition
CBCL The parent-completed CBCL consists of two modules,
one for ages 1.5–5 years and one for ages 6–18 years.
For analysis, the authors selected muscles that were
common to both modules and showed improvements
in previous interventional studies (e.g. scales including
anxious/depressed, withdrawn and withdrawn/
depressed, attention and DSM-oriented scales attention
deficit hyperactivity). The authors provide a reference
RBS-R RBS-R The parent-completed RBS-R consists of six subscales:
stereotyped, self-injurious, compulsive, ritualistic,
sameness and restricted behaviours and a total scale.
The scale is validated in children. Subscales were selected
for analysis that had shown improvements in prior
interventional studies (e.g. stereotyped, compulsive and
restricted behaviours). The authors provide a reference
Reed et al.129 Child daytime behaviour
and cognition
PCQ The PCQ is a validated parent-completed
questionnaire used to assess the presence and
severity of 13 developmental and behavioural
concerns expressed by parents of children with ASD.
Domains include those related to core symptoms of
ASD (e.g. language delay and social interaction) and
related symptoms (e.g. hyperactivity and compulsive
behaviours). The authors provide a reference
RBS-R RBS-R The RBS-R is an observer-completed questionnaire
validated in adults with ASD. A total score and scores
for the subscales of stereotyped, self-injurious,
compulsive, ritualistic, sameness and restricted behaviour
are calculated. The authors provide a reference
Yu et al.151 Child daytime behaviour
and cognition
CBCL The CBCL measured the daytime behaviour of each
child and is a commonly used questionnaire to identify
social/emotional and/or behavioural problems in
children. It is also used to aid diagnosis and evaluate
emotional and behavioural problems in children with
ASD. The form includes 100 problem items – 99 closed-
ended items and one open-ended item that requests
respondents add any additional problems not previously
listed. Parents rate each item as 0 not true, 1 for
somewhat true and 2 for very true or often true. A total
problem score is calculated by totalling the scores on all
of the items, including emotional reaction, anxious/
depressed syndrome, somatic complaints, withdrawal,
sleep problems, attention problems and aggressive
behaviour. The internalising score is the sum of the
scores on items in the withdrawal, somatic complaints
and anxious/depressed syndrome profiles. The
externalising score is the sum of the scores on the items
on attention problems and aggressive symptoms. The
authors provide a reference
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TABLE 41 Child-related outcomes for studies evaluating parent-directed non-tailored interventions (continued )
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Daytime behaviour PCQ The PCQ is used to assess daytime behaviour. It is a
13-item parent-interview screening instrument
assessing the severity of core developmental and
associated psychiatric symptomology using a 4- point
scale. Parents are asked to describe the extent that
each symptom has been a problem with 1, 2, 3 and
4 representing no, mild, moderate and severe
problems, respectively. The authors provide a reference
DSM, Diagnostic and Statistical Manual of Mental Disorders; GAS, Goal Attainment Score; VAS, visual analogue scale.
a As defined by study authors.
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Appendix 15 Parent sleep-related outcomes for
studies evaluating parent-directed non-tailored
interventions
TABLE 42 Parent sleep-related outcomes for studies evaluating parent-directed non-tailored interventions
Study
Parent sleep-related
outcome assessed
Method of
assessment Definitionsa
Parent-carer-related quality of life
Bramble149 Maternal stress Rutters’ Malaise
Inventory
Rutters’ Malaise Inventory measured changes in
maternal stress and is scored from 0–11. The authors
provide a reference
Reed et al.129 Parental stress Parenting Stress Index –
Short Form
A 36-item abbreviated version of the Parenting Stress
Index, which provides a Total Stress Score and
subdomain scores of parental distress, difficult child
and parent–child interactions. The measure has been
used to measure parental stress in autism disorder.
The authors provide a reference
Yu et al.151 Parental stress Parental Stress Index –
Short Form
Used to assess parental stress. A validated reliable and
widely used instrument for measuring parenting
stress. Parents rate each of the 36 items on a 5-point
scale ranging from strongly disagree to strongly agree.
A total score is calculated. The authors provide a
reference
Quality of sleep
Bramble149 Maternal sleep quality Maternal Sleep Scale Mothers appraised their own sleep quality using an
adapted version of De Diana’s175 sleep rating scale –
the maternal sleep scale, which requires yes/no
responses to 11 statements (e.g. ‘I usually sleep well
during the night’) and is scored from 0 to 11. The
authors provide a reference
Yu et al.151 Sleep quality Pittsburgh Sleep Quality
Index
The Pittsburgh Sleep Quality Index is used to assess
parental sleep habit, quality and quantity in a range
of populations. It is a self-rated questionnaire
consisting of 19 questions that generate a total score
and seven subscores, including sleep quality, SOL,
sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleep medication and daytime
dysfunction. The authors provide a reference
a As defined by study authors.
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Appendix 16 Measures of perceived confidence
and/or efficacy and/or understanding of sleep/sleep
management for studies evaluating parent-directed
non-tailored interventions
TABLE 43 Measures of perceived confidence and/or efficacy and/or understanding of sleep/sleep management for
studies evaluating parent-directed non-tailored interventions
Study Method of assessment Definitionsa
Beresford
et al.162
PSOC (satisfaction and
efficacy subscales)
The PSOC is a validated self-reported 17-item scale developed to assess parents’
self-esteem. Two subscales provide a measure of self-efficacy, indicative of the
parent’s sense of his/her own problem-solving ability and capability as a parent,
and a measure of satisfaction with parenting that reflects frustration, anxiety
and motivation with the parenting role. A higher score indicates a higher
parenting sense of competency
Beresford
et al.163
PSOC (satisfaction and
efficacy subscales)
The PSOC is a validated self-reported 17-item scale developed to assess parents’
self-esteem. Two subscales provide a measure of self-efficacy, indicative of the
parent’s sense of his/her own problem-solving ability and capability as a parent,
and a measure of satisfaction with parenting that reflects frustration, anxiety
and motivation with the parenting role. A higher score indicates a higher
parenting sense of competency
Malow
et al.128
PSOC (satisfaction and
efficacy subscales)
The PSOC is a validated self-reported 17-item scale developed to assess parents’
self-esteem. Two subscales provide a measure of self-efficacy, indicative of the
parents’ sense of his/her own problem-solving ability and capability as a parent,
and a measure of satisfaction with parenting that reflects frustration, anxiety
and motivation with the parenting role. The authors provide a reference
a As defined by study authors.
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Appendix 17 Child-related outcomes for studies
evaluating non-comprehensive parent-directed
interventions
TABLE 44 Child-related outcomes for studies evaluating non-comprehensive parent-directed interventions
Study
Child sleep-related
outcome assessed
Method of
assessment Definitionsa
Global measures and composite scores
Peppers
et al.155
CSHQ CSHQ total score Parent completed measure used to assess sleep in
children who met the inclusion criteria and agreed to
participate. A sleep disturbance score of ≥ 42
indicated a paediatric sleep disorder. The authors
provide a reference
Wiggs and
Stores152
Composite sleep index
(bedtime resistance,
night waking, early
waking and sleeping in
places other than bed)
Composite sleep index
of the modified version
of the Simonds and
Parraga Sleep
Questionnaire
Calculated from parental questionnaire information
obtained through a modified version of the Simonds
and Parraga Sleep Questionnaire. Scores ranged from
0 to 12. Settling and night waking were scored in
terms of frequency and duration, and early waking
and sleeping in the parents’ bed for frequency only.
Frequency = problems occurring more than several
times a week = 2. Duration was scored as following:
settling problems lasting up to 1 hour= 1; > 1 hour= 2.
Night wakings were scored as if lasting a few
minutes= 1 and if they lasted longer= 2. The authors
provide a reference
TST Actigraphy Time from sleep onset to the time the child woke up.
Referred to as sleep period
Sleep maintenance
Wiggs and
Stores152
Non-specified night-
time sleep disturbance:
l Movement
during sleep
l Movement index
Actigraphy Defined as the sum of the epoch scores divided by
total number of epochs in the sleep period
Actigraphy Defined as the number of thirties epochs with a value
> 0 (i.e. with movement), divided by the total number
of thirties epochs in the sleep period × 100
Night waking:
l Fragmentation
index
Actigraphy Defined as the number of discrete thirties epochs with a
value of 0 (i.e. with no movement) divided by the total
number of immobile phases of any duration × 100
Child-related quality of life, daytime behaviour and cognition
Peppers
et al.155
ADHD symptoms Parent Vanderblit
ADHD symptom
checklist
A parent-/caregiver-completed screening tool to assess
ADHD behaviour. No further definition or reference
provided
Wiggs and
Stores152
Child daytime
behaviour and
cognition
ABC parent and
teacher versions
reported
The ABC was used to assess the following types of
challenging behaviour: self injury, aggression,
screaming, temper tantrums, non-compliance and
impulsivity. The authors provide a reference
a As defined by study authors.
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Appendix 18 Child sleep-related outcomes for
studies evaluating other non-pharmacological
interventions
TABLE 45 Child sleep-related outcomes for studies evaluating other non-pharmacological interventions
Study
Child sleep-related
outcome assessed Method of assessment Definitionsa
Global measures and composite scores
Francis and
Dempster156
TST Sleep diary No definition provided
Gringras et al.36 CSHQ CSHQ (no data
reported)
–
Composite sleep
disturbance index;
frequency and
duration of sleep
problems
Composite sleep
disturbance index;
frequency and duration
of sleep problems
No definition provided, reference to key papers
provided
Sleep efficiency Parental diary The proportion of time spent in bed asleep
TST Parental diary,
actigraphy
No definition provided
Guilleminault
et al.158
TST Parent report (actigraphy
verified)
Nocturnal TST
Oriel et al.159 CSHQ CSHQ No reference provided. The authors state that
the CSHQ developed by researchers at Brown
University was used to quantify sleep problems
and consisted of eight subscales (bedtime
resistance, sleep onset delay, sleep duration,
sleep anxiety, night wakings, parasomnias, sleep
disordered breathing and daytime sleepiness)
and 33 items for the total sleep disturbance
score. Maximum score of 99
TST Telephone call from
researcher
The average number of hours of sleep for each
participant during each study phase
Yu and Hong161 CSHQ CSHQ No reference provided, the authors state the
scale was used to assess the sleep state of
patients before and after treatment. Scale
included: the total time of sleep’ the time of
getting into bed for sleep; sleep habit; sleep
behaviour; wake state at night; state at getting
up in the morning; sleep state at daytime and
total score
Sleep initiation
Francis and
Dempster156
Bedtime settling: SL Sleep diary Time taken to fall asleep
Gringas et al.36 Bedtime settling: SOL Parental diary,
actigraphy
No definition provided
continued
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TABLE 45 Child sleep-related outcomes for studies evaluating other non-pharmacological interventions
(continued )
Study
Child sleep-related
outcome assessed Method of assessment Definitionsa
Oriel et al.159 Bedtime settling: SOL Telephone call from
researcher
The average number of minutes to fall asleep for
each participant during each study phase
Piazza et al.157 Bedtime settling: exactly
what time the child fell
asleep at night
Observations No definition provided
Sleep maintenance
Francis and
Dempster156
Night waking: time
spent awake during
the night
Sleep diary ‘Where nightime awakenings for the child fell in
the parent’s sleep period, only those which
disturbed the parent to awakening were
recorded’156
Gringas et al.36 Night waking: number
of night wakings
Time awake after sleep
onset
Actigraphy and parental
diary
No definition provided
Proportion of nights
with > 1 wakes
Actigraphy and parental
diary
No definition provided
Actigraphy and parental
diary
No definition provided
Guilleminault
et al.158
Non-specified night-
time sleep disturbance:
longest wake and
sleep periods during
24-hour cycle
Sleep diary (actigraphy-
validated sleep diary)
No definition provided
Sleep diary (actigraphy-
validated sleep diary)
No definition provided
Oriel et al.159 Night waking: number
of night wakenings
Telephone call from
researcher
No definition provided
Piazza et al.234 Night waking: time of
night wakes and
return to sleep
Observations No definition provided
Non-specified night-
time sleep disturbance:
hours of disturbed
sleep
Observations No definition provided
Waking time: exactly
what time the child
awakened in the
morning
Observations No definition provided
Sleep scheduling
Francis and
Dempster156
Sleep quality Sleep diary No definition provided
Gringas et al.36 Sleep improvement Children and parent
blanket scale
No definition provided
Quality of sleep Child smiley-face rating
and parent blanket scale
No definition provided
Guilleminault
et al.158
Distribution of sleep
bouts during 24-hour
cycle
Parent report, actigraphy
(validated sleep diaries)
No definition provided
Yehuda et al.160 Degree of fatigue in
general during the day
Parent blanket scale No definition provided
Quality of sleep Short questionnaire No definition provided
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TABLE 45 Child sleep-related outcomes for studies evaluating other non-pharmacological interventions
(continued )
Study
Child sleep-related
outcome assessed Method of assessment Definitionsa
Child-related quality of life, daytime behaviour and cognition
Francis and
Dempster156
Child daytime
behaviour and
cognition
Sleep diary No definition provided
Gringas et al.36 Daytime behaviour and
cognition
ABC (total score and
subscales)
No definitions provided, reference to checklist
manual provided
Sensory Behaviour
Questionnaire
Sensory Behaviour
Questionnaire; sensory
stimuli response profile
Reference to unpublished original paper
provided
Yehuda et al.160 Level of good mood in
general
Level of ability to
concentrate during the
day, mainly at school
Percentage of
homework completed
in general
Short questionnaire ‘5 point Likert scale’
SL, sleep latency.
a As defined by study authors.
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Appendix 19 Studies evaluating family
experience
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TABLE 46 Studies evaluating family experience
Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Pharmacological interventions
Wright
et al.106
Sample: 20 study participants
Data were recorded within usual trial data
collection processes
One parent (1/20) withdrew their child from trial
because they found that it was too difficult to
administer the medication (oral melatonin)
Not specifically
asked
Non-pharmacological: parent-directed tailored interventions
Bramble149 Sample: 15/15 study participants
Data collected: 4-month follow-up
Fixed response question regarding style of
intervention approach. Response options: too
tough; rather tough; just right; rather soft; too
soft
Overall rating of helpfulness: visual analogue
scale [0 (no help) to 10 (extremely helpful)]
Checklist of 10 key components of
intervention (referred to as ‘advice items’):
respondents ticked those that they felt had
changed the child’s sleep problems and rated
helpfulness [+ 2 (very helpful) to –2 (very
unhelpful)]
12/15 reported the treatment was ‘just right’; 3/15
rated it ‘rather tough’ but were willing to continue
Overall rating of helpfulness: mean score 8.9 (SD 1.9)
Mean ratings of helpfulness of ‘advice items’:
l Parents back one another up, 1.64
l Pre-bedtime wind down, 1.40
l Setting and sticking to a regular bedtime, 1.34
l Ignoring child once in bed unless unwell, 1.27
l Regular settling routine, 1.13
l Bedroom made safe and secure, 1.07
l No-fuss prompt put-back of child during
night, 1.00
l Bedroom light off and door closed, 0.93
l Short settling time and settling phase, 0.86
l Removing sources of stimulation from
bedroom, 0.67
Not specifically
asked
Austin
et al.123
Sample: 5/6 study participantsa completed
23-item CATS designed for study
Response format: five-point Likert Scale
(maximum score 35)
Domains: treatment goals, training and
resources, appropriateness and acceptability
of intervention plan, treatment compliance,
outcomes and implications, most valued
aspects of programme, programme difficulties
and suggestions for future sleep interventions
Domains of CATS:
l ease of implementation
l incorporation of parent priorities in
plan development
l stressfulness of the intervention plan
Mean score 27.6 (SD 4.73) of a maximum score of 35
Three out of five parents reported that using bedtime
restriction and/or bedtime fading with response cost
was stressful to implement
Domains of CATS:
l suitability, acceptability and relevance – mean
score 31.6 (SD 1.82)
l preparation, assistance and ability to
understand training and resources – mean
score 18.0 (SD 1.22).
l improvement outcomes and usefulness of
programme to address the problem – mean
score 22.4 (SD 1.52)
5/5 would
recommend
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Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Johnson
et al.107
Sample: 13/15 (active arm) and 17/18
(attention control)
Parent Satisfaction Questionnaire developed
for study. Parents rated the quality of various
elements of the intervention:
l number and length of sessions
l usefulness of teaching tools (e.g. video
vignettes, in-session worksheets
and homework)
l the helpfulness of specific elements
Response format: three- or four-point Likert
scales (higher scores reflecting greater levels
of satisfaction)
Adherence to intervention:
l clinician-completed checklists of
observations of evidence of completion
of homework and implementation of
recommended strategies
l attendance rates at intervention
programme recorded
Parent Satisfaction Questionnaire
l Overall satisfaction rating:
¢ Active arm – 90% (range 70–100%)
¢ Attention control – 88.2% (range
63–100%)
Clinician report
l Adherence:
¢ Active arm – 93% (range 75–100%)
¢ Attention control – 98% (range 75–100%)
l Attendance:
¢ Active arm – 73/75 sessions attended by all
parents (97.3%)
¢ Attention control – 89/90 sessions attended
by all parents (98.9%)
Parents in the active arm only
Helpfulness of specific elements of the
intervention:
l 69% reported that behaviour principles
training was very helpful
l 89% reported that the session on ‘addressing
prevention techniques and bedtime
routines’107 was very helpful
l 77% reported that the session on ‘addressing
reinforcement and extension procedures for
bedtime struggles, night awakenings and early
morning awakenings’107 was very helpful
l 77% reported that the session on ‘addressing
sleep onset and sleep association
procedures’107 was very helpful
l 61% reported that the ‘booster and
maintenance session’107 was very helpful
All other responses were ‘okay’; there were no
ratings of ‘not helpful’
Not specifically
asked
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TABLE 46 Studies evaluating family experience (continued )
Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Moss et al.124 Sample: 26/26 study participants
Completed ‘an informal survey designed by
study authors assessing acceptability of the
programme’s goals, workshops and resources,
treatment plans, and outcomes’.124 Referred
to as CATS. Response format: five-point Likert
scale. Total number of items not reported.
Not clear if same as used by Austin et al.123
Subsample (6/26) participated in a
semistructured interview. (20/26 not available
for interview.) Method of data analysis not
reported
Parent report
l Responses to CATS:
¢ satisfaction with intervention – 21/26
responded satisfied or very satisfied
¢ programme goals – 24/26 responded
acceptable or very acceptable
¢ implementation of the treatment plans –
21/26 responded acceptable or
very acceptable
¢ workshop materials – 24/26 responded
acceptable or very acceptable
¢ programme worthwhile – 24/26 responded
mostly worthwhile or completely
worthwhile
Semistructured interviews
l Elements of the programme that were
spontaneously mentioned as what was ‘least
liked’ about the intervention:
¢ nothing to report – 5/6
¢ early morning time of workshop – 1/6
l None felt that there was any aspect of the
intervention that needed to be improved
l Perceived barriers to other parents completing
the intervention:
¢ time pressures or putting in initial time
commitment needed for the intervention –
5/6
¢ reluctance or fear of change – 2/6
Semistructured interviews
l Elements of programme that were
spontaneously mentioned as what was ‘most
liked’ about the intervention:
¢ follow-up support – 5/6
¢ workshops – 2/6
¢ individualised approach – 2/6
l Elements of the child’s sleep management
plan that were spontaneously identified as
‘most useful’:
¢ communication strategies – 5/6
¢ sensory strategies – 2/6
¢ behavioural strategies – 2/6
Not specifically
asked
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Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Scibberas
et al.125
Sample: 27/27 study participants asked to
complete a study-designed scale. The number
completing the scale not reported
The ‘study-designed scale’ captured parents’
reports of the helpfulness of the intervention
and use sleep management strategies learnt
during the intervention. No further
information provided
‘Most caregivers reported that they could
implement sleep management strategies “at least
half of the time” ’125 (p. 934). Note: ‘most’ not
further specified
‘Most . . . reported sleep strategies as helpful,
including:
l advice about normal sleep (94%)
l setting bedtimes (94%)
l sleep hygiene (87%)
l using a sleep diary (93%)
l a sleep plan (82%)
l limit setting (93%), using rewards (85%)
l relaxation strategies (83%)
l returning the child to bed overnight (75%)
l checking method (73%)
l bedtime fading (67%)’125 (p. 934)
‘All but one’125
(p. 934) would
recommend the
intervention
Weiskop
et al.126
Sample: 12/12 study participants
Parents completed a modified version of the
PEQ (Griffin and Hudson, 1978235), which
comprised:
l Three open-ended questions about
the programme:
¢ what the parents liked best?
¢ what the parent liked least?
¢ what they would change?
l Five items (5-point Likert scale response):
¢ approval of techniquesb
¢ improvements seen in child’s sleepb
¢ improvements in child’s
general behaviour
¢ reduction in parental stress levels
¢ how strongly parent would
recommend intervention programme
l Approval of techniquesb
Approval of techniques: 7/12 gave the maximum
positive rating
Overall satisfaction: mean score 13.8 (range 11–15)
Least-liked elements were:
l ‘sticking to a bedtime routine’126 – 2/12
l the sessions were too long – 1/12
l referred to the ‘overall time-consuming nature
of the programme’126 (p. 102) – 3/12
‘Responses to the PEQ indicated that the best
aspects of the programme were . . . the support
provided, the telephone calls, and the method of
instruction’126 (p. 102)
12/12 would
recommend
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TABLE 46 Studies evaluating family experience (continued )
Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Non-pharmacological: parent-directed non-tailored interventions
Adkins
et al.127
Sample: 6/9 study participants in active arm
(n= 9)
Parents in the active arm (who received a
sleep education pamphlet) were ‘asked a
series of questions to collect parent feedback
on pamphlet use’127 (p. S141) and what was
‘most useful about the pamphlet and what
might have been more useful’127 (p. S140)
Parents commented that the pamphlet contained
good information, but that it would have been
more useful to be given specific examples of how to
take the information and put it into practice
Feedback from parents suggested that the pamphlet
was useful as it contained good information, for
example they liked that it included ‘basic rules for
sleep’ and ‘important of consistent bedtime’. They
commented that they would have found it more
useful if it had included specific suggestions of how
to take the information and put it into practice
Not specifically
asked
Malow
et al.128
Sample: 80 study participants. (individual-
mode arm, n= 41; group-mode arm, n= 39)
Parents completed an ‘anonymous survey’ at end
of education element of intervention. A 4-point
Likert scale was used to capture views on general
satisfaction with content of intervention and
educator, whether or not they would
recommend it to others, whether or not the
intervention had improved the child’s sleep habits
and whether or not they would have preferred
alternative mode of intervention delivery
Preferences for alternative mode of delivery:
l Individual-mode arm – 3/41 reported would
have preferred group delivery
l Group-mode arm – 8/39 reported would have
preferred a one-to-one session
Response to statement: ‘The information covered
was relevant and useful’
l Individual-mode arm – 35/41
l Group-mode arm – 29/39
Authors report: ‘There were no differences
between responses in the “end of evaluation”
survey based on mode of parent education’128
(p. 223)
‘Strongly agreed’
that they would
recommend:
l individual-
mode arm –
38/41
l group-mode
arm – 32/39
Reed et al.129 Sample: 18/20 study participants
Parents completed an ‘anonymous
evaluation’. No further details were given
Duration of the workshop was sufficient: 10/18 The information conveyed was relevant and useful:
17/18
18/18 would
recommend
Montgomery
et al.49
Sample: 23/33 study participants who
received copy of booklet regarding managing
sleep
Brief questionnaire was given to evaluate the
booklet in terms of relevance, ease with
which it can be understood and usefulness on
a four-point Likert scale (low = poor/negative
experience; high= good/positive experience).
The maximum score was 12
Mean total score on the questionnaire evaluating
the booklet: 10.17 (SD 1.87)
Not specifically
asked
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Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Non-pharmacological: parent-directed: two tailored and two non-tailored
Beresford
et al.130
Sample: 35 parents purposively sampled
(in terms of intervention outcome, child’s
diagnosis, parents’ education and partner
involvement in the intervention) from a total
sample of parents (n= 74) who had received
one of four parent-directed interventions
included in this review:
l two tailored interventions (n= 12);
l two non-tailored [a half-day workshop
(n = 8) and a four-session (one per week),
group-delivered intervention (n= 15)]
Semistructured interviews (individual telephone
interviews and focus groups) were used to
gather data on parents’ views and experiences
in terms of (1) parents’ descriptions of the
processes by which a sleep management
intervention leads to improvements in their
child’s sleep, (2) parents’ views of the factors
that hinder the achievement of positive
intervention outcomes and (3) parents’ views on
intervention intensity and mode of delivery
Parents referred to the demands that the
intervention places on parent/caregivers, including
the challenge of changing and sustaining new sleep
management strategies
Implementing new approaches to managing their
child’s sleep could be hampered by a number of
factors: (1) a lack of consistency across caregivers,
(2) changes and disruptions in usual routines
(e.g. illness, holidays) and (3) issues with the home
environment, particularly when the child shared a
bedroom siblings)
Features of the intervention identified by parents
as supporting positive outcomes:
l information that changed or developed
parents’ understanding of sleep and its
management, and clarifying any links between
the child’s condition and sleep issues
l attention being paid to building and
developing parents’ sense of competence and
ability to make changes to the way they
managed their child’s sleep
l learning that many parents of disabled
children experience sleep management issues
(this was particularly pertinent for parents
receiving group-delivered interventions)
l training on sleep management behaviours and
strategies. Two key areas of change described:
setting up or improving bedtime routine and
handling night wakings
l parents who were receiving sleep management
interventions delivered over a number of weeks
spoke about the value of ongoing support to
help them persevere with new or changed
routines
l several parents said that keeping a sleep diary
kept them motivated by revealing progress
over time
l improvements in their own well-being through
getting better sleep themselves, this allowed
them to have more energy and mental
resources to further implement changes in
sleep management
Not specifically
asked
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TABLE 46 Studies evaluating family experience (continued )
Study Sample
Experiences of receiving or implementing the
intervention (parent report unless specified)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention
Recommend the
intervention?
Features of the intervention identified by parents
as hindering positive outcomes:
l training not sufficiently tailored to child’s
particular needs and abilities. (Reported by
those receiving non-tailored interventions,
particularly a single workshop)
Other non-pharmacological interventions
Gringras
et al.36
Sample: 73 study participants. Data recorded
within usual trial data collection processes
Child report
l Responses to the ‘Children’s Blanket Scale’:
Which best describes how you have felt about
the blue blanket you have been using over the
past 2 weeks?
¢ really liked the blanket: 48 vs. 31%
(weighted blanket vs. control)
¢ blanket was just OK: 37 vs. 39%
(weighted blanket vs. control)
¢ really disliked the blanket: 15 vs. 29%
(weighted blanket vs. control) (p= 0.110)
Parents’ views on the value/relevance and/or
usefulness of different elements of the
intervention: parents favoured the weighted
blanket
Not specifically
asked
CATS, Caregivers Acceptance of Treatment Survey; PEQ, Program Evaluation Questionnaire.
a In controlled study, this refers to the number of participants in the active arm.
b Scores combined to give an overall measure of participant satisfaction (maximum score 15).
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Appendix 20 Study quality: studies of
acceptability/feasibility and experiences of
implementing sleep interventions
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TABLE 47 Study quality: studies of acceptability/feasibility and experiences of implementing sleep interventions
Study
Abstract
and title
Introduction
and aims
Method
and data Sampling
Data
analysis
Ethics
and bias Results
Transferability/
generalisability
Implications
and usefulness
Score
(maximum 36)
Beresford et al.
(2016)130
Good Good Good Fair Good Fair Good Good Good 34
Comments: sample drawn from sample recruited to outcomes evaluations. The recruitment to the outcomes evaluations had limitations
Bramble (1996)122 Poor Fair Fair Poor Poor Poor Fair Fair Fair 23
Comments: lacks clear description of presentation of questions and method of recording. No report of parent characteristics. No account given of data analysis. Ethics approval not reported.
Some further analyses needed/reported, for example table 3. Evaluation of a specific intervention. Findings not (necessarily) transferable to other parent-directed interventions. No mention
of authors’ biases – study conducted by one author with clinical experience
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Appendix 21 Study quality: quality assessment of
non-pharmacological interventions
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Summary of quality assessment using the Cochrane risk of bias for randomised controlled trials tool62
TABLE 48 Summary of quality assessment using the Cochrane risk of bias tool for RCTs
Study
Domain
Additional questions
for crossover trials
1. adequate sequence
generation?
2. allocation
concealment? 3. blinding?
4. incomplete outcome
data addressed?
5. free of selective
reporting? 6. free of other bias?
Parent-directed tailored interventions
Beresford et al.
21
Unclear
No details are provided
Unclear
No details are provided
No
No details are provided,
but it would have been
difficult to achieve
blinding given the nature
of the intervention
No
Response rates were
reported as 92% (post
intervention) and 62%
(12-week follow-up) (i.e.
5/12 lost to follow-up). No
reasons for loss to follow-up
were given or if/how this
was dealt with in the
analysis. No indication was
given of which arm of the
trial the participants were
lost from
Unclear
No protocol but data analysis
detailed in appendix E. It seems
to be an explanation of what
analyses were carried out
rather than an a priori
plan/protocol. This intervention
is part of larger study of
multiple interventions – the
same analyses will be carried
out on all interventions, as
applicable. All measures
appear to have been reported
No
Small study sample (n= 13).
The intervention was
suspended on two
occasions, which affected
the small sample size
N/A
Hiscock et al.
138
Yes
Computer-generated
random number sequence
Yes
Sealed opaque envelopes
No
Parents were aware of
the intervention (see
discussion in the paper).
It would be difficult or
impossible to blind given
nature of intervention
Yes
Missing data were imputed,
and both imputed and
non-imputed reported
Intervention and control
group at baseline: n= 122
in each group
Number lost to follow-up
at the 3-month follow-up:
intervention, n= 36; control,
n= 33
Number lost to follow-up
at 6-month follow-up:
intervention, n= 16; control,
n= 33
Yes
Protocol available. All
specified outcomes reported
Yes N/A
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Study
Domain
Additional questions
for crossover trials
1. adequate sequence
generation?
2. allocation
concealment? 3. blinding?
4. incomplete outcome
data addressed?
5. free of selective
reporting? 6. free of other bias?
Numbers included in the
primary analyses varied for
parent-and teacher-reported
ADHD symptoms (n= 99
and n= 83 in the
intervention group; n= 85
and n= 77 in the control
group, respectively)
Multiple imputation used in
intention-to-treat analysis.
There were n= 122 in each
group
Johnson et al.
107
Unclear
The authors state that
participants were equally
randomised using block
randomisation with a
block size of 10, but no
information is provided
about how they generated
a sequence
Unclear
No details of this are
provided
No
Parents and therapists
were not blinded
No
Only participants for whom
baseline and 4-week
follow-up data were
available were included in
the analysis
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
Yes N/A
Moss et al.
124
Unclear
No details are provided
Unclear
No details are provided.
Allocation was by research
team but it is not clear if
any attempts were made to
conceal this (e.g. opaque
envelopes)
No
Owing to the nature
of the intervention,
participants and staff
would know which group
they were in
Unclear
A total of 26 children were
recruited: post treatment,
n= 22 (treatment group,
n= 12; control group,
n= 10); follow-up, n= 18
(treatment group, n= 10,
control, n= 8). Reasons for
dropout (from the control
and intervention groups
after treatment) were family
work/carer commitment,
child health problems or
family tragedy. There was
no mention of pre-
intervention dropouts
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
Yes
One child in sample was
taking melatonin, but we do
not think this would be
enough to introduce bias
N/A
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
0
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
8
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
B
e
re
sfo
rd
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
6
9
TABLE 48 Summary of quality assessment using the Cochrane risk of bias tool for RCTs (continued )
Study
Domain
Additional questions
for crossover trials
1. adequate sequence
generation?
2. allocation
concealment? 3. blinding?
4. incomplete outcome
data addressed?
5. free of selective
reporting? 6. free of other bias?
Sciberras et al.
125
Yes
Computer-generated
random number sequence
Unclear
Allocation was done by
independent statistician, but
there is no detail on the
process of this and if/how
it was concealed
No
Owing to the nature
of the intervention,
the researchers and
participants would know
which group they were in
Unclear
The authors do not state
how loss to follow-up
was addressed (n= 8 at
2 months and n= 4 at
5 months)
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
Yes N/A
Parent-directed non-tailored interventions
Adkins et al.
127
Unclear
No details are provided
Unclear
No details are provided
about allocation
concealment
No
Blinding would have been
difficult to achieve – both
to parents and those
taking the assessments/
collecting data. First,
parents receiving the
leaflet intervention would
know that they were in
that intervention, and
those not receiving a
leaflet would know they
were in the control group.
In the discussion, the
authors state they could
have used a generic leaflet
for the control group to
promote better blinding.
In addition, the clinicians/
researchers knew who
received the leaflet
because they instructed
parents to read it
Unclear
A total of 18 were
randomised into each group
(n= 36), but in table 2, it
says there are n= 19 in the
pamphlet condition and
n= 17 in the no pamphlet
condition. There is no
explanation in the text
about this discrepancy and,
therefore, it is not clear if
the loss of one participant
in one group means that
there were missing data,
and if and how these were
dealt with
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
Unclear
The authors say that the
leaflet used for the
intervention is available from
a website. Is it possible that
the leaflet was available on
this website pre intervention
and, therefore, parents
could have accessed it
before the trial, which
would introduce bias? It is
impossible to clarify this, as
it is not clear if the leaflet
was already in use and
available publicly
N/A
A
P
P
E
N
D
IX
2
1
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
7
0
Study
Domain
Additional questions
for crossover trials
1. adequate sequence
generation?
2. allocation
concealment? 3. blinding?
4. incomplete outcome
data addressed?
5. free of selective
reporting? 6. free of other bias?
Malow et al.
128
Yes
Database software
randomly assigned
participants in a 1 : 1 block
in each site
Unclear
Allocation was carried out
using software but still not
clear in the paper if this
was concealed from the
researchers
No
Participants were not
blinded. It would have
been difficult to do given
nature of the intervention
No
A total of 114 participants
were enrolled into study. Of
these, 80 completed all
study procedures. Only the
80 with complete data
were included in analysis.
Reasons for non-completion
were that it was too
time-consuming, SOL not
confirmed by actigraphy,
children could not tolerate
the actigraphy device,
the child started new
medications or parents
opted for other ways of
addressing sleep problems
In total, 41 were
randomised to the group
arm and 39 to the individual
arm. Six families switched
from the group arm to the
individual arm because of
logistical reasons. Analysis
was made with and without
switchover
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
Yes
Six participants randomised
to the individual arm were
then moved to the group
arm. This could introduce
bias, but the authors
analysed and present results
both with and without these
six participants in the
individual arm. After
reporting results from the
two arms (both intervention
groups, no control group),
they combined data from
the two and report together
as before and after.
However, this is not a bias in
the design, but a possible
bias in the presentation of
the results
N/A
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TABLE 48 Summary of quality assessment using the Cochrane risk of bias tool for RCTs (continued )
Study
Domain
Additional questions
for crossover trials
1. adequate sequence
generation?
2. allocation
concealment? 3. blinding?
4. incomplete outcome
data addressed?
5. free of selective
reporting? 6. free of other bias?
Montgomery
et al.
49
Unclear
No details are provided
Unclear
Opaque envelopes were
used but there was no
evidence that envelopes
were sequentially
numbered. Envelopes
were ‘selected’ by an
independent researcher
No
There was no blinding of
participants, which would
have been difficult given
nature of the intervention
Yes
A total of 2/66 were missing
at follow-up owing to
families moving. Families
moving is not related to the
study treatment and so this
is unlikely to affect fidelity
of outcomes
No
No protocol was referenced
in the paper and one was not
found after searching. The
paper reports Composite
Sleep Disturbance Score
as the main outcome
and evaluation of the
programme, but we would
expect to see objective
measures of sleep
No
No detail on age or gender
of the two groups and, thus,
comparability of groups. Not
clear what type of statistical
analysis was used in some
places
Was use of a crossover
design appropriate?
Yes
Is it clear that the order
of receiving treatments
was randomised?
Yes
Can it be assumed that
the trial was not biased
from carry-over effects?
There would be no
possibility of carry-over
effect as the only
crossover is from the
control group to the
treatment group
Are unbiased data
available?
A Kruskal–Wallis test is
used
Other parent-directed interventions
Wiggs and
Stores
152
Unclear
No details are provided,
other than that the schools
were randomised. The
number of ‘clusters unclear’
Unclear
No details are provided
No
Owing to the nature
of the intervention,
the researchers and
participants would know
which group they were in.
The paper does not
describe the study as
blinded
Unclear
No details are provided as
to whether or not there was
loss to follow-up
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without a protocol, it is
difficult to be certain
No
Reporting of the trial design
was unclear. It was also
unclear how the control
group was ‘matched’, as the
trial randomised schools
(clusters) but matched
intervention and control
children (individuals)
It is not clear if the analysis
accounted for the study
being a cluster trial. The
authors state that there was
no explicit hypotheses but
data were analysed in an
‘exploratory manner’
N/A
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Other non-pharmacological interventions
Piazza et al.
157
Unclear
No details are provided
Unclear
No details are provided
No
Owing to nature of the
intervention, assessors
would know which group
(of the two treatment
groups) participants were
in. Data were collected in
a sleep laboratory by
trained observers and
the potential for bias in
recording was mitigated
by having two observers
on 86% of days across all
clients
Unclear
Data were presented for
14 participants. There were
no details about the number
of participants who were
initially approached/
recruited or if it was ≥ 14
Unclear
No protocol was referenced
in the paper and one was not
found after searching. The
outcomes reported are those
that are expected. However,
without protocol, it is difficult
to be certain
Yes N/A
Francis and
Dempster
156
Yes
Random numbers table
Unclear
Allocation was done by a
senior investigator. The
paper reports that this
senior investigator had
no contact with the
participating children and
parents (who self-completed
the data collection). Codes
were known only to the
senior investigator. But, it is
not clear if this process was
concealed to the
investigator
Unclear
Investigator who held the
codes had no contact
with participants and the
placebo and treatment
capsules were similar in
appearance; therefore,
blinding to participants is
plausible. It is possible that
research staff (except the
senior investigator) were
blinded, as only the senior
investigator had the key to
the codes, but it is also not
clear what involvement this
investigator had in the
subsequent research
process and whether or not
this would introduce bias
The authors state that there
was blinding by the senior
investigator who had no
contact with patients or
parents. Outcomes were
self-reported so the
outcome is unlikely to be
influenced
Yes
There was no loss to
follow-up and a total of five
participants
Unclear
No protocol was referenced
and one was not found after
searching. The study is listed
on European Union Clinical
Trials Register, but little
information is provided on
the study records and there
is not enough to make a
judgement about whether
or not all outcomes are
reported. However, relevant
sleep outcomes are reported
The description of measures
other than primary outcomes
is poor. There is no detail of
what was included in end-of-
study interviews; therefore, it
is difficult to determine
whether or not there was
selective reporting
No
Only night wakings that
occurred during parents
sleep period were recorded;
therefore, other night
wakings outside the parent
sleep period would not be
recorded. Authors say these
data must be regarded as
conservative
Some of the children were
taking other medications for
sleep
The study had very small
numbers (n= 5). There are
no details of the recruitment
process other than that it
was through schools/
organisations for children
with LD. There is no
indication of the total
numbers approached or
if these five patients
self-selected
Was use of a crossover
design appropriate?
Yes
Is it clear that the order
of receiving treatments
was randomised?
Yes
Can it be assumed that
the trial was not biased
from carry-over effects?
Yes, washout period
used, but no analysis of
carry-over effect
Are unbiased data
available?
Yes. A repeated
measures ANOVA was
used
continued
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TABLE 48 Summary of quality assessment using the Cochrane risk of bias tool for RCTs (continued )
Other non-pharmacological interventions
Gringras et al.
36
Unclear
Block randomisation with
random variable block
lengths of 2 and 4,
stratified by centre, but no
detail of sequence
generation was given
No
Authors report that the trial
investigators and the
statistician were blind to
treatment allocation, but
researchers were not.
Although randomisation
was done remotely, the
researchers dispensed the
allocated treatments
No
Researchers were not
blinded to initial allocation
but trial investigators and
the statistician were all
blinded throughout the
trial and analysis
It is impossible to blind
parents/children to the
weight of the blankets but
all other aspects of the
blankets were the same
No
A total of N= 73 were
randomised. The loss
to follow-up n= 0.
Discontinued intervention
and not included in the
analysis n= 6
The reasons were that the
child could not tolerate the
blanket (n= 4, not clear
which arm of trial these
participants were from), the
child was ill (n= 1) or parent
withdrew child (n= 1).
There was no discussion of
the effect on analyses of
loss resulting from not
being able to tolerate
blanket but this is a key
finding and so likely to have
an impact on results
A total of n= 13 were
excluded from analysis
owing to insufficient or
missing data. Missing data
for questionnaire were
prorated if < 10% were
missing, or excluded
otherwise. There was no
detail on the reasons for
missing data
Unclear
Tried to access the protocol
(the URL to this is listed in the
paper), but when clicking on
the link it takes you to a web
page about ongoing projects.
From this unable to find the
protocol. The study reports all
the outcomes expected, but
it is difficult to be certain
without protocol
Yes Was use of a crossover
design appropriate?
Yes
Is it clear that the order
of receiving treatments
was randomised?
Yes
Can it be assumed that
the trial was not biased
from carry-over effects?
The authors report
(p. 299) that there were
no breaks between
interventions, and so
no ‘washout’ period.
Although this is not a
study of a drug, there
might have been a
carryover of the effects of
the weighted blanket. For
example, if the child had
grown accustomed to
better sleep?
Are unbiased data
available?
Data were presented as
baseline, weighted and
control, regardless of
order. Authors use an
independent t-test to rule
out a period effect and
then undertook a paired
t-test
ANOVA, analysis of variance; LD, learning disability; N/A, not applicable.
Yes, low risk of bias; unclear, unclear risk of bias; no, high risk of bias.
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Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI63
TABLE 49 Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI
Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
1.1 Is confounding of the effect of the
intervention unlikely in this study?
PN
A total of 40 children received treatment
and 38 received placebo. There are no
details on why participants were allocated
(if they were allocated) to each group. The
characteristics of participants is not provided
in detail (only overall age range, diagnosis
of ADHD and reported sleep deprivation).
A non-ADHD group served as a control
group. The group was reported to have
corresponding ages and socioeconomic
statuses but details were not provided
NI
It is hard to judge given the little information
about the sample. The sample were selected
based on whether or not they had ADHD,
were male and were sleep deprived. I cannot
think of a prognostic factor (other than the
above, which were the reasons for receiving
the intervention) that would predict the
participants receiving the sleep intervention
(fatty acids). One possibility might be
whether or not there was a nutritional
intolerance to fatty acids (which might
predict if someone would not get the
intervention) but this is not reported
Guidance for ACROBAT-NRSI, states that NI
is not an option for this question. I would
agree with KB that PN is appropriate as
there is some information, albeit a limited
amount of it is provided. Agree with KB
and AS that PN is appropriate given that
very limited information is provided on
allocation and participants
1.2. If N or PN to 1.1:
Were participants analysed in accordance
with their initial intervention group
throughout follow-up?
Y NI
It appears so but there is no information
about dropout or whether or not participants
switched groups
NI – insufficient information provided to
enable judgement
1.3. If N or PN to 1.2:
Were intervention discontinuations or
switches unlikely to be related to factors
that are prognostic for the outcome?
NI – insufficient information provided to
enable judgement
N/A NI – insufficient information provided to
enable judgement
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TABLE 49 Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI (continued )
Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
If Y or PY to 1.3, answer questions 1.4 to 1.6, which relate to baseline confounding. If N or PN to 1.1 and 1.2 and 1.3, answer questions 1.7 and 1.8, which relate to time-varying
confounding
1.4. Did the authors use an appropriate
analysis method that adjusted for all the
critically important confounding domains?
NI N/A N/A – in line with guidance
1.5. If Y or PY to 1.4:
Were confounding domains that were
adjusted for measured validly and reliably
by the variables available in this study?
N/A N/A N/A – as per above guidance
N/A – in line with guidance
1.6. Did the authors avoid adjusting for
post-intervention variables?
Y
Authors presented before and after scores
for each group with no adjustments
N/A N/A – as per above guidance
N/A – in line with guidance
1.7. Did the authors use an appropriate
analysis method that adjusted for all the
critically important confounding domains
and for time-varying confounding?
N/A N/A N/A
N/A – in line with guidance
1.8. If Y or PY to 1.7:
Were confounding domains that were
adjusted for measured validly and reliably
by the variables available in this study?
N/A N/A N/A
N/A – in line with guidance
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Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
Bias in selection of participants into the study
2.1. Was selection into the study unrelated
to intervention or unrelated to outcome?
N
Children in the intervention and placebo
groups were selected into study because
of ADHD and sleep deprivation. In total,
6/7 outcomes related to ADHD and/or sleep
deprivation
The comparison group was unrelated to the
intervention or the outcomes
NI
There is not enough information in the paper
about recruitment to make a judgement on
this. This applies to all the outcomes
N – some but very limited information is
provided explaining that children were
recruited on the basis of ADHD and sleep
deprivation
2.2. Do start of follow-up and start of
intervention coincide for most subjects?
Y
The intervention lasted 10 weeks.
Questionnaires were completed on day 1
and at end of 10 weeks
Y
Participants answered a questionnaire/data
collected on day 1 of study. This was
applicable for all outcomes, which were
assessed by the same questionnaire
Y – participants completed a questionnaire
on the first day of the study and at the end
of the 10-week intervention period
2.3. If N or PN to 2.1 or 2.2:
Were adjustment techniques used that are
likely to correct for the presence of
selection biases?
N/A
Overall judgement = ?. Selection into the
study was not related to intervention/
essential fatty acids but was related to
outcome, but when testing the impact it has
on sleep, you have to select those having
trouble with sleep
N/A PN?
N/A
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TABLE 49 Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI (continued )
Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
Bias in measurement of interventions
3.1 Is the intervention status well defined? Y
Two capsules/day of an essential fatty
acids mixture composed of alpha-linolenic
0.95 g/ml and linolenic 0.90 g/ml free fatty
acids, both 99% pure. Each capsule
contained 360 g of linolenic acid and 90 g
of alpha-linolenic acid in mineral oil. The
placebo was composed of mineral oil in an
identical capsule
Y
Detail of the treatment is given on p. 1167.
It applies to all outcomes
Y – A specific mixture of essential fatty
acids was used that were created in the
researchers’ laboratory. Highly purified
alpha-linolenic and linoleic acids were used
to avoid the variations that occur in
commercially prepared fatty acid oils, which
may introduce possible confounding effects
of other fatty acids or lipid mixtures. The
essential fatty acids mixture was composed
of alpha-linolenic (0.95 g/ml) and linoleic
(0.90 g/ml) free fatty acids, both 99% pure.
Each capsule contained 360 g of linoleic
acid and 90 g of alpha-linoleic acid in
mineral oil. The placebo was mineral oil in
an identical capsule. The treatment lasted
10 weeks and each participant took two
capsules per day
Y
3.2 Was information on intervention status
recorded at the time of intervention?
Y
Given that capsules were created to be
identical in the intervention and placebo,
participants must have been allocated to
intervention or placebo group; therefore, the
group was known at start of intervention
NI
There is not enough detail in the paper to
make a judgement about this
PY – Given that capsules were created
to be identical in control and placebo,
participants must have been allocated to
the intervention or placebo group;
therefore, group was known at start of
intervention
PY
3.3 Was information on intervention status
unaffected by knowledge of the outcome
or risk of the outcome?
Y
This was an experimental study with groups
assigned
NI
There is not enough detail in the paper to
make a judgement about this
NI – there is not enough detail in the paper
to make a judgement about this
NI – insufficient information
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Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
Bias because of departures from intended interventions
4.1. Were the critical cointerventions
balanced across intervention groups?
NI
No data were available on possible
cointerventions, that is, nothing on what
other drugs/behavioural methods were being
used at the same time/started during the
10-week study period
NI
Possible cointerventions include melatonin,
sleep hygiene and/or behavioural techniques.
However, there is no information in the
paper about whether or not participants used
such cointerventions
NI – no data on possible co-interventions
were provided
NI
4.2. Were numbers of switches to other
interventions low?
NI See above NI – as above
NI
4.3. Was implementation failure minor? NI NI
There is not enough information about
implementation fidelity in the paper (e.g. no
detail on compliance in taking the capsules)
NI – there is not enough information about
implementation fidelity in the paper (e.g.
there is no detail on compliance in taking
the capsules)
NI
4.4. If N or PN to 4,1, 4.2 or 4.3:
Were adjustment techniques used that are
likely to correct for these issues?
NI See above NI – as above
NI
Bias because of missing data
5.1 Are outcome data reasonably
complete?
NI
There were no data about missing data
NI
There is little detail in the paper, other than
that 40 participants received the intervention.
It is not clear if the 40 participants were the
original 40 recruited or if there were more
recruited but only 40 proceeded to take the
intervention. There is no detail on if there
were incomplete outcome data
NI – no information regarding missing data
is provided
NI
continued
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TABLE 49 Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI (continued )
Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
5.2 Was intervention status reasonably
complete for those in whom it was sought?
Y
It is clear who was in which group
See above NI – as above
NI – insufficient information
5.3 Are data reasonably complete for other
variables in the analysis?
NI
There were no data about missing data or
other variables
NI
There is no detail about whether or not any
participants were excluded from the analysis
NI – there were no data about missing data
or other variables
5.4 If N or PN to 5.1, 5.2 or 5.3:
Are the proportion of participants and
reasons for missing data similar across
interventions?
See above See above
5.5 If N or PN to 5.1, 5.2 or 5.3:
Were appropriate statistical methods used
to account for missing data?
See above See above
Bias in measurement of outcomes
The outcomes for this study are as follows: co-operation, good mood, ability to concentrate, fatigue during the day, preparing homework, quality of sleep and haemoglobin
6.1 Was the outcome measure objective? N
All measures except the haemoglobin level
were based on self-completed questionnaire
N
For all measures except the haemoglobin test
N
All outcomes were based on self-completed
questionnaire data, with the exception of
the haemoglobin test, which was measured
by a blood assay on the first day of the
study and at the end of the 10-week study
period
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Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
6.2 Were outcome assessors unaware of
the intervention received by study
participants?
N
Assume that the participants were blind to
the treatment group (owing to identical
capsules). If so, then as the participant
assessed their own outcomes, then they
were unaware of intervention received. It is
not clear if the person who took and
measured the haemoglobin level was
blinded
N
Data were collected by self-report of
participants and analysed/assessed by
researchers. Neither group were blinded/
unaware of the intervention received
N
No information regarding blinding
was provided. The questionnaire was
self-reported data for five or six outcomes.
It was unclear if the haemoglobin
measurement was undertaken by a blinded
individual
N – for all measures except haemoglobin
level, as these were based on a
self-completed questionnaire
6.3 Were the methods of outcome
assessment comparable across intervention
groups?
Y
All outcomes were measured through
self-completed questionnaires at day 1 and
10 weeks plus a haemoglobin test
Y Y – all outcomes were measured through
self-complete questionnaires at day 1 and
10 weeks plus a haemoglobin test
Y
6.4 Were any systematic errors in
measurement of the outcome unrelated to
intervention received?
NI Not sure how to judge this NI – no information regarding errors were
provided. For instance, reliability of
haemoglobin measurement?
NI
continued
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TABLE 49 Summary of quality assessment for controlled before-and-after studies using ACROBAT-NRSI (continued )
Other non-pharmacological intervention (Yehuda et al.160)
Bias because of confounding
Domain Reviewer 1 quality appraisal Reviewer 2 quality appraisal Reviewers 3 and 4 quality appraisals
Bias in selection of the reported result
Is the reported effect estimate unlikely to be
selected, on the basis of the results, from
. . . multiple outcome measurements within
the outcome domain?
?NI
All domains are reported but there is no
protocol
NI
The paper does not refer to a published
protocol, and with little detail provided on
the analysis (i.e. intended analysis and actual
analysis), it is difficult to make a judgement.
It is impossible to know whether or not there
were multiple outcome measurements and
whether or not those reported were in fact a
subset (or not) of these
NI – agree with reviewer 2
NI
Is the reported effect estimate unlikely to
be selected, on the basis of the results,
from . . . multiple analyses of the
intervention–outcome relationship?
?NI
Two-way ANOVA reported
NI
As above. With little information and no
protocol, it is impossible to judge whether or
not the analysis reported are a selective
subset of a wider analysis or not
NI – agree with reviewer 2
NI
Is the reported effect estimate unlikely to
be selected, on the basis of the results,
from . . . different subgroups?
?NI
No subgroup analysis
NI
As above. With little information and no
protocol, it is impossible to judge whether or
not there were any subgroups analysed. No
subgroup analysis is reported
NI – agree with reviewer 2
NI
ANOVA, analysis of variance; N, no; N/A, not applicable; NI, no information; PN, probably no; PY, probably yes; Y, yes.
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Summary of quality assessment for before-and-after studies64
TABLE 50 Summary of quality assessment for before-and-after studies
Study
Were the selection/
eligibility criteria
adequately reported?
ls the sample likely to be
representative?
If yes,
was it a
random
sample?
Were patients recruited
prospectively?
Were patients
recruited
consecutively?
Was the participation rate
adequate (> 80% of those
eligible)?
Was there ≥ 80%
follow-up from baseline?
Questions 1–7
Parent-directed tailored interventions
Austin
et al.
123
No
Details of the sample
were given, but they
were not clearly stated
in terms of whether or
not these details were
inclusion or exclusion
criteria
No
The sample size was very small – six parents
of seven children (but it was described as a
preliminary evaluation)
N/A Unclear
No detail is given to be
able to assess this
Unclear
No detail is given to
assess this
Unclear
There is no detail given in the
paper about the numbers of
eligible children it cannot be
assessed whether or not
there was > 80%
participation rate
Yes
7/8 were followed up
Beresford
et al.
21
No
The inclusion/exclusion
criteria are not described
No
Small sample (n=12)
N/A Yes Unclear
No detail is given to
assess this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so cannot
assess whether or not there
was a participation rate of
> 80%
Unclear
Follow-up loss is not
reported so unable to
assess this
Quine and
Wade
146
Unclear
Inclusion criteria are
reported but no
exclusion criteria were
reported
No
Authors report that the sample was a ‘highly
selective group’ owing to the bias towards
males. They also compared the group to a
previous sleep problem prevalence study that
they undertook. From this, they noted that
the sample had more sleep management
problems and a longer duration of sleep
problems than the prevalence study group,
and that there was more marital unhappiness
and maternal irritability than the prevalence
study. In addition, the sample was selected
from playgroups for preschool children, so
although the ages of the sample are not
reported they will be biased towards the
younger ages
N/A Yes Unclear
Participants were
volunteers not referrals
and so there was not
really an ‘order’ to be
consecutive from
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or not
there was > 80%
participation rate
Yes
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TABLE 50 Summary of quality assessment for before-and-after studies (continued )
Study
Were the selection/
eligibility criteria
adequately reported?
ls the sample likely to be
representative?
If yes,
was it a
random
sample?
Were patients recruited
prospectively?
Were patients
recruited
consecutively?
Was the participation rate
adequate (> 80% of those
eligible)?
Was there ≥ 80%
follow-up from baseline?
Weiskop
et al.
126
Yes No
The age range of the sample is biased
towards younger children. This was
intentional as the authors felt that the
intervention would be more suitable to
younger ages. All but one were in specialist
education services. This may make the
sample quite specific in terms of
representativeness. Furthermore, the
sample was partly recruited through a
disability newsletter, but there is no
information given on who receives this
newsletter and if it represents a specific
subset of families
N/A Yes Unclear
There is insufficient
detail to make a
judgement on this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
No
77% were followed up
Parent-directed non-tailored interventions
Beresford
et al.
21
No
The inclusion/exclusion
criteria were not
described
No
Small sample (n= 22)
N/A Yes Unclear
No detail is given to
assess this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
No
70% (post intervention),
65% (12-week follow-up)
and 78% (24-week
follow-up) were followed
up
Beresford
et al.
21
No
The inclusion/exclusion
criteria are not described
No
Small sample
N/A Yes Unclear
No detail is given to
assess this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
No
69% were followed up at
12 weeks and 62% at
24 weeks
Bramble
149
Unclear
Inclusion criteria
reported but exclusion
criteria not reported
No
Small sample of 15 participants
N/A Yes Yes Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
Yes
Reported that there were
no dropouts but there
were missing data for at
least five children on one
score and seven on
another
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Study
Were the selection/
eligibility criteria
adequately reported?
ls the sample likely to be
representative?
If yes,
was it a
random
sample?
Were patients recruited
prospectively?
Were patients
recruited
consecutively?
Was the participation rate
adequate (> 80% of those
eligible)?
Was there ≥ 80%
follow-up from baseline?
Reed et al.
129
Yes Unclear
There was some variability in some
demographics (e.g. ethnicity), but some
were very homogenous. The authors report
that child care was offered to minimise
selection bias
N/A Unclear
Some participants were
recruited via a medical
centre with a record
review used but it is
unclear in the paper
whether or not this record
review was used after
prospective recruitment or
to select and recruit
participants
Unclear
There is insufficient
detail to make a
judgement on this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
Yes
80% follow-up
Yu et al.
151
Yes No
The sample was biased towards younger
children and, other than autism, it excluded
those with neurological conditions that
could have affected sleep (e.g. epilepsy)
N/A Yes Unclear
There is insufficient
detail to make a
judgement on this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or
not there was a > 80%
participation rate
Yes
85% follow-up
Other parent-directed interventions
Peppers
et al.
155
Yes No
Small sample (n= 23), demographics of
only intervention group reported
N/A Yes Unclear No Yes
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TABLE 50 Summary of quality assessment for before-and-after studies (continued )
Study
Were the selection/
eligibility criteria
adequately reported?
ls the sample likely to be
representative?
If yes,
was it a
random
sample?
Were patients recruited
prospectively?
Were patients
recruited
consecutively?
Was the participation rate
adequate (> 80% of those
eligible)?
Was there ≥ 80%
follow-up from baseline?
Other non-pharmacological interventions
Guilleminault
et al.
158
No Unclear
Little detail on the sample is given
N/A Unclear
Participants were those
referred to a clinic but it is
not clear if they were
recruited at the time of
referral or retrospectively
Unclear
No detail is given on this
Unclear
There is no detail given in the
paper about the numbers of
eligible children so it cannot
be assessed whether or not
there was a > 80%
participation rate
Yes
N= 14. It is reported that
5/14 children responded to
treatment. Non-responders
to treatment described as
five boys and four girls.
The implication is that
none was lost to follow-up
Oriel et al.
159
Yes Unclear
Participants were recruited through letters
sent home through local ASD support
classrooms
N/A Yes Unclear Unclear Yes
Yu and
Hong161
Yes Unclear N/A Unclear Unclear Unclear Yes
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TABLE 51 Summary of quality assessment for before-and-after studies of non-pharmacological interventions
Study
Was loss to
follow-up reported?
Were relevant
prognostic factors
reported?
Were other relevant
confounding factors
reported? (e.g. use of
co-interventions)
Was an
appropriate
measure of
variability
reported?
Was there an appropriate
statistical analysis?
Were there any other important
limitations?
Questions 8–13
Parent-directed tailored interventions
Austin et al.123 Yes No No Yes
It reports SDs
Yes
Repeated-measures t-tests
Yes
Small sample. Note: described as preliminary
evaluation
Beresford
et al.21
Unclear
There is no detail in
the report to assess
this
Unclear
There is little detail about
the sample to assess this
Unclear
There is little detail about
the sample to assess this
Yes
It reports SDs
Yes
Appendix E notes that, owing
to a very small sample size,
tests of statistical significance
were not applied
No
Quine and
Wade146
Yes No
Very little detail about the
sample is reported,
including possible
prognostic factors
No
Very little detail is
available on the sample
Yes
It reports SDs
No
Descriptive before-and-after
data are reported, but a test
of difference is reported for
some but not for all variables.
It is not always clear what type
of test was used
Yes
The multiple baseline design data collection was
stopped [i.e. the plan was to collect diary data
for all from time of entering the study (all at
same time point)] but as the parents were tired
and because some had to wait a long time to
start the intervention, for most families, data
were only collected for the first and second
weeks at baseline. Therefore, it was not possible
to compare baselines and interventions in ‘real’
time. The follow-up period immediately after
the intervention is not reported, so it is not clear
what the ‘after’ measurement relates to. A
further 3-month follow-up was used but most
of the data reported pertain to the first
(unknown) follow-up
Note: the authors say they used an age-matched
control group for comparison but this is not
reported in the results and only before-and-after
results are reported
continued
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TABLE 51 Summary of quality assessment for before-and-after studies of non-pharmacological interventions (continued )
Study
Was loss to
follow-up reported?
Were relevant
prognostic factors
reported?
Were other relevant
confounding factors
reported? (e.g. use of
co-interventions)
Was an
appropriate
measure of
variability
reported?
Was there an appropriate
statistical analysis?
Were there any other important
limitations?
Weiskop
et al.126
Yes No
It is not clearly reported
whether or not there were
any comorbidities that
could have influenced the
outcome (e.g. if any
participants experienced
seizures or duration of
sleep disturbance)
Yes
The paper reports that
some children were
taking medication for
behaviour and/or sleep
problems
No No
The authors report that
emphasis is placed on clinical
significance and use of goal
attainment scaling and visual
analysis of graphs. There is no
analysis of difference using a
particular test, but perhaps
this is correct given the small
sample size (n= 13)
Yes
Small sample (n= 13). Two studies were
conducted (one with a sample of children with
ASD and one with a sample of children with
fragile X syndrome) and then combined ‘in the
interest of brevity of results’126. It is not clear
why two separate studies were conducted and
so it is difficult to establish the validity of
combining the two. One study had a 12-month
follow-up, whereas the other did not. In
addition, the treatment duration varied for
participants, with a minimum of 7 weeks, but
it was longer if treatment was interrupted
(e.g. because of illness)
Parent-directed non-tailored interventions
Beresford
et al.21
No
The paper deals with
missing data reported
but not the
characteristics of those
lost to follow-up
No No Yes
It reports SDs;
CIs were
plotted but
not reported
in text
Yes
Repeated measures ANOVA,
paired t-tests if appropriate,
effect sizes reported
No
Beresford
et al.21
No
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TABLE 51 Summary of quality assessment for before-and-after studies of non-pharmacological interventions (continued )
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Were relevant
prognostic factors
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confounding factors
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co-interventions)
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appropriate
measure of
variability
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statistical analysis?
Were there any other important
limitations?
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Appendix 22 Parent sleep-related outcomes
for studies evaluating non-comprehensive
parent-directed interventions
TABLE 52 Parent sleep-related outcomes for studies evaluating non-comprehensive parent-directed interventions
Study
Parent sleep-related
outcome assessed
Method of
assessment Definitionsa
Global measures and composite scores
Wiggs and
Stores152
TST Actigraphy Time from sleep onset to the time the child
woke up
Parent-carer-related quality of life
Wiggs and
Stores152
Parental stress Malaise Inventory,
reported separately for
mothers and fathers
The Malaise Inventory is a 24-item binary
choice questionnaire that has been used in a
number of studies of disabled children to
measure carers’ stress. Scores of 5 or 6 are
considered to indicate stress outside the
normal range. Scores of ≥ 7 are said to have
critical implications for physical and mental
health
Sleep maintenance
Wiggs and
Stores152
Parent sleep (sleep period,
activity score, movement
index and fragmentation
index)
Activity monitors Sleep period: time from sleep onset to the
time the child woke up. Referred to as sleep
period
Activity score: the sum of the epoch scores
divided by total number of epochs in the
sleep period
Movement index: the number of thirties
epochs with a value > 0 (i.e. with
movement), divided by the total number of
thirties epochs in the sleep period × 100
Fragmentation index: the number of
discrete thirties epochs with a value of 0
(i.e. with no movement) divided by the total
number of immobile phases of any
duration × 100
Sleep scheduling
Wiggs and
Stores152
Daytime sleepiness
(mothers and fathers)
Epworth sleepiness
scale
An 8-item self-report scale concerning the
likelihood of falling asleep in everyday
situations. Sleeping propensity was
measured on a 4-point scale and scored as
follows: 0=would never sleep, 1 = slight
chance of sleeping, 2 = quite likely that they
would sleep, 3= very likely that they would
sleep. The possible score range was from
0 to 24. Scores of ≥ 11 may indicate
hypersomnolescence. The authors provide a
reference
continued
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TABLE 52 Parent sleep-related outcomes for studies evaluating non-comprehensive parent-directed interventions
(continued )
Study
Parent sleep-related
outcome assessed
Method of
assessment Definitionsa
Quality of sleep
Wiggs and
Stores152
Parental satisfaction with
own sleep
A six-point Likert scale,
reported separately for
mothers and fathers
A six-point Likert scale; the responses were
totally satisfied, satisfied but could be better,
more often satisfied than not satisfied, more
often unsatisfied than satisfied, unsatisfied
but could be worse and totally unsatisfied
Other outcomes
Wiggs and
Stores152
Parental satisfaction with
child’s sleep and parental
satisfaction with their
ability to cope with their
child’s sleep pattern and
daytime behaviours
A six-point Likert scale,
reported separately for
mothers and fathers
A six-point Likert scale; the responses were
totally satisfied, satisfied but could be better,
more often satisfied than not satisfied, more
often unsatisfied than satisfied, unsatisfied
but could be worse and totally unsatisfied
a As defined by study authors.
APPENDIX 22
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
Appendix 23 Measures of perceived
confidence and/or efficacy and/or understanding
of sleep/sleep management for studies evaluating
non-comprehensive parent-directed interventions
TABLE 53 Measures of perceived confidence and/or efficacy and/or understanding of sleep/sleep management for
studies evaluating non-comprehensive parent-directed interventions
Study Method of assessment Definitionsa
Behavioural
Peppers et al.155 Parent Satisfaction Likert Survey No further definition or reference provided
Wiggs and
Stores152
The parents’ perceived control to
manage own and partners’ sleep
difficulties (VAS), reported separately for
mother and father
VAS (100mm) scored from 0 to 100. Parents rated their
ability on a scale of not at all able to control it to totally
able to control it. Parents also rated their partners
The parents’ locus of control: internally/
externally control scale reported
separately for mother and father
A 29-item forced choice questionnaire that includes six
filler items to make the test purpose ambiguous. It was
used to measure parents’ orientation to internal or
external beliefs. External control beliefs: events are
caused by some attribute of the environment including
powerful others, fate or luck. Internal control beliefs:
events are contingent on own actions or own relatively
permanent characteristics. Individuals scoring highly on
an internal belief scale tend to be more resilient to
negative events and are less likely to develop subsequent
psychological or physical characteristics. The authors
provide a reference
VAS, visual analogue scale.
a As defined by study authors.
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